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Management of Hi-tech Health Care in the Community Setting 
Summary
Drugs and health technologies have advanced to such an extent that it is now 
possible to treat patients at home or in the community with hi-tech health care 
that would have traditionally required an inpatient admission, for example 
parenteral nutrition or chemotherapy infusions. In order that patients receiving 
complex therapies are managed effectively in the community setting shared care 
agreements have been drawn up between the patient’s GP and hospital specialist.
This study used surveys of Health Authorities (HAs) to establish the extent to 
which different models of shared care have been developed throughout England 
in response to the government directives EL(91)127 and EL(94)72. It found that 
in most HA areas some shared care guidelines are in use, mainly for higher cost 
regimens. A survey of general practitioners (GPs) in South and West Devon was 
carried out to investigate the merits of one model of shared care. This model was 
found to provide GPs with a robust framework for sharing care of patients, on 
complex treatments, with secondary care colleagues.
The arrangements for purchasing and provision of hi-tech healthcare at home 
(HTHH) under EL(95)5, were studied using questionnaire surveys of HAs, NHS 
Trusts and commercial providers of HTHH. The effectiveness of EL(95)5 in the 
delivery of HTHH to patients was evaluated with emphasis on the role of the 
pharmacist. It was found that there is considerable variation in both the extent to 
which HTHH is purchased throughout England and the quality of care received 
by patients. Pharmacists played an important role but were rarely involved with 
quality assurance of the home care service.
The need for a benchmarking tool to assist in improving the quality of care 
received by patients receiving HTHH was identified and addressed by the 
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1.1.1 The National Health Service
The National Health Service (NHS) was founded in the United Kingdom in 1948 
based upon the principle that it would be available to all, irrespective of means, 
on the basis of need and that most services would be provided free of charge at 
the point of use [1]. It is a government-funded organisation and as such is 
subject to political influences.
The NHS is organised so that patients register with a local doctor, a General 
Practitioner (GP). GPs are generalists and act as “gatekeepers” to the rest of the 
NHS. They are responsible for most community-based services and they are, for 
most patients, the first entry point to the NHS, hence the term “primary care”. 
Practitioners in primary care may refer patients to specialist consultants usually 
based in hospitals (secondary care) who may then refer on again to doctors in 
specialist centres (tertiary care). Currently specialists practising from hospitals 
have little or no experience of community based services. This system is very 
different to that in the United States and in other countries where private health 
insurance is the norm and there is no gatekeeper role. The structure of the NHS 
in England is further described in Chapter 2, Section 2.1.
There has, in recent years, been a movement of health care more traditionally 
provided in the hospital setting into the community. This is in line with the 
government agenda of providing care, where appropriate, as close to the patient’s 
home as possible and having decisions about health care made locally [2-5]. In 
recent reorganisations of the NHS funding has been allocated to primary care 
organisations so that NHS purchasing decisions can be taken at a local level [2]. 
The change in emphasis from secondary to primary care has been brought about 
by increasing costs of hospital care, pressure on hospitals to increase their 
throughput, advances in technology allowing treatment to be managed at home 
and the need to optimise quality of life in chronically sick patients [6].
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1.1.2 Advances in Therapeutics and Technologies
Advances in two areas have led to the possibility of community-based care for 
many patients who would traditionally have required a hospital visit or admission 
[7-13].
Drugs have been developed with better pharmacokinetic and pharmacodynamic 
profiles which allow for less frequent administration to patients with fewer side 
effects. Many treatments are now available in formulations that are easier to 
administer such as via the oral or subcutaneous routes rather than the intravenous 
route. Once patients are stabilized the monitoring requirements are relatively 
simple allowing GPs in the community setting to manage the day-to-day care of 
the patient, sharing care with their hospital consultant colleagues. Examples of 
such therapies include newer or more complex drugs such as apomorphine, 
erythropoietin, domase alpha, interferon, growth hormone, immunoglobulins, 
octreotide and oral ganciclovir.
Advances in health technologies such as intravenous access devices and infusion 
pumps and more sophisticated clinical monitoring techniques mean that patients 
can also be treated at home with therapies which traditionally required a hospital 
visit or admission because of complex administration techniques such as 
intravenous (IV) infusions.
Intravenous access devices such as peripherally inserted central cannulae (PICC 
lines) made of hi-tech materials are associated with less irritation and fewer 
iatrogenic complications then traditional access devices. Advances in pump 
technology mean that small ambulatory pumps can be used to administer 
accurate doses of drugs to patients whilst they go about their everyday lives.
They can be programmed to administer complex regimens or have lock out 
periods when no more drug can be administered and can record accurate histories 
of drug administration. They can even be reprogrammed over telephone lines 
using increasingly complex information technology. Implantable pumps with 
reservoirs have been developed which allow local administration of, for example,
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intrathecal or intrarticular infusions. Stability of some drug infusions has 
improved due to better understanding of agents such as stabilizers and buffers 
and developments in materials used for containers.
These developments mean that patients are now able to receive home infusion 
therapy such as parenteral nutrition, continuous chemotherapy or antibiotic 
infusions safely in their own homes.
1.2 Prescribing of New and Complex Therapies in the Community
General practitioners are often unfamiliar with these newer therapies and 
administration technologies and will not have the experience of a specialist in the 
field. The numbers of patients requiring these treatments are small and a general 
practitioner is unlikely to have come across them before and is unlikely to have 
more than one patient on their list that requires growth hormone or home 
parenteral nutrition for example. In order that these therapies can be managed 
successfully in the community setting a shared care arrangement between the 
patient’s GP and hospital consultant is desirable [14, 15].
Shared care guidelines or protocols are locally agreed management guidelines 
usually based around a diagnosis or a drug treatment. They seek to overcome 
communication problems between primary and secondary care through both the 
development of the guideline and it’s content. Guidelines are often developed by 
a multidisciplinary group. The guidelines seek to give a GP some background on 
the subject, outline respective responsibilities of members of the healthcare team 
and highlight monitoring requirements, side effects, interactions etc. The 
guideline may also specify when it has been agreed that shared care is suitable 
and the circumstances under which the patient should remain under the care of 
the secondary care physician.
The specialist may be responsible for one aspect of the patient’s care but the GP 
will be responsible for any other medical problems that may arise whilst the 
patient is at home and it is important that they are aware of complications that 
may be attributable to a hi-tech, specialist or new therapy.
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It has been recognized that the sharing of care between the hospital consultant 
and general practitioner is a rational and practical approach to the long-term 
management of patients with chronic but stabilized illness [16]. This approach 
has been successful for the management of diseases such as diabetes, epilepsy 
and hypertension [17, 18]. Providing hi-tech therapies in the community setting 
has led to the need for much closer working between primary and secondary care 
practitioners but there have been barriers to this.
Appreciating that discharging patients on hi-tech therapies into the community 
requires a joint management approach from both secondary and primary care, the 
NHS Management Executive in 1991 issued a directive in the form of EL(91)127 
[19]. This directive contained guidance on the responsibility for prescribing at 
the hospital/general practitioner interface covering situations where a patient was 
referred to a hospital specialist who prescribed, an often complex therapy, for a 
patient until the patient was stabilized. The specialist then asked the general 
practitioner to take over prescribing and in some cases the monitoring of the 
patient. EL(91)127 [19] reinforced the basic premise that the doctor who has 
clinical responsibility for the patient should prescribe and focused on the concept 
of shared care. It emphasized the need for proper hand-over procedures from 
hospitals to make sure that the general practitioner was properly informed and 
could monitor treatment and adjust the dose if necessary suggesting that there 
should be provision of protocols for treatment.
EL(91)127 [19] lists some of the concerns around interface prescribing. One of 
the major concerns of GPs is about accepting clinical responsibility for patients 
on specialist initiated drugs with which they are unfamiliar [19]. The concept of 
shared care aims to overcome this by a sensible, collaborative approach 
providing appropriate support, training and good communication channels 
between the relevant hospital consultant and general practitioner. However, it 
does not overcome the fact that medico-legally responsibility must always lie 
with the doctor who signs the prescription [20].
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Further guidance from the government in 1994, EL(94)72 [21] asked purchasers 
to develop a policy on the managed entry of new drugs making use of evidence 
of their clinical and cost effectiveness. It directed Health Authorities to develop 
and agree strategies for improving prescribing across the primary/secondary care 
interface and ensure appropriateness of hospital-led prescribing whilst taking into 
account the total cost of drugs to the NHS. It advised that formally agreed shared 
agreements or protocols be used as a tool to formalise the managed entry of new 
drugs into primary care.
In a recent report on the prescribing of costly medicines the Royal College of 
Physicians [22] noted that the development of formal shared care guidelines had 
helped to overcome some of the interface problems around prescribing high cost 
medicines and recommended that prescribers in secondary care take into 
consideration the anxiety that those in primary care may have about prescribing 
certain new medicines.
Some of the difficulties in implementing shared care schemes have led to the 
development of outreach services from hospitals into the community, the 
involvement of private health care providers and the development of systems to 
educate and support GPs involved in caring for patients receiving more complex 
treatments [14, 18].
1.3 Hi-tech infusions administered in the community
The treatment of patients at home with drugs requiring complex administration 
techniques such as intravenous infusions of antibiotics, total parenteral nutrition 
(TPN), chemotherapy, opioid infusions, chelating agents and bronchodilators has 
become accepted as a safe and effective model of health care [7, 12, 23-25]. For 
chronically ill patients requiring long term infusions, treatment at home improves 
their quality of life often enabling them to return to work or school, giving the 
patients greater opportunity to be with their families and means that they play an 
active role in their treatment [26, 27]. Few problems have arisen and 
complication rates have been shown to be low [28-30], possibly, in part due to a 
decreased risk of nosocomial infections [31].
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Patients in the United States commonly receive hi-tech therapies in the 
community to the extent where even patients relying on artificial respiration are 
successfully managed in their own home [32]. Hi-tech health care at home 
(HTHH) has been slower to become accepted in the UK and the rest of Europe 
[28-30] and other countries such as Japan [33] [34] and Australia [35]. This 
could be due to a number of factors, amongst them, the way the National Health 
Service (NHS) is funded [36]. There is no direct cost to a patient or an insurer 
when a patient is admitted to hospital in the UK and therefore no direct pressure 
from them to reduce hospital length of stay or frequency of outpatient visits [37].
The numbers of patients being treated with HTHH in England are steadily 
increasing, as is the cost. Treating these patients at home offers benefits for 
hospitals in that it enables earlier discharge of patients, frees-up hospital beds 
and is cost effective in terms of overall efficiency in health delivery [30, 38, 39]. 
It has however also been argued that if a patient is discharged from a hospital 
another patient will be admitted or fill that outpatient appointment the total cost 
to the NHS will increase [40].
With the increasing acceptance of use of hi-tech administration techniques in the 
community setting during the 1980s and early1990s, concern was raised 
regarding pressures being placed on GPs to provide the necessary equipment and 
supplies for these patients. This led to the NHS Executive issuing further 
guidance in January 1995, in the form of EL(95)5 [41]. This guidance instructed 
Health Authorities (HAs) to purchase care to support patients at home whose 
treatments included the delivery of drugs together with other products and 
equipment needed to administer them. These were typically provided as 
packages of care including everything that is required for the patient to 
effectively manage their treatment at home including training of the patient and 
carer, 24 hour emergency back-up, syringes, needles, infusion pumps, supplies of 
the drug and often a refrigerator. Examples of packages of care covered by 
EL(95)5 [41] include Total Parenteral Nutrition (TPN), intravenous antibiotics 
for cystic fibrosis and chemotherapy infusions.
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Prescribing of these services by general practitioners (GPs) was stopped from 1st 
April 1995. Health Authorities were directed to purchase care for these patients 
though their commissioning mechanisms. GP prescribing budgets were top- 
sliced so that money spent on HTHH in primary care could be used by the HAs 
to commission care for these patients. It made no provision for funding new 
patients requiring home therapy, or patients who were receiving infusions at 
home which were not being prescribed by GPs previously (on FP10 
prescriptions). Bryan [15] predicted that EL(95)5 [41] may make the most 
expensive shared care arrangements flavour of the month on both sides of the 
primary/secondary care prescribing divide.
There have been two major reports focusing on the purchasing of HTHH 
(including enteral nutrition and continuous ambulatory peritoneal dialysis) since 
the introduction of EL(95)5 [41]. The first was a study commissioned by the 
North West Regional Health Authority [6] to provide information and guidance 
to purchasers and ultimately providers of HTHH, to determine key 
considerations for a purchaser strategy and make recommendations of effective 
purchasing. This report highlighted the fact that communication between 
stakeholders was generally poor and that purchasing HTHH is a complex issue 
for Health Authorities and NHS Trusts due to the possibilities for subcontracting 
the provision of some services. It was found that all stakeholders acknowledged 
the importance of implementing appropriate policies and procedures to ensure 
quality and value for money and recommended that purchasers have sound 
monitoring arrangements in place and access to good comparative information 
about the quality and costs of HTHH services. It went further to recommend 
Lead Purchasing arrangements which in 1996-7 contracted with commercial 
organisations but from 1997-8 placed contracts with NHS tertiary centres.
The second was a report published in 1998 commissioned to explore the national 
response of purchasers to EL(95)5 [42]. It found that little priority had been 
given by Health Authorities to their responsibilities for purchasing HTHH which 
had led to inefficient contracting and poor value for money. Temporary 
arrangements established when implementing EL(95)5 [41] continue and 
purchasers express little willingness to review these mechanisms. Short and
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Norwood [42] also recommended consortium or lead purchaser purchasing and 
highlight the lack of monitoring of contracts.
In the same year the proposed merger of Fresenius AG and Caremark Limited, 
both commercial providers of HTHH, led to a Monopolies and Mergers 
Commission Report [43]. This report collated detailed information on UK home 
care market and highlighted a lack of competition.
1.4 Background to this work
This project arose to evaluate a scheme which was set up, during the late 1980s 
and early 1990s, for patients to receive continuous ambulatory chemotherapy 
infusions at home. The scheme was very successful and it was hoped that the 
primary care team would get more involved with sharing the care of these 
patients with their secondary care colleagues to allow more patients access to this 
treatment. The original aim of this project was to evaluate home ambulatory 
infusions as a GP shared care initiative.
The publication of government directives on shared care [19], the managed entry 
of new drugs [21] and particularly the provision of HTHH [41] set a framework 
for the development of this project and the aims were adapted as follows:
SHARED CARE 
AIM 1
To establish the current situation in England regarding the implementation of 
shared care arrangements under EL(91)127 [19] and subsequently under 
EL(94)72 [21] and to identify models which had been successful or otherwise.
AIM 2
To evaluate and critically analyze one example of an initiative intended to 
implement and facilitate shared care between primary and secondary care 
practitioners in South and West Devon.
27
HI-TECH HEALTH CARE AT HOME
AIM 3
To establish the current position in England on the purchasing and provision of 
HTHH under EL(95)5 [41].
AIM 4
To evaluate the effectiveness of EL(95)5 [41] in the delivery of HTHH to 
patients with an emphasis on the role of the pharmacist.
1.5 Development of a Benchmarking Tool for the Provision of Home 
Infusions
This work identified a severe inadequacy in both quality and outcomes 
monitoring of the provision of home infusion therapy in England. It was found 
that contracts are rarely put out to competitive tender, service specifications are 
rarely set and the outcomes of home infusion therapy are largely unknown by the 
purchasers of the care. Both purchasers and providers of home infusion therapy 
expressed concern regarding the lack of monitoring of quality. This was in 
contrast to the situation in the United States where home infusion providers must 
be accredited and benchmarking of the processes and outcomes of home infusion 
therapy has become normal practice.
Clinical audit has become a widely accepted tool for improving the quality of 
clinical care received by patients in the NHS but benchmarking has been 
demonstrated both in the manufacturing industry and more recently in service 
industries including health services to lead to greater improvements in outcomes. 
This is achieved by searching for and learning from best practice, which leads to 
superior outcomes, and adapting and implementing that practice to improve 
current performance. Benchmarking has been proven to produce improved 
patient outcomes in the home infusion industry in the United States [44-46] so 
this methodology was adopted in developing a tool to monitor quality and 
improve outcomes in the provision of home infusions in England.
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The need for a benchmarking tool having been identified was addressed. The 
final aim of the project was therefore developed using this inductive approach.
BENCHMARKING 
AIM 5
To develop a benchmarking tool for use by providers of home infusion therapy to 
monitor quality of care and improve patient outcomes (Chapter 4, Development 
of a Benchmarking Tool for the Provision of Home Infusions).
Chapter 5 draws conclusions and makes recommendations based on this work.
A review of the literature was carried out at the outset and forms the introduction 





2.1.1 A Primary Care Led NHS
There has been much inefficiency in the NHS over the decades which have led in 
recent years to ever increasing costs of delivering health care and to a rethinking 
of the way the NHS functions.
The idea of creating an internal market within the NHS was first floated by 
Enthoven in his analysis of the NHS published in 1985 [1]. Two main pressures 
on the NHS were identified. Firstly, limited prospects for real growth in the level 
of resources. Secondly continued pressure to increase service levels due to 
demographic factors and increasing costs of new medical technology. The 
obvious solution, he suggested, would be to improve the effectiveness of the 
service within the available resources. Barriers to this included the fact that there 
was no incentive, other than job satisfaction, to deliver better quality of care at 
lower cost and that forces, particularly professional staff, made it difficult to 
bring about change within the NHS.
The Conservative government during the 1980’s, took up the idea of a 
competitive internal market to give an incentive to increase activity, improve 
efficiency and quality, improve patient choice and to increase managers ability to 
manage the service by devolving decision making to a local level [1],
Three important white papers were published during the late eighties:
Promoting Better Health, 1987 [47]
Working for Patients, 1989 [48]
Caring for People, 1989 [49]
The main aim of ‘Promoting Better Health’ was to raise standards of health and 
healthcare, to place better emphasis on health promotion and disease prevention,
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and to offer wider choice and information to patients. Many of these reforms 
were introduced through the contracts under which general practitioners provide 
services.
‘Working for Patients’ was the outcome of a ministerial review, established to 
address underlying problems in the management and funding of the NHS. 
Resource management programmes were implemented, general practitioners 
were provided with prescribing, analysis and cost (PACT) data to enable them to 
monitor prescribing patterns, medical audit was introduced across primary and 
secondary care and managers were expected to play a bigger part in the 
management of clinical activity. With contractual funding, responsibility for the 
funding and provision of services were separated. This put provider units under 
competitive pressure to improve quality and efficiency.
Local authorities were given the responsibility for the planning of community 
care in the white paper, ‘Caring for People’. This was in an effort to overcome 
the uneven development of services across the country and was closely linked to 
new funding arrangements for residential care.
The ‘NHS and Community Care Act’, 1990, gave the government the legal 
power to implement the proposed changes and the internal market became a 
reality. General practitioner fundholding was introduced in 1991. Building upon 
the changes introduced by ‘Working for Patients’ came the idea of a primary- 
care led NHS whereby general practitioners either directly purchased or 
influenced the Health Authority purchasing through commissioning. The main 
aim of the proposals in ‘Towards a primary care led NHS’, 1994, was to ensure 
that decisions about purchasing were taken as close to the patient as possible 
[50].
Dinsdale [51] reported that fundholding general practitioners had begun to offer 
more services previously provided in hospitals but were slow to face the funding 
issues and bid for contracts so that the care of their patients could be brought 
nearer to their homes. He also reported guidance from the British Medical 
Association’s General Medical Services Committee (GMSC) recommending that
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general practitioners bill the health agency for individual items of service and 
suggests that Local Medical Committees (LMC) should agree the pricing of more 
common services in advance such as the monitoring of rheumatoid arthritis 
patients being treated with disease-modifying agents.
Brown, suggested [52] that reimbursements were probably the key to 
encouraging general practitioners to take on more secondary care patient services 
in the primary care sector. The secondary care directive, HSG[93]14 [53], 
allowed fundholding practices to become secondary care providers and make 
charges. It also allowed virements (where funding could be transferred from one 
fundholding budget category to another) and private contracts with providers, 
who were at that time the Family Health Service Authorities (FHSAs) and Health 
Commissioning Authorities (HCAs).
A primary care led NHS was becoming a reality and papers in management 
journals began to reflect this with articles on the need for Trusts to market their 
service to general practitioners [54] and others questioning the future need for 
district general hospitals [55].
Changing clinical behaviour in prescribing, referrals and other resource 
consumption allowed the release of resources which were subsequently spent on 
clearing waiting lists and improving community services [56]. This led to the 
potential problem of a two-tier system whereby patients of fundholders were 
treated quicker than those of non-fundholders. A study by the Organisation for 
Economic Co-operation and Development [56] concluded that fundholders were 
better purchasers than District Health Authorities (DHAs), were more willing to 
challenge hospital practices and to finally demand improvements. The best 
DHAs were however out performing their fundholders and the ethical question 
was raised whether it is appropriate to use fundholding to worsen the service. 
Addressing the question of whether a Labour government would change 
fundholding it was reported that Labour has been anxious to abolish fundholding 
but appeared to want to keep the benefits. It was concluded that the broad 
direction of a primary care led NHS was likely to continue with a Labour
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government, with changes only in terminology and the detailed rules of 
fundholding.
By May 1996 there were about 50 total fundholding schemes underway. 
Purchasing consortiums were being formed by fundholders in a locality to 
become total fundholders but spread the financial risk [57]. Multifunds were 
also being created where a consortium of practices pooled their management 
allowance to enjoy economies of scale [58]. The National Association of 
Fundholding Practices was set up in 1992. Their view was that decisions made 
at grass-roots level are more likely to meet local need [59].
During the period of this research the Labour government came to power in May 
1997. In December of the same year they released a White Paper [60] setting out 
a new structure and priorities for the NHS. As predicted fundholding was 
abolished, Primary Care Groups (PCGs) and later Primary Care Trusts (PCTs) 
were introduced. PCGs were formed from GPs in an area typically serving a 
population of around 100,000 people.
Within PCGs GPs were given responsibility for purchasing health services for 
their patients. They were given responsibility for controlling a single unified 
budget giving them choice on how to best meet the health needs of their local 
population. They were given freedom to make decisions about how they use 
their resources as long as they are consistent with an agreed Health Improvement 
Plan (HImP). The role of PCGs and PCTs is to work closely with Social 
Services Departments and City and District councils and to be accountable to the 
HA for commissioning health care. Four levels of Primary Care Group were 
introduced as a mechanism whereby they gradually took on more responsibility 
culminating in the Primary Care Group becoming a free standing body, a 
Primary Care Trust accountable to the HA for commissioning care and also 
having responsibility for providing community services. The first PCTs were 
formed in April 2000.
Health Authorities will still be responsible for strategic planning and 
prioritisation of health services. They will support GP commissioning groups
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and have a new duty of partnership ensuring that they work closely with social 
services and local government [61].
Other developments introduced in the White Paper included:
• introduction of “NHS Direct” a 24 hour help-line for the public,
• speedier treatment for patients such as tighter targets on breast cancer 
referrals
• “NHSnet” linking all GP practices on the NHS’s own information 
technology network,
• formation of the National Institute for Clinical Excellence (NICE) to promote 
clinical and cost effectiveness of NHS (A First Class Service: quality in the 
new NHS) [62].
• formation of the Commission for Health Improvement to ensure that clinical 
governance leads to high quality services being provided by all NHS 
organisations and to identify and disseminate best practice [62].
• The introduction of Personal Medical Services (PMS), Personal Dental 
Services and Local Pharmaceutical Services which are new types of contract 
with professional staff under independent contractors status.
The Green Paper, “Our Healthier Nation” [3] set targets to reduce deaths from 
heart disease and stroke, cancer and suicide and to cut the number of accidents. 
National Service Frameworks (NSFs) were introduced and will be developed and 
used as benchmarks to establish clear national standards for services to improve 
quality and reduce unacceptable variations in standards [62]. The first of these 
for Mental Health, Coronary Heart Disease and Care of Older People have been 
issued and National Service Frameworks on further subjects such as diabetes are 
expected.
In August 2000, the National Plan [5] was published with far ranging reforms 
across the NHS and targets for achieving them announced. A public consultation 
performed by the government in 2000 concluded that the public wanted to see
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• a health service designed around the patient
• more and better paid staff using new ways of working
• reduced waiting times and high quality care centred on patients
• improvements in local hospitals and surgeries.
Whilst recognising that the NHS had been underfunded the government 
identified other problems
• a lack of national standards
• old-fashioned demarcations between staff and barriers between services
• a lack of clear incentives and levers to improve performance
• over-centralisation and disempowered patients.
The Labour government states that the March 2000 Budget settlement will mean 
that the NHS will grow by one half in cash terms and by one third in real terms in 
five years. However, investment will be linked to reform. The Department of 
Health will set national standards, matched by regular inspection of all local 
health bodies by the Commission for Health Improvement. The National 
Institute for Clinical Excellence will ensure that access to cost effective drugs is 
equitable and a Modernisation Agency will be set up to spread best practice. 
Social services and the NHS will come together with new agreements to pool 
resources. There will be new Care Trusts to commission health and social care 
in a single organisation to help prevent patients - particularly old people - falling 
in the cracks between the two services or being left in hospital when they could 
be safely in their own home.
2.1.2 Organisation o f the NHS
Changes in the funding of the NHS have led to the need for reviews of the 
structure of the organisation. On April 1st, 1996 100 Health Authorities became 
statutory bodies [63]. The Health Authorities Act, 1995 which allowed for this 
change legally repealed the NHS Reorganisation Act, 1973. The Regional 
Health Authorities were disbanded and instead one central and eight regional
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offices of the NHS Executive (NHSE) were introduced. The NHSE was set up in 
1991 and since then has played an increasingly prominent role in the operation 
and development of the NHS [64]. It is a part of the Department of Health and 
its staff are civil servants rather than employees of the NHS [63]. Its job is to 
develop NHS policy and be responsible for the management of the NHS [64] 
(Figure 2.1).


















Before April 1999 the NHSE managed the NHS directly through Health 
Authorities. HAs replaced separate DHAs and FHSAs and also the interim 
bodies that were created such as health commissions and health agencies. The 
HAs were responsible for planning for the health needs of their local population, 
and within that, for developing new patterns of service and effecting health 
improvements. They were expected to make sure that the public and patients 
understood and supported any changes necessary. This all had to be done within 
the budgetary allocation which was set by the NHSE from within the total 
amount agreed for health by Parliament. The amount allocated at parliamentary
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level was however, maintained within two separate budgets namely that for 
hospital and community heath services (HCHS) and that for primary care, 
including contractors. Money could not be transferred from one budget to the 
other [63],
Responsibilities of the Health Authorities (HAs) were outlined by the NHS 
Executive in a letter titled ‘Managing Change’ dated 28/7/94 and included 
implementation of NHS health policy, integrating purchasing across primary and 
secondary care boundaries and regulation and management of primary care 
services. The core functions of NHS taken on by the HAs were to evaluate the 
health and healthcare needs of the local population, establish and implement a 
local health strategy, and to monitor and evaluate change to ensure that strategic 
objectives were met.
With the introduction of PCGs, which happened after the collection of data for 
this project, it was again necessary to amend the structure and accountability of 
the NHS, the new structure as of April 1st 1999 is outlined in Figure 2.2.
Many of the roles of HAs are gradually being passed over to the PCGs and PCTs 
who will have statutory accountability to the HAs [65]. PCGs/PCTs are 
becoming responsible for allocating resources to meet the health needs of their 
local populations. They will be responsible for a unified health care budget and 
will take over commissioning from the HAs. The aim of this is to “align clinical 
and financial responsibility so that those who prescribe, treat and refer have 
control of the financial decisions they make” [4]. Avery [66] expressed concern 
that the government does not intend to support practices and their respective 
PCGs with the level of management allowances given to fundholding practices 
and with HAs becoming leaner bodies the government needs to be careful that it 
does not stifle attempts to improve primary care by failing to provide the funding 
needed to properly manage and support PCGs and PCTs.
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The effect recent changes in the NHS might have on prescribing were discussed 
by Avery [66]. He predicts that with cash limited budgets GPs and PCGs will 
have to make difficult choices about rationing. However, unified budgets will 
allow greater pressure to be put on Trusts to take into account the cost of care 
such as drugs in the community when making their purchasing decisions. This 
may also be helpful in reducing the perception of cost shifting when care is 
shared between a Trust and a general practice.
As Dean [67] reported in 1996, GPs will have to be prepared to explain 
reasoning behind prescribing decisions to their patients. This could have a 
considerable effect on the special GP-patient relationship.
The data reported in this thesis were collected over the time period October 1996 
to August 1999. The NHS structure pre April 1999 applied for most of the 
duration of this work. Regional HA boundaries were also changed on 1st April 
1999. The data are reported in the regions, as they were when the information
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was collected. The structure of the new NHS will be considered in the 
discussion of the work.
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2.1.3 Shared Care
In November 1991, the NHSE produced guidance on the responsibility for 
prescribing at the hospital/general practitioner interface, in the form of 
EL(91)127 [19]. It reinforced the basic premise that the doctor who has clinical 
responsibility for the patient should prescribe and it focused on the concept of 
shared care, emphasising the need for proper hand over procedures from 
hospitals to make sure that the general practitioner was properly informed and 
could monitor treatment and adjust dose if necessary based on protocols for 
treatment.
Following this EL(94)72 [21] asked purchasers to develop a policy on the 
managed entry of new drugs making use of evidence of their clinical and cost 
effectiveness. They were instructed to develop and agree strategies for 
improving prescribing across the primary/secondary care interface and ensure 
appropriateness of hospital-led prescribing (taking into account total cost of 
drugs to the NHS). This made shared care initiatives part of the managed entry 
of new drugs and focused many shared care initiatives on the newer, often high 
cost and more complex therapies.
2.1.3.1 History of Shared Care in the NHS
The idea of sharing care between a hospital consultant and a general practitioner 
in the NHS is not a new one. It has proved a successful way of managing 
patients with conditions such as diabetes, hypertension, thyroid disease, 
rheumatoid arthritis and pregnancies for many years [14, 16, 18], although most 
arrangements have been on an informal basis.
2.1.3.2 Models of Shared Care
There have been a number of models of shared care. Shared care guidelines have 
been drawn up not only for shared care between GPs and hospital specialists but
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also to outline respective responsibilities within a multidisciplinary team, either 
in primary care or in secondary care or across the interface [68-71], Some shared 
care models in pregnancy [72] and HIV/AIDS [73], use a patient held record to 
facilitate communication between primary and secondary care, other models 
have involved the development of guidelines or protocols, flowcharts and 
computer programmes for managing a particular group of patients [17, 74],
Edwards et al [18] state that two models of GP responsibilities in shared care 
have emerged, “routine monitoring” or “investigation and treatment”. They 
noted that the most common pattern of review was an annual review in hospital 
with three or four visits in general practice.
Evans [75] gives examples of three different models of shared care
• referral protocols specifying the investigations to be conducted before a 
patient is referred to a particular clinic
• prescribing protocols to smooth the shared care of patients on expensive 
drugs by stating whether the consultant or GP is responsible for the drug
• shared care protocols, known as collaborative care plans written by a 
multidisciplinary team. They state agreed interventions for a given diagnosis, 
symptom or procedure within a certain time.
Another model of shared care is that where hospital consultants hold outpatients 
clinics in primary care settings. Black et al [76] studied outreach clinics and 
found that, although they reduced travelling distance and waiting times for 
patients, the expected improvement in communication only generally resulted 
from a chance meeting in a corridor rather than a structured communication 
method and even when clinics were held in the general practitioner’s own 
surgeries communication was still by letter. Orton [14] reported the same 
problem, outreach clinics held in the early evening whilst GPs are having their 
surgeries do little to improve care, since they are simply outpatient clinics 
relocated, with no change in the primary/secondary care interface. However 
outpatient clinics held in the surgeries jointly with general practitioners or with
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joint follow up and a meeting to discuss cases did improve communication. The 
main advantage was the potential for mutual professional education and the 
efficient use of primary and secondary care skills. Disadvantages included 
inappropriate use of resources, loss of close contact with other hospital 
departments, loss of immediate access to hospital facilities and a reduction in 
research and education activity.
2.1.3.3 Appropriateness of prescribing in secondary care/clinical responsibility
Evans [75] makes an important point that the debate on shared care protocols 
should not be whether they should be used but about their quality, as generally 
good guidelines are undoubtedly an asset to patient health care and poor ones a 
liability. The importance of clinician-led, practical protocols backed up by 
continuing education and audit of the effect of the guidelines was stressed with a 
suggestion that they could be updated by computer to ensure they do not get out- 
of-date.
2.1.3.4 Communication
Good communication and collaboration between health professionals in primary 
and secondary care have been a major key to success of these initiatives [77-79].
The lack of good communication is highlighted by Edwards et al [18] who report 
studies looking at communication between primary and secondary care. One 
shows that less than half of the questions asked by GPs on referral letters were 
answered by hospital consultants and another criticises most specialities for 
omitting information, although letters from psychiatrists were criticised for being 
too long and containing information the GP did not consider relevant.
2.1.3.5 Development of Guidelines
Experience of shared care in the Trent region has been reported by Wilson [77] 
(Symposium “Shared Care or Cost Dumping”, 3rd March 1994). The guidelines 
that had been developed were mostly for newer, hi-tech drugs such as 
erythropoietin, intravenous nutrition and cyclosporin. The primary objective of
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the shared care scheme was to improve patient’s quality of life by allowing the 
patient to lead as normal a life as possible (in his or her own home rather than in 
hospital). The Trent Regional Drug Information service suggested that the 
realistic concerns that GPs have expressed about accepting responsibility for 
such patients could be overcome by a sensible, collaborative approach providing 
appropriate support, training and good communication [16]. They suggest that 
essential principles include GP agreement, giving GPs the opportunity to decline 
shared care arrangements without being put under pressure, involvement of 
general practitioners in drawing up the agreements, support and training for 
general practitioners, good communication channels between the relevant 
hospital consultant and general practitioner, not using the patient to communicate 
information and not using shared care as a means of shifting prescribing costs 
into general practice.
Edwards et al [18] recommend that the chair of a guideline development panel 
should not be an expert on the subject in question, there should be a full analysis 
of the literature, the guidelines should lead to the expected health or cost 
outcomes, they should be written from the perspective of general practice and 
should be comprehensive and flexible in approach. Local ownership of the 
guidelines is widely considered important to their success.
Martin [80], a hospital pharmacist with responsibility for drawing up shared care 
guidelines in Leeds for the managed entry of new drugs under EL(94)72 [21], 
advises that to maintain a good relationship between primary and secondary care 
sectors, GPs must only prescribe drugs when it is appropriate clinically and 
financially for them to do so. The Pan Leeds Prescribing Committee with 
representatives of the HA, three Trusts and local GPs ultimately approve the 
guidelines developed in Leeds.
The need to formalise shared care through guidelines is discussed by Joshua [81]. 
She states that an important component of shared care is the cost shifting element 
whereby GPs agreed to be responsible for the financial burden of treatment 
which might not otherwise be available to the patients because of the cash limits 
imposed on hospitals. For shared care to be truly effective she argues that GPs
43
must have a real clinical involvement in patient management and must be able to 
accept shared care patients without prejudice to their indicative prescribing 
amounts, prescribing targets or future funding. If this was not the case GPs 
would interpret shared care as merely a cost-shifting exercise which would cause 
resentment.
A study carried out in the North West region in 1996 [82] asked hospital 
pharmacy departments whether they had requested that GPs prescribe any of a 
list of eight treatments not normally used at the time within general practice and 
if so whether they had any shared care protocols for these drugs. 95% had asked 
GPs to prescribe at least one of the drugs. 69% had no written shared care 
protocols for any of the eight treatments listed. Half of the hospitals which asked 
GPs to prescribe Continuous Ambulatory Peritoneal Dialysis fluids, fertility 
treatments, cytotoxics and proton pump inhibitors had no written protocols for 
these treatments in operation or under development. Shared care protocols 
available included those for domase alpha, goserelin, interferon, cyclosporin, 
diabetes, asthma and gastrointestinal disease.
Fellows [20] claims that many hospital consultants do not understand the legal 
issues of prescribing and the fact that when a GP signs a prescription this confers 
legal responsibility to him or her. He states that concern about costs blurs the 
professional issues and uncomfortable feelings of cost dumping are not 
misplaced. PCGs with unified budgets he predicts will solve some of these cost 
considerations but the clinical and legal responsibility, workload shift and patient 
convenience problems will remain. He makes the point that GPs have the right 
to refuse to prescribe when they do not feel competent to do so but that GPs are 
often in a difficult position when their patients are in rural areas and would have 
difficulty collecting prescriptions from the hospital. He suggests a change in the 
law so that a GP could prescribe as a consultant’s deputy in situations where they 
are not happy to accept the full responsibilities of shared care. He feels a 
payment for this would be in order so that it would not be used to dump 
workload. Another alternative would be to develop a new form of consultant 
prescription which could be authorised for repeat dispensing from a community 
pharmacy.
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Dean [67] discussed the prescribing dilemma that general practitioners will be 
increasingly facing with the introduction of more expensive drugs, such as 
interferon p for multiple sclerosis. He suggested that, whilst it was not currently 
the case that the cost of parenteral home therapy be bome by general practice, it 
would no doubt be an issue for the future and the drugs used, such as expensive 
antibiotics like teicoplanin, may well have a significant impact on their 
prescribing budget and rational prescribing decisions about therapies would have 
to be made.
2.1.3.6 Evidence of the Effectiveness of Shared Care
2.1.3.6.1 Studies
There have been many reports of shared care arrangements but very few well- 
designed studies demonstrating evidence for the success or otherwise of various 
models of shared care.
The use of computers to assist shared care in hypertension was reported by Petrie 
et al [78] in 1985. A shared care scheme for the long-term follow-up and 
management of hypertensives was set up in the Grampian region of Scotland.
The study looked at what is still today the most important tool for shared care, 
the exchange of information between doctors in the primary and secondary care 
settings. The principal effects of introducing shared care were a reduction in the 
number of patients under regular long-term follow-up at the hypertension clinic, 
a reduction in hospital clinics, an intensification of the attention paid to the 
highest risk patients, and a reduction in patient contacts with inexperienced 
hospital staff.
A similar project was reported, again in Scotland, in 1994 [17]. Patients were 
randomly allocated to shared care or outpatient clinic follow-up. After two years 
82% of shared care patients had had a complete review, compared with 54% of 
outpatient clinic attendees and 75% of nurse practitioner clinic attendees. Blood 
pressure control was similar in each group. 61% of questionnaire respondents
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subsequently wanted shared care to continue 25% were unsure. The rank order 
of cost effectiveness ratios was shared care, nurse practitioner care and 
conventional outpatient care. It was concluded that shared care for hypertension 
was feasible, acceptable to the majority of participants and was a cost-effective 
method for long-term follow up.
Griffin [83] performed a meta-analysis of randomised controlled trials of 
diabetes care in general practice. He found that in shared care schemes featuring 
more intensive support, through a computerised prompting system for GPs and 
patients, there was no difference in mortality between care in hospital and care in 
general practice. Glycolated haemoglobin tended to be lower and losses to 
follow-up were significantly lower, in primary care. However, schemes with less 
well-developed support for family doctors were associated with adverse 
outcomes for patients. The value of this meta-analysis being extrapolated to 
primary care outside of clinical trials was questioned by Greenhalgh [84].
The GRASSIC project [85] used a computer-based patient records scheme in the 
shared care of asthma patients, where patients were reviewed by a chest 
physician annually and by their GP, three or four times a year. The reduction in 
the amount of specialist contact was not associated with worse asthma 
management, patients benefited financially and they were at no clinical, 
psychological or social disadvantage than patients treated under the traditional 
model of outpatient care.
Kirby at al [74, 86] [87] developed a shared care flow diagram for the shared 
care of benign prostatic hyperplasia (BPH) between urologists and GPs. A 
questionnaire survey of 2020 urologists, general practitioners and other interested 
clinicians achieving a 28.7% response rate revealed that there was consensus 
among respondents that a shared care approach to the management of benign 
prostatic hyperplasia may improve the standard of care provided by GPs and 
allow urologists to focus greater attention on those patients who require their 
surgical expertise.
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Rapporteurs at a joint conference of the Royal Colleges of Physicians and 
General Practitioners on shared care in HIV and AIDS [88], reported Shaunak’s 
description of a model of shared care set up “before the complexities of 
combination therapy”. A locally relevant management guide was constructed 
and a one-page standard summary of patient attendances and admissions and 
information relevant to primary care was faxed to the GP. The GP had 24-hour 
access to an HIV consultant. The project reduced the number of outpatient visits, 
halved the average duration of inpatient admissions, increased GP consultations 
and reduced costs to specialist units. The motivation and determination of the 
facilitator in encouraging GPs, specialists and patients was vital to the success of 
this project. This specialist HIV unit was subsequently closed, due in part to the 
reduction in activity as a result of the success of the shared care model.
The benefits of shared care have however been called into question. Sowden et 
al [89] queried the national adoption of shared care schemes. They report an 
extensive literature review on the shared care of diabetes patients. In none of the 
randomised trials did shared care improve clinical outcomes, compared with 
hospital care and in two of the studies it was associated with poorer care or 
outcomes. They called for further research and some definition of the key 
features of a shared care programme, as those aspects of shared care that might 
be important in influencing process and outcome may otherwise remain unclear. 
It is also noted that most studies involve volunteer practices who may well be 
more motivated and achieve better results. The authors conclude that the 
effectiveness and cost-effectiveness of shared care remain uncertain and that 
trials that take into account the complexities and interactions of setting, provider 
interest, and consumer preference are needed.
McGhee and Hedley [90] disagree with this and give examples of studies in 
diabetes and hypertension where shared care was associated with lower drop out 
rates and was more cost effective for the patients. They also point out studies in 
hypertension and thyroid disease that have shown cost effectiveness for the 
health service and a reduction in the number of patient-clinician contacts while 
the standard of review was maintained. They suggest that further research
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should be directed at identifying the best approaches to shared care rather than 
comparison with traditional methods.
Tucker et al [72] showed that care given by a midwife and GP is at least as 
effective for the routine antenatal care of low risk patients as shared care with a 
hospital consultant and in fact those cared for by the primary care team had lower 
incidences of pregnancy-induced hypertension, proteinuria and pre-eclampsia.
2.1.3.6.2 Case studies
Most publications that have extolled the virtues of shared care have been based 
upon anecdotal evidence. A number of centres have reported their experience of 
the pros and cons of shared care arrangements. The issues of clinical 
responsibility, appropriateness of prescribing some complex therapies in primary 
care, cost shifting and workload shifting are common themes [15, 16, 20, 67, 88, 
91].
Shared care initiatives in managing patients with HIV and AIDS have been 
widely discussed [73, 88, 92, 93]. Williams [93] in a letter to the British Medical 
Journal called for more primary care involvement in the treatment of AIDS 
patients for the patients’ benefit. It was reported that many general practitioners 
use the high cost of the drugs involved as a reason for not being involved with 
the care of these patients but the author believed that expensive drugs should be 
funded centrally regardless of whether the patient is managed in primary or 
secondary care. Grun and Murray [73] contributing to a debate about the funding 
of the treatment of these patients described a trial of a shared care protocol that 
had been in place for the treatment of HIV and AIDS patients. The patient held a 
card with a summary of relevant medical history and current drug therapy and a 
chart for completion at each consultation. After baseline investigations were 
completed at the hospital clinic, the general practitioner saw the patient at three 
monthly intervals and the patient was reviewed at the hospital annually. 
Advantages of the scheme included the chance to build-up a good doctor-patient 
relationship early on whilst the patient was still well and relieving pressure for 
hospital appointments.
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Sharing the care of patients with infertility problems has caused much debate as 
it has often been the high cost of the drugs involved which has been the factor 
which has prompted the request from secondary care for the general practitioner 
to prescribe the drugs. Most GPs try to treat the more obvious causes of 
infertility such as obesity and thyroid function themselves but refer to secondary 
care when more complex investigation is warranted. Hospital pharmacy budgets 
often preclude hospital practitioners from prescribing more than one or two 
weeks supply of infertility drugs and this has thrown the burden of prescribing 
into the community [94]. Equally some Health Authorities exclude in-vitro 
fertilisation from their contracts with NHS Trusts and this has led to a variety of 
private practice with requests to prescribe coming from the private sector. With 
more intensive forms of ovulation induction therapy adequate monitoring and 
experience of managing complications is necessary but not usually available in 
primary care where the drugs are prescribed. Taylor and Braude [94] 
recommended that general practitioners should ask for written assurance from the 
unit treating the patient that they will monitor the cycle appropriately and take 
responsibility for, and care of, any complications that may arise as a result of this 
type of therapy. Private specialists have been known to put general practitioners 
in a difficult position by sending patients to their general practitioner for 
prescriptions of gonadotrophins and gonadotrophin releasing hormone analogues.
Patients with prostate cancer are another group in whom shared care has been 
advocated. Gingell [95] described how, once the patient has been stabilised on 
maintenance treatment by the specialist the general practitioner can take over 
responsibility. The patient must be seen regularly to assess performance status 
and analgesic requirements and to encourage compliance with oral medications. 
Side effects can be monitored and where necessary treatment modified. 
Monitoring of the patient using appropriate blood tests, weight and blood 
pressure can be performed by the general practitioner. Patients can benefit from 
the timely intervention of radiotherapy to painful metastases, blood transfusion 
and good pain control if good communication and co-operation are achieved 
between the professionals in primary and secondary care.
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The involvement of general practitioners in clozapine therapy for schizophrenic 
patients was described by Launer [96]. Even though general practitioners could 
not prescribe this drug, it was reported that they helped to identify patients 
suitable for treatment with a poor quality of life. They should be aware of the 
potential drug interactions and adverse effects of clozapine. They can also 
provide support for families who may have difficulty coming to terms with their 
‘awakened’ sons and daughters. The issue of shared care in long term mental 
illness was discussed by Wright [79] in an editorial. General practitioners have 
reported an increase in workload resulting from patients being discharged from 
mental health hospitals due for closure. He reports a follow up study of 
schizophrenic patients one year after discharge into the community which 
revealed considerable use of general practitioners but little use of community 
facilities.
Twin conferences were held, in 1994, in London and Llandridnod Wells, 
sponsored jointly by the Royal College of General Practitioners and the Royal 
College of Psychiatrists called ‘Making shared care work’ [79]. The need for 
multidisciplinary training and reliable information was highlighted. A lack of 
provision of information to patients and their carers have been identified as 
problems that need to be overcome by both the primary and secondary care 
teams.
Pinn [97] reported that services for epileptic patients could be improved through 
local agreements between general practitioners and specialists. He points out the 
relatively high incidence of epilepsy and the low numbers of neurologists, 
particularly those professing to have a specific interest in epilepsy. New and 
better drugs are becoming available but expertise is required to use them sensibly 
and efficiently. He reports a survey of 200 consultant neurologists which 
highlighted very low usage of formalised shared care arrangements between 
general practitioners and hospital specialists and points out that in the meantime 
general practitioners are left to deal with the day-to-day management of patients 
with epilepsy without any clear cut idea of where their responsibilities begin and 
end.
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2.1.3.7 Shared Care of Hi-tech Health Care at Home
Hi-tech Health Care at Home (HTHH), as defined by EL(95)5 [41] was one of 
the more common subjects of shared care guidelines developed through the early 
1990s [77].
Nelson [98] reported experience of the shared care of children with cystic 
fibrosis, receiving intravenous antibiotics at home. Most of the patients preferred 
to be treated at home and thought that they were given adequate support for 
home treatment. A questionnaire revealed that patients thought that their general 
practitioner should be more involved. Parental anxiety was a problem as there 
was concern that other medical problems would not be recognised. Drugs and 
treatment were delivered in one of three ways, the cheapest being directly from 
the hospital. General practitioner prescriptions from the local pharmacy were 
expensive and no more convenient than the hospital. Unicare, a commercial 
organisation was a cheaper alternative and allowed delivery direct to the patients’ 
homes.
Orton [14] notes that shared care must also be flexible and carried out in the 
home setting where patients are increasingly being treated with more complex 
problems. In the United Kingdom he says the key question as to whether general 
practitioners are willing to extend their role to inpatient care has not been 
answered. Shared care he concludes offers the opportunity to alter the balance 
between primary and secondary care and to question whether secondary care is 
always needed. It will be facilitated by new technologies that provide support for 
practice decisions and enhance the exchange of information.
Bryan [15] reported that general practitioners were invariably happy to prescribe 
insulin or an ACE-inhibitor when asked to by a hospital consultant but when a 
suggestion was made of sharing the care of a myeloma patient with the local 
oncologist and prescribing alpha-interferon, for example, neither the general 
practitioner or FHSA had been quite so keen. She reports that attempts by the 
NHS Executive going back to 1991 had failed to convince general practitioners
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and FHSAs that indicative prescribing and fundholding schemes should not deter 
them from taking part in shared care arrangements. She suggests that EL(95)5 
[41] may, at last, make the most expensive shared care arrangements ‘flavour of 
the month on both sides of the primary/secondary care divide’. Shared care 
schemes set up successfully at the Christie Hospital in Manchester were 
described. The importance of consultation with all parties in drawing up 
guidelines was stressed. Around 50 cancer patients at any one time were signed 
up for shared care arrangements. They were mostly receiving alpha-interferon, 
5-FU or octreotide, but only 5-FU was covered under the arrangements outlined 
in EL(95)5 [41]. In South Thames the EL had been pre-empted and a system 
was in place where drugs were categorised into red and amber groups. Red 
meaning general practitioners should not prescribe. This list contained most 
drugs covered by EL(95)5 [41] and amber meaning they may choose to. Initially 
all new drugs went on the red list but could be transferred to amber as experience 
with them was gained. In Manchester a survey showed that more than 50% of 
patients liked the system, mainly because visiting the general practitioner was 
much more convenient than the hospital. However a study in Birmingham [15] 
had found that patients were dropping out of an interferon shared care protocol 
because they were having difficulty giving themselves injections.
General practitioner involvement in sharing the care of patients being treated at 
home with intravenous antibiotics was advocated by Conlon [99]. He notes that 
some general practitioners may view home intravenous antibiotic therapy as yet 
another attempt by hospitals to transfer the clinical workload to the community. 
Others, however may be excited by the prospect of being able to diagnose a soft 
tissue infection requiring intravenous antibiotics, arrange for an intravenous line 
to be inserted and then manage most of the therapy at home, referring to the 
hospital team only for specific problems. He comments that it is possible to run 
a home intravenous programme, with community nurses administering the 
antibiotics, without general practitioners taking on any of the work themselves.
It is also possible for general practitioners to become actively involved and even 
to operate a small intravenous team from a health centre.
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A study in East Anglia [100] found that prevalence of home artificial nutrition 
had doubled form 1988 to 1993 but overall standards of care were not keeping 
pace. They found that GPs were confused about the legislation and their clinical 
responsibility for these patients treated with home TPN and enteral nutrition. In 
a recent article Pennington [101] describes the importance of the primary health 
care team in the support and management of home TPN patients in dealing with 
this demanding and disrupting treatment.
With almost any chronic condition or drug therapy, shared care has been 
practiced or studied. Pharmaceutical companies are even sponsoring and 
distributing shared care guidelines for their drug, such as Britannia 
Pharmaceuticals Limited with apomorphine for Parkinson’s Disease and Novartis 
Pharmaceuticals UK with letrozole in breast cancer. These guidelines should be 
looked upon with caution as in studies undertaken so far, a factor in the success 
of shared care guidelines has been local development and agreement by those 
who will be using them [16, 18].
2.2 Shared Care Surveys
2.2.1 Project Aims
• To establish the current situation in England regarding the implementation of 
shared care arrangements under EL(91)127 [19] and subsequently under 
EL(94)72 [21] and to identify models which had been successful or 
otherwise.
• To evaluate and critically analyse one example of an initiative intended to 
implement and facilitate shared care between primary and secondary care 
practitioners in South and West Devon.
2.2.2 Objectives
Questionnaire survey of the 100 Health Authorities in England to establish:
• if shared care guidelines have been developed and implemented and if so for 
which drugs/conditions
• who has been responsible for the development and implementation of shared 
care guidelines?
• which aspects of shared care have been successful/unsuccessful?
Questionnaire survey of General Practitioners (GPs) working in the area covered
by South and West Devon Health Authority to:
• find out the opinions of local GPs on the concept of “shared care”
• establish if the local procedure for the development of guidelines is successful
• establish whether the guidelines being produced locally fulfil GP expectations
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2.2.3 Background On The Local Shared Care Situation In South And West 
Devon
2.2.3.1 Formation of the South and West Devon, Cornwall and Isles of Scilly Shared 
Care Working Group.
Within South and West Devon there are three main secondary care providers, 
Plymouth Hospitals NHS Trust and Plymouth Community Services NHS Trust 
covering Plymouth and the surrounding area and South West Devon Health Care 
NHS Trust covering the Torbay area . Plymouth Hospitals NHS Trust is also the 
main secondary provider for a large part of Cornwall and has substantial 
contracts with Cornwall and the Isles of Scilly Health Authority. It was felt that 
for shared care to work meaningfully a joint approach between the two Health 
Authorities was required and therefore, in response to both EL(91)127 [19] and 
EL(94)72 [21], the South and West Devon, Cornwall and Isles of Scilly Shared 
Care Working Group (SCWG) was formed. The SCWG drew representatives 
from Health Authorities, the local acute Trusts, primary care and the relevant 
Local Medical Committees. Terms of reference were drawn up and a quorum 
established.
Key points of the terms of reference of the SCWG are shown below:-
a) to achieve clinical consensus on shared care guidelines which will be 
clinically appropriate and acceptable for GPs and consultants in South and 
West Devon and Cornwall and the Isles of Scilly.
b) to consider those drugs where there is a common view between clinicians 
(and Health Authorities) that the drugs are suitable for shared care 
arrangements.
The focus of the group was on clinical rather than financial issues and the 
appointment of a GP chairperson helped reinforce this message. The main role 
of the Health Authority was one of facilitation and providing a secretariat to 
service the work of the group.
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2.2.3.2 Guideline Development
It was soon found that clinical consensus was not easy to obtain, especially 
where one consultant took the lead on drawing up a guideline, so a procedure 
was adopted whereby a Health Authority pharmacist drew up draft guidelines 
from readily accessible and respected reference sources such as the British 
National Formulary, Martindale, Association of the British Pharmaceutical 
Industry Data Sheets, Summaries of Product Characteristics and consensus 
statements from the Royal Colleges. A standard template was adopted which 
covered the areas of guidance specified in EL(91)127 [19] together with 
information on adverse drug reactions, drug interactions and some basic 
background pharmacology.
After initial discussion by the multidisciplinary SCWG consultation with hospital 
specialists was undertaken. Areas of difference were resolved by adherence to 
some key principles:
a) Conformance with product licence/data sheet
b) The presence of a body of evidence to support a view.
c) Identification of minor differences in local practice which did not 
substantially alter the management of a patient under the guideline.
2.2.3.3 The Working Agenda
It was felt important to respond to locally perceived need and priorities. Referral 
to the SCWG from Health Authority prescribing committees generated the early 
working agenda, which led to development of guidelines for erythropoietin, 
riluzole, domase alpha and cyclosporin. As part of the Health Authority’s 
programme to manage the entry of new drugs, policy statements on new drugs 
included information on whether the drug was considered appropriate for shared 
care and if it was the SCWG was asked to add the drug to it’s work plan. 
Concerns of GPs raised with Health Authority Pharmaceutical and Medical 
Advisers also led to the tabling of drugs where shared care guidelines would be 
helpful such as for lithium prescribing. The work of this project elicited opinions 
of GPs on which drugs/diseases they would like shared care guidelines for
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(2.2.5.2.5) and this information was fed back to the SCWG for development of 
the work plan.
2.2.3.4 Guideline Dissemination
The two Health Authorities took different approaches to dissemination of the 
shared care guidelines, South and West Devon funded ring binders for each GP 
with an updated cumulative index when new guidelines were distributed. 
Cornwall and the Isles of Scilly Health Authority adopted an “available on 
request” approach.
2.2.4 Methods
All questionnaires used in this research were developed in the same way. The 
questionnaire that went to Health Authority Medical/Pharmaceutical Advisers 
covered both shared care and HTHH. To avoid repetition the methodology for 
all questionnaires will be described in this chapter and differences noted in the 
relevant chapters.
2.2.4.1 Literature Review
A detailed, fully referenced literature review was prepared (2.1). The reference 
database was stored on a computerised library system using Endnote® software. 
NHS Management journals were scanned for relevant articles and used as a basis 
for collecting other recent articles and discussion papers. Previous work of this 
institution was collected and the Director of Pharmacy of the Trust and the 
Pharmaceutical Adviser of the local Health Authority were asked for any 
information that they had been sent or had collected on the issues of shared care 
or HTHH. Colleagues known to have an interest in HTHH were contacted to 
discuss the various models of provision of HTHH currently in use. The literature 
review was used as a basis for further work.
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2.2.4.2 Health Authority Survey -Response To EL(91)127 And EL(94)72
The initial aim of the project was to establish the current level of development of 
shared care initiatives in England. Both EL(91)127 [19] and EL(94)72 [21] gave 
Health Authorities responsibility for developing strategies to break down barriers 
between primary and secondary care by facilitating the introduction of shared 
care arrangements for prescribing at the hospital/general practitioner interface. 
For this reason a survey of Health Authorities was used for determining the 
progress made on shared care throughout the country.
2.2.4.3 General Practitioner Survey
The second aim was to evaluate and critically analyse the shared care 
arrangements implemented locally in South and West Devon. General 
practitioners are central to the concept of shared care and it was considered 
important to seek their views on both current and future arrangements for sharing 
the care of patients with their secondary care colleagues.
2.2.4.4 Development Of The Questionnaires
2.2.4.4.1 Questionnaire Design
Questionnaire design techniques were researched from textbooks and courses 
before the questionnaires were developed [102-105] (Questionnaire Design 
Course, Research Support and Development Unit, Plymouth Hospitals NHS 
Trust). All questionnaires were sent out with a stamped addressed envelope for 
return of the questionnaire and a covering letter explaining the aims of the 
project, who was funding it and what the data would be used for (Appendices 1 
and 2).
2.2.4.4.1.1 Development O f The Health Authority Questionnaire
It was known that Pharmaceutical and Medical Advisers of Health Authorities 
commonly represent the Health Authority on committees discussing shared care 
arrangements. It was therefore decided to aim the questionnaire at 
Pharmaceutical Advisers or Medical Advisers of Health Authorities.
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The NHS Executive was approached for a current list of Health Authorities in 
England. They provided the eight regional directories for 1997/98 listing all the 
Health Authorities, Trusts and Community Health Councils in each region with 
addresses and telephone numbers. Other sources of information were explored 
but this was considered to be the most up-to-date.
A questionnaire was drafted, based upon the aims and objectives of the project 
listed in Sections 2.2.1 and 2.2.2. The draft questionnaire was sent to the local 
Pharmaceutical Adviser, the local Research and Development Support Unit 
(RDSU) and the supervisors of this project for comment. Based on their 
comments the questionnaire was adapted and the second draft was again sent out 
for comments. Using these comments a pilot questionnaire (Appendix 1) was 
drawn up and was distributed at a regional meeting of Pharmaceutical Advisers 
for the South and West region. 11 questionnaires were distributed with a letter 
(Appendix 1) asking for the recipient’s comments on the content and design of 
the questionnaire and what, in their opinion, was the best way to distribute the 
questionnaire.
After six weeks a telephone call was made to each of the remaining recipients to 
prompt a response to the questionnaires and a letter sent to any Pharmaceutical 
Adviser who could not be contacted by telephone. After a further four weeks a 
further telephone call was made and a further questionnaire sent.
A database was set up (using Microsoft Access® software) to keep a record of the 
recipients of the questionnaire and details of telephone and written reminders.
The design of the final questionnaire (Appendix 2) was based upon the 
comments received from the pilot. It was made shorter and less detailed 
information was requested. The major comment from the pilot was that the 
questionnaire was too long. The questions regarding shared care committees 
were changed to ask which committee was responsible for agreeing shared care 
guidelines and the layout of the questionnaire was improved. The length of time
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taken in the pilot to complete the questionnaire was used as a guide on the final 
questionnaire.
Results from the pilot and comments from the respondents suggested that a good 
response rate would not be achieved if the questionnaires were merely distributed 
by mail. Taking advice from the pilot and from Regional Pharmaceutical 
Advisers to the NHS Executive and with their help the researcher elected to try to 
visit the eight regional meetings of Pharmaceutical and/or Medical Advisers in 
England. The aim was to personally distribute the questionnaire (Appendix 2) at 
the same time as explaining the aims of the importance of receiving information 
from all Health Authorities.
As completion of the questionnaire required considerable input from the 
respondents to obtain the information required, and as changes as a result of the 
pilot were minor, requiring in most cases less detailed answers, the pilot 
questionnaires from the South and West Region were used in the final data 
analysis.
Between May and November 1997 the researcher was able to attend six regional 
meetings, some of solely Pharmaceutical Advisers and some joint meetings with 
Medical Advisers. The questionnaires were distributed at the meetings with an 
explanation of the aims and objectives of the project either from the researcher, 
or where the meeting was not attended, from the Regional Pharmaceutical 
Adviser.
During visits to the regions other unpublished projects and reports that had been 
commissioned came to light [6,42, 106] and these together with comments that 
came from the discussions with the Pharmaceutical and Medical Advisers were 
taken into consideration when formulating future questionnaires.
2.2 .4 .4 .1 .2  D evelopm en t O f  The G eneral P ractitioner Q uestionnaire
Due to the very large number of GPs in England, a sample population was
chosen for the purpose of the survey. For ease of distribution and because the
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local Health Authority were interested in the attitudes of local GPs to the 
procedure for agreeing and implementing shared care guidelines in South and 
West Devon, the questionnaire survey targeted all GPs working in the area 
defined by the South and West Devon Health Authority geographical boundaries.
A draft questionnaire was drawn up and distributed to the Chair of the Local 
Shared Care Committee, the Health Authority Pharmaceutical Adviser, Trust 
Director of Pharmacy and supervisors of this project for initial comments. Based 
on this, the pilot questionnaire was prepared (Appendix 3). Six GPs were asked 
for comments on the design of the questionnaire and responses were received 
back from five. These comments were used to develop a final questionnaire 
(Appendix 4).
The paragraph explaining EL(91)127 was felt to be difficult to follow so the 
main points were pulled out into bullet points both for the letter and the front 
cover of the final questionnaire. Suggestions were made about the order of the 
tick box responses in Section 1, question 2 by two GPs. In Section 1, question 3 
the word “generally” was moved to cover all answers and a further response was 
added “prescribe it providing it is not too expensive”. In Section 1, Question 5 it 
was suggested that it would be helpful to include some examples. In Section 2 
Question 1 the wording of the first bullet point and the last two bullet points was 
changed to make the question clearer.
The objectives of the survey are listed in Section 2.2.2.
The final questionnaire was sent out via the Health Authority courier and names 
and addresses were obtained from the HA database. 357 questionnaires were 
sent.
2.2.4.4.2 Interpreting The Results/Coding The Data
A Microsoft Access® database was set up for each questionnaire with a form for 
entry of data that resembled as closely as possible the questionnaire from which 
the data was being entered to ensure accurate data entry. Codes were developed 
to allow faster data entry for the simplest questions. In the case of open
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questions where respondents were asked to comment, the prose was entered onto 
the database. An independent person (a Senior Pharmacy Technician) checked 
all of the data entered for accuracy.
2.2.4.4.3 Health Authority Questionnaire
The respondents of the Health Authority questionnaire were asked six open 
questions regarding aspects of shared care that had been successful or 
difficult/problematic. Common concepts and themes in the data were identified 
and developed in order to classify the data into a coding frame.
In order that the coding of this data be validated three groups were asked 
independently to code the data. An inductive approach was taken whereby the 
coding frame(s) were developed after the data collection exercise by the various 
groups asked to code the data. This method was employed so that the depth and 
quality of the data collected was not lost. The researcher facilitated the meeting 
but had no input into discussions regarding the data. The meetings were 
recorded on audiotape in order that the reasoning of the groups in coming to their 
decisions could later be compared.
The three groups asked to code the qualitative data were
I. 3 hospital pharmacists
II. 4 members of the Health Authority Team (including one GP who chairs 
the local Shared Care Committee, one member of the contracts 
department and two members of the prescribing team, one of which was a 
pharmacist)
HI. 3 members of the Trust finance staff
The raw data is shown in Appendix 5. The groups were given data in this format 
to code and the original questionnaires were available for them to refer to for 
clarification.
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2.2.4 A A GP Questionnaire
Qualitative data obtained from the survey of GPs was analysed by a group of two 
GPs and a Health Authority Pharmaceutical Adviser. One GP from the Torbay 
area and one from the Plymouth area were chosen as these areas are covered by 
different secondary care providers. Similar methodology was used to that 
described in Section 2.2AA.2.
The results of the survey were fed back to the South and West Devon, Cornwall 
and the Isles of Scilly Shared Care Working Group, a summary of findings was 
sent to anyone who requested one on the questionnaire and the findings were 
presented orally at the National Prescribing Centre Conference for Health 
Authority Advisers, 18th-19th June 1998, Hinckley, Leicestershire.
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2.2.5 Results
2.2.5.1 Health Authority Questionnaire
2.2.5.1.1 Response Rate
Questionnaires were distributed to each of the 100 Health Authorities in England 
via the Pharmaceutical or Medical Adviser. 87 responses were received. The 
number received from each of the eight regions is shown in Table 2.1.
Table 2.1, Number of Responses by Region, Health Authority Questionnaire
region No. of replies No. of HAs No of non­
responders
Anglia and Oxford 8 9 1
North and Yorkshire 12 13 1
North Thames 10 14 4
North West 14 16 2
South and West 12 12 0
South Thames 11 12 1
Trent 9 11 2
West Midlands 11 13 2
TOTAL 87 100 13
75 were completed by a Pharmaceutical Adviser, 4 by a Medical Adviser, 3 
jointly by a Pharmaceutical Adviser and Contracts Manager and one entirely by 
a Senior Contracts Manager, the other 4 were completed jointly with the help of 
a Consultant in Public Health, Medical Adviser, Directors of Pharmacy of Trusts 
and a Commissioning Support Manager, respectively.
2.2.5.1.2 Current Guidelines
81 of the 87 (93.1%) respondents had some kind of shared care guidelines for 
sharing the care of patients between primary and secondary care in their area. 
This included three Health Authorities (HAs) who had generic guidance but most 
had disease or drug specific guidelines. There were five HAs, all in one region, 
who said that guidelines were regionally produced and 3 other HAs who were 
using shared care guidelines as part of a virement project from primary to 
secondary care.
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Figure 2.3 shows the number of HAs with a guideline for the drugs/conditions 
specified on the questionnaire. Erythropoietin was the most common subject of 
the shared care guidelines, where 65/87 HAs (56%) had a guideline that was 
either “formally agreed” (41), “informally agreed” (17) or “being developed” (7). 
The least common subject of a shared care guideline was home chemotherapy 
with only 7/87 (8%) HAs having any sort of shared care guideline, (2 “agreed”, 3 
“informally agreed” and 2 “being developed”).
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Other shared care guidelines being used are shown in Figure 2.4. They include 
growth hormone (16 HAs), psychiatric disorders (10 HAs), Gonadotrophin 
Releasing Hormone Analogues (8 HAs).
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Figure 2.4, Health Authority Questionnaire -  Other Shared Care Guidelines





















The mean number of guidelines per Health Authority was six. Figure 2.5 shows 
the mean number of guidelines per Health Authority by region. There was little 
regional variation.
Figure 2.5, Health Authority Questionnaire -  Mean Number of Shared Care 
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2.2.5.1.3 Who Is Responsible For Agreeing And Implementing Shared Care 
Guidelines?
When asked “Who is responsible for agreeing and implementing shared care 
guidelines?”, the majority replied that it was a Health Authority Prescribing 
Committee. Some HAs gave more than one answer to this question (Figure 2.6). 
There were 17 HAs who ticked the ‘other’ box, their answers are shown in 
Table 2.2. Some HAs agree these guidelines with other HAs in the region on an 
area or regional basis. Some Health Authority Pharmaceutical Advisers drew up 
guidelines and in other areas of the country guidelines were drawn up by the 
relevant Trust consultants.
Figure 2.6, Health Authority Questionnaire -  Committee Responsible to 





SCC = Shared Care Committee
DTC = Trust Drug and Therapeutics Committee
PC = HA Prescribing Committee
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Table 2.2, Health Authority Questionnaire, Other Committees Responsible
for Agreeing Shared Care Guidelines
Survey
Number
Other committees responsible for agreeing and implementing Shared
Care Guidelines
23 Committees can only draw up ’skeleton’ protocols. Detail has to be between participating 
professionals and the patient. Having said that most of ours com e from within the Trust and are 
individually ’tweaked’.
24 individual consultants
25 Normally done at the request of GP and done by consultants.
27 W e have no panel which approves shared care guidelines but we do have a countywide 
Prescribing Policy Group which m anages the introduction of new drugs
34 also other adhoc arrangements exist but ideally everything needs to go through the D&T
45 Local Area Prescribing Committee
46 Been developed ad hoc or by the MAAG
49 District Professional Committee, members of the local Trusts, HA and GPs
52 Agreed and produced regionally.
55 Regional committee for guidelines produced to date. Local Trust based groups.
62 Clinical Protocols Evaluation Committee
65 Pharmaceutical Adviser
67 HA prescribing committee for which drugs and overall policy. Trusts for implementation at a 
drug/condition level.
75 Health Authority Drug & Therapeutics Committee
101 Typically drawn up by G Ps and consultants in association with other interested parties e.g. HA 
representatives, nurses, pharmacists, etc then adopted formally by the prescribing committees, 
LMC, HA, etc. For shared care we tend to develop d isease  based approach NOT drug based.
112 Clinical Guidelines Group
113 A subgroup of the area prescribing committee plus "experts" as necessary. All the donkey work 
done by the Pharmaceutical Advisers
The representation on the committee responsible for agreeing and implementing 
shared care guidelines is shown in Figure 2.7. The representation on the 
committees did not vary substantially between HAs. Most had Health Authority 
doctors and pharmacists, Trust consultants and pharmacists and GPs (often 
including Local Medical Committee (LMC) representation). Community 
pharmacists were not as commonly represented with 17 fewer committees having 
a Local Pharmaceutical Committee (LPC) representative than an LMC 
representative, although 5 HAs mentioned community pharmacists as other 
groups represented on the committee. Some (32) committees had contracts 
managers and administration staff, other members included 8 HAs who said there 
was a Community Health Council representative on the committee or a patient
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(or lay view) and 5 who said there were finance staff on the committee. The 
designation of other representatives on the committee responsible for agreeing 
and implementing shared care guidelines are shown in Table 2.3.
Figure 2.7, Health Authority Questionnaire -  Representation on Committee 
Responsible for Agreeing Shared Care Guidelines (n=87)
Groups represented
69
Table 2.3, Other Representatives on the Committee Responsible for 




Other representatives on the com m ittee responsib le  for agreeing and im plem enting shared
care gu id elin es
6 Community pharmacists
23 patients, specialist and practice nurses
24 nurses, finance department
26 Non-executive director to present a  lay view.
27 HA Director of Public Health, HA Finance
29 Community pharmacists
33 Patient representative from CHC
34 GP representatives, nursing representatives
36 D&T chairs, medical directors of Trusts
40 Drug Information Pharmacist, Community Pharmacists
42 Community pharmacist, pharmacist from local military hospital.
43 Representatives from groups with relevant interest invited (e.g. Alzheimer’s  Soc rep for donepezil). 
Primary Care Audit (HA), North Devon D&T Committee chairman
60 clinical pharmacologist
65 Health economist
66 Chairs of Trust D&T Committees, Trust formulary pharmacists/interface Pharmacists
67 HA finance staff
69 Community pharmacists
70 hospital nurse
73 Medical advisers to HA also represent LMC and are GPs. Trust consultants and pharmacy 
representatives invited along to discuss specific issues, a s are contract managers. Finance staff sit 
on committee as do Senior managers of the healthcare directorate.
74 Practice nurse
89 Community Health Council
96 To start:- CHC/ Ethics committee members
100 CHC rep, HA finance rep.
106 CHC
108 Trust consultants - a s and when
109 CHC
CHC = Community Health Council
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2.2.5.1.4 Successful And Difficult Aspects Of Shared Care Initiatives 
The qualitative comments regarding successful and difficult aspects of shared 
care and further comments made on the subject of shared care are shown in 
Appendix 5. The coding of these comments by a group of three hospital 
pharmacists from Plymouth Hospitals NHS Trust, a group of Health Authority 
representatives and a group of Trusts finance staff as described in Section
2.2.4.4.3 is shown in Appendices 6, 7 and 8 respectively.
57 Health Authorities requested and were sent the summary of finding shown in 
Appendix 9.
2.2.5.2 Local GP Survey
2.2.5.2.1 Response Rate
228 responses were received out of 357 questionnaires distributed (64%), nine of 
these were returned blank and were therefore unevaluable leaving a response rate 
of 219/357 (62%).
2.2.5.2.2 Familiarity With Local Shared Care Guidelines
190 (87%) of the respondents had seen a guideline produced by the South and 
West Devon, Cornwall and Isles of Scilly Shared Care Working Group. 47% 
had used one or more of the guidelines and 40% had seen but never used the 
guidelines (see Figure 2.8).
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Figure 2.8, GP Questionnaire -  Have you ever seen a Shared Care Guideline 
produced by the S&W Devon, Cornwall and Isles of Scilly Working Group?
have never seen  
one no answer
have used one or 
more
12.8% 0.5% 47.0%
have se e n  but 
never used  
39.7% n=219
2.2.5.2.3 Opinion Of Current Guidelines
Most GPs who answered questions about the usefulness, length and complexity 
of the guidelines available thought they were about the right length and 
complexity and “of some use” (Figure 2.9). Thirty-six (16%) GPs thought the 
guidelines were “too long”, twenty (9%) thought they were “too complex” and 
only one thought they were “not very useful”. Seventy-nine (36%) of the GPs 
thought that the guidelines available were “very useful”.
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Figure 2.9, GP Questionnaire, W hat GPs think about the information the 
guidelines contain (n=219)
Do you think the information the guidelines contain is ...
too long 
about right 










of some use | 88
not very useful | 1
no answer
0 20 40 60
no of positive responses
80 100 120
2.2.5.2.4 Prescribing Unfamiliar Drugs Recommended By A Hospital 
Consultant
Responding GPs (n=219) in South and West Devon preferred to prescribe a drug 
of which they had little experience, recommended by a secondary care colleague 
if a shared care guideline is available (97), if they have a recommendation from 
the hospital in writing (91) or if the request to prescribe is accompanied by 
sufficient clinical information (77) (Figure 2.10). 22 GPs said they would 
generally prescribe if it was not too expensive. Most GPs gave more than one 
answer to this question. Two ticked other, the first said they would “prescribe it 
if the hospital consultant continues to take overall responsibility for 
monitoring/dose adjustments” and the second said “I would only prescribe it if I 
felt happy to do so - bearing in mind if anything goes wrong 10 years later it 
would be the prescriber (i.e. the GP who signed the script) who would be wasting 
considerable time dealing with the resulting litigation. See for example the use 
of growth hormone contaminated with CJD - it took some years for this problem 
to come to light”.
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Figure 2.10, GP Questionnaire, (n=219) -  If you are asked to prescribe a 
specialist initiated drug of which you have little clinical experience do you .
prescribe it only if pt would have difficulty obtaining 
supplies otherwise
prescribe it if you have a recommendation from the hospital 
in writing
prescribe it if there is a shared care guideline
ask hospital consultant to prescribe it
prescribe it if it is not too expensive
prescribe it
97




0 20 40 60 80 100 120
number of positive responses
2.2.5.2.5 What Drugs/Diseases Would You Most Like To See A Shared Care 
Guideline For?
The answers to the question “what drugs, diseases would you most like to have a 
shared care guideline for e.g. risperidone, DMARDs?” are shown in Appendix
The largest number of suggestions were for the two examples given, second line 
rheumatology agents and psychiatry drugs especially the new atypical 
antipsychotics such as risperidone and olanzapine. Methylphenidate, fertility 
treatments and cyclosporin were the next most requested drugs. 
Immunosupressive drugs, chemotherapy agents, gonadatrophin releasing 
hormone analogues, erythropoietin and drugs abused or used in drug and alcohol 
abuse were commonly mentioned.
Nine GPs said “new” drugs and gave examples such as new anti-Parkinsonian 
therapies, drugs for dementia and drugs used to treat male impotence, eight said 
drugs which are initiated in secondary care of which GPs have little experience,
10.
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eight mentioned expensive drugs, six said they didn’t want any more and four 
said they would like guidelines for drugs which needed monitoring.
2.2.5.2.6 Opinion Of GPs On The Concept Of Shared Care 
The results of Section 2 of the questionnaire are shown in Figure 2.11. The 
statement that most GPs strongly agreed (66) with was that “shared care is about 
cost shifting to primary care”. The largest number in agreement (“strongly 
agree”, 33 + “agree”, 136 = 169) was with the statement that “the shared care 
working group is able to suggest that a drug is unsuitable for prescribing in 
secondary care”. More GPs (14 “strongly agree” + 145 “agree” = 159) felt that 
using shared care guidelines gives them the opportunity to opt in to sharing the 
care of a patient for whom they do have the experience to prescribe than felt that 
shared care guidelines give them the opportunity to opt out of sharing the care of 
a patient for whom they do not feel qualified to prescribe (“strongly agree” 17 + 
“agree” 99 = 116). The statement that the greatest number of GPs disagreed with 
(both “strongly disagree”, (13) and total of “disagree” and “strongly disagree”, 
(71) was that shared care guidelines empower GPs to prescribe more complex 
medication.
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Figure 2.11, General Practitioner Questionnaire -  Views of General 
Practitioners on the Concept of Shared Care (n=219)
useful means of defining 
respective responsibilities of 
1o&2o care physicians
development of something 
that's been going on for 
years ■
transferring care from 
secondary into primary care
guidelines empower GPs to 
prescribe more complex 
medication
give GPs opportunity to opt 








■  strongly disagree
□  no answer
cost shifting to primary care
working group able to 
suggest drug is unsuitable 
for prescribing in 1o care
unresolved medico-legal 
problems when sharing the 
care with a 2o care colleague
opportunity to opt in if GP 
feels he has the experience 
to prescribe
I
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
percentage of respondents giving answer
N.B. lo = primary and 2o = secondary.
62 GPs gave further comments regarding shared care, which are shown 
Appendix 11. They were coded as described in Section 2.2.4.4.4. The results of 
the coding exercise are shown in Table 2.4.
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Table 2.4, Coding Of Further Comments From GPs
Category Sub-category Number of 
responses
Workload shift general 3
resourced 0
not resourced 9
Funding transfer for drugs general 4
not organised 10
agreed m echanism 0
Best care 1
Format of guidelines general 1
positive 0
negative 4
Concern about responsibility transfer 
from secondary to primary care
16
Knowledge base general 0
positive 1
negative 1
Comments on questionnaire general 0
positive 1
negative e.g. no tim e to com plete 5
Risk transfer 4
Concept of Shared Care general 2
positive 3
negative 9
Answer not relevant/coded 15




2.2.6.1 Health Authority Survey
2.2.6.1.1 Response To Questionnaires
A good response rate was achieved with this questionnaire (87%). This could 
have been attributed to the fact that Health Authorities received both written and 
telephone reminders on a number of occasions. It may also have helped that the 
questionnaire was, in most cases, distributed personally by the researcher with 
some sort of presentation or explanation of the objectives of the project. The 
range was 71% (North Thames), where 4 of the 14 HAs did not respond to 100% 
(South and West) of questionnaires sent returned*.
There was no sample bias as the whole population of Health Authorities in 
England was included in the study. Response bias may have occurred, as non­
responders may not have had any involvement with shared care or HTHH and for 
this reason did not return the questionnaire. As the response rate was so high this 
effect should be minimal. There was no obvious pattern to the non-responders.
2.2.6.1.2 Geographical Distribution
It can be seen from Figure 2.5 that the mean number of guidelines was similar in 
all of the regions (standard deviation 0.87). The mean number of guidelines per 
HA at any stage of development was six. The North Thames region, which had 
the highest proportion of non-responders also had the smallest mean number of 
shared care guidelines (Table 2.1 and Figure 2.5).
2.2.6.1.3 Subject Of Guidelines
It can be seen from Figure 2.3 and Figure 2.4 that shared care guidelines are 
being produced for the newer, higher cost therapies rather than those disease 
states such as rheumatology and diabetes where informal shared care has been 
practised extensively for many years. Erythropoietin was by far the most 
common subject of a shared care guideline followed by cyclosporin, domase
The regions used are those which existed when the surveys were carried out prior to the change 
o f boundaries in April 1999.
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alpha, the interferons, donepezil, riluzole and infertility treatments. Growth 
hormone was the most common subject of a guideline that was not covered in the 
list in the questionnaire. The introduction of the newer, more expensive 
recombinant product has probably prompted this. These data combined with 
those in Section 2.2.6.1.5 suggest that shared care is playing an important part in 
the managed entry of new drugs into the NHS.
2.2.6.1.4 Who Is Responsible For Implementing Shared Care Initiatives?
It appears that it is the Health Authorities who are facilitating the development of 
shared care guidelines for interface prescribing, bringing primary and secondary 
care representatives together at Health Authority prescribing committee 
meetings. 52 HAs said it was a HA prescribing committee who were responsible 
for agreeing and implementing shared care guidelines, 10 had a separate shared 
care committee, 15 used the Trust Drug and Therapeutics Committees, as 
suggested in EL(91)127 [19], and 17 used a variety of other committees usually 
specific to their area or stated that GPs and consultants draw them up between 
themselves. The view was also expressed that it should be up to the consultant 
and GP to set up a shared care procedure on an individual patient basis.
One concern of GPs with shared care initiatives is that of cost shifting [19] (later 
discussed in Section 2.2.6.2). It is interesting that a number of committees feel it 
useful to have finance staff represented, possibly to suggest solutions such as 
high cost drug contingency funds or virement of money from primary to 
secondary care or vice versa. 5 Health Authorities mentioned virement projects 
and in the comments regarding successful and difficult aspects of shared care the 
view was commonly expressed that expensive therapies were difficult to get 
agreement on whereas cheaper therapies were easier.
2.2.6.1.5 Successful And Difficult Aspects Of Shared Care
Although this survey was aimed at collecting quantitative information the two 
open questions included provided more depth to the data collected.
Triangulation of the coding of the qualitative data by three different groups of 
staff was employed as described in Section 2.2.4.4.3. It was decided that if a 
coding frame were developed from the data prior to the groups coding it bias
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would be introduced. It was therefore left to the groups to develop a coding 
frame using grounded theory [107]. In this way they coded into categories which 
they felt were important subject areas drawn from the raw data. Depth of the 
data would be maintained and by comparing the coding frames developed the 
major concepts could be identified and triangulated.
The data were difficult to code and the three groups took different approaches. It 
was interesting that whereas the hospital pharmacists and Health Authority 
coding groups put emphasis on differentiating the comments regarding cost, the 
staff from finance grouped all comments regarding cost into one category. The 
Health Authority group went through the data twice, first extracting all the 
comments about cost and developing a coding frame for those, and then drawing 
up a second coding frame for the remaining data (Appendix 7).
Table 2.5 compares the coding frames of the three groups. It can be seen from 
this that although the groups took different approaches to coding the data twelve 
common themes were identified. There were few codes developed by one group 
that were not mirrored by the other two groups. It can be seen that the groups 
developed very similar categories thereby validating the inductively derived 
concepts. Most of the categories used by the groups were split into negative and 
positive comments or successful and difficult aspects, adding dimension to the 
coding of the data. The Health Authority group took this further developing 
further sub-categories.
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Table 2.5, Coding Frames developed by the Groups
Health Authority Finance Pharmacy
Communication/Colla
boration
joint approach GPs, trusts, HAs 
qualitative improvements - 
communication, collaboration, 




poor communication (difficult) 
poor collaboration (difficult)
co-operation, communication, 
debate, time practicalities 
HAoprimary care<-»secondary 
care <->tertiary caree>HA etc
Framework/
infrastructure
infrastructure, process clear guidance framework
(successful)
lack of clear guidelines
(difficult)
framework - appropriate drug 
for primary care prescribing, 
needs a protocol, drug 
selection
comment on generic guidelines
Specific drug/ 
disease














Education qualitative improvements - 
communication, collaboration, 
relationships, wider knowledge, 
involvement
education (successful) 
lack of education, knowledge, 
training (difficult)
education - GP provided with 
information
Tertiary centres tertiary referrals tertiary centre (difficult) co-operation, communication, 
debate, time practicalities 
HA«-»primary care<-»secondary 
c a r e «-»tertiary care«-»HA etc
Responsibility clinical responsibility reluctance to accept 
responsibility (difficult)
Medico-legal responsibility





too difficult - individual
difficulties not specified
failure to obey guidelines
(difficult)
not used, not successful
Audit/evaluation evaluation, audit (difficult) audit - comment on need to 
evaluate
Managed entry of 
new drugs
managed entry of drugs managed entry of new drugs
Defining shared care definition of shared care principle of shared care, what it 
m eans, how interpreted
No comment/not sure uncertain no comment/unsure
(successful)
no comment (difficult)
early stages, no data to 
comment on yet
(increased paperwork?) politics, general comment on 





(non-drug payment) shared vs transfer of care 
comments on transfer
patient selection who gets what
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It can be seen from the Appendices (6, 7 and 8) that the Health Authority and 
hospital pharmacist groups coded the data into the frame they had developed 
whereas the finance group came up with a coding frame but did not have time to 
code their data into it. The most common concepts developed from the data by 
the three groups are discussed below.
2.2.6.1.5.1 Finance
There were numerous comments regarding financial issues around shared care 
and from these data this appears to be one of the major problems encountered in 
shared care initiatives. Comments such as those shown in Box 2.1 were 
common.
Box 2.1
“Often seen pu rely  as a cost shifting exercise fro m  secondary to p rim a ry  care ”. 
“M any o f  the G P s still f e e l  it is "cost-shifting” fro m  the h o sp ita ls”
“ When is it sh ared  care?  When is it cost-sh iftin g?”
“A ttitude is often "I am  a consultant, so  do  as I say  and p rescrib e  drug x  because  
the hospita l cannot afford it! ” ”
Various methods are being used in an attempt to overcome this. Virement 
projects where money is vired from primary to secondary care and vice versa  to 
follow prescribing have been tried. Some HAs keep contingency funds to try and 
cover the cost of these therapies in primary care so that shared care may be taken 
on by a practice without it taking on the cost of the drug. However the money 
still ultimately comes from primary care funds.
There was a feeling that shared care would be more easily agreed once unified 
prescribing budgets become a reality (Box 2.2). This may happen with the 
introduction of Primary Care Groups of Levels 3 and above. It may be that the 
GPs decide they would rather prescribing remained in secondary care.
Practically, with tertiary referral centres and patients living a long way from their 
secondary provider GPs will inevitably be prescribing some complex hospital
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initiated therapies unless a mechanism is developed to overcome this. It is hoped 
that the true debate about clinical and therefore prescribing and medico-legal 
responsibility for various therapies will then be able to take place without being 
clouded by the financial implications to either provider. PCGs are still very 
young organisations and PCTs even more so. The unified budget has become a 
reality in the way that HAs allocate resources to the PCG/PCTs. However, it will 
take time for the PCGs to gain experience of commissioning and to develop 
novel approaches to make the best of this unified budget. In the first year of 
PCGs commonly historic indicative budgets were uplifted and the unified budget 
had little effect. This may change in the second year of PCGs some of whom 
have now moved to PCT status with the effect of cash limited budgets for 
prescribing for the first time. Many of the PCGs will have overspent their 
primary care prescribing budgets and will be looking to find resource from other 
areas to support prescribing. This is another factor which may be preventing GPs 
from taking on the prescribing of hi-tech and often high cost drugs in the 
community.
Box 2.2
“  M ay becom e m ore m eaningful when unified budgets are in p lace. ”
“ U nlikely to w ork p ro p er ly  until a ll funding in sam e pot.  ”
“Life m ay be easier i f  w e had jo in t p rim a ry  and secondary care prescrib in g  
budgets!! ”
Another issue that came both from these data and those obtained from the survey 
of local GPs (Section 2.2.5.2.) was the lack of funding for the extra workload 
associated with shared care in addition to increased pressure on prescribing 
budgets (Box 2.3).
Box 2.3
“LM C  core/non-core p aym en t f o r  work undertaken. ”
“The whole area o f  sh ared  care seem s to have becom e caught up in the  “core  
-n o n  core p o litica l debate. ”
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2.2.6.1.5.2 Com m unication and  Collaboration
Both groups that coded the data showed that there were more difficulties with 
communication and collaboration than successes. Although, in general the 
development of shared care guidelines was seen to enhance communication 
between primary and secondary care and it was lack of communication that was 
perceived to prevent the successful development and implementation of the 




“The p ro cess  o f  developing  a g reed  approach es to d isease  m anagem ent betw een  
spec ia lis ts  and  gen eralists (both G P s and n on-specia list consultants) has 
open ed com m unications betw een  these groups on m any fron ts. It has p ro v id ed  
a useful cornerstone to developing  the input o f  profession a ls into Trust an d  HA 
m anagem en t”.
“C ollaboration  has im proved  com m unication and ensured equity o f  c a r e ”. 
Difficult Aspects
“G etting p eo p le  to meet, le t alone try and a g r e e ”.
“H ospita l attitude is a serious problem , they do not p u t fo rw a rd  p ro p o sa ls  but 
try  an d  im pose their ideas. ”.
It may be that with improving electronic communication between health 
professionals in a much more timely manner than is currently the case, there will 
be at least the facility for better communication and collaboration between 
primary and secondary care. The introduction of the NHS-net should help 
facilitate this but it will be a number of years before this is available in all 
General Practices as not all are computerised. The development of NHS-net 
could eventually lead to one set of medical records being held for each patient 
rather than having a different set of records in primary, secondary and sometimes 
also in tertiary care. Wright [79] points out that joint records seem acceptable to 
patients but less so to their doctors.
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It is also a change in attitude and way of working together that is required.
Shared care guidelines do, in places, seem to have had a beneficial effect on this 
relationship. They lay out the various responsibilities in a structured way helping 
health care professionals in both primary and secondary care to know exactly 
where their respective responsibilities lie when care is shared. Their existence 
does not solve the ongoing problem of lack of timely and accurate 
communication between health care professionals.
2.2 .6.1.5.3 Responsibility
One of the major problems with sharing the care of a patient is taking over the 
prescribing of a complex and often unfamiliar drug by the GP. In signing the 
prescription the GP is accepting clinical responsibility [20]. Hospital consultants 
often do not seem to appreciate this as can be seen from the comments in Box
2.5.
Box 2.5
Difficulty “G etting the consultants to understand that p rescrib in g  and clin ical 
respon sib ility  are attached, not separable. ”
“Lack o f  acceptance that G Ps hold  respon sib ility  f o r  prescrib ing . ”
“Still there is a view  that G P s w ill au tom atically take on the prescrib in g  fo r  a ll 
drugs regard less o f  the clin ical respon sib ility  issu es”.
“View o f  hospita l consultant o f  "why should  we have to d iscu ss/agree this with  
G Ps in advance. We ju s t  tell them and they should p rescrib e  it"!!!”
This is supported by an audit conducted by Brighton University [106] where 
hospital consultants were interviewed. The consultants’ perceptions of shared 
care included the following:
• GP concerns about clinical responsibility were sometimes used as a smoke 
screen for more predominant budgetary concerns.
• GPs have a duty to prescribe for their patients in the community and refusal to 
participate in shared prescribing of hi-tech medicines may represent an 
abdication of this responsibility.
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• Relatively few saw the need to discuss arrangements on a personal basis with 
individual GPs.
Advice obtained from the Medical Defence Union [108] states that “there is no 
doubt that legal responsibility for prescribing falls to the doctor who signed the 
prescription”. This was also made very clear in EL(94)72 (5). So it remains that 
if a GP does not feel qualified to prescribe the drug and is not willing to take 
legal responsibility for the prescription they should not prescribe. However they 
may decide to accept an arrangement whereby they share the care of the patient 
without prescribing, such as in the case of a patient receiving a home TPN or 
antibiotic infusion [99]. The current situation is that the GP can be in a very 
difficult position if for example they are asked to prescribe a drug by a tertiary 
centre (see Section 2.2.6.1.5.4.), they may have to explain to the patient their 
reasons for not wanting to prescribe. The patient may well not understand that 
this is in his or her own interest. After all, where else will they obtain their 
drugs?
It has recently been suggested [20] that a change in the law could allow a GP to 
prescribe as consultant’s deputy. The consultant could give written authorisation 
for a GP to repeat prescribe while agreeing to maintain clinical responsibility for 
the patient. Another solution suggested was that a consultant prescription could 
authorise repeat dispensing from a community pharmacy. The Crown Report 
[109] has also suggested a distinction between categories of prescriber 
“independent” and “dependent”. GPs could potentially take on the role of 
dependent prescriber when prescribing on behalf of a hospital consultant.
2.2.6.1.5.4 Tertiary Centres
Setting up shared care arrangements between GPs and tertiary centres was a 
problem (Box 2.6). It is commonly going to be the case that a tertiary provider 
will be geographically distant from the patient’s home. It is not practical for the 
patient to collect prescriptions from the hospital pharmacy and often the GP is 
asked to continue therapy of which he has very little other input or 
understanding. It is very difficult for the GP to refuse to prescribe. It may not be
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advantageous to ask a consultant from the local hospital to prescribe because 
they may have no other clinical input and this can lead to further communication 
problems with more people involved.
Box 2.6
“Tertiary centres cause the prob lem s most, especia lly  com m unication on issues 
abou t p rescrib in g  responsibility. It doesn  *t really w o rk ”
There is not an easy answer to this as ownership of shared care guidelines is 
often key to their acceptance and it is obviously not possible for all of the GPs 
who may potentially be asked to take on prescribing and care of the patient from 
the tertiary provider to agree the guidelines. It seems that it would nevertheless 
be useful for these centres to produce guidance for a GP who chooses to accept 
responsibility for this type of patient. The agreement would then have to be 
made on an individual basis between the GP and the specialist centre. This has 
the disadvantage for the tertiary centre in that it is difficult to have varying 
arrangements with many different GPs. It might again be that the ideas of 
prescribing as a consultants deputy, dependent prescribers or having consultant 
repeat prescriptions dispensed from community pharmacies would be a useful 
solution but would require changes to be made to current NHS legislation. 
Training of community pharmacists would also be required so that they are not 
dispensing medicines, which are unfamiliar to them and for which they cannot 
provide appropriate pharmaceutical care.
This is perhaps an area that PCGs and PCTs should be looking at as part of their 
commissioning arrangements with tertiary centres. FPIO(HP) forms have been 
used in some areas to allow hospital practitioners to prescribe drugs for patients 
when the clinic is held away from the hospital pharmacy. These can be 
dispensed by community pharmacists and are charged to the NHS Trust. A 
problem with FP10(HP)s is that it is currently difficult to monitor prescribing 
using these prescriptions as the Prescription Pricing Authority do not produce 
Prescribing Analysis and Cost Data on them.
87
2.2.6.7.5.5 Fram ew ork/Infrastructure
There were several comments regarding agreeing an infrastructure or processes 
for implementing shared care initiatives. The view was held in some cases that 
detail of a shared care arrangement should be agreed between the consultant and 
the GP concerned on a patient by patient basis. Some of these Health Authorities 
produced generic guidance to be followed when drawing up an individual 
arrangement. Others favoured making decisions as to whether drugs were 
suitable for prescribing in primary care (Box 2.7). Two Health Authorities 
mentioned a traffic light approach where drugs were classed as red- hospital 
only, amber- initially hospital only for a specified period or green-suitable for 
prescribing in primary or secondary care.
Box 2.7
“...w e  have a p ilo t running in which the G P drugs budget has been top -sliced  
and m oney is given  to the consultants to p ro v id e  drugs which should  be 
consultant prescribed . ”
2.2.6.1.5.6 M anaged Entry O f  N ew  D rugs
EL(94)72 [21] suggests that shared care initiatives can form a part of the process 
of the managed entry of new drugs. It appears that at least in some Health 
Authorities this has been the case (Box 2.8). Many shared care initiatives 
include agreement on whether drugs are suitable for prescribing in primary care, 
this helps the managed entry of drugs into primary care and complements the 
work of Drug and Therapeutics Committees in secondary care. The main aim of 
shared care [19, 21] must still be to improve patient care by improving the 
patients understanding of their therapy and improving communication between 
professionals jointly responsible for their care, making sure that there is a clear 




“very few , except now  w e have our ac t togeth er abou t new  d ru g s”
“D evelop ing  sh ared  care gu idelines is an im portant p a r t o f  this A uthority's 
approach  to the m anaged  in troduction o f  new  drugs and technologies . ” .
2 .2 .6 .1 .5 .7  Specific D rug/D isease
Many o f the comments regarding which aspects of shared care had been 




“H om e P aren tera l N utrition ”
“don epezil, riluzole, in fertility”
Difficult Aspects
“P rescrib ing  issues in m ental health currently provin g  to be difficult.
G eneral reluctance to take on sh ared  care f o r  certain  groups o f  m entally ill 
pa tien ts  fo llo w in g  publica tion  o f  G M SC  p a p er  "Mentally D iso rd ered  People: 
Continuing C are in the Community". F ertility  issues cause general prob lem s  
because o f  the d ifficu lty o f  p r iva te  services. ”
“A reas such as beta  interferon where the loca l consultants don't w ish to use 
the drug. ”
There was no consensus on this and it appeared to be where agreement had been 
reached and the guidelines had been successfully implemented, this drug or 
disease was considered successful and where problems had arisen in reaching 
agreement and there had been poor uptake of the guideline this was considered 
problematic. For example different Health Authorities listed p-interferon as 
being both successful and difficult.
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2.2.6.1.6 Shared Care for HTHH
There were some shared care guidelines for HTHH. These would involve a 
model of shared care different from most of the examples given as the GP would 
not be taking on prescribing responsibility for a patient receiving a home infusion 
under EL(95)5 [41]. There were nearly as many shared care guidelines for home 
antibiotic infusions (14) as home TPN (15) which was surprising considering 
many more of the Health Authorities contracted for home TPN than for home 
antibiotic infusions (section 2.2.5.1.2. and Chapter 3).
2.2.6.1.7 Limitations
The main limitation of this work is that it has taken one perspective, that of the 
Health Authorities, and therefore may have missed shared care initiatives in 
which the Health Authority has little involvement and where Trusts or local GPs 
are taking the lead. However the responsibility for facilitating shared care 
initiatives was given to the Health Authorities in the form of EL(91)127 [19] and 
EL(94)72 [21]. It would therefore be the exception rather than the rule that a 
Health Authority adviser would be unaware of shared care initiatives in their 
area. This is not an in depth analysis of the different models used in shared care 
initiatives and their relative effectiveness but gives an overview of the current 
position and identifies the main factors having an influence on shared care 
initiatives at the primary secondary care interface.
2.2.6.2 Local GP Survey
2.2.6.2.1 Response Rate
The response to the survey was pleasing when compared to response to other 
surveys distributed in a similar manner in the past by the Health Authority to the 
GPs in South and West Devon. The results of this survey are obviously not 
representative of all GPs but look specifically at the situation in South and West 
Devon. There was no sample bias of this defined population as again the whole 
population was included in the survey. Response bias may have had a greater 
impact on this survey as it may have been that GPs who were unfamiliar with the 
shared care guidelines produced by the SCWG were less inclined to complete the
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questionnaire than those who had seen or had experience of using them.
2.2.6.2.2 Familiarity With The Guidelines
The dissemination of the guidelines to all GPs in South and West Devon was a 
successful way of ensuring that most GPs were aware of the guidelines. Even if 
it were assumed that all of the non-responders have never seen a guideline 
produced by the SCWG most GPs (54%) in the area would be familiar with 
them.
2.2.6.2.3 Content of the Guidelines
Nearly half of the GPs (47.0%) who responded to the questionnaire had used one 
or more of the guidelines. This suggests that they are useful and this is 
confirmed by the fact that 79/219 GPs rated them as “very useful” and 88/219 
rated them “of some use”. From these data (Figure 2.9) it seems that the 
consensus is that the complexity of the guidelines is “about right”, and should not 
be made any more complex. 20/219 GPs thought they were “too complex”. The 
majority thought they are about the right length but there were 36/219 who said 
they were “too long” suggesting that the SCWG should not make guidelines any 
longer and should reduce the length where practical.
2.2.6.2.4 Prescribing Unfamiliar Drugs Recommended By A Hospital 
Consultant
The question regarding prescribing unfamiliar drugs recommended by a hospital 
consultant was asked partly to assess whether the GPs were under the false 
impression that the hospital specialist was able to retain medico-legal 
responsibility even if the GP was signing the prescription. Most GPs gave more 
than one answer to this question.
GPs are more comfortable prescribing in this situation if a shared care guideline 
is available. This is possibly because they feel that prescribing within the 
recommendation of a guideline agreed locally by specialists in the field and 
agreed by a multidisciplinary committee, would be easy to defend in a medical 
negligence case. It might be easier to prove that the action taken was “capable of 
support from an informed reasonable body of clinicians of similar training and
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experience” [108], It should be noted that the GP still retains clinical 
responsibility for the prescription when prescribing in line with a shared care 
guideline.
Ninety-one GPs said they would prescribe it if they “had a recommendation from 
the hospital in writing”. This suggests that they feel they would be able to 
defend their prescribing with evidence that the recommendation came from a 
hospital specialist. This may be the case but does not give them the “opinion of a 
reasonable body of clinicians” and again by signing the prescription they are 
accepting clinical responsibility. In a similar vein 77/219 said they would 
prescribe if the request was accompanied by sufficient clinical information. This 
might be that they would require enough clinical information to base their own 
informed decision on whether to prescribe and therefore take clinical and 
medico-legal responsibility. It is perhaps worrying that more GPs said they 
would just “prescribe it” (38) than said they would “ask the hospital consultant to 
prescribe it”(36). Reassuringly there were relatively few GPs (22) said that they 
would prescribe it if it was not too expensive which suggests that cost is not a 
major consideration when accepting shared care arrangements. There may have 
been some bias in that the GPs were unwilling to admit this as they were aware 
that the results were being fed back to the SCWG (Hawthorne effect [110]).
The problem of tertiary centres raised in the Health Authority questionnaire 
(Section 2.2.6.1.5.4.) may lead to patients having difficulty obtaining supplies of 
complex therapies if their GP does not prescribe them. Twenty-five GPs said 
that they would prescribe if “the patient would have difficulty obtaining supplies 
otherwise”. This is often a very difficult position for GPs as there is an 
emotional response from the patient if the GP is considered to be hindering their 
therapy in any way. By virtue of the fact that the patient has been referred to a 
tertiary centre the problem is often serious and it is important to maintain a good 
patient-GP relationship. However the GP will probably not be familiar or feel 
able to take clinical responsibility for drugs initiated in tertiary settings.
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2.2.6.2.5 Subject Of Further Guidelines
GPs would most like shared care guidelines for newer, more expensive therapies 
of which they have little experience and which may need monitoring. Areas 
where guidance was not as clear as it might have been, such as drugs used in the 
treatment of drug and alcohol abuse and fertility treatments, were also commonly 
requested. In 1999, after this survey was carried out, national guidelines for 
shared care of drug users were published by the DOH (www.doh.gov.uk/ 
drugdep/htm). The information shown in Appendix 10 was fed back to the 
SCWG. Some GPs pointed out that it was precisely the drugs that they didn’t 
know about that they most needed shared care guidelines to cover. It is therefore 
useful that the SCWG has a dual approach whereby the Area Prescribing 
Committee refers new drugs for the development of guidelines and GPs request 
guidelines for drugs with which they are familiar.
2.2.6.2.6 GP Views On The Concept Of Shared Care
The GPs in South and West Devon consider that the SCWG has the authority to 
decide which drugs are unsuitable for prescribing in primary care and make this 
recommendation. This is one solution to the problem but is not commonly 
adopted throughout the country (section 2.2.5.1.3). It might be that Primary Care 
Groups will want more prescribing of these specialist initiated therapies to stay in 
secondary care and they may well vire money into secondary care prescribing 
budgets to ensure that this happens.
In line with the Health Authority survey and also with a survey which used 
structured interviews to obtain the opinions of GPs on shared care [106] one of 
the major problems identified is that shared care is seen by GPs as a cost shifting 
and workload shifting exercise by secondary care.
61.6% of respondents agreed that there are “unresolved medico-legal problems 
when sharing care with a secondary care colleague” (35 “strongly agree” +100 
“agree”). The largest number (57) of “undecided” answers were given to this 
statement. It is of concern that GPs are not aware of the medico-legal 
responsibility they are taking on when agreeing to take part in shared care 
arrangements.
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Interestingly more GPs felt that shared care guidelines gave them the opportunity 
to opt into sharing care if they feel they do have the experience to prescribe than 
to opt out if they don’t feel qualified to prescribe. This question was originally 
intended as a validation question but it is apparent that GPs find it more difficult 
to opt out of shared care than opt in. It has been reported to the SCWG that 
when a GP has declined to share care they have been pressurised by the 
consultant to change their mind. This is a situation that is obviously not 
acceptable and must be resolved if shared care initiatives are to be successful.
Another common concern raised by local GPs was that of transfer of clinical 
responsibility from secondary to primary care. This is in line with the national 
situation identified in the Health Authority survey (2.2.6.1.5.3). There were also 
comments that the funding for shared care was not organised and that consequent 
workload shift was not funded. Nine GPs who commented on the concept of 
share care gave negative comments.
The results of this survey are in line with the University of Brighton audit, which 
interviewed GPs to elicit their perspectives of current shared care arrangements 
[106]. This study found that GPs felt that prescribing of hi-tech medicines was 
not truly “shared” as the GP is prescribing from a position of relative ignorance 
about the medication which leads to concerns about clinical management and 
possible litigation. GPs saw the main motive for sharing care as cost shifting 
from secondary to primary care budgets. The concerns of the South and West 
Devon GPs about workload shift and lack of funding for this in addition to 
prescribing costs were however not reported in the Brighton study. Their 
emphasis was much more on appreciating a personal approach from the 
consultant preferably by telephone rather than letter. GPs in South and West 
Devon did not show as much dissatisfaction with the type of information that 
they receive. As the Brighton survey took a sample of GPs from a region rather 
than a local Health Authority area it is not clear what “current” shared care 
arrangements were in place.
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2.2.62.1 Limitations of GP Survey
This work was only concerned with one side of the shared care partnership, that 
of the GPs. In order to conclude that this model of shared care is successful the 
opinion of hospital consultants would have to be sought and the patient outcomes 
monitored. It is a very local survey looking at arrangements peculiar to South 
and West Devon and care should be taken in extrapolating the views of this small 
number of GPs on the situation in South and West Devon to the rest of the 
country. However, the views of this sample of GPs do seem to be in line with 
those expressed in the literature (2.1.3.5).
In order that a good response rate was achieved the questionnaire was kept short 
and therefore in depth information was not obtained. A tick box style of 
questionnaire was used to reduce the time and effort required to complete the 
questionnaire. This may have led to bias in opinions as they had to be predicted 
to be included in the tick box responses and the GPs may not have expressed 
these views if they had not been prompted by the questionnaire. Sixty-two GPs 
did however contribute more than the minimum requested in the questionnaire by 
adding their further comments.
2.2.7 Conclusion
The local procedure for the development of shared care guidelines in South and 
West Devon appears to be successful. They do, for the most part, fulfil GP 
expectations and GPs are reasonably happy with them. This work has 
established that the major concerns of GPs about shared care are over cost 
shifting, lack of funding for the associated shift of workload from secondary to 
primary care and taking on clinical and therefore medico-legal responsibility for 
the patient. The results of this survey have been fed back to the SCWG. The 
future working agenda has been drawn up from Appendix 10 of this project. 
Comments of the GPs on the design of the guidelines will be noted when future 
guidelines are drawn up.
Shared care initiatives have been implemented successfully throughout England 
using various models. There have been few shared care guidelines/protocols
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produced. The greatest successes have mostly been for complex, new and high 
cost drugs, often to manage the entry of new drugs and broker an agreement 
between primary and secondary care on prescribing responsibility. Health 
Authority led prescribing committees have, in the majority of cases, been 
responsible for the development and implementation of shared care guidelines.
Shared care does appear to play a useful role in managing the entry of new drugs 
into the NHS as intended by EL(94)72 [21]. The perception of cost shifting has 
been a major barrier to the implementation of shared care initiatives but this may 
become less of a problem if unified budgets become a reality with the new 
Primary Care Groups and Primary Care Trusts. It remains to be seen what 
differences some of the changes in GP Terms of Service will bring about as more 
practices move to Personal Medical Services contracts rather than the traditional 
General Medical Services contracts.
There are concerns regarding clinical and medico-legal responsibility when GPs 
enter into shared care arrangements. These cannot be readily overcome but this 
may come a step closer with review of legislation following the Crown [109] 
report. It is crucial that communications and collaboration between primary and 
secondary care health professionals are improved if shared care initiatives are to 
be successful.
Increasingly expensive drugs and higher expectations partly raised by the 
government’s clinical governance initiatives, promises to end postcode 
prescribing and the National Service Frameworks mean that managing the entry 
of new drugs into the NHS has been difficult. The National Institute for Clinical 
Excellence is facing more appeals than were expected and patient pressure 
groups are leading media campaigns to pressurise the government into making 
drugs available on the NHS. A recent example of this is the NICE technology 
appraisal on beta-interferon for multiple sclerosis (www.nice.org.uk.
The challenge is not just who is the most appropriate clinician to prescribe but 
how will advances in drug therapy continue to be funded. In 2000 Alan Milbum 
the Minister for Health announced a plan of increased spending on the NHS but
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much of the finance is non-recurring and linked to specific government targets 
(Department of Health Press Release, 2000/0666). Unified budgets may 
eventually herald the end of shared care being considered as cost shifting but 
they will not solve the problem of how these hi-tech therapies will be afforded. 
Individual Health Authorities and PCTs will still have to prioritise funding. This 
was recognised by the Royal College of Physicians in their working party report 
“The Prescribing of Costly Medicines” [22] which recognised that unless certain 
treatments are disallowed on the basis of cost, the quality of health care must 
suffer.
This debate has been raised in the treatment of Gaucher’s disease with 
alglucerase [111]. GPs may be happy to share care or it may be more appropriate 
for an outreach team or commercial provider to care for the patient but funds 
must be identified to pay for this care. Moving the provision of some of these hi- 
tech infusions to the community setting has been used as a way of reducing 
overall health costs to afford new therapies in countries like the United States by 
health insurers.
As new, more effective and higher cost treatments become available the NHS 
must seek to reengineer the way care is provided to provide a patient centred 
health service making use of new technologies but ensuring that patients have 
access to the appropriate expertise. It may be, in the future, that developments in 
telemedicine, electronic conferences and data transfer via modems will enable 
GPs or hospital outreach staff and their patients to gain access to specialist 
advice and support from the community setting and there will be less need for 
patients to travel to hospitals for their care. An area where this has begun to 
happen in the UK is in the delivery of home infusions. It was therefore decided 
that this study should investigate the development of home infusion therapy in 
the NHS in England in more detail.
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3 Hi-tech healthcare at home
3.1 Literature Review HTHH
The term “hi-tech health care at home” (HTHH) has been used to describe those 
treatments described in EL(95)5 [41] which usually require special compounding 
and complex administration techniques. This can be considered to range from 
continuous ambulatory peritoneal dialysis and enteral nutrition (both outside the 
scope of this project, as they were later excluded from EL(95)5 [41]) to the 
administration of intravenous parenteral nutrition, chemotherapy and other drugs. 
There has been much technological advancement over the past 20 years in 
intravenous access, infusion devices and drug therapy which has made it possible 
for infusions to be administered safely to patients in the domiciliary setting. 
Patients have been proved well able to manage infusion therapy at home as long 
as appropriate patient selection, training, back up and quality assurance are 
employed in a home care scheme [7, 8, 112-115].
In 1970 Scribner et al [116] described the first home infusion. They gave details 
of an artificial gut system for patients incapable of enteric feeding. They 
reported a case where a patient had concentrated nutrients introduced into the 
circulation via an arterio-venous shunt, either delivered in the daytime by a 
portable pump or at night by gravity feed. The system was operated by the 
patient in his own home. This programme offered major advantages to the 
patient over conventional parenteral nutrition in that he received his entire fluid 
and calorific requirements over 10-12 hours allowing time to pursue other 
activities.
Since then the home infusion market has grown enormously, particularly in the 
United States but also in Canada [27, 117-120], Australia [35, 121, 122], Europe 
[99, 123-127] and Japan [33, 34]. Patients receive many different infusions 
safely and cost effectively in the home care setting including antibiotics [128], 
anti-virals [25, 129], chemotherapy [127, 130], pain relief [131, 132], 
apomorphine [11] and immunoglobulins [9].
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Winters [133] reports that, Rucker and Holmstead’s estimate of home infusion 
industry revenue, in the USA, in 1983 was $265 million. They forecast that it 
would grow to more than a billion dollars by 1988. In fact it had grown to over 
$1.5 billion by 1988 and to $4.2 billion by 1993, although the compounded 
annual growth rate shrank from 58% per year between 1982 to 1987 to 13% per 
year between 1991 and 1993 [133].
During the early eighties in a cost containment exercise in the United States, 
Medicare introduced its prospective payment system based on Diagnosis Related 
Groups (DRGs) which introduced an economic pressure to reduce hospital length 
of stay [133, 134]. Payers began to see the financial benefits of providing 
healthcare at home as it reduced cost of care due to the lack of need to pay hotel 
fees.
During the huge growth of the home infusion market, in the USA, in the 1980s 
many commercial providers of home infusions emerged and the number of 
hospital pharmacy departments providing home infusions declined. Winters 
[133] reports that the key to the success of these companies was the nursing 
services they provided. Nurses were recruited from acute care hospitals and 
instructed patients and their carers on infusion techniques prior to discharge and 
made home visits on a regular basis after discharge to provide necessary 
monitoring and surveillance. Since a low was reached of approximately 17% in 
1989, the number of hospital pharmacy departments providing home infusions 
started to rise to 26.9% in a survey in 1990 [135].
3.1.1 Home intravenous antibiotic therapy
3.1.1.1 History
3.1.1.1.1 Cystic fibrosis
Providing domiciliary hi-tech antibiotic therapy was a concept first reported in 
the USA in 1974 [136]. Cystic fibrosis patients requiring frequent and often long
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courses of intravenous antibiotic therapy were trained to reconstitute and 
administer their own antibiotics at home once they had recovered from the acute 
phase of their infection. The results were promising with no serious 
complications in 127 courses of therapy.
The success of home parenteral therapy in cystic fibrosis has since been 
confirmed. Winter et al [137] in the UK found no difference between patients 
treated at home or those treated in hospital. Bosso et al [138] gave infusions of 
aminoglycosides via a portable syringe pump and found outpatient 
administration to be convenient, safe and to result in considerable cost savings.
A prospective controlled trial [24] comparing cystic fibrosis patients matched 
according to age, sex, pulmonary function and arterial blood gas values, also 
found no significant difference between patients treated at home with 
medications delivered in metered dose bags by an independent home care 
pharmacy and those treated in hospital. Wolter [10] in a prospective randomised 
trial of 17 patients and 31 admissions in Australia also found that no clinical 
compromise associated with home therapy but both advantages and 
disadvantages in terms of quality of life.
Following this were a number of reports from the United Kingdom of home 
treatment schemes for cystic fibrosis sufferers being set up in London [139], 
Leeds [140], Manchester [141, 142] [143], Nottingham [144] and Birmingham 
[145] and Staffordshire [146].
This reflected both the governments push towards a primary care led NHS (2.1.1) 
and the preference of these patients to remain at home for their therapy. Other 
reasons were that throughout the late eighties and early nineties it became 
accepted practice in many, but not all, centres to give a two week maintenance 
course of intravenous antibiotics every three to four months [140, 147]. This 
resulted in patients who were not acutely ill spending two months each year in 
hospital with the associated disruption to their lives and at great cost to the NHS. 
A bed was not always available at the specified time and in hospital, doses of 
intravenous drugs are often not administered at the prescribed time intervals and 
admissions are costly in terms of staff time [140, 147]. There is also the risk of
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cross infection with resistant bacterial strains and viruses which are prevalent in 
the hospital setting [140, 147],
Gilbert et al [141] in Leeds reported their experience with a cystic fibrosis liaison 
sister having an essential role. They used a formal, structured approach to 
patient selection and training and a variety of intravenous access devices ranging 
from intermittent injection, peripheral or central lines to a totally implantable 
intravenous access device. Patients went home on any one of seven drugs with 
which they would have been treated in the hospital. Many parameters were 
measured in order to compare hospital with home treatment in the same patients. 
Home therapy did not appear to be inferior to inpatient treatment. The provision 
of a team member who regularly monitors stress, compliance and progress in the 
home as well as providing support to the patient and family was considered to be 
vital to the safety and effectiveness of home antibiotic therapy.
Similarly the team in Manchester considered the support given by a cystic 
fibrosis liaison sister when the patient first went home a key part of their home 
care service [142, 144]. David [144] reported reservations about the use of 
central lines and implantable infusion devices so all antibiotics were 
administered peripherally but a more recent article from the same centre states 
that long lines and implantable IV access devices are commonly used [143]. In 
Nottingham some cystic fibrosis patients were being provided with an ad hoc 
home care service [139].
The use of elastomeric infusion devices or pumps for cystic fibrosis patients was 
not reported in the United Kingdom until 1992. Duncan-Skingle et al [148] 
reported that patients had found that home antibiotic therapy was stressful and 
time consuming and a study had been conducted in 93 patients to determine 
whether the Intermate® device (Baxter Healthcare), filled aseptically by the 
hospital pharmacy, could reduce the time and stress involved in intravenous drug 
administration. The results were favourable as patients were able to perform 
other tasks or even receive physiotherapy whilst their antibiotics were being
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administered. However, there were restrictions as to which antibiotics could be 
used in the device.
Later the same team reported their first year’s experience in a prospective study 
and concluded that home care using “intermates” had saved 1442 inpatient days 
and had improved patient’s lung function and quality of life [149]. These pumps 
were in use in other centres such as Leeds [150] and Birmingham [151].
Pharmacists working in Leeds put in a bid to provide the home care service 
which was being provided by a commercial company [140]. They won the 
contract from the local Health Authority and reported financial savings of 
approximately £125,000 (45% reduction) in its first year of operation. Similar 
conclusions that infusion pumps were less time consuming and tiring for both the 
patient and carer, especially with the newer programmable pumps where patients 
were on multiple antibiotics with different schedules, were being reached in the 
United States [138, 139, 152].
In all the United Kingdom studies the general practitioner had at least partial 
responsibility for prescribing drug therapy. The agreement of the general 
practitioner was always sought before the patient went home and care was shared 
between the primary care and secondary care teams to varying extents. North 
Staffordshire Hospital won a Pharmaceutical Care award for shared care in 1998 
for its multidisciplinary team providing home infusions for cystic fibrosis 
patient’s [146].
Latham [153] discusses the fact that care for cystic fibrosis patients is not 
provided equitably around the United Kingdom and when a quality service is 
provided it is dependent on the enthusiasm of an individual clinician to treat the 
illness. She reports a study of six health regions showing that cystic fibrosis 
patients were hospitalised at least once a year, for an average of 11 days, with the 
longest stays for the 0 to 4 and the 15 to 20 age-groups. Another study showed 
the cost of treating these patients is £10,000 per patient in a specialist centre and 
the cost of drugs alone in a study in Birmingham in 1989 was £95,000 for 
inpatient drugs and £216,000 for outpatient drugs for a population of 92 cystic
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fibrosis patients. One general practitioner costed the drugs for his one cystic 
fibrosis patient in London in 1993/94 as being £16,740, 8% of his entire practice 
budget. Latham suggests a solution would be to share care and cost between the 
local provider and expert specialist centre so that the local hospital (or general 
practitioner) does not have to bear the largest financial burden, when extra 
funding goes to the specialist centre who do less clinically. This was written in 
the pre-EL(95)5 [41] period and since then some progress has been made in 
taking responsibility for funding intravenous antibiotics given at home away 
from the general practitioners.
The Royal College of Physicians published guidance for purchasers on the kind 
of care they should be arranging for patients with cystic fibrosis. It was prepared 
by the Cystic Fibrosis Trust in conjunction with the British Paediatric 
Association and British Thoracic Society and was drawn up by 15 senior 
consultants [154]. Littlewood [154] explains that in Leeds there is a separate 
contract for cystic fibrosis patients sub-divided into adults and children and 
further divided into five lines which are the contract currency. Home care is one 
of these five lines.
3.1.1.1.2 Other indications for home antibiotic therapy 
Following the work of Rucker [136] in 1974, researchers in the United States 
looked into home treatment for many other infections which required prolonged 
hospital admission purely for the administration of intravenous antibiotics.
These included bone and joint infections, endocarditis, pyelonephritis, 
pneumonia and soft tissue infections [23, 120, 123, 155-157].
In 1978 Antoniskis et al [156] compared 14 patients treated at home with 
antibiotics for infective endocarditis or osteomyelitis with seven controls treated 
conventionally in the hospital. The major concern was the potential hazards of 
home therapy but the study reassured the researchers that outpatient parenteral 
antibiotic self-administration was no more dangerous, and no less efficacious, 
than inpatient nurse-administered parenteral antibiotics providing patient 
selection and education are appropriate.
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Stiver and his team [155] reported the results of treating 23 patients over 12 
months for a range of both fungal and bacterial infections. The results were 
compared to those of matched controls. The patients were visited by a nurse in 
their homes daily and antibiotics were aseptically prepared by the hospital 
pharmacy department and delivered to the patient’s homes in a frozen state. The 
same team later described their experience with 95 patients with similar success 
[120]. Home therapy failed in 10 patients who required subsequent treatment in 
hospital. Of the remainder of the 102 courses of home therapy the patient 
returned to school or work in 29 instances, and could not work but resumed 
social activities in 64 instances.
Kind et al [157] studied 15 patients with infective endocarditis and 
osteomyelitis. These patients returned to the hospital for catheter changes and to 
pick up new supplies every 48 hours. They were provided with heparin and the 
antibiotics prepared aseptically in the hospital pharmacy. The intravenous nurse 
team, based in the pharmacy department, was the first to report a problem with 
patient compliance with one of the patients finishing her antibiotic course 
prematurely. As with the previous studies no major problems were reported.
The benefits were that the patients could return to their usual way of life and 
even to work or school and that this method of treating patients was substantially 
cheaper than conventional methods. The issue of compliance and adherence to 
protocols by patients was later studied by Boyer [158] and the need to monitor 
this is now recognised [143].
A larger study was reported by Poretz et al [23], 150 patients were treated for 
osteomyelitis, septic arthritis, pyelonephritis, endocarditis and other infections. 
Antibiotics used included penicillins, cephalosporins, aminoglycosides, 
clindamycin, chloramphenicol, vancomycin, piperacillin, moxalactam and 
ceftriaxone. Antibiotic solutions were prepared in the hospital pharmacy and 
given to the patient to keep refrigerated until use. The programme was co­
ordinated by a hospital pharmacist from the pharmacy with the help of an 
intravenous nurse. Complications were not serious and occurred infrequently. 
Patient acceptability was high allowing patients to return to their normal 
lifestyles and representing a cost saving and more prudent use of acute-care beds.
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In an editorial commenting on the work of Poretz, Frame [159] stated that control 
systems were mandatory and required the involvement of hospital-based 
pharmacies, intravenous therapy services and 24-hour-a-day availability of 
medical personnel to ensure the high rates of efficacy reported in the literature
Rehm et al [112] reported treating 48 patients with antibiotics at home for 
conditions such as osteomyelitis, wound infections and endocarditis. The 
patients were taught to reconstitute and administer mostly p-lactam antibiotics by 
a pharmacist. By this time subclavian central (Hickman) catheters were being 
used for patients requiring longer-term treatment to obviate the need for 
continual replacement of peripheral cannulae. The importance of a multi­
disciplinary team being involved in patient selection, education and follow-up 
was stressed in this study. 49% of patients referred for possible home therapy 
were rejected after evaluation by the team. These stringent selection criteria 
were considered vital to the success of the project.
3.1.1.2 Advances in Drug Therapy
Studies treating patients with p-lactam antibiotics found that a four or six hourly 
dosing schedule put a lot of stress on the patients, was time consuming and 
resulted in sleep deprivation [152, 160]. The introduction of newer 
cephalosporins with pharmacokinetic profiles allowing once or twice daily 
administration in the early eighties meant that the time spent administering 
antibiotics could be reduced and patients could call into the hospital, or doctor’s 
office or be visited by a community nurse for the daily dose [123]. It was shown 
that patients could be effectively treated on an outpatient basis attending a clinic 
or hospital each day for administration of the antibiotic and their introduction 
was followed by many studies showing that newer cephalosporins could be 
safely and effectively administered in the home setting [161-164].
Francioli et al [126] evaluated the safety and efficacy of ceftriaxone in the 
treatment of Streptoccocal endocarditis in an open, multicentre, non-comparative 
study. Fifty-nine patients in three European countries were treated with 
ceftriaxone once a day for four weeks and were followed-up for periods of 4
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months to 5 years. No relapses occurred but therapy had to be stopped because 
of drug allergy in four cases and reversible neutropenia in two. When the 
condition of the patient permitted and there was adequate care available near to 
the patient’s home patients were discharged from the hospital. It was concluded 
that this was a safe and efficacious treatment for streptococcal endocarditis, was 
easy to administer and allowed outpatient treatment for carefully evaluated and 
stabilised patients.
The safety of home intravenous antibiotic therapy for endocarditis patients was 
questioned by Colford and colleagues [165]. They retrospectively studied the 
notes of seven patients with blood cultures positive for viridans group 
streptococci, all of whom had been treated with home intravenous antibiotic 
therapy. Only four of the seven patients successfully completed their course of 
antibiotics. Therapy was interrupted in two patients because of line-related 
complications and one patient was readmitted due to recurrent emboli. The 
authors concluded that until relative safety and efficacy have been assessed in a 
prospective, randomised, controlled clinical study it was premature to assume 
that hospitalised and home-based antimicrobial therapy are associated with 
similar outcomes. Durack et al [166] who were embarking on a prospective trial 
of home therapy for endocarditis commented that these problems were those of 
home therapy and not specifically of the treatment of endocarditis. Tice et al 
[167] stated that complications such as phlebitis and line infections have been 
reported as being lower at home than corresponding hospital rates and that these 
complications may well have been just as likely to happen in a hospitalised 
patient.
Provision of antibiotic infusions in a frozen form was used by Stiver [155] in 
1978. During the mid-eighties commercial home care companies started to 
provide home antibiotic therapy and partnerships between hospitals and 
companies were formed. The commercial availability of pre-mixed antibiotics 
with stability when kept frozen at -20°C for 30 days or more with no loss of 
activity on thawing for up to 24 hours if refrigerated further expanded the
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flexibility in selection of antimicrobial agents and patients eligible for 
participation in home antibiotic therapy schemes [168].
The choice of antibiotic to use in a home care programme was discussed by Reed 
[169]. He suggested a formulary of drugs be drawn up and evaluated for use in 
the relatively uncontrolled home environment. The phamacokinetic parameters 
of the drug are important as infrequent drug administration allows minimal 
interference with the patients day to day life, potentially increases compliance 
and broadens the population of patients who can plausibly be treated with home 
intravenous antibiotic therapy. Newer longer acting drugs may however increase 
patient morbidity if compliance is a problem. Pharmaceutical considerations 
must be taken into account if an antibiotic is to be used in the home environment. 
Stability data showing the drug to retain potency in the conditions of home, work 
or school must be considered. Monitoring requirements and toxicity should be 
taken into account, as problems may not be discovered as quickly if the patient is 
in the domiciliary setting.
Ball [170] was prompted to allow the home administration of teicoplanin for line 
infections in children with leukaemia by the parents of the children. In order to 
limit the number of hospital attendances and maintain the children at home for as 
long as possible indwelling Hickman or Broviac central catheters were used.
This allowed the administration of parenteral analgesia and blood products.
When a line became infected the patient was admitted to hospital or given 
teicoplanin during a daily visit to the hospital. The parents felt that they were 
already familiar with heparinising these lines and felt able to administer the dose 
of teicoplanin themselves rather than travelling to the hospital each day. Five 
children received teicoplanin at home and in all five the treatment was effective 
with symptoms resolving within 2-3 days. No adverse effects were reported. It 
was concluded that this treatment improved the quality of patients’ lives and was 
cost-effective saving hospital admission costs. Teicoplanin has since been 
shown to be safe and effective for non-inpatient therapy [171, 172] [173, 174] 
[175].
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3.1.1.3 Advances in Drug Administration
The administration of antibiotics to patients with osteomyelitis via an 
implantable pump was reported by Perry et al [176] in 1986. This novel 
approach was aimed at increasing local levels of antibiotic at the site of infection, 
whilst reducing the toxicity associated with high systemic levels of amikacin.
The length of hospital stay was decreased as patients could be discharged home 
with the pump in situ.
The innovative use of computerised ambulatory drug pumps (the CADD-VT® 
manufactured by Pharmacia/Deltec) was reported by Brown et al [160], This 
method of drug delivery was found, in 38 patients, to permit accurate drug 
volumes, exact dosing schedules and a reduction in nursing visits. It caused 
minimum disruption to the patient’s lifestyle and allowed four hourly dosing 
regimens without the need for the patient to wake during the night. Patients who 
previously could not be considered for home antibiotic therapy because of the 
lack of skills to self-administer were able to receive home intravenous antibiotic 
therapy. A peripheral intravenous access device was used for some therapies but 
the evolution of the long-line or percutaneous central venous catheter gave an 
alternative to subclavian or Hickman catheter placement in extended antibiotic 
therapies. Stability of drugs for 24-hour periods at room temperature or above 
and the need for concentrated solutions of the drugs in 50 or lOOmls of diluent 
created some pharmaceutical challenges. Acceptance by physician and patient 
was immediate and overwhelming but nursing staff were slow to become 
comfortable with the equipment.
Others were also able to demonstrate the success of programmable ambulatory 
infusion devices such as the CADD-VT®, Pharmacia Deltec for the 
administration of antibiotics in the home environment [114, 177]. Disadvantages 
included the fact that the patient is continually attached to a pump, that the pump 
itself is heavy and that the cassette forming the drug reservoir only 
accommodated 100ml of fluid. Williams et al [177] discuss the relative benefits 
of other pumps available for home therapy. The use of these programmable 
infusion devices was found to extend the range of patients eligible for home 
intravenous antibiotics, avoid the use of newer, more expensive antibiotics with
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longer half-lives and cost no more than using the intravenous mini-bag system 
[114] [12].
A large prospective, open-label (unblinded), multicentre trial was reported by the 
home intravenous antibiotic therapy (HIAT) study group, in 1994 [128]. It 
highlighted the results of treating a variety of infections on an outpatient basis 
using cefotaxime and the CADD-PLUS ambulatory, programmable infusion 
pump (Pharmacia Deltec). A total of 238 patients in five infection categories 
were enrolled from 10 sites. Of the 211 patients who completed the study 95.3% 
exhibited a satisfactory or improved clinical response following treatment. It 
was concluded that the administration of cefotaxime via an ambulatory delivery 
system to outpatients was a clinically effective treatment of serious infections 
and may be less expensive than inpatient antibiotic therapy. In addition the 
patient’s quality of life may be improved and loss of income or interruption of 
education minimised and the risk of nosocomial infections may be reduced. The 
effectiveness of sub-populations of patients with diabetes mellitus, HIV [26], 
skin and soft tissue infections [178], patients suffering from pneumonia [179] 
and patients over 60 years of age [180] were also reported.
Baptista et al [8] reported their experience with 211 courses of home intravenous 
antibiotic therapy. 150 patients were treated including 56 with acquired 
immunodeficiency syndrome (AIDS). Antiviral, antifungal, antibiotic and 
antiprotozoal therapies were given in the domiciliary setting. Most courses were 
administered via a central access device ranging from implantable disks and 
tunnelled temporary catheters to Hickman lines and other central access methods.
Bernstein [181] wrote an update on home intravenous antibiotic therapy in 
elderly patients. These patients often require longer treatment than comparable 
disease in younger patients and are much happier in their home environment. 
Infections often have a less obvious presentation in the elderly and even serious 
infections, such as sepsis and pneumonia, may not result in noticeable fever or 
white blood count elevation. The initial refusal of Medicare and Medicaid to pay 
for home intravenous antibiotic therapy meant that few studies had included the 
older population. Starting in 1990 the Medicare Catastrophic Coverage Act of
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1988 would have covered drugs administered at home [39] but this act was 
repealed [181]. By 1991, many private insurers did cover home intravenous 
antibiotic therapy based on criteria established by the individual company.
3.1.1.4 Infusion Centre Model
These advances in administration techniques and in drugs with superior 
pharmacokinetic profiles led to the infusion centre becoming a model for 
outpatient antibiotic therapy. Poretz [182] described a separate building where 
pharmacy, laboratory, physician’s offices, examination rooms and finance 
departments were centralised for efficiency, flexibility and convenience. Each 
patient was seen by a pharmacist, nurse and doctor who shared data about the 
patient and offered 24-hour assistance. Costs in the centre ran at between 50 and 
60% lower than those in the hospital. Similarly Tice [183] reports the success of 
his office-based service using a wider range of drugs and reported treating more 
than 1,200 patients with no serious complications. Gourdeau et al [117] reported 
a slightly different model of providing home intravenous antibiotic therapy 
through a medical day unit.
3.1.1.5 Standards
Poretz [184] comments that it was nursing staff who were the first to recognise 
officially the growing importance of home intravenous therapy when the 
National Intravenous Therapy Association published guidelines for nurses 
involved with outpatient intravenous drug delivery in 1984. Much later in 1992 
the American Medical Association published guidelines for physicians involved 
in home infusion therapy. It was not until 1993 [185] that the American Society 
of Hospital Pharmacists drafted guidelines for pharmacists and minimum 
standards for the provision of home infusions were not published until 1999
[186].
Rich [115] reported that standards both in the form of guidelines from 
professional organisations and as law in certain States were becoming more 
common with the most extensive set of standards being those developed by the 
Joint Commission on the Accreditation of Healthcare Organisations (JCAHO)
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[187]. Approximately half of the home intravenous antibiotic therapy 
programmes in the USA in 1994 were hospital-based with about 2000 hospitals 
in the home care business. The home care agency was either established as a 
division of the hospital or an agency was set up as a separate affiliated company. 
Hospital pharmacies usually provided the pharmaceuticals and equipment, and 
the nursing staff of the home care division, the care. The other major sources of 
home intravenous antibiotic therapy were independent home infusion companies 
and a small number of home intravenous antibiotic therapy programmes run from 
physicians offices. Rich [115] went on to discuss the roles of the various 
members of the home care team and suggested that the provision of home care 
involves a major change in roles for health care providers. He also stated that 
home intravenous antibiotic therapy would continue to expand so long as 
adequate reimbursement is available and with the current emphasis on the cost- 
effectiveness of healthcare from government officials that looked likely.
3.1.1.6 Home Antibiotic Infusions in the United Kingdom
Littlewood [188] reported the findings of a study of the US National Alliance for 
Infusion Therapy (NAIT) of February 1993. The most common home infusion 
therapy in the United States was found to be antibiotics followed by enteral 
nutrition, parenteral nutrition, chemotherapy and analgesics, accounting for 58% 
of the patients receiving home infusion therapy from the 60% of the home care 
market surveyed. 38% of these patients were receiving home intravenous 
antibiotic therapy. Littlewood [188] points out that although the other four 
categories of home therapy are being developed in the United Kingdom home 
intravenous antibiotic therapy has been slow to gain acceptance and there seems 
to be no good reason for this. It can often be administered peripherally rather 
than by a central line and the drugs and administration cause far fewer 
complications than TPN or chemotherapy. It is more cost-effective than 
hospitalisation and although in the United States 70% of patients receiving home 
intravenous antibiotic therapy use pumps, gravity feed is perfectly safe and the 
availability of pumps ought not to be a limiting factor. She suggested that the 
problem of transferring this treatment and associated costs from secondary to 
primary care and agreeing shared-care protocols and shared budgets for these
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patients was one of the obstacles in the path of the development of home 
intravenous antibiotic therapy in the United Kingdom and asked whether 
pharmacists ought to be playing a more active role in promoting and developing 
this service.
Conlon [99]discussed the issue of sharing the care of patients receiving home 
intravenous antibiotic therapy (2.1.3.7). He reports that in the United Kingdom 
the drive to develop home intravenous therapies is as much about quality of care 
and appropriate bed-usage as it is cost and that the aim of home intravenous 
antibiotic therapy should be “to provide the best treatment for the patient’s 
infection with the least disruption to the patients life while optimising safety and 
bed usage”. The importance of a written protocol was stressed so that all parties 
were aware of their role. The availability, 24 hours a day, of a help-line for the 
patient, general practitioner or community nurse to contact the hospital home 
care team was also considered vital to the success of a home antibiotic service. 
Monitoring could be shared and the clinical legal and financial responsibilities 
for the patient should be made clear in the shared care protocol.
Nathwani [189] [40] also discusses outpatient and home antibiotic therapy 
programmes in the context of shared care. He reported that 76% of GPs saw no 
advantage to themselves and a substantial disadvantage (70%) in terms of 
increased workload. However 94% thought that patients would benefit from 
being treated in their home environment. The current models in the United 
Kingdom for delivering outpatient and home antibiotic therapy are demonstrated 
in Figure 3.1. Parker et al [190] demonstrated a saving of 532 bed days in a year 
using non-inpatient intravenous antibiotics but point out that real progress in this 
area will require better co-operation between hospital and community services.
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Nathwani and Davey [37] again questioned the slow emergence o f home 
intravenous antibiotic therapy in Britain and Europe compared to the USA. The 
authors comment that intravenous antibiotics are used far less frequently in 
Britain than in the USA and a change in treatment philosophy of serious 
infection would have to come about before a large increase in home intravenous 
antibiotic therapy would be seen in Britain. They report the findings of a survey 
of hospital doctors who stated that obstacles to this model of therapy include 
reluctance to try something new, lack of good clinical data relevant to the British 
health infrastructure, practical organisation problems including funding the likely 
increase in drug costs and concern about reducing the number of available 
hospital beds. Despite this reluctance there is growing experience of community 
intravenous antibiotic therapy in Britain for recurrent infections in patients with 
cystic fibrosis and cancer, chronic orthopaedic infections and for infections 
complicating AIDS. The problem arises that early discharge of patients does not 
save the hospital money in the short term as beds are immediately filled with 
other patients and in fact the cost per patient day may increase. Purchasers and 
providers need to develop a business plan including home intravenous antibiotic
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therapy with realistic short and long-term budgets. Quality assurance standards 
for these services including the processes of selecting, assessing, training and 
treating patients as well as monitoring outcome are in place in other countries 
and should be adopted here. The future of home intravenous antibiotic therapy in 
Britain depends very much on the shift of funding from secondary to primary 
care. It was concluded that there ought to be a strategy outlining adequate 
community support and clear definitions of clinical responsibility between 
hospital and community services. Their call for a nation-wide NHS strategy for 
purchasing outpatient intravenous treatment was supported by Conlon et al 
[191].
Kayley reported experience of a home based programme [25] developed through 
caring for AIDS patients with cytomegalovirus retinitis requiring lifelong 
foscamet or ganciclovir. Sixty-seven patients were treated with home 
antimicrobial therapy for conditions including osteomyelitis, septic arthritis, 
discitis, vascular graft sepsis, endocarditis, fungal sepsis and cytomegalovirus 
retinitis with a range of antibiotic, antiviral and antifungal drugs. Depending 
upon the patient the antibiotics were either self-administered, administered by a 
partner, a district nurse or a doctor. District nurses were trained to look after 
these patients and a clear shared-care protocol was written which gave back-up 
telephone numbers and clearly stated who was responsible for what. The home 
care team included a consultant in infectious diseases, a community specialist 
nurse in intravenous therapy, a hospital pharmacist, an infectious diseases senior 
registrar, clinical microbiologist and clinical nurse specialist in TPN. All 
patients had a subclavian central venous line. Complications were few and the 
three line infections reported all occurred in AIDS patients with lines in situ for 
more than six months. The programme resulted in a considerable saving in 
hospital beds and patient, community nurse and physician satisfaction.
Fay and Evans [192] describe their experience of providing non-inpatient 
intravenous therapy from a paediatric oncology ward. They note that parents feel 
that practical involvement gave them a feeling of control and alleviated, rather 
than added to their anxiety. However it may be too demanding at certain stages 
of their child’s illness.
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A consensus statement on outpatient and home parenteral antibiotic therapy 
(OHPAT) in the United Kingdom was published in 1998 [193], It stated that 
OHPAT has low government priority and existing activity is poorly co-ordinated 
and under-resourced. There have been calls within the NHS for approaches that 
reduce delays in discharging patients and lessen the need for admitting them in 
the first place, both of which OHPAT achieves. The consensus statement advises 
healthcare workers and managers on how best to develop, fund, implement and 
evaluate a new or existing programme.
An audit to evaluate the effects and treatment outcomes of orthopaedic patients 
receiving home antibiotics via a PICC line was carried out in Chester [194]. A 
model was used whereby a nurse specialist placed a PICC line and taught the 
patients to administer their own antibiotics and supported them at home. The 
audit consisted of a patient questionnaire, staff questionnaire, and examination of 
documentation and drug and equipment costs. Patients were satisfied with 
education and emotional support, staff were easy to contact and problems were 
dealt with quickly. 86% of nurses were confident in dealing with patients with 
PICC lines and documentation was 100% complete. 75% of patients had no 
incidence of line occlusion and 81% had no incidence of line sepsis. There was 
one incident of mechanical phlebitis.
Newland and Ketley [173] report treating haematological malignancy patients 
with teicoplanin and ciprofloxacin as non-inpatients instead of their inpatient 
regimen of gentamicin and piperacillin. They reported favourable outcomes, 
acceptance by patients and cost savings although highlighted the fact that vacated 
beds do not remain empty. Non-inpatient treatment increases the efficiency of 
the unit but does not reduce operating costs. They also noted that issues of 
payment and medicolegal responsibility need clarifying.
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3.1.2 Home Parenteral Nutrition (HPN)
3.1.2.1 History
In a brief history of home parenteral nutrition (HPN) Grundfest and Steiger [195] 
attribute the idea of providing enough nutritional support intravenously to 
achieve positive nitrogen balance to Elman in 1948. In 1952, Aubaniac went on 
to describe the technique of percutaneous subclavian venipuncture and in 1968 
Dudrick et al proved that hypertonic solutions of dextrose, amino acids vitamins 
and minerals could be delivered safely and easily through a polyethylene central 
venous catheter and that such solutions could provide normal growth and 
positive nitrogen balance while putting the bowel at rest.
Scribner et al [116] first described the concept of an artificial gut system for 
patients incapable of enteric feeding (3.1). In 1973 the same team introduced a 
right atrial catheter which facilitated self-administration of nutrients and also had 
a cap which allowed heparinisation to keep the line patent [196]. Experience 
with 22 catheters placed in 18 patients requiring long-term total or supplemental 
parenteral nutrition was reported. The development of an indwelling silastic 
catheter was an important advance. It had a Dracon-cuff and was made of 
silicone rubber. This had the advantage of allowing TPN to be delivered to high 
blood flow areas such as the right atrium. The silicone was biologically inert and 
decreased catheter obstruction and thrombosis. It’s pliability allowed it to be left 
in place for long periods in the right atrium and superior vena cava without 
causing perforation. One catheter had been in place for 15 months but the 
average life span was 3.9 months. The cuff was placed in a subcutaneous tunnel 
and growth of fibrous tissue around it acted as a barrier to infection. Broviac and 
colleagues [196] recommended the use of this catheter in-hospital or at-home for 
parenteral alimentation that was required for four weeks or longer. It later 
became known as a Broviac catheter.
In 1978 came the development of the wider bore Hickman catheter which was 
widely used in home parenteral nutrition (HPN) patients because of it’s improved 
construction durability and dependability [197].
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In 1973 a Canadian study [198] reported experience with one patient who was 
treated for 23 months with HPN via an indwelling silastic catheter. A 36 year 
old house-wife and mother of three young children was successfully rehabilitated 
100 miles away from the centre looking after her. A pneumatic pressure system 
was used to infuse the nutrients overnight. The patient suffered no episodes of 
infection. This was attributed to the use of filters as solutions had grown visible 
organisms and fungus had been cultured from solution remaining in the bag at 
the end of the infusion period. During a total of 30 months of infusion the 
silastic catheter was retained with no incidence of reaction or thrombosis.
The same team later reported their experience of treating 12 patients with HPN, 
surviving 4 months to 5 years [199]. The patients either had massive 
gastrointestinal loss from vascular injury or inflammatory bowel disease or had 
chronic intestinal obstruction. Venous access was via Broviac catheters 
introduced into the superior vena cava. The mean survival of these catheters 
without complication was 15.8 months but in four patients they had lasted for 
more than 28 months. All but two patients were able to maintain ideal body 
weight and were socially rehabilitated. Three patients developed catheter 
infections which were all successfully treated. These were all patients who 
suffered from continuing abdominal sepsis. These rates of infection were no 
higher than might have been expected in the hospital setting [200]. It was 
concluded that quality of life was improved for all of these patients who were 
able to return to family life and some to work or classes. One even managed to 
take a holiday across the Atlantic. The alternative for these patients would have 
been a chronically malnourished state or permanent residence in hospital. 
Depression was a problem in the two patients who had a history of depression 
but most patients coped well. Centralised preparation of the nutrients was 
carried out in the hospital pharmacy and was reported to have many advantages 
over preparation by the patient. These included freeing up the patient’s time, 
reducing the frequency of visits to the pharmacy, modification of composition 
without patient re-education and quality control. It was concluded that HPN was 
safe and required a remarkably simple delivery system but there remained a huge 
scope for further research into nutritional requirements of such patients.
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Fleming et al [201] used the same tunnelled catheter to deliver home parenteral 
nutrition (HPN) in seven patients with extensive Crohn’s disease of the small 
bowel and malnutrition. They successfully provided HPN for a total of 120 
patient months. Patient care was co-ordinated through a multidisciplinary HPN 
team which consisted gastroenterologists, pharmacists, a gastrointestinal surgeon, 
a social worker, a psychiatrist, a nurse and a business manager. Pharmacists took 
the leading role in teaching HPN techniques which took on average 2Vi weeks in 
hospital after the insertion of the catheter. In this study the patients were taught 
aseptic technique and made up the solution themselves. A local pharmacist 
supplied the necessary nutrients. HPN was not found to reverse or prevent 
complications of Crohn’s disease other than malnutrition. Depression was again 
noted in some patients. No line infections were seen. After the patients started 
on HPN the number of hospital admissions was halved when compared to an 
equal period before HPN. Quality of life for these patients improved with return 
to more normal lives and pain relief requirements for abdominal pain decreased.
Two years later the same team reported further experience with 23 patients 
treated with cyclic nocturnal HPN [202]. Average weight gain was 13.6kg. 12 
patients had returned to work or school, six were active housewives and the 
remainder remained disabled by their underlying disease. One death occurred 
from a hyperosmolar coma, there was one episode of bacteraemia, one of 
infection at the catheter entry site and 4 displaced and 5 damaged catheters.
HPN was concluded to be a safe alternative to prolonged hospitalisation which 
could dramatically replete the chronically malnourished patient.
In 1978, Strobel et al [203] reported treating 34 paediatric patients with HPN. 34 
patients, ranging in age from IV2 months to 2OV2 years, were treated for 23 to 786 
days. Solutions were infused over a 10-14 hour period each day via a volumetric 
pump. They were obtained from and prepared by the hospital pharmacy and 
refrigerated until used. All patients experienced weight gain sufficient to 
improve their percentile standing on standard growth charts and, regardless of 
disease state, all experienced a decrease in symptomatology and improved 
general state of well-being whilst receiving HPN. Normal lifestyles were 
encouraged including participation in sporting activities. Infection of the
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catheter tip occurred in four instances and sepsis in a further four. In all 22 
catheters were removed because of complications, a rate of one per 359 days. It 
was concluded that HPN is a safe, simple and effective means of maintaining 
optimal nutrition in paediatric patients with severe digestive tract disorders and 
that patients and their families benefit psychologically by being at home and 
resuming relatively normal lives.
Byrne et al [204] noted that total published experience with the techniques used 
for home parenteral nutrition (HPN) was still small and presented data on a 
further 106 patients. Following this there were many further reports, all of which 
concluded that HPN, was safe and effective, with low complication rates. A 
Danish team [205] reported treating 19 patients with long-term parenteral 
nutrition mostly at home for six to 63 months, Grundfest et al [195] treated 43 
patients at home for 45 months reporting that obstruction was less of a problem 
with the wider bore Hickman catheters. Fleming et al [206] used Broviac 
catheters tunnelled subcutaneously down the anterior chest wall in 27 patients 
and found a difference in complications and life span of the catheter between 
adolescents and adults and Dudrick et al [197] reported their experience of 100 
patient years of ambulatory home TPN in 133 patients between May 1974 and 
December 1983. Average implantable catheter life was 250 days with the 
longest being in place for eight and a half years. The catheter sepsis rate was 
once every 2.6 catheter-years.
A questionnaire survey was carried out in the USA during 1979 [207] to 
establish a baseline of pharmacy involvement in HPN. It was found that the 
“typical” hospital providing HPN services was a private, non-profit, greater-than- 
400-bed, university-affiliated teaching hospital. The mean length of existence of 
the HPN programme was 3 years and majority (67%) of the hospitals were 
treating 2 or fewer patients. In 57% of the programmes the hospital pharmacy 
exclusively provided pre-prepared parenteral nutrition solutions to the patients 
and in 25% the patient or family member prepared the solution at home.
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3.1.2.2 The United Kingdom
The first report of HPN being used in the United Kingdom came from Hope 
Hospital in Manchester in 1980 [208], Five patients were treated at home for W2 
to 9 months. Four of the patients were able to return to oral alimentation and the 
fifth was likely to require TPN indefinitely. Broviac catheters were used and the 
patient was taught to use a constant infusion or overnight gravity infusions. It 
was commented that HPN was effective and added a new dimension to the 
treatment of these patients but the place of this expensive form of therapy in a 
society where health care was being subject to tight cash limits required further 
evaluation.
Later in the same year a symposium was held on HPN in England and Wales 
[36]. It was postulated that the reason HPN had not been developed in the 
United Kingdom to the extent it had in Europe and the USA was due to the 
absence of the need to pay hospital fees, medical inertia and problems with 
organisation and funding. A statement of the position regarding HPN was 
published [36]. Six centres had treated a total of 25 patients with HPN over the 
previous two years. Most were between 20 and 40 years of age. Crohn’s disease 
was the most common indication for treatment. Seven patients had died but only 
one death was caused by a complication of the treatment. At the symposium 
there was general agreement about which patients should be treated and that a 
subcutaneously tunnelled silastic catheter should be used for administration. 
There was disagreement as to the necessity of a pump. Catheter-related sepsis 
was virtually universally lower when the patients were at home than when they 
were in the hospital. The cost of maintaining these patients at home was high but 
considerably cheaper than undertaking the same treatment in hospital. The most 
satisfactory results were those where patients were tided over until their bowel 
adapted or disease remitted. Following this symposium the United Kingdom 
HPN register was set up to obtain information on the indications and benefits of 
HPN so that selection criteria could be developed for it’s more efficient use.
A report of the first 200 cases of HPN in the United Kingdom and Ireland from 
the HPN register was published in 1986 [7]. 28 centres contributed case-reports 
but 7 centres registered 15% of cases. Most patients were between 10 and 40
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years old with the majority of patients suffering from Crohn’s disease (90 
patients) or mesenteric vascular disease (27). 85 patients required treatment for 
less than a year and 17 for more than two years. It was found that patients whose 
indication for HPN was a primary intestinal disease had a better quality of life 
than those in whom the intestinal failure was secondary to a systemic disorder. 
There were 34 deaths, 10 due to complications of treatment, but 56 patients 
managed to return to enteral feeding. The mean incidence of catheter related 
sepsis was 0.35 episodes per year. This varied from 0.2 to 0.9 depending on the 
length of experience of the supervising centre and was probably related to 
experience of the nurses dealing with the patients and their ability to teach 
catheter manipulation and infusion techniques.
This finding was in line with results of studies from the USA [197, 206] showing 
that catheter-related sepsis can be reduced through adherence to a strict catheter 
care protocol and adopting a team approach to parenteral nutrition. Of the 200 
patients registered since 1977, 92 were still on treatment. It was noted that many 
centres rely on commercial firms to supply HPN patients directly with 3 litre 
bags containing one days supply of nutrients. Most used volumetric pumps to 
infuse the solution overnight. The authors estimated that about 2 patients per 
million in the United Kingdom need HPN each year and suggested that if this 
was the case there would be 100 new registrations each year. It was concluded 
that although HPN cost about £25,000 per patient per year in the United 
Kingdom, used discriminately it is cost-effective. The ability to look after a 
family or work gainfully offsets the cost of HPN to some extent.
The largest centre in the United Kingdom at Hope Hospital in Manchester 
published a review in 1988 of 100 patient years of HPN in 76 patients [209].
The most common primary disease was Crohn’s and the most common post- 
surgical complication, short bowel syndrome. 40% of patients required HPN for 
six months or less but one patient had been on treatment for seven years. 
Catheters used included Broviac (56%), Hickman (13%), Vygon Nutricath 
catheters for shorter-term cases (28%) and Portacath in 2 patients. The quality of 
life measured on a four-point scale was good for the majority of patients. 35 
went to work full-time and 13 part-time, school children were able to take exams
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and four healthy babies were bom to three of the women. Three of these 
pregnancies were reported separately [210]. Sepsis and superior venal caval 
thrombosis were the main problems encountered. The overall mortality rate was 
18%. Five deaths could be related to HPN. The sepsis rate was 0.14 episodes 
per patient per year and the overall complication rate was equivalent to one 
complication every 3.1 patient years. It was concluded that HPN is an effective 
and safe treatment of intestinal failure and recommended that dedicated units for 
providing HPN be established on a regional or supraregional basis.
Puntis [211] drew attention to the importance of training patients and parents 
prior to discharge from hospital, including adequate psychological preparation 
together with explanations regarding the indications for nutritional support and 
instruction in safety and hygiene. He states that some parents will be unable to 
cope with the technical and emotional demands of HPN, which are far greater 
than those for home enteral nutrition. HPN has the benefit of possibly preventing 
the developmental retardation and adverse emotional effects which are otherwise 
virtually unavoidable consequences of long-term hospitalisation. However in 
selecting children for HPN he stresses that it is necessary for parents to be highly 
motivated, have a stable relationship, adequate housing and to be of above 
average intelligence. In a review of ten children on HPN all parents regarded 
HPN as infinitely preferable to hospital care. The importance of planning, good 
training and formalised shared care was echoed by Long [212].
Initially most patients receiving HPN in the US had undergone massive bowel 
resection for Crohn’s disease or mesenteric vascular injury or suffered from 
severe short bowel syndrome [201, 204]. In 1991 the American Society for 
Parenteral and Enteral Nutrition (ASPEN) published a report [134] on outcome 
of home parenteral and enteral nutrition. Cancer was the most common 
diagnosis requiring such therapy and the percentage of new patients infected with 
the HIV virus and diagnosed with AIDS who received parenteral nutrition was 
found to equal the number of new Crohn’s patients. Mughal and Irving [7] had 
reported in 1986 that there appeared to be less emphasis on the treatment of 
malignant disease with HPN in the United Kingdom than in the United States 
where malignancy was the indication in a third of those registered. The numbers
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of patients with malignant disease and AIDS being treated with home TPN in the 
UK are increasing [213]. The ASPEN report also stated that most patients on 
HPN had either no hospital readmissions or one and that related mortality was 
3%.
A systematic review of home parenteral nutrition was published in the UK in 
1997 [213]. This concluded that the quality and range of evidence of 
effectiveness was disappointing. The types of patients being treated were well 
documented as were complications, survival, duration of therapy and reasons for 
discontinuing treatment, however organisational models had been poorly 
assessed particularly the contribution of the organisational model to patient 
outcomes. A need was identified to properly evaluate all changes in delivery 
management.
Home TPN has become an established therapy in the UK [101, 213].
3.1.2.3 National Standards for HPN
The American Society for Parenteral and Enteral Nutrition (ASPEN) have 
published standards for home nutrition support the most recent update being in 
1999 [214] with the aim of assuring sound and efficient home nutrition support 
care and assist organisations and health professionals in providing safe and 
appropriate nutrition care. The standards give examples to ASPEN’s 
multidisciplinary members of implementation of specific standards. After the 
first version of these standards was published there was a call for standards and 
structures of service to be defined nationally in the United Kingdom for the 2,300 
patients on home enteral nutrition and 210 patients receiving HPN [215]. The 
question of funding required clarification and the quality of training and support 
materials needed to be improved [215].
In 1994 a working party of the British Association for Parenteral and Enteral 
Nutrition (BAPEN) produced standards to guide those responsible for organising
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the care of a person who needs parenteral nutrition at home. There had recently 
been a change in the way HPN was funded, the contract for the provision of 
nutrient solutions, equipment and all other needs had to be agreed between a 
Health Authority, acting as purchaser, and a supplier. Included in these 
standards was the requirement to produce guidance on the contribution and 
responsibilities of the general practitioner and agree a shared-care protocol, 
provide adequate training to meet goals laid down in the document and well 
organised, timely supply of the feed and equipment. The financial clarification 
came later in the form of EL(95)5 [41].
As experience grows with techniques for central venous access and establishing 
long term nutritional requirements and more efficient monitoring becomes 
available, the complications associated with the provision of HPN are decreasing. 
A comparison of the catheter-related sepsis rates related to home TPN in the 
studies reviewed here is shown in Table 3.1.
All of these studies have not only contributed to the development of the model of 
delivering TPN at home but have also contributed to overall knowledge of the 
nutritional requirements of the human body in the longer term. The aim with the 
majority of patients who have been treated has been bowel adaptation, inducing 
remission of the underlying disease or managing fistulae which might otherwise 
have led to life-threatening sepsis but there are some patients who would have no 
hope of survival if TPN was withdrawn and the availability of this therapy in 
their home environment has undoubtedly lead to a quality of life for these 
patients that was previously impossible to attain [7, 197, 216].
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Table 3.1, Comparison of Catheter Sepsis Rates in Published Reports of HPN Programmes
Study Year Institution N o o f  pts in 
study
Catheter sepsis rate Deaths from sepsis/
Total deaths related to HPN
[28] 1994 Hope Hospital, 
Manchester, 
United Kingdom
50 13 episodes of bacterial catheter sepsis, 10 
episodes of exit-site sepsis 
1 septic-complication per 113 patient months of 
HPN
0.12 episodes per year of treatment
Not reported.
[209] 1988 Hope Hospital,
Manchester,
United Kingdom
76 0.14 episodes per patient per year 1 sepsis
5 related to HPN
[7] 1986 United Kingdom and Ireland register
of HPN, Hope Hospital, 
Manchester
200 0.35 episodes per year of treatment, (range 0.2-0.9) unknown sepsis
10 related to complications of
treatment
[197] 1984 St Luke’s Episcopal Hospital, 
University of Texas,
USA
133 0.38 episodes per year for implanted catheters (4 
patients sustained 24 of the 33 episodes) and 
0.33episodes per year for temporary catheters
0 sepsis
No deaths reported
[208] 1980 Hope Hospital, 
Manchester, 
United Kingdom.
5 septicaemia occurred in 2 patients during the 





Study Year Institution N o o f  pts in 
study
Catheter sepsis rate Deaths from  sepsis/
Total deaths related to HPN
[195] 1980 Cleveland Clinic Foundation, 
Cleveland, Ohio, USA.
43 Unknown. Most frequent reason for catheter 
removal was suspected sepsis
Unknown. 1 patient died from 
iatrogenic causes
[206] 1980 Mayo Clinic, Mayo Foundation, 
Rochester, Minnesota, USA.
27 6 episodes of septicaemia in 5 patients 
0.11 episodes per year on HPN
0 sepsis 
0 due to HPN
[36] 1980 6 United Kingdom centres 25 unknown but less when patient at home than when in 
hospital
1 sepsis 
1 due to HPN
[204] 1979 UCLA Centre for Health Sciences, Los 
Angeles, USA.
106 18 episodes in 12 patients 
0.27 per year on HPN
0 sepsis 
0 due to HPN
[202] 1979 Mayo Clinic, Mayo Foundation, 
Rochester, Minnesota, USA.
23 1 episode of bacteraemia in 34.17 years of patient use 
0.03 per year on HPN
0 sepsis
1 HPN
[205] 1978 Rigshospitalet, 2100 Copenhagen, 
Denmark
19 0.6 episodes per year on HPN 1 sepsis
2 due to HPN
[203] 1978 UCLA Medical School, Los Angeles, 
California, USA.
34 0.22 episodes per year on HPN 0 sepsis
No deaths reported
[201] 1977 Mayo Clinic, Mayo Foundation, 
Rochester, Minnesota, USA.
7 0 in 10 patient years on HPN 0 sepsis
No deaths reported
[199] 1976 Toronto University & Toronto General 
Hospital, Ontario, Canada & Veteran 
Administration Hospital, Albany, NY, 
USA.




Traditionally cytotoxic chemotherapy has been delivered as intermittent bolus 
doses to achieve the highest possible levels of those drugs that the patient could 
tolerate to produce the maximum chance of significantly reducing the tumour 
burden and then allow recovery of haematological and immunological function. 
This has been successful in treating various cancers and very high doses have 
been shown to overcome resistance to a particular drug. Rescue techniques have 
also been developed so that a patient may be given a potentially lethal dose of a 
cytotoxic agent and be rescued with an autologous bone marrow transplant [217]. 
Most cytotoxic agents work by interfering with the process of cell replication but 
unfortunately they are not specific for cancer cells and have a narrow therapeutic 
index [218-220].
Attempts to improve the efficacy and side-effect profile of chemotherapy 
regimes led to the concept of infusional chemotherapy, the rationale being that, at 
any one time, for the majority of tumours only about 5% of the cells are in cell- 
cycle and therefore affected by the chemotherapeutic drug. The doubling rate for 
most common tumours is measured in months whereas the half-life for most 
cytotoxic drugs can be measured in minutes or hours. The idea therefore was to 
expose the tumour to the drug throughout its doubling phase and therefore 
expose all the cells to the cytotoxic drug. It was the tumours that had a rapid 
doubling time that responded best to traditional bolus chemotherapy, the 
postulated reason being that more cells were in the cell-cycle phase and exposed 
to the drug when it was administered [221].
There have been few prospective controlled trials comparing continuous 
chemotherapy with the traditional models. Continuous infusions have been 
shown to reduce toxicity associated with the peak levels reached with bolus 
dosing schedules [219, 222, 223] and permit a larger cumulative dose to be 
administered. However, some side effects such as hand-foot syndrome with 5- 
fluorouracil (5-FU) are increased when the drug is administered by continuous
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infusion [218] and one Dutch study [224] found that when vindesine was 
administered at low doses for 21 days it did not have a more favourable dose 
toxicity ratio, in fact it caused severe neurotoxicity. This was in contrast to the 
results of earlier studies [225]. It has been shown in some cases that continuous 
infusional chemotherapy does induce objective tumour regression but there is 
little evidence to show that this is superior to traditional regimens [217].
Seifert et al [219] compared continuously infused 5-FU with bolus injection in 
patients with colorectal adenocarcinoma and found the continuous infusion to be 
superior, most strikingly because of the lack of myelotoxicity in those treated 
with continuous infusions. Stomatitis was found to be the dose-limiting factor in 
the continuously infused group. Lokich et al [223] reported their experience of 
50 trials of home. Gastrointestinal toxicity was virtually eliminated for all five 
drugs used, alopecia was not observed at all in 3 out of 5 patients treated with 
adriamycin but hand-foot syndrome was observed with 5-FU. It was concluded 
that constant infusion cancer chemotherapy was feasible, reliable and safe.
Legha et al [222] reported a reduction in the cardiotoxicity of doxorubicin when 
administered as a continuous infusion. A control group treated with a standard 
regimen in hospital were prospectively compared with a treatment group who 
had doxorubicin administered as a continuous infusion via a portable infusion 
pump as an outpatient. 14 of the 30 patients in the control group showed severe 
changes in biopsy specimens precluding further doxorubicin administration 
compared to 2 of the 21 patients receiving the drug by continuous infusion. 
Antitumour activity was not compromised.
Coates et al [226] compared quality of life in two groups of patients receiving 
chemotherapy for advanced breast cancer. Continuous chemotherapy was found 
to be associated with a better quality of life than intermittent chemotherapy with 
similar efficacy.
Recent advances in technology such as advances in maintaining central venous 
access with catheters [196] or implantable systems [227], the availability of 
small, lightweight, accurate, infusion pumps and better assay techniques to
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evaluate stability have facilitated using regimens at home that could previously 
not be achieved.
There are few established regimens that use only one drug and there is some 
concern that resistance might develop to these drugs if they are continuously 
present in low concentrations. The possible use of pulses of high doses has been 
suggested to overcome this [217].
The EFC regimen of three-weekly inpatient therapy with epirubicin and cisplatin 
and continuous ambulatory infusion of 5-FU has been reported as being so 
astonishingly efficacious in a variety of solid tumours, including those of the 
stomach, oesophagus, breast and ovary that home infusion therapy may be 
established as a mainstay treatment rather than a novelty for enthusiasts [219, 
228], A multicentre study in the United Kingdom [229] has added further 
support to this. Overall response rate was found to be 45% in the ECF group 
compared to 21% with a standard regimen (5-FU, doxorubicin and methotrexate 
(FAMTX)). Median survival was 8.9 months with ECF and 5.7 months with 
FAMTX. The authors recognised that the routine use of palliative chemotherapy 
in advanced gastric cancer is controversial. This view was supported by Abang 
[230] studying chemotherapy versus best support care for advanced non-small- 
cell lung cancer. A Medical Research Council trial is now going ahead to study 
the use of the ECF regimen to shrink the tumour before surgery in patients with 
less advanced gastric cancer.
An advantage to continuous ambulatory chemotherapy is that patients are able to 
remain in the familiar environment of their own home rather than spending days 
in hospital receiving chemotherapy and then recovering from the devastating side 
effects. Family members often feel useless and unable to help but they can take 
an active role in care and the patients themselves can feel more in control 
administering their own chemotherapy [231, 232]. Familiarity with techniques in 
handling and manipulating drugs as well as knowing and understanding what 
problems may arise and knowing how to cope with them takes away much of the 
mystique surrounding this particular group of drugs. The familiar environment 
of the home setting and support of family and friends may also lead to a greater
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sense of well-being, an improved tolerance to drug-related side-effects and an 
overall improved quality of life [134],
Sewell et al [233] described a programme in the United Kingdom where 
continuous infusions of chemotherapy were administered via a subclavian line to 
outpatients over days or weeks. Accurate and reliable infusion delivery was 
achieved by using portable infusion pumps. Pre-filled syringes were supplied to 
the patient from the hospital pharmacy and a team approach was taken to patient 
care. The ward pharmacist carried out training and the patients were taught in 
advance how to deal with problems that may arise. More than 250 patients had 
received outpatient continuous cytotoxic infusions and it was concluded that if 
numbers were to increase further the co-operation and involvement of both 
hospital and community-based healthcare professionals would be necessary.
The same team reported the continued success of the HOPE (Home Oncology 
Programme, Exeter) in 1989 [127]. More than 350 patients were treated at home 
using a portable pump, with few difficulties and excellent patient acceptability. 
Patients with solid tumours of the breast, colon, oesophagus, pancreas and other 
sites, often with metastatic disease were considered for treatment in the HOPE 
programme. The catheter sepsis rate was less than 1% and the incidence of other 
adverse effects low.
A prospective randomised trial comparing inpatient with outpatient continuous 
infusional chemotherapy in patients with locally advanced head and neck cancer 
was reported by Vokes et al [234]. Patients chose to be inpatients or outpatients 
and crossed-over to the alternate delivery method for the second cycle. 11 
patients were treated as outpatients and 8 chose to stay in the hospital. The 
patients who received 5-FU as outpatients reported that it was convenient and 
effective and all chose it again. No significant difference between the frequency 
or severity of side-effects was found. It was again concluded continuous 
infusion outpatient chemotherapy was a viable alternative to in-hospital 
administration.
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A consultant oncologist advocated links between hospital oncology departments 
and general practice. He reported three patients who were receiving 
chemotherapy at home [235]. The drugs were given either by the patient’s 
general practitioner or by a specially trained practice nurse. General practitioners 
had not been reluctant to take on the administration of home chemotherapy but 
some had been reluctant to take on the cost.
A study to determine the quality of life of patients receiving low dose ambulatory 
chemotherapy and to identify areas where patients may need further help or 
advice was conducted in Exeter [236]. A questionnaire was designed, piloted 
and finalised using patient feedback. A researcher interviewed the patients 
during their fortnightly visit to the outpatient clinic. Results from the pilot (14 
patients) showed that 50% felt anxious and depressed and 93% stated how 
important their visits to the oncology outpatient clinic were. Giving up work was 
a particular problem for the male patients interviewed. Only 3 patients were 
aware of their ambulatory pump and six were worried about damaging the pump. 
70% of patients interviewed had either lost or gained weight and 79% said they 
no longer felt sexually attractive. Few problems were reported with the 
chemotherapy. This tool could also be used for comparisons of the quality of life 
of patients receiving traditional chemotherapy regimes in the hospital with 
patients receiving infusional chemotherapy at home.
Vasey and Steward [220] look at how GPs can improve the quality of life of 
patients receiving palliative chemotherapy. They note that the availability of 
small portable electric pumps has made it possible to treat these patients at home. 
The general practitioners role in shared care of these patients includes good 
communication with the hospital or cancer centre, monitoring between courses of 
chemotherapy or hospital visits, looking for the first signs of infection, 
monitoring pain and well-being, prescribing appropriate opioids, antidepressants 
and other medication and taking blood samples to cut down on the frequency of 
visits to the hospital. The general practitioner or district nurse may also be 
involved in helping the patient with the care of an indwelling central line to 
prevent infection or blockage.
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A prospective, controlled evaluation of home chemotherapy in children with 
cancer was reported by Close et al in 1995 [237]. Quality of life, billed medical 
charges and out-of-pocket expenses were compared when chemotherapy was 
given in hospital or at home. The first two courses of chemotherapy were given 
in the hospital and if suitable further courses were given at home. Quality of life 
was measured using a parent-scored Likert scale. Consumption of supplies and 
hours of professional’s time were measured in an unsuccessful attempt to relate 
costs to charges. 76 courses of home chemotherapy were administered avoiding 
312 days of hospitalisation. Charges for home chemotherapy were 17% less than 
for inpatient chemotherapy. Although this reduction was less than expected, 
home care was found to be far less disruptive to family life and quality of life 
was better at home.
Provision of a home chemotherapy service involves considerations which may 
not apply to other forms of home infusional therapy [134]. The importance of 
handling of cytotoxic drugs and disposal of waste must be stressed to the 
patients, families and anyone else involved. The patient and their relatives 
should be considered at risk to accidental exposure and cytotoxic waste may be 
excreted in the patients’ urine and faeces. Extravasation is more of a problem 
with this very toxic group of drugs and toxicities may be more severe and 
dehabilitating than with other home therapy. Chemotherapeutic agents should be 
made up in the doses required for infusion aseptically in a designated area of a 
pharmacy to minimise exposure to the drug, the risk of microbial contamination 
and the risk of an incorrect dose being administered.
The literature suggests that home continuous chemotherapy infusions with the 
potential for greater risk [134] have been more widely accepted in the UK [127, 
130, 228, 233, 235, 238] than the relatively lower risk home antibiotic infusions 
[37, 193].
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3.1.4 Home Opioid Infusions
Home infusions of opioids for the terminally ill have a well-established place in 
the clinical management of terminal disease where the primary concern becomes 
the quality of the patient’s remaining life. Various methods are available for pain 
control in these patients and include oral medication, transdermal opioid, 
intermittent injections, continuous infusions, epidural blocks, transcutaneous 
electrical nerve stimulation (TENS) and neurosurgical procedures. Pain is very 
patient specific as is pain relief. A drug, route and method of administration 
must be chosen that is effective and best suits the patient’s needs. When 
continuous opioid infusions are used they are most commonly administered by 
the subcutaneous route and most district nurses in the United Kingdom are very 
familiar with syringe drivers.
For some patients the subcutaneous or intramuscular route may not be the best 
choice due to lack of cutaneous tissue or coagulopathy may led to severe bruising 
after intramuscular or subcutaneous injection. Intravenous infusions of opioids 
have been shown to be very effective for pain relief following surgery [134] and 
for terminal illness [132, 239] and with the development of pumps, patient 
controlled analgesia (PCA) has become widely used both in the inpatient and 
home care settings [240]. There is no reason why patients who are terminally ill 
or recovering from surgery cannot be treated in the domiciliary setting with 
intravenous opioid infusions, providing that this is their only reason for staying 
in hospital. Reports of home intravenous opioid infusions are few but whether 
this is a reflection of the extent to which it is used is not known.
Fraser [239] reviewed the literature of the experience with continuous 
intravenous infusions of morphine reporting that experience has been favourable 
to date. He stated that intravenous infusions could provide uniform pain control 
by avoiding fluctuations and that the total daily dose of morphine that the patient 
receives may actually decrease. Caution was advised due to the potential for 
accidental overdose or suicide. This could be a problem if the patient was treated 
at home, however newer pumps have sophisticated lock-out devices. Miser et al 
[132] found continuous intravenous morphine infusions to be both safe and
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efficacious in the control of severe pain, regardless of the cause, in eight children 
with terminal malignancy. Side effects were common but mild and easily 
controlled. Adams et al [241] and Citron et al [131] report the use of intravenous 
morphine for severe cancer pain, finding it to be a safe, effective means of 
relieving pain, even in patients with borderline pulmonary status[131].
In 1988, Kerr et al [240] treated patients with chronic cancer pain at home with 
patient-controlled analgesia (PCA). 18 patients with poorly controlled cancer 
pain or significant side effects from regular administration of various narcotics 
were taught how to use a portable pump capable of delivering a continuous 
narcotic infusion with bolus capabilities. Patients received the drug 
intravenously or subcutaneously. Pain control was good and side effects 
acceptable. There were significant lifestyle improvements in several patients. 
One returned to work and three were able to travel outside the country with good 
pain control. Five patients were able to die at home with family support. It was 
concluded that this was a highly acceptable and safe method of controlling 
chronic cancer pain in an outpatient setting and that large doses of narcotics 
could be administered on an outpatient basis without significant problems.
A United Kingdom study [242] reported treating children with cancer at home.
A home terminal care team worked with the patient’s general practitioner and 
family to allow the patients to stay at home and to die at home with their family 
in a familiar environment. 12 patients died at home and received all the drug 
therapy that would have been administered had they been in hospital. Three 
patients had a central catheter inserted for administration of diamorphine and/or 
blood products and one patient received parenteral antibiotics at home. Care was 
shared between the staff at the specialist centre and the general practitioner, some 
choosing to become more involved than others. Hain and Goldman [243] 
advocate a similar model.
Local spinal administration of medication through epidurally or intrathecally 
inserted catheters and an indwelling infusion pump was reported by Muller et al 
[244] in 1988 to produce a considerably better efficacy and lower side effect 
incidence than conventional medication routes. If the catheter was inserted in the
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epidural space the dose required was about one eighth of the systemic dose 
whereas by the intrathecal route only one thirty-sixth of the systemic dose was 
required. 63 tumour-pain patients had been successfully treated using a 
continuous infusion through an implanted or external pump either intrathecally or 
epidurally. It was concluded that many of the patients treated would have had to 
undergo lengthy or perhaps even life-long treatment as inpatients but this 
treatment enabled most of the patients to be discharged to their own homes for 
continuing treatment with the pump systems.
3.1.5 Other home therapy
3.1.5.1 Haemophiliacs
Some of the very first patients to be treated with home infusional therapy were 
haemophiliacs. In 1970, Rabiner et al [245] reported a programme of training 
relatives of haemophiliac patients deficient in antihaemophilic factor to 
administer concentrate of the factor intravenously at home after telephone 
consultation with the physician. Consumption of antihaemophilic factor 
increased during the study. This was thought to be due to the greater willingness 
of the patients to report haemorrhages. The number of school or work days lost 
decreased when patients were admitted to the programme and it was postulated 
that in the long term there would be lower morbidity in terms of permanent joint 
damage as prompt treatment of joint haemorrhages would reduce trauma and 
delay onset of chronic arthropathy. Patients and their relatives were enthusiastic 
about the programme because of the time saved, rapid relief of pain and the 
opportunity of helping the patient within the family unit. It was concluded that 
the benefits of home therapy outweighed the theoretical risks.
In 1972, the same team reported three years experience with the home care 
programme with 36 patients [246]. Minimal technical problems had occurred but 
no serious transfusion reactions. The number of reported haemorrhages 
increased but the number of hospital admissions decreased. The incidence of 
severe orthopaedic problems decreased as did days lost from school or work.
The psychological impact on the families was considered to be of equal
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importance providing them with a sense of self-reliance, an increase in mobility 
and freedom from fear.
Another team working in Massachusetts came to the same conclusion [247].
They formally instructed 45 patients with haemophilia A and B in the 
management of their bleeding problems. Home infusion was permitted without 
prior consultation with a physician. Data from the study period was compared 
with data from the previous year. There was a 74% reduction in absenteeism, 
89% reduction in days hospitalised, 76% reduction in outpatient visits and 45% 
reduction in healthcare costs. No patient had morbidity attributable to this 
programme, although one relative was exposed to hepatitis from contaminated 
needles. There was a trend to more normal life patterns and six families took 
vacations away from home for the first time since the haemophilic member had 
been bom. A study of long term effects on orthopaedic problems was called for 
but it was concluded that self-therapy would seem to merit trials in the health 
care delivery of other chronic illnesses.
Similar success has been reported by teams in the UK [248, 249].
Recombinant factor VIII has since been developed with the advantage of a much 
lower risk of virus transmission. Many haemophiliac patients in recent years 
have died of AIDS because they were given contaminated factor VIII before the 
HIV virus was identified. In the United Kingdom products produced using 
recombinant technology are classified as drugs rather than blood products and 
pharmacy departments will be responsible for these products and possibly co­
ordinating home care arrangements.
3.1.5.2 AIDS
Pizzo et al [129] reported treating children with symptomatic HIV infection with 
continuous intravenous infusions of zidovudine (AZT). The rationale behind this 
was to produce concentrations of zidovudine (AZT) in plasma and cerebrospinal 
fluid that would provide constant inhibition of the replication of HIV. A portable 
programmable infusion pump was used to administer the drug. Children as
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young as one year of age were able to carry the device with no impediment to 
their daily activities. Bone marrow suppression was the only evidence of toxicity 
that occurred. Improvement of neurodevelopment abnormalities occurred in all 
13 children who had presented with encephalopathy before treatment. Most 
patients had increased appetite and weight gain, decreased lymphadenopathy, 
hepatosplenomegaly and immunoglobulin levels and increased numbers of CD4 
cells. It was concluded that a continuous infusion of AZT was beneficial in 
children with symptomatic HIV infection, especially those with encephalopathy.
3.1.5.3 Obstetrics
The use of home infusions in high-risk obstetric patients was reviewed by Romeo 
and Jones in 1994 [250]. The first indication in obstetrics was for women at risk 
of giving birth prematurely but more recently infusional therapy at home had 
expanded for this group of patients to include hydration, TPN, heparin infusions, 
terbutaline administration and antibiotic therapy.
3.1.5.4 Anti-spasmodics
In section 3.1.4 the administration of opiates intrathecally via an implantable 
pump was described. The same technique has been used to administer baclofen, 
an antispasmodic, to patients in the domiciliary setting. Muller et al [244] report 
that intrathecal administration of baclofen controls even the most severe and 
hitherto untreatable forms of spasticity and resultant pain. Local spinal action 
diminishes the undesired cerebral side effects. The 47 patients treated all had an 
implantable multi-dose pump inserted as therapy was likely to be long-term. Of 
the patients treated in this study therapy was judged to have achieved results 
which were excellent in 54%, good in 35%, moderate in 11% and poor in 0%. A 
multicentre study involving 35 German centres into the long-term effects of such 
therapy was planned.
3.1.5.5 Other
Experience with treating patients with home infusions continues to expand and it 
has become accepted practice in many areas to administer infusions of insulin for
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diabetes [251], apomorphine for Parkinson’s disease [11], desferrioxamine for 
thallassaemia, algluterase for Gaucher’s disease [111], terbutaline and 
aminophylline for brittle asthma/COPD [252], immunoglobulins [9, 253] [254] 
and insulin infusions for diabetes [255] in the home setting. In the United States 
even such complex therapies as vasopressin for gastrointestinal bleeding [256] 
and inotropic therapies [257] are administered in the home care setting.
3.1.6 The Pharmacist’s Role In Hi-Tech Health Care At Home 
Pharmacists have been widely reported in the literature to have played an 
important role in the setting-up and running of hi-tech heath care at home 
schemes.
In 1979, Kind et al [157] first reported a home antibiotic scheme which was run 
from the hospital pharmacy department with a pharmacy-based intravenous nurse 
team and a centralised intravenous admixture service. The patients attended the 
pharmacy every 48 hours to pick up supplies, have their catheter changed and 
sort out any problems. They saw a physician once a week.
Gaffron et al [258] reported the organisation and operation of a home parenteral 
nutrition programme. The patients were managed by a multi-speciality team, the 
pharmacist being the person with whom the patients had most contact during 
their two-week training period. In addition to education the pharmacist was 
responsible for co-ordinating the transition to home care, offered in-service 
education on home parenteral nutrition to nurses and house officers, tested and 
evaluated equipment, co-authored the training manual and edited the quarterly 
newsletter to patients who were on home parenteral nutrition.
Similar pharmacist involvement was reported by Swenson [259]. In this study 
the clinical pharmacist was responsible for patient selection, training of patients 
and their families and co-ordinating the home care team. The paper concluded 
that a non-distributive pharmacist function had been identified that produced 
substantial health care cost containment and that insurance carriers needed to
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recognise the value of a pharmacist’s knowledge and be willing to pay for that 
knowledge as a separate commodity.
Many studies stress the importance of a multidisciplinary team in the care of 
patients receiving home infusional therapy [112, 115, 258].
A survey of hospital-based home health care agencies undertaken by Galt et al 
[260] determined the types of pharmaceutical services being provided, the extent 
to which they were being provided and which pharmaceutical services were 
perceived as being important. They found that although 85% of home care 
agencies used the services of a pharmacist, less than 4% actually employed a 
pharmacist on their staff. The directors of the health care agencies viewed 
educational programmes, drug regimen review and drug information services the 
most important functions of pharmacists in health care agencies.
McAllister [261] reported that the evolution of home health care to encompass 
complicated home infusion services had created new responsibilities for hospital 
pharmacists. In his introduction to a 13 part series designed to acquaint the 
hospital pharmacist with home care McAllister [262] states that actively 
participating in the provision of home health care allows the pharmacist to 
contribute in an important way to the hospital’s viability in the new economic 
and competitive environments. Assisting in screening, selection, education and 
training, and clinical monitoring of home health care patients increases 
opportunities for interaction with patients and adding a home care service may 
enable the pharmacy manager to increase employee productivity and use 
resources more efficiently by assuming additional work load. Pharmacists must 
also become sensitive to psychosocial factors associated with home care and 
prepare patients and their families for their new lifestyle.
Zilz [263] went on to look at trends in home health care and concluded that the 
hospital pharmacy department could become even more valuable to the 
institution and that successful planning of home health care programmes and 
other alternate modalities should enable the pharmacist to contribute more
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substantially to the financial well-being of the institution as well as contribute to 
better patient care.
Schneider [264] reported that pharmacists were developing training programmes 
for patients about to be discharged and providing outpatient support services, 
some where developing entire home care programmes for the care of patients 
with haemophilia, chemotherapy, hyperalimentation and administration of 
parenteral steroids and antibiotics. He describes how a pharmacist can develop 
and implement a home antibiotic programme starting with evaluating the market 
potential and cost feasibility, then running a pilot project and suggests that joint 
ventures with vendors or other hospitals may be a way to provide a home care 
service without making a major commitment of resources from the hospital.
The role of the community pharmacist in monitoring chronic outpatient 
infections has been discussed by Ackerman and Wolfe [265] and New et al 
[114]. They noted the increasing shift of management of acute illness to 
community practitioners and the expansion of community pharmacy into home 
health care. Community pharmacists were reported to be gaining experience in 
areas traditionally the domain of their hospital colleagues, such as in clinical 
pharmacokinetics, total parenteral nutrition, intravenous infusion systems, 
intravenous catheters and parenteral antibiotics. Expertise in therapeutic 
monitoring of chronic disease states and dose adjustment of medication based 
upon analysis of blood concentrations was being performed by pharmacists in the 
community.
A working party report published, by the Community Pharmacy Subcommittee 
and Council of the Royal Pharmaceutical Society of Great Britain [238] 
concluded that, in the case of continuous infusions of cytotoxic chemotherapy, 
monitoring could be conducted by General Practitioners (GPs) and there was a 
role for community pharmacists involving the provision of infusion pumps and 
associated medication.
Monk-Tutor [266] reported that home infusion services provided by pharmacists 
consisted of drug compounding and delivery, patient education and training and
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follow-up care including clinical management and monitoring of prescribed 
drugs and fluid therapies. Despite a growth in the home care market a steady 
decrease in the provision of home infusion services by hospital pharmacies was 
reported. In 1985,40% of hospital pharmacy departments in the USA were 
providing home infusion therapy services but by 1987 that was down to 29% and 
by 1989 it was only 17%. An ASHP survey of hospital-based pharmaceutical 
services [267] in 1994 found that 27% of respondents to their questionnaire 
offered home infusion therapy services. A study published in 1994 [115] 
contradicted this stating that "approximately half of the home intravenous 
antibiotic therapy programmes today are hospital based". A questionnaire survey 
was carried out [266] to identify pharmacist activities related to these services 
and reasons for their discontinuation. It was found that many of the hospitals 
that had ceased to provide home infusion services had done so due to lack of 
resources including personnel, space and money.
Rich [115] reported that a well co-ordinated team of pharmacists, physicians, 
nurses and other health care professionals was at the heart of a successful 
programme for home infusion therapy. Besides the traditional role, the 
pharmacist was usually responsible for the proper cleaning, maintenance and 
initial programming of the infusion pump, disposal of hazardous waste products 
and quality control. Most importantly the pharmacist was responsible for 
assessing the patient’s goals for drug therapy, monitoring the patient for 
development of drug-related problems and keeping abreast of the patient’s 
progress. The pharmacist was also the source for professional education and 
drug information for other members of the health care team as well as for 
patients.
Steel et al [268] reported an English project where care for AIDS patients with 
cytomegalovirus retinitis was shared between the hospital consultant and local 
general practitioner. This increased communication between primary and 
secondary care and improved patient care. Both the hospital and community 
pharmacist played important roles in the care of the patient. The community 
pharmacist was able to monitor the prescriptions and intervene based on 
laboratory test results and money was saved by not making up unnecessary
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infusions when there had been a change in the patient’s condition or 
circumstances. The hospital pharmacy appointed a pharmacist to co-ordinate the 
home infusion service and support community pharmacists in providing care to 
HIV infected patients. Other centres have also reported employing a dedicated 
home infusion pharmacist [269] with responsibility for co-ordinating the patients 
care in their home from start to finish: - developing and managing the home care 
service, patient selection, training, provision of all equipment, meeting service 
specifications and monitoring the patients in their homes.
Describing some of the pitfalls of home infusional therapy Goldenburg [113] 
pointed out that the legal accountability of each member of the home care team is 
unknown but it is crucial that pharmacists, physicians and nurses remain active in 
the selection process to ensure adequate instruction, safe and effective outpatient 
treatment regimens and minimisation of medical and legal risks. Prescription 
management requires the diligent involvement of both physicians and clinical 
pharmacists. He concludes that multidisciplinary surveillance by pharmacist, 
physician and nurse will provide optimal care and satisfactory co-ordination of 
patient and programme needs. The exclusion of any one of these professions will 
preclude the successful maintenance of an outpatient parenteral programme.
This is the message still coming through in more recent literature [193].
In 1993 the American Society of Hospital Pharmacists (ASHP) published 
comprehensive guidelines on the pharmacist’s role in home care [185], these 
were updated in 2000 [270]. They applied to pharmacists providing home care in 
all settings including hospital, community, home health agencies and specialised 
home infusion companies and noted that when different aspects of home care are 
provided by different organisations pharmacists have a professional 
responsibility to ensure that all patient care responsibilities are defined, 
understood, agreed upon and documented in advance. These guidelines [270] 
state that pharmacists should be active participants in performance improvement 
activities, monitoring patient satisfaction and outcomes and list some examples 
of aspects of care that should be monitored.
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The role of the pharmacist in ensuring high quality, effective care to patients 
receiving infusions in the home care setting has been highlighted. Benchmarking 
services against those of others to assure service level agreements are met and 
standards of patient care and clinical outcomes are the best achievable is another 
role in which pharmacists have become very involved in the United States [271- 
273] and is further discussed in Chapter 4.
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3.2 Hi-tech Health Care At Home Surveys
3.2.1 Aims
To establish the current position in England on the purchasing and provision of 
HTHH under EL(95)5 [41].
To evaluate the effectiveness of EL(95)5 [41] in the delivery of HTHH to 
patients with an emphasis on the role of the pharmacist.
3.2.2 Objectives
3.2.2.1 Health Authority Survey
Questionnaire survey of the 100 HAs in England to establish
a) to what extent patients are being treated in their homes with hi-tech therapies
b) whether there are geographical or demographic trends in the provision of 
HTHH in England
c) expenditure on HTHH
d) who is currently providing the various aspects of care for patients being 
treated at home with hi-tech therapies
e) what contracting arrangements have been made for providing HTHH
f) which aspects of HTHH have been successful/unsuccessful.
3.2.2.2 Trust Survey
Questionnaire survey of Trusts in England to establish
a) how many Trusts are providing home infusions and for how many patients
b) who is providing drugs, supplies and nursing care
c) if there are any audit systems in place to measure quality of care received by 
these patients and patient outcomes
d) the role of the pharmacist in the provision and monitoring of HTHH
e) in which patients home infusions have worked best and why
f) what have been the barriers to providing HTHH.
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3.2.2.3 Commercial Home Care Company Survey
Questionnaire survey of commercial home care companies in England to
establish
a) the number of home infusions being provided
b) for which indications home infusions are being provided by commercial 
home care companies
c) whether they are subcontracting for any of the services they provide
d) who is responsible for setting service specifications for their contracts
e) who is responsible for auditing the quality of care received by patients and 
patient outcomes.
3.2.2.4 Combining the Results of the Surveys
From synthesis of the data obtained from these three surveys determine
a) whether the information received from HAs correlates with information 
received from Trusts and commercial home care companies
b) who is responsible for measuring quality of care and patient outcomes for 
patients receiving HTHH
c) geographical and demographic trends in the provision of HTHH in England
d) and gain a greater understanding of the current arrangements for purchasing 




A detailed, fully referenced literature review 3.1 was prepared as described in 
Section 2.2.4.1.
3.2.3.2 Establishing The Current Position
The initial objective of the project was to establish the current position in 
England on HTHH and to determine the level of involvement of pharmacists. It 
was established from the literature review and experience of local health care 
providers that there were three major groups involved with the purchasing, 
provision, contracting and co-ordination of HTHH.
3.2.3.2.1 Health Authorities
The first of these was the HAs who are the main purchasers of HTHH in England 
and have the responsibility for contracting and strategic planning for these 
patients as laid down by EL(95)5 [41].
3.2.3.2.2 NHS Trusts
The second were the NHS Trusts who function as both purchasers and providers 
of HTHH. They are often given responsibility by the HA for purchasing HTHH 
but may also submit a tender to the HA to provide the package of care to patients 
receiving home infusions under EL(95)5 [41], usually through their pharmacy 
departments.
3.2.3.2.3 Commercial Home Care Companies
The third major player in the home care market were the commercial home care 
companies who in recent years in Britain, much as they have done in the United 
States have become important providers of HTHH. The range, level and extent 
of services offered vary from company to company. It was felt that the inclusion 
of information from the commercial sector was vital to achieving a global picture 
of the present home care market in England.
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3.2.3.3 Questionnaire Design
As this questionnaire formed the second part of the Health Authority survey 
described in Chapter 2, design of the questionnaire is described in section
2.2.4.4.1.
3.2.3.3.1 Development of the Questionnaires
In order to achieve the aim of establishing the current position in England on 
HTHH, questionnaire surveys were designed to elicit the required information 
from HAs, Trusts and the commercial home care companies.
3.2.3.3.2 Development of the Health Authority Questionnaire
The Pharmaceutical and Medical Advisers and Contracts Managers of HAs were 
the people known to be involved in the implementation of EL(95)5 [41]. It was 
therefore decided to aim the questionnaire towards these HA employees. This 
formed Section 2 of the questionnaire survey of HAs described in Section
3.2.4.1.1. The questionnaires were distributed between April and September 
1997.
3.2.3.3.3 Development Of The Trust Questionnaire
It was decided to aim the Trust questionnaire at hospital pharmacists as they 
were likely to be responsible for preparing home infusions in their aseptic 
production units and, more then any medical or nursing speciality, would know 
about the full scope of HTHH within their Trust.
The objectives of the questionnaire are listed in Section 3.2.2.2.
A questionnaire was drafted based upon EL(95)5 [41], the available literature, 
local knowledge and experience of contracting, discussions with Pharmaceutical 
and Medical Advisers of HAs throughout England and questions which had 
arisen as a result of the HA questionnaire.
Comments were solicited from pharmacists within the Plymouth Hospitals NHS 
Trust, pharmacists from neighbouring Trusts, the local Research Development
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Support Unit, the Pharmaceutical Adviser of South and West Devon Health 
Authority and the supervisors of this project.
The pilot was prepared (Appendix 13) based upon their comments and sent to 10 
pharmacists known to have had some involvement with HTHH. A covering 
letter was sent with each explaining the aims of the project and asking for their 
help in commenting on the design of the questionnaire. Comments were also 
solicited from a researcher in Keele who had just completed a questionnaire 
survey to purchasers on the contracting mechanisms for HTHH [42].
Of the 11 pilot questionnaires distributed 7 were returned. Most found the 
questionnaire “moderately easy” to complete. The first two questions were 
removed as it was commented that they were unclear and did not elicit the 
required information. They were subsequently covered by a telephone survey, 
(see below). The table in Question 3 seemed daunting to some and one 
suggested putting a tick box question first. This was tried but as all other 
questions referred to the patients in the first question it was not possible to do 
this. The table was pivoted to try to make it clearer. Ambiguous replies were 
received to some questions and so these questions were subdivided and better 
explained. A final version of the questionnaire was designed based upon the 
comments from the pilot (Appendix 14). The covering letter was also adapted to 
explain the content of EL(95)5 [41], as it was commented that the pharmacists 
completing the questionnaire may not have received the Executive Letter from 
their Chief Pharmacist.
It was difficult to know how to target the questionnaire to those Trusts that had 
an input into HTHH. If the questionnaire was sent to all Trusts, those with no 
involvement would be unlikely to respond. This would make it difficult to 
extrapolate results with any degree of accuracy. In order to find out how many 
acute and community Trusts were involved with HTHH an initial telephone 
survey was conducted. This was followed up with a written questionnaire to 
those Trusts who were involved with HTHH. Ambulance Trusts, Learning 
Disabilities Trusts and Mental Health Trusts were excluded from the survey.
148
A number of sources for identifying the Trusts and the person to contact within 
the Trust were considered. These included asking the Regional Pharmaceutical 
Advisers for lists of the Trusts and Chief Pharmacists for their region, using 
Chemist and Druggist, Bourne’s Directory, the Hospital and Health Services 
Year Book, the NHS Executive Regional Directories for 1997/98 or finding out 
if there was a list of hospitals with MCA Special’s Licences. The NHS 
Executive Regional Directories were more complete and up-to-date than any 
other available source and using these was consistent with the method used for 
identifying HAs. A list was drawn up of 349 Trusts for the telephone survey. 79 
Trusts were excluded from the survey on the basis that they were Ambulance 
Trusts, Learning Disability Trusts or Mental Health Trusts.
A structured interview questionnaire was designed for the telephone survey 
(Appendix 15) but after a pilot, which involved telephoning 10 Trusts it became 
apparent that this structured, formal approach was not flexible enough to obtain 
the required information. A flow chart (Appendix 16) was drawn based upon 
this trial and used for subsequent telephone calls. It gave a structured approach 
to obtaining the correct person to answer questions regarding HTHH. If the 
Trust did not have a Pharmacy Department an attempt was made to establish who 
provided pharmacy services to the Trust. It was decided that the pharmacist 
responsible for aseptic services would be most likely to know whether infusions 
were being used by any group of patients at home. If there was not an aseptic 
service the researcher asked to speak to one of the pharmacists and asked them 
who the most appropriate person to speak to would be.
Pharmacists (or in a small number of cases pharmacy technicians) of Trusts who 
were involved with the care of HTHH patients were asked if they would 
complete the written questionnaire (Appendix 14). This was posted to them as 
soon as possible after the telephone call.
The Trusts were telephoned over the period November-December 1997 and a 
questionnaire posted out to the named contact on the same or the following day. 
By 13 February 1998, 77 had been received, a reminder letter was sent to the 
remaining 90 Trusts.
149
A difficulty arose when a Trust had distinct units which functioned 
independently from each other such as Guy’s and St Thomas’s Trust. One 
questionnaire was sent to each hospital. The data was collected over the time 
period November 1997 to April 1998.
3.2.3.3.4 Development of the Commercial Home Care Company Survey 
There were six commercial companies providing HTHH in England at the time 
of this survey. Competition for contracts meant that the companies may not have 
been willing to divulge certain information which may be commercially 
sensitive. This questionnaire was designed in consultation with two companies 
so that the questionnaire was developed within these limitations. The same two 
companies commented on a pilot questionnaire that was then used to develop the 
final questionnaire (Appendix 17). This was sent by post or delivered in person 
to all six commercial providers. Non-responders were followed up by telephone 
after 6 weeks.
3.2.3.4 Interpreting the Results/Coding the data
A similar approach was taken to that used to code the shared care data described 
in Section 2.2.4.4.2.
3.2.3.4.1 Health Authority Questionnaire
Coding of the qualitative comments received was performed by a group 
consisting of
a) 2 Trust pharmacists from different NHS Trusts
b) 1 HA Pharmaceutical Adviser
c) (1 Commercial Home Care Company nurse who was unfortunately called 
away shortly after the meeting had started).




Qualitative data was coded by the same group of people who coded the HA data 
at the same meeting (section 3.2.3.4.1).
Question 1 of the Trust Questionnaire (Appendix 14) asked respondents to 
identify who provided various aspects of care for HTHH patients. Many Trusts 
gave very similar answers or answers with the same meaning such as “hospital 
doctor” and “cancer unit doctor”. The researcher coded these answers. This 
method of coding was validated by asking a home care pharmacist and a 
pharmacy technician involved with home infusions to independently code the 
answers to the first three parts of the question. The coding was compared and as 
there were very few discrepancies, the researcher went on to code the remaining 
data in the same manner. Where there were answers that were difficult to code 
or ambiguous a group decision was made by the researcher, home care 
pharmacist and pharmacy technician.
The results of the Trust questionnaire were validated by comparing the answers 
given during the telephone survey with those obtained on the postal 
questionnaire from the same Trust 20% of the answers were compared 
(Appendix 21). A computer was used to generate 18 random survey numbers 
from those returned and the information obtained in the telephone survey was 
compared with that later obtained from the same Trust in answer to the written 
survey.
3.2.3.4.3 Commercial Company Questionnaire




3.2.4.1 Health Authority Survey
3.2.4.1.1 Response Rate
The questionnaires were returned over the time period April 1997 to February 
1998. The response rate to this survey is discussed in Section 2.2.5.1.1. Many of 
the HAs did not answer questions regarding numbers of patients under the 
jurisdiction of their HA receiving the various home infusions.
27/87 (31.0%) HAs either could not or did not answer Section 2 Question 1 of 
the Health Authority questionnaire (Appendix 2) regarding numbers of patients 
receiving HTHH. In 9 cases it was left blank, 10 made comments regarding the 
Trusts. Many had handed the responsibility over to the Trusts and therefore did 
not know how many patients were being treated at home and the cost of their 
therapy, 5 made comments such as “no idea”, “exact figures not available” and 4 
said that the person who knew was not available or would have to be asked.
Table 3.2 shows in more detail the responses for each drug/condition.
Table 3.2: HA Questionnaire: Number Of Responses To Question Asking 
Numbers Of Patients Receiving HTHH And Cost Of Their Treatment
(n=87) didn’t know or no 
answer
answer
cystic fibrosis 43 49% 44 51%
chemotherapy 67 77% 20 23%
HIV 66 76% 21 24%
TPN 35 40% 52 60%
desferrioxamine 54 62% 33 38%
3.2.4.1.2 Numbers of Patients
Figure 3.2 shows the percentage of HAs treating patients with the various HTHH 
therapies. 54% had one or more patients on home TPN or specialised enteral 
feeds and 46% had patients being treated at home with antibiotics for cystic 
fibrosis.
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The numbers of patients being treated at home with various therapies is shown in 
Figure 3.3. Some HAs gave a range as an answer in which case the mid-point of 
that range has been included, others gave the answer “varies” and those answers 
have been excluded. Table 3.3 shows numbers of patients being treated with 
HTHH according to the HA survey.
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Table 3.3 Current Number Of Patients Being Treated At Home, HA 
Questionnaire
n=87 total mean* upper limit of range
cystic fibrosis 388 9.0 50
chemotherapy 29 1.9 18
HIV 22 1.4 6
TPN 204 4.2 21
desferrioxamine 99 3.3 25
"“total no of patients currently being treated divided by no of HAs who gave an 
answer >0






3% (22) 4% (29)
Total number = 742
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3.2.4.1.3 Other Indications For Home Infusions
Other conditions and drugs provided in the domiciliary setting are shown in 
Figure 3.4. There were few patients being treated with HTHH for other 
conditions. The two most commonly specified therapies were enzymes for 
Gaucher’s disease and continuous ambulatory peritoneal dialysis (CAPD). 
(CAPD was covered under EL(95)5 [41] but this study has concentrated on 
infusions of drugs in the home setting and it is therefore outside the scope of this 
research). Those not shown in the graph because they were only mentioned by 
one HA were enteral feeding, intrathecal baclofen, calcium gluconate infusions 
for ricketts, home oxygen and paediatric Still's disease.
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3.2.4.1.4 Expenditure On Home Infusions
The expenditure by HAs on the various home therapies can be seen in Figure 3.5. 
Home TPN was the area of highest expenditure. The largest peak was for HAs 
who spent under £50K a year on home antibiotic infusions for cystic fibrosis 
patients. The expenditure by HAs on other home therapies is shown in Table 
3.4.
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It was difficult to interpret the answers to the question regarding whether HTHH 
was purchased as a separate contract or as part of a bulk contract by the HA.
They are listed in Appendix 18. Figure 3.6 shows a broad interpretation of the 
answers given, coded by the researcher. This does show that the majority of HAs 
contract for these services as a separate contract but over a quarter of respondents 
have just added the money from top-slicing GP budgets in 1995 to their bulk 
contracts with the Trusts and passed on the responsibility for contracting 
for/providing packages of care for these patients.
Figure 3.6 Health Authority Questionnaire, HA Contracts for the Provision 
of HTHH
Bulk contract S ep a r a te  contract
N o a n s w e r  
10%
Don't know
3% S ep a ra te  for s o m e  
drugs and  bulk for 
oth ers  
15%
None of the 87 HAs knew of any GPs who directly purchase HTHH for their 
patients.
3.2.4.1.6 Future Plans For HTHH
When asked if the HA had any future plans for the care of these patients only 17 
(20%) said yes. The comments given are shown in Table 3.5.
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17 Yes W e are allowing diversity of provision dependent on circumstances. May consider 
moving responsibility to Trusts but that has inherent difficulties.
24 Yes May consider a competitive tendering exercise.
100 Yes Service going out to tender, contract to com m ence 1/4/98.
5 No New patients identified by Trusts a s requiring hi-tech home health care would be the 
responsibility of individual clinicians to agree the most appropriate mechanism for 
providing this care in consultation with hospital pharmacists etc
41 No NB. Local Trust were sent copy of questionnaire and answered yes
73 No Initially wanted to move away from companies, now decided it’s  easier to keep patients 
with the provider that they are used to. Currently just watching.
88 No All so  varied an overall approach seem s difficult.
103 No Not at the moment.
113 No Patients have long term illness
61/86 don’t know
3.2.4.1.7 Providers of HTHH
It appears from this data that it is the commercial providers who provide most of 
the “packages of care” to patients at home (Table 3.6, Figure 3.7). Commercial 
companies were the top providers of nursing services, drugs and other equipment 
and supplies. They were followed closely by the acute Trusts, especially in the 
area of drug supply.
Table 3.6: Providers Of HTHH, HA Questionnaire
nursing se r v ic es drugs other equipm ent/ 
su p p lies
commercial company 39 53 47
acute trust 22 48 35
community trust 25 10 13
combined acute/community trust 6 5 8
combination of above 4 3 3
other 0 1 1
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Figure 3.7: HA Questionnaire, Provision of Services to Patients at Home
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3.2.4.1.8 Successful and Difficult Aspects of HTHH
The qualitative comments received regarding the aspects of HTHH that had been 
difficult/problematic or successful and other comments on the subject of HTHH 
were coded as described in Section 3.2.3.4.I. They are listed in Appendix 3, in 
the format in which they were given to the group for coding. The coding and the 
coding frame developed by the group are shown in Appendix 20.
3 .2 .4 .2  T ru st Q u e st io n n a ir e
3.2.4.2.1 Validation Of The Data
Comparison of the answers obtained to the written survey and the telephone 
survey from 18 randomly selected Trusts are shown in Appendix 21. It can be 
seen that on 10 out of 18 (55.6%) of occasions the questionnaire was completed 
by the same person who answered the telephone survey, on 6 occasions it was 
impossible to tell who filled in the questionnaire as no name was given and on 2 
occasions the questionnaire was filled in by a different person. On both of these 
occasions the questionnaire was handed on to the Chief Pharmacist of the Trust 
to complete.
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There are discrepancies in the data but they are broadly in line. Some 
discrepancies would be expected as the written questionnaire asks for current 
numbers of patients whereas the telephone survey asked if patients under the care 
of the Trust were ever treated with HTHH.
3.2.4.2.2 Trusts Providing HTHH
At the time of the survey there were 428 NHS Trusts in England. 79 of these 
were excluded from the survey being ambulance, learning disabilities or mental 
health Trusts. When telephoned 167 of the 349 Trusts said that they were 
providing or had provided some sort of HTHH service (see results of telephone 
survey Appendix 22). These Trusts were sent the written questionnaire 
(Appendix 14) as described in Section 3.2.3.3.3.
3.2.4.2.3 Response Rate
105 questionnaires were received from 104 Trusts. 167 written questionnaires 
were sent out giving a response rate of 63%. There were 94 evaluable 
questionnaires giving a revised response rate of 56% (Table 4.6).
Table 3.7: Responses From Trusts By Region
Region Number of evaluable  
su rveys returned
No. of questionnaires  
se n t out
% returned
Anglia & Oxford 11 18 61
Northern & Yorkshire 8 23 35
North Thames 16* 26 62
North W est 15 27 56
South & W est 14 19 74
South Thames 9 19 47
Trent 11 18 61
W est Midlands 10 17 59
Total 94 167 56
*16 questionnaires were returned from 17 Trusts. For subsequent analysis these w ill be included  
as if  they were separate Trusts.
Even after the telephone survey to screen out Trusts with no patients being 
treated at home 11 questionnaires were returned that were not evaluable. These 
are shown in Table 3.8.
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Table 3.8: Surveys Not Evaluated
Survey No
2 Blank with letter explaining that patients dealt with by local acute trust.
33 No HTHH, Community Trust, rehabilitation and psychiatry only
46 HTHH program not up and running yet.
88 TPN ST Marks, Oncology Hammersmith, Collaborative care team administer antibiotics at home, HIV 
St Mary’s, Sickle cell Centre in Brent.
133 Will be dealt with in the Thameside questionnaire.
145 Patients receiving HTHH go to Christies.
229 Community Trust, all HTHH initiated by acute Trust, the only involvement the community trust has is 
of the district nurses.
262 No involvement, no patients.
297 No HTHH patients.
312 Community Trust can’t get hold of the answers.
365 No patients in the past year, gave home TPN years ago, very occasionally have home chemotherapy 
arranged by oncology nurse and pharmacy.
3.2.4.2.4 Number of Patients Receiving Home Infusions
The numbers of patients receiving infusions at home or as outpatients are shown
in Table 3.9.
Table 3.9: Numbers Of Patients Receiving HTHH, Trust Questionnaire
Drug/condition Actual number Number normalised* Upper end of range
antibiotics for cystic 
fibrosis
530 879 130
chemotherapy 597 990 150
antivirals for HIV 50 83 12
adults receiving TPN 230 381 84
children receiving TPN 41 68 12
Desferrioxamine 159 264 58
*167 sent questionnaires -1 1  no involvement = 156 Trusts involved with HTHH
94/156 = 60.3% normalised to 100%. NB. Does not take into account that som e non-responders may not 
provide HTHH.
3 .2 .4 .2A . 1 O ther H om e In fusions
Other therapies that patients were receiving at home not mentioned in the 
questionnaire are shown in Table 3.10.
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Table 3.10: Other Home Infusions, Trust Questionnaire
Drug/condition No of Trusts No of patients Where therapy 
administered
Immunoglobulin 5 8-9 all at home
Enzymes for Gaucher’s  D isease 5 6 all at home
Pain relief in palliative care 6 >27 all at home
Terbutaline 2 >14 all at home
Aminophylline 1 1 all at home
Apomorphine 1 not specified all at home
CMV treatment for transplant 
patients
2 6 all at home
G-CSF 1 12 all at home
Magnesium infusions 1 1 all at home
Sodium chloride 0.9% infusions 1 1 all at home
lloprost 1 1 all at home
CAPD 1 38 all at home
home inotropes 1 2 in local hospitals
methotrexate - arthritis 2 >15 at GP surgeries
subcutaneous cytotoxic therapy 1 not specified all at home
nebulised colomycin 1 not specified all at home
line Iocs for oncology patients 1 2-3 all at home
3.2.4.2.5 Where do patients receive their drug therapy?
Most patients were receiving their therapy at home, but it was commented that 
often patients would start therapy as an inpatient and then be discharged and 
either receive therapy as an outpatient or at home. For chemotherapy it was 
difficult to interpret the data as ambulatory pumps were often set up in the 
hospital and the patient then received most of the therapy outside of the hospital. 
The perception of where the drug was administered in this situation varied. The 
data was coded as described in Section 3.2.3.4.2. The results of this are shown in 
Figure 3.8.
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3.2.4.2.6 Who Provides Various Aspects Of Their Care?
3.2.4.2.6.1 Who Administers the Therapy?
In all but one instance it was the patient or a relative or carer who most often 
administered the therapy. The exception was chemotherapy which was more 
often administered by a nurse. Again it was difficult to interpret the answers 
given to this question because often the patient came to the hospital to have a 
pump reservoir changed or set up and there were differences as to who was 
perceived to be administering therapy. It can be seen from Figure 3.9 that when 
therapy was administered by a nurse it was most commonly by a hospital or 
district nurse.
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3.2.4.2.6.2 Who is responsible fo r  training the patient
Training o f  the patients in all instances was undertaken far more frequently by a 
hospital nurse than by any other person. Commercial company nurses, other 
nurses and pharmacists featured much more frequently than doctors (Figure 
3.10).
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3.2.4.2.6.3 Who provides the drugs ?
The drugs were most often supplied by a hospital pharmacy department but large 
numbers were also supplied by commercial home care companies (Figure 3.11). 
In the case of adult HPN almost as many Trusts said that a commercial company 
supplied the TPN as said that it was supplied by the Trust. TPN for children was 
supplied more often by commercial companies than hospital pharmacy 
departments. Community pharmacists were said to be supplying children’s TPN 
and desferrioxamine.
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Figure 3.11: Trust Questionnaire, Who Provides the Drugs?
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3.2.4.2.6.4 Who provides the nursing care?
Nursing care was most commonly provided, for all the specified indications, by 
hospital nurses (Figure 3.12). These varied from nurses on the wards or in 
outpatients to various kinds of specialist nurses and community liaison nurses. 
Although respondents were asked to specify, in certain cases it was difficult to 
tell whether the nurses were hospital or primary care based e.g. “children’s 
community nurse”. The other category in Figure 3.12 includes family or parents 
providing nursing care and patients who did not require nursing care e.g. a GP 
receiving home therapy.
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3.2.4.2.6.5 Who provides the equipment and supplies?
When asked who provides equipment and supplies the answers were different for 
the different groups of patients (Figure 3.13). It was more common for HPN 
patients (both children and adults) to receive supplies from a commercial home 
care company whereas the other patients more commonly received supplies via 
the hospital. This happened in various ways via the pharmacy, stores 
departments, nursing staff, wards or outpatients. Some patients were obtaining 
equipment and supplies from their GP.
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Figure 3.13: Trust Questionnaire, Who Provides Equipment and Supplies?
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3.2.4.2.6.6 Who provides a 24 hour help-line?
A 24 hour help line was again most commonly provided by the hospital for all 
groups of patients but in all cases commercial companies were the second largest 
provider (Figure 3.14). The “other” section of the graph includes 6 Trusts who 
did not know who provided a 24 hour help line for these patients and also 
“Intensive Home Nursing Service” and “community liaison team” which were 
difficult to fit into the primary or secondary care categories.
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Figure 3.14: Trust Questionnaire, Who provides A 24 Hour Help Line?
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3.2.4.2.7 Expenditure
The questionnaire asked for the approximate annual expenditure for a total 
package of care for all patients in the group to the nearest £10,000. It also said 
“if you only supply part of this service please specify which part and give the 
cost”.
The figures given for expenditure on home infusions are shown in Appendix 23. 
Many did not give any information on the cost of home infusions (Table 3.11).
Table 3.11 Proportion of Trusts Providing Information on their Expenditure
Number of Trusts 
with >0 patients 










No answer/ didn’t 
know/ unable to  
supply information 
n=94
Cystic fibrosis 43 22 51.2% 72 (76.5%)
Chemotherapy 39 15 38.5% 79 (84.0%)
HIV 14 8 57.1% 86 (91.4%)
TPN adults 34 15 44.1% 79 (84.0%)
TPN children 14 9 64.3% 85 (90.0%)
Desferrioxamine 30 15 50.0% 79 (84.0%)
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3.2.4.2.8 Role of the Pharmacist
Figure 3.15 and Table 3.12 show the response to Question 2 of the survey of 
NHS Trusts. This question asked, “Which aspects of HTHH have pharmacists in 
your Trust been involved with?” The clinical, co-ordination and communication 
and supply areas were where pharmacists had the greatest involvement.
If pharmacists had no involvement respondents were asked to specify who is 
responsible. Often this section was not completed. Most said that specialist 
nurses or consultants were responsible for setting up the service and market 
analysis, directorate and business managers were involved with contracting and 
setting service specifications.
Nurses and occasionally doctors were responsible for co-ordinating the HTHH 
programme and communication with patients, their families and other health care 
staff. Specialist nurses and commercial providers were responsible for education 
and if the pharmacy did not supply drugs it was almost always a commercial 
company that supplied them.
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Figure 3.15, Role of the Pharmacist in Hi-the Health Care at Home
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e) Quality Assurance
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Table 3.12, Role of the Pharmacist in Hi-tech Health Care at Home






Som e + 
very
CONTRACTING
setting up the HTHH program* 35 29 26 5 64
market analysis 9 24 50 11 33
contracting for HTHH* 19 24 43 9 43
setting service specifications 26 33 30 5 59
CO-ORDINATION AND COMMUNICATION
Co-ordinating the HTHH program 25 38 26 5 63
with other pharmacists 29 30 25 10 59
with other health care profs 41 41 9 3 82
with commercial home care co 28 21 37 8 49
with patients and families 19 56 15 4 75
patient selection 9 22 56 7 31
EDUCATION
design of written info 12 30 47 5 42
training of pts & carers 6 35 48 5 41
education other health care staff* 16 45 29 5 61
com petency assessm ent of pt/carer 5 14 69 6 19
SUPPLY
supply of drugs 55 15 21 3 70
aseptic reconstitution of drugs* 54 16 20 5 70
selection of infusion pump 23 31 36 4 54
maintenance of infusion pump 11 8 70 5 19
QUALITY ASSURANCE
QA of HTHH program 8 33 44 9 41
compliance with service specifications 14 25 44 11 39
compliance with regs e.g. GMP 34 25 25 10 59
QA of infusion pumps 9 14 60 11 23
CLINICAL
pharmaceutical advise to prescriber 58 26 7 3 84
choice of appropriate drug therapy 32 37 22 3 69
selection of venous a ccess  device 1 20 70 3 21
formulation & stability data 62 19 10 3 81
pharmaceutical care plan 18 24 43 9 42
prescription records 55 21 13 5 76
interpreting lab tests 22 31 36 5 53
monitoring patient adherence 8 30 52 4 38
24 hour help line 7 27 56 4 34
* columns add up to 95 not 94 because some Trusts ticked more than one answer.
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Two Trusts said that the commercial provider was responsible for quality 
assurance of the home care programme, other answers included ward staff, 
consultant, clinician, specialist nurse and business manager for the nutrition 
ward, four Trusts were unsure and two admitted that no-one was performing this 
task. Five Trusts named someone responsible for ensuring compliance with 
service specifications (home care company, business manager, ward staff, 
specialist nurse and consultant), one said they get general feedback, two said “not 
known”, two “not done” and one said “no service specifications that I know o f ’. 
Most said that medical electronics or commercial HTHH providers were 
responsible for quality assurance of the infusion pumps.
The clinical role was almost entirely performed by nursing and medical staff if 
not undertaken by the pharmacist. Home care companies, on-call doctors and 
ward staff provided a 24-hour help line for HTHH patients.
3.2.4.2.9 Patients outside the scope of EL(95)5 receiving home infusional 
therapy.
When asked “ Do any patients outside the scope of EL(95)5 [41] receive home 
infusional therapy e.g. apomorphine for Parkinson’s disease?”, 10 of the 94 
(10.6%) Trusts said yes, 6 gave no response to this question and 78 said no. The 
other drugs/conditions specified are listed in Table 3.13.
One Trust said that although oncology and haematology treatments should be 
included in EL(95)5 [41], the local HA does not include them and another stated 
that the list of treatments in EL(95)5 [41] was not exhaustive and therefore all 
home intravenous therapy comes under EL(95)5 [41].
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Table 3.13: Patients Outside The Scope Of EL(95)5 Receiving Home 
Infusions, Trust Questionnaire
Drug/condition No of Trusts who gave this answer
apomorphine 5










enzymes for Gaucher’s disease 1
3.2.4.2.10 Patients receiving HTHH prior to EL(95)5.
Are there any patients under the care of your Trust who were receiving HTHH 
prior to EL(95)5 [41] and continue to do so as part of a bulk contract e.g. 
chemotherapy?
15 gave no answer, 57 said no and 22 (23.4%) said yes. The drug/conditions 
specified are listed in Table 3.14.
Table 3.14: Patients Receiving HTHH Prior To EL(95)5, Trust 
Questionnaire
Drug/condition No of Trusts who gave this answer
TPN 11





antivirals for HIV 1
All home patients 2
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3.2.4.2.11 Reason Current Provider Chosen
Why was your current home care provider chosen to provide care for this group 
of patients?
The major reason was quality of service, as can be seen from Figure 3.16. Most 
Trusts gave more than one answer to this question. Other reasons for choosing 
the current home care provider are shown in Table 3.15.
Figure 3.16: Trust Questionnaire, Other Reason Current HTHH Provider 
Chosen
no answ er  
other
no available alternative 
financially attractive 
patient acceptability  
con ven ien ce
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Number of Trusts Giving Answer
30 35
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Table 3.15: Other Reasons for Providing A HTHH Service, Trust 
Questionnaire
Survey no o ther reason  for providing HTHH, specify
1 Experience in field; multinational
3 Contacts with HA
57 Unknown
66 No information
74 We do not currently use one for IVs (Caremark for enteral has been used).
90 Provided by pharmacy and hospital as not enough work to contract out.
100 No in house manufacturing capacity/no NHS alternative
111 Clinical indication continuous infusion of cytotoxic
118 Actually use 5 home care providers
124 We were unhappy with our previous provider and we were approached by this care 
provider to work in partnership with them with us providing the aseptic
158 Don’t know
172 Dictated by which provider individual purchasers had drawn up a contract with.
177 Unknown - set up before in post
214 Small numbers and infrequent need mean that pharmacy is best able to meet needs of 
patient.
219 Above as partner with ourselves
222 It is an in house group set up for this purpose.
230 Contract decided by the HA ?parameters used?
232 Did not want to change.
241 Current system = pilot study of aseptic preparation by hospital pharmacy previously vials 
were supplied for reconstitution by parents at home.
258 Better treatment decided by consultants.
282 Developed from our aseptic service provision to inpatients. All patients were initially 
inpatients at the hospital.
283 No company currently used
317 We use a variety
344 TPN
349 At the time needed for our first TPN patient.
352 "Caremark" was recommended by one consultant at St Georges to the consultant here 
a t ............
1005 Used hospital pharmacy staff
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3.2.4.2.12 Shared Care Guidelines For HTHH
Do you have any guidelines for sharing the care of these patients between 
primary and secondary care?
10 (10.6%) of the 94 Trusts had any form of shared care guideline for patients 
being treated with HTHH. Table 3.16 shows further details from these 10 Trusts. 
72 Trusts said they have no guidelines and 12 gave no answer to the question.
Table 3.16: Details of Shared Care Guidelines for HTHH, Trust 
Questionnaire
Survey no shared care 
guidelines for HTHH?
Details and other comments
27 yes W e have developed guidelines for shared care of these  patients. Document for GPs and 
document for hospital staff.
28 yes Written guidelines on procedures, drugs, etc sent to GPs
74 yes "Shared care" protocols being developed with local HA
98 yes No of written protocols for som e specific disorders.
172 yes Shared care protocols - ganciclovir, foscarnet, amphotericin B
230 yes Sam e shared care protocols a s you!
337 yes Details are determined individually according to the needs of each family.
349 yes Shared care protocol based on one obtained from Grimsby Hospital, prior to EL(95)5 and 
then modified when EL(95)5 cam e into effect.
999 yes If HIV patients want district nurse to set up infusions we train them in use of infusion 
devices.
2222 yes Joint procedures/protocols
72 no No primary care involvement
165 no No formal guidelines
180 no The nutrition guidelines.
223 no Guidelines are being developed through area prescribing committee
323 no Primary care will not agree to be involved.
327 no Not yet
222 I’m not sure! I don’t think so. W e do it all!
227 Chose your commercial company carefully.
244 Som e were drawn up before EL(95)5; now we do everything so  they are obsolete! (for 
HIV only)
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3.2.4.2.13 Audit to Measure Quality of Care
Is there an audit system in place to measure the quality of care received by these 
patients?
12 Trusts gave no answer, 4 didn’t know, 18 said yes, 58 said no, 1 said “sort o f ’ 
and 1 said “very few patients therefore patients questioned regularly and 
encouraged to report problems” (Figure 4.16).






When asked who measures the quality of care received the number of positive 





When asked “how is this measured?” 8 of the 18 HAs who gave an answer used 
a questionnaire. The answers given are listed in Table 3.17.
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Table 3.17: Trust Questionnaire, How Is Quality Of Care Measured?
Survey no How is  quality of care m easured?
1 Patient satisfaction
27 Patient questionnaire is our only audit tool at present.
74 Patient questionnaire - usually.
92 patient satisfaction questionnaire
98 May be som e feedback from the HA
116 service a sse sse d  periodically
118 Questionnaires, patient groups etc
123 Questionnaires and monitoring of any problems.
124 Depends on what the individual Trust requires.
146 don’t know!!
180 - s e e  Business Manager
227 Very little known about it.
283 ?Probably such small scale that feedback is easier and patients are actively followed up.
327 Regular questionnaires
337 Only just being set up - not complete.
349 Patient monitored clinically - U&E results from fortnightly blood sam ples and attends outpatient 
clinic to s e e  the consultant to whom all hospital TPN patients are referred.
355 Questionnaire
2222 Patient questionnaire - F.U.
3.2.4.2.14 Audit to Measure Patient Outcomes
Is there an audit system in place to measure patient outcomes?
12 Trusts said yes, 57 said no and 25 gave no answer or did not know (Figure 
4.16).
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Figure 3.17, Trust Questionnaire, Auditing of HTHH
■  Audit system  to measure patient outcom es?
■  Audit system  to measure quality of care?
no answer/don't know
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3.2.4.2.14.1 H ow  is this achieved?
76 trusts gave no answer. The answers of the 18 who did are listed in Table 3.18.
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Table 3.18: Measurement of Patient Outcomes, How is this Achieved? Trust 
Questionnaire
Survey no How patient outcom es are measured.
27 Long term follow-up of iv antibiotic patients.
72 Data collection on service - Clinical Outcomes
74 Not at the moment. It is hoped to address this with the shared care protocols under development.
83 Respiratory nurses a s s e s s  informally.
98 Internal TPN audit
99 Unaware as pharmacy involvement nil.
180 Regular audit and review m eetings
219 Informal review of patient records/history at routine clinic appointments
241 only really tried in paediatric cf patients - antibiotics given from syringes not as infusion therapy
258 Oncology patient survival rate/cancer cure.
282 Various small audits have been carried out by medics, nurses and pharmacists.
283 By default - pts reviewed regularly a s outpatient therefore outcome visible
303 Formal annual audit of all TPN patients. Copies of report to all involved persons and recommendations.
321 Audit Department follow up chemotherapy patients, cystics are routinely monitored
327 via nursing audit system
337 Medical/nursing audit.
349 Patient monitored clinically - U&E results from fortnightly blood sam ples and attends outpatient clinic to s e e  
the consultant to whom all hospital TPN patients are referred.
2222 home data
3.2.4.2.15 Groups of Patients in Which Home Infusions Have Worked Best 
In which group of patients has home infusion worked best and why?
The answers given to this question are given in Appendix 4. These results were 
coded as discussed in Section 3.2.3.4.2 and the coding frame developed is shown 
in Appendix 20. It can be seen from this coding frame that the main positive 
comment was that the service provided post EL(95)5 [41] was better than that 
provided before. Home TPN (22), chemotherapy infusions (14) and antibiotics 
for cystic fibrosis (11) were the therapies which had worked best. The data was 
also coded by the researcher as shown in Table 3.19. This also shows that TPN 
and chemotherapy were the home infusions considered to be most successful. 
The reasons for this were patient preference for being at home and the resulting 
increase in their quality of life and good organisation of the home infusion 
service.
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Table 3.19: In Which Patients Have Home Infusions Worked best and Why?













All home patients 3
Limited Experience 4
Why? Number of comments
Patients prefer to be at home/ can get on with life. 17
Frees up hospital beds/clinic time. 9
Good organisation and backup for home care programme 14
Motivated patients 8
3.2.4.2.16 Barriers to Providing HTHH
What are/have been the barriers in providing infusion therapy at home in your 
area?
The answers to this question are shown in Appendix 24. Again they were coded 
as described in Section 3.2.3.4.2. The major barrier to the provision of home 
infusions was that of insufficient funding. Other problems included unclear 
patient selection criteria and hand over issues/poor communication (Table 3.20).
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Table 3.20, Trust Questionnaire, Barriers to Providing HTHH
Barriers to providing HTHH Number of comments
financial 26
T ransport/geographical 7
Lack of trained staff/facilities 7
Patient, carer, home not happy or suitable 6
None 6
Lack of co-ordination/communication 5
Timeliness 3
Lack of awareness of HTHH 3
3.2.4.2.17 Reason Trust provides HTHH
The answers to this question are shown in Figure 3.18. The other reasons and 
further comments given in answer to this question are given in Table 3.12.












/quality of life 
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Table 3.21: Other Reasons Trust Provides HTHH, Trust Questionnaire
Survey
no
Specify o ther reaso n s Further com m ents
1 It has to (all of the above)
28 reduce patient stay, therefore reduce risk of 
hospital acquired infection
90 Cancer patients are dying and receive chemo at 
home for palliative reasons
98 essential that children can start to lead 
some kind of normal life - attend school, 
play with other children (not in hospital 
setting) brothers and sisters.
124 This is the current reason. Some of the 
other categories may also become relevant 
later in the year.
222 Give patients sense  of dignity - feel they 
are helping themselves not reliant on 
nurses all the time
227 Patient able to stay at home with family.
244 to treat people with long term IV requirement
258 recommended treatment for their type of cancer.
261 better clinical outcome for 5FU patients
271 Benefit of infusional chemotherapy in response 
rates and survival.
322 All of the above apply but very often it is 
initiated by the patients who request the 
option of home care.
323 for paed’s, to avoid patient coming in to hospital 
in the first place to reduce exposure to hospital 
environment.
344 I for TPN and f for cytos
373 when patient is too ill to attend outpatient clinic 
for chemotherapy
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3.2.4.2.18 Collaboration with the Health Authority Prescribing Team 
Is there any collaboration between the Trust and the Prescribing Team (e.g. 
Pharmaceutical Adviser) on issues regarding HTHH?
30 of the 94 Trusts (31.9%) said that there was some collaboration. This varied 
from limited contact regarding contracts or the cost of therapy to regular update 
meetings and clinical case conferences. The responses given are shown in Table 
3.22. This also includes comments from the 38 Trusts who said they had no 
contact and 26 who did not answer or gave other answers to the question such as 
“don’t know”.
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Table 3.22: Collaboration with Health Authority Prescribing Team
Survey no collaboration  
with HA?
com m ents
96 yes we are attempting to understand the current situation, a precursor to monitoring and 
standard setting.
212 yes discussion of costs
180 yes I think so, as the business manager has regular meetings with the purchasers.
3 yes contracts for TPN at home provision
165 yes There is informal contact between the HA pharmaceutical adviser and the hospital 
pharmacists.
123 yes HAs som etim es have contract with alternate Home care company and do not want to 
use our major supplier. Have tried to persuade them to use our main supplier.
219 yes with HA contracts manager to maximise use of resources, with HA Prescribing 
Adviser - co-supervision of home care MPhil project
117 yes specify type of supplier i.e. licensed unit
194 yes to agree provision of health care at hom e and obtain funding from the HA to go  
ahead.
92 yes collaboration between Trust and HIV purchasers at HA
74 yes shared care protocols are currently being developed
72 yes regular update meetings clinical c a se  conferences
37 yes limited telephone contact
28 yes communication when problems arise e.g. dealing with EL(95)5, high cost drugs
12 yes mainly between directorate business managers and the Health Authority
118 yes The PA of the HA the patient lives in is always contacted and treatment discussed  
before pt sent home on therapy (include in contracting process)
321 yes Membership of prescribing committee
227 yes sort of
368 yes advice available from a pharmaceutical adviser
337 yes Purchasers are consulted prior to patient discharge since they are charged for 
services directed from this Trust.
244 yes previously
322 yes In som e Has there is collaboration with the pharmaceutical adviser in setting up 
contracts with the commercial companies.
283 yes Discussion on patient by patient basis, e.g. funding
287 yes to sort out funding only
172 yes Only in the initial se t up period for individual patients.
223 yes adviser is aware of current level and would be contacted by me re any specific 
issues/new  service requirements
323 no At the initiation of secondary care responsibility post EL(95)5 there was collaboration. 
Since then no further money allocated by main HA and not considered relevant for 
HA prescribing team.





No, none, don’t know, not yet, uncertain, ?
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3.2.4.2.19 General Level of Awareness of HTHH Amongst Staff Groups 
The pharmacists were asked for their opinion of what was the general level of 
awareness of HTHH amongst various staff groups. The answers are shown in 
Figure 3.19. Generally other professions were thought to have a fairly low 
awareness and pharmacists a moderate level of awareness. There were some 
comments that specialist nurses or doctors working on units where patients were 
treated at home had a high level of awareness whereas a much lower level of 
awareness was the norm.
Figure 3.19: Trust Questionnaire, General Level of Awareness of HTHH 
amongst Staff Groups
staff groups
no of positive  
r e sp o n se s  from 30  
Trusts
level of a w a r en ess
At the end of the questionnaire there was an opportunity for the hospital 
pharmacists to make further comments regarding HTHH. The comments 
received are shown in Appendix 24. These were coded with the other qualitative 
data as described in Section 3.2.3.4.2 and the results incorporated into the coding 
frame (Appendix 20).
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3.2.4.3 Commercial Home Care Company Survey
3.2.43.1 Response Rate
All six commercial providers of home infusions replied to the questionnaire 
survey giving a response rate of 100%. The data was collected over the time 
period November 1998- January 1999.
3.2.4.3.2 Which aspects of care does your company provide?
Five provide an entire package of care to patients at home under EL(95)5 [41] 
and the other provides the entire package of care jointly with a hospital or other 
organisation.
All six of the commercial providers directly provide equipment such as 
refrigerators and pumps, disposables, delivery to the patient’s home, a 24-hour 
help line, training of the patient/carer and education for other health care 
professionals. Other services were, in some cases, either subcontracted or 
provided by a hospital or other organisation.
Three companies provide their own nurses, two have some company nurses and 
also subcontract and one of these also said that the hospital or other organisation 
sometimes provides. One company subcontracts for all of the nursing care 
provided.
Three companies do their own aseptic reconstitution/filling of infusion devices 
whilst two subcontract this. One company said that the hospital or other 
organisation provides this part of the service.
One company subcontracts waste disposal and the others do it themselves. The 
company maintains infusion pumps themselves in four cases, one subcontracts 
this work and the other company said that the hospital or other organisation 
provides this service.
The only other service specified was company generation of custom compiled 
management reports.
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3.2A3.3 Number of treatment doses per week supplied?
Three companies provide more than 120 treatment doses per week, two provide 
between 30 and 60 treatment doses and one provides between 10 and 30 
treatment doses per week.
3.2A3.4 Treatment Supplied
The only two treatments that all six companies were providing at the time of the 
survey was home TPN and desferrioxamine infusions for thalassaemia (Table 
3.23).
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Table 3.23: Indications for which commercial providers are supplying
HTHH
currently have have never m ay provide  
provide provided in provided in the future 
past
intravenous antibiotics for cystic 
fibrosis patients
4 2 0 0
intravenous chemotherapy agents for 
patients with cancer
5 1 0 0
intravenous anti-infectives for HIV 
patients
5 1 0 0
total parenteral nutrition (TPN) 6 0 0 0
intravenous desferrioxamine for 
Thallasaemics
6 0 0 0
continuous intravenous anticoagulant 
treatment
1 1 0 4
intravenous antibiotics for other 
conditions
4 1 0 1
intravenous terbutaline for asthma 2 0 3 1
intravenous prostacyclin 1 1 2 3
intravenous immunoglobulins 2 1 0 3
subcutaneous beta-interferon 1 0 1 4
enzym e replacement for Gaucher’s  
d isease
2 0 1 2
intrathecal baclofen (for relief of 
spasticity as a result of spinal cord 
disease)
0 0 2 4
intravenous calcium gluconate 
infusions (for ricketts)
0 1 1 4






3.2.4.3.5 How many Health Authorities/Trusts do you currently have contracts 
with?
Table 3.24 shows the number of contracts that commercial providers have with 
HAs and Trusts. One company stated that all of their contracts were with 
hospitals not HAs. Two others made the point that contracts are often on an 
individual patient basis Box 1.
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Table 3.24 How many HA/Trusts do you currently have contracts with?
Range Health Authorities Trusts







“Virtually a ll o f  our business is non-contractual (N.B. Often pa tien ts  are  
ten dered  fo r  individually but in a n on-form alfash ion  i.e. hosp ita ls ring fo r  
quotes an d  usually go  f o r  the cheapest!). ”
“Only one fo rm a l H ealth  A uthority contract, others are p e r  nam ed patien t. 
C ontracts a t Trusts norm ally p e r  nam ed patient. ”
3.2.4.3.6 Who sets service specifications?
All six companies stated that Trusts set service specifications. Two companies 
just mentioned Trusts, three said HAs and Trusts, and one said HA, Trust and 
NHS supplies in conjunction with the HAs and Trusts.
3.2.4.3.7 Audit Systems
The audit systems that the commercial providers were aware of put in place by 
HAs or NHS Trusts with whom they have contracts are shown below in Figure 
3.20 and details of these systems are shown in Table 3.25.
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Figure 3.20: Commercial Home Care Company Questionnaire, Are You 
Aware Of Any HA Or NHS Trust With Whom You Have A Contract 
Having An Audit System in Place?
Benchmark your service against that of other 
providers?
Measure your service against agreed service  
specifications?
Measure patient outcomes?
Monitor the service you provide?
0 1 2 3 4 5
Table 3.25: Details of Audit Systems
Survey no Details of audit system s.
1 Monitor -quarterly review meetings on service performance.
2 Quarterly reviews are undertaken with a number of customers to ensure our service 
continues to meet the agreed standards. We are constantly compared with our 
competitors, there are a number of Health Authority and Trusts who will have patients 
on different home delivery systems in order to compare both costs and standards.
3 The audit systems we have in place with HAs and Trusts have all been initiated by our 
company. In our opinion many companies, particularly those using Agency nurses, 
provide sub-optimal care and we would like to differentiate ourselves on quality 
grounds
5 We hold quarterly review meetings. We have just carried out a patient satisfaction 
survey for our cystic fibrosis patients. We are in the process of setting up a customer 




A better response rate was achieved to the commercial home care company 
questionnaire (100%) and HA questionnaire (87%) than the Trust questionnaire 
(56%). This may be due to the fact that one mailing with one reminder letter was 
sent out to the Trusts but non-responders to the Health Authority survey received 
both written and telephone reminders on up to 5 occasions. It may also have 
helped that the HA questionnaire was in most cases distributed personally by the 
researcher with some sort of presentation or explanation of the objectives of the 
project. It was easier to follow up non-responders to the commercial home care 
company questionnaire than the others because of the small numbers involved. 
Two companies helped to design the questionnaire and the researcher explained 
the aim of the surveys to the commercial providers by telephone or in person to 
the others.
Both the HA and Trust surveys produced a response in approximately equal 
number from all the regions (Figure 3.21), allowing for the fact that some regions 
are larger than others. For the HA survey the range was 71 % (Anglia and 
Oxford) to 100% (South and West) of questionnaires returned. The figure was 
lower for the Trusts for the reasons discussed above ranging from 35% (Northern 
and Yorkshire) to 74% (South and West), (Figure 3.22). It may be in areas such 
as the Anglia and Oxford where the response rate from HAs was relatively low 
and that from the Trusts relatively high that responsibility for HTHH has been 
passed to the Trusts and therefore the Pharmaceutical Advisers knew little about 
the HTHH being provided (see Section 3.2.5.1.2) whereas the hospital 
pharmacists knew more and were therefore more likely to complete the 
questionnaire.
The largest numbers of responses were received from HAs in the North West 
region and Trusts in the North Thames and North West regions. These were also 
the regions which had the largest numbers of HTHH patients (Section 3.2.5.1.2.). 
The largest proportion of both HAs and Trusts responding to the questionnaire
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were from the South and West region. This may have been due to the fact that 
the research was being conducted from within the region.
Figure 3.21: Number of Responses by Region
HA Survey Trust Survey
Figure 3.22: Percentage Response Rate by Region




There was no sample bias to be taken into account, as in all three surveys the 
entire populations were included.
3.2.5.1.1.2 Response Bias
There was no response bias in the commercial home care company survey as a 
100% response rate was achieved. There may have been some response bias in 
the HA survey and this is discussed in Section 2.2.6.1.1. It is important when 
interpreting the data collected from the Trust survey that the possible effects of 
response bias are taken into account. It could be that non-responders found the 
questionnaire difficult to complete because of their limited experience of HTHH. 
Care is therefore needed when extrapolating data obtained from the 
questionnaire. It is also worth noting that a non-response from one of the major 
tertiary centres providing HTHH for a large number of patients may skew the 
data in the other direction when it is extrapolated.
3.2.5.1.2 Geographical Distribution
Data from both HAs and Trusts were grouped by region so identification of 
individual HAs and Trust would not be possible and then plotted on a map to 
show the geographical distribution of the provision of HTHH (Figure 3.23).
The geographical distribution of patients receiving home infusions would be 
expected to be more accurate from the HA questionnaire than from the Trust 
questionnaire as the HA would pay for home infusions for all patients under it’s 
jurisdiction whereas the Trust data would be skewed by the presence of tertiary 
centres. This can be seen to be the case for home TPN (Figure 3.23e). Of the 93 
home TPN patients in the North Thames region 65 were from one Trust and of 
the 92 in the North West region 84 were from one Trust. It is known that these 
are two large tertiary centres.
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Figure 3.23b - Number Of Patients Receiving Intravenous Antibiotics 
For Cystic Fibrosis Normalised*





When considering these data it must be remembered that both cystic fibrosis and 
thalassaemia are hereditary conditions and the incidence in the population may 
not be the same around the country. The incidence of HIV is also not evenly 
distributed geographically [274]. The incidence in the North Thames and South 
Thames regions accounts for more than 70% of the incidence in the whole of 
England. Accurate demographic data of this kind is difficult to obtain and would 
be necessary before any firm conclusions could be reached.
It can be seen from Figure 3.23a and b that the numbers of patients being treated 
with home antibiotic infusions for cystic fibrosis, reported by the Trusts were 
much higher than those from the HAs for the Northern and Yorkshire, Trent, 
Anglia and Oxford and Northern and Yorkshire regions but the reverse was true 
for the North West, West Midlands and South Thames regions. This is possibly 
due to the fact that Trusts were choosing to treat and fund patients with home 
infusions in the first case whereas the HAs are purchasing care for these patients 
under EL(95)5 [41] in the second case. Demographics of the areas must be taken 
into account. A study in the South and West region reported that there were 664 
patients with cystic fibrosis receiving care within the region and a further 
estimated 53 patients living in the region but receiving care outside at 31st 
December 1995 [275]. This would mean that in the South and West region 
approximately 5% of all cystic fibrosis sufferers were receiving home antibiotic 
infusions.
In all cases the numbers of patients being treated with home chemotherapy 
infusions was larger from the Trust survey than from the HA survey. This was 
substantially so in most cases. There were very few patients receiving home 
chemotherapy infusions whose care was being purchased through the HA. It 
appears from these data that patients in the West Midlands and Trent regions are 
less likely to receive their chemotherapy at home than those in areas such as the 
North West, Anglia and Oxford and South Thames. Five of the eight regions had 
no HAs purchasing home chemotherapy infusions.
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Figure 3.23c - Actual Number of Home Chemotherapy Infusions
HA Survey Trust Survey
Figure 3.23d - Number of Home Chemotherapy Infusions Normalised* 
*divided bv % response rate from region multiplied bv 100
a
a
HA Survey Trust Survey
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Figure 3.23e - Actual number of Patients Receiving Home TPN
HA Survey Trust Survey
Figure 4.22f - Number of Patients receiving Home TPN Normalised* 






There was slightly more correlation between the figures received from the HA 
and Trust survey on the numbers of patients receiving home TPN. The 
geographical distribution from the Trust survey is skewed as previously 
discussed by tertiary centres. This could account for the difference between the 
HA and Trust figures for the North West and North Thames regions. More HAs 
were responsible for contracting for TPN under EL(95)5 [41] than for other 
home infusions. In two instances the number of patients was larger from the 
HAs than the Trusts suggesting that care is being purchased by the HAs directly 
from commercial providers.
As would be expected the largest densities of population of HIV patients were 
around London, the North and South Thames regions. It appears that in the West 
Midlands and Northern and Yorkshire regions all of these infusions for HIV are 
purchased by the HA. However in South Thames and North Thames the Trusts 
are responsible for arranging care for nearly all of the patients.
In most cases the number of patients receiving home infusions of 
desferrioxamine was larger from the Trusts survey than the HA survey. By far 
the largest numbers of patients were in the North Thames region and this is 
probably due to the immigrant population in this area.
There were seven Trusts who said that there were geographical or transport 
barriers to the provision of HTHH. This was a particular problem in rural areas 
where patients live a long way from the hospital but although the provision of 
high quality HTHH is more difficult in these areas it is precisely the patients who 
live many miles away from the nearest hospital who can ultimately benefit more 
from the availability of home treatment. It enables them to keep in regular 
contact with their friends and family and does not mean that extra strain is put on 
the family by a carer having to travel many miles or stay away from home whilst 
the patient is in hospital.
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Figure 3.23g - Actual Number of Patients Receiving Home Infusions for 
HIV
HA Survey Trust Survey
Figure 3.23H - Number of Patients Receiving Home Antiviral Infusions for 
HIV Normalised*




Figure 3.23i- Actual Number of Thalassaemics Receiving Home 
Desferrioxamine Infusions
HA Survey Trust Survey
Figure 3.23j - Number of Thalassaemics Receiving Home Desferrioxamine 
Infusions Normalised*
*divided by % response rate from region multiplied by 100
HA Survey Trust Survey
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3.2.5.1.3 Proportion Of Trusts And HAs Unable To Provide Answers Re HTHH 
Patients
In many cases neither the Trusts nor the HA were able to specify the number of 
patients receiving HTHH. While the HA may take on responsibility for 
contracting for the provision of, for example, HPN for the patients in their area 
they may leave the provision of other home infusions such as chemotherapy or 
desferrioxamine entirely to the local Trust, this can be seen from the data in 
Section 3.2.5.1.2. The HA may not even be aware that patients are being treated 
at home with other such infusions.
It was not easy to interpret the answers regarding numbers of patients from the 
questionnaires. When the question was left blank it could mean that no patients 
were being treated at home with that drug or for that condition, but equally it 
could mean that the responder did not know if there were any of these patients.
It is difficult to distinguish at times between home patients and outpatients. A 
patient may receive therapy as an inpatient, outpatient and home patient at 
different times and therefore the numbers of patients can be difficult to estimate. 
This is also compounded by the fact that the number of patients receiving home 
infusions is never a static number. It should also be noted that the questionnaire 
may not have been targeted at the most appropriate person in the HA or Trust 
and for this reason answers may not have been obtained.
3.2.5.1.4 Proportion Of HAs/Trusts Providing Various Home Infusions 
Figure 3.2 shows the proportion of HAs and Trusts providing HTHH for various 
indications. It is striking that the proportion of Trusts providing home 
chemotherapy infusions is far larger than the HAs. These data would be in line 
with the assumption that the HAs are only purchasing those home infusions 
previously prescribed on FP10. It is unlikely that GPs were prescribing home 
chemotherapy infusions prior to EL(95)5 [41] and therefore EL(95)5 [41] did not 
affect the purchasing of this service.
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Figure 3.24: Proportion of HAs and Trusts Providing Various Home 
Infusions
60
h o m e infusion
The proportion of HAs purchasing HTHH (shown in Figure 3.3) differed from 
the results obtained in a telephone survey conducted by The Medicines 
Management Unit, Keele University [42]. This study asked whether packages of 
care were being purchased under EL(95)5 [41] for TPN, intravenous 
chemotherapy and intravenous antibiotics for cystic fibrosis. The proportion of 
HAs who said they purchased care for these patients were 92%, 37% and 81% 
respectively (cf. 54%, 6% and 46% in this survey). The survey was conducted 
over a period of 6-12 months before the data from this survey was collected.
The researchers at Keele wrote to the HA Chief Executive asking who was the 
most appropriate person to contact regarding the provision of HTHH under 
EL(95)5 [41]. Pharmaceutical, Medical Advisers and Contracts Managers were 
the most common people cited, suggesting that this survey was aimed at the same 
people within the HAs. The Keele survey only asked whether the HA purchased 
hi-tech packages of care for the indications specified whereas this survey asked 
for an approximate number of patients under the care of the HA currently 
receiving HTHH in accordance with EL(95)5 [41] for the specified indications. 
Fewer HAs were able to answer the question regarding numbers and this may 
account for some of the difference in the results obtained. It could be argued that
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a written response that a person had time to look up the answers to might be 
more accurate than an off the top of the head response to a telephone survey. It 
may also be that there is much confusion within HAs as to what is covered by 
EL(95)5 [41] and exactly what the HA is purchasing from whom and for how 
many patients. This is consistent with the fact that monitoring of provision of 
HTHH is poor, as there is poor understanding of whose responsibility this is (see 
Section 3.2.5.2.5).
3.2.5.1.5 Numbers of Patients receiving HTHH
The total numbers of patients receiving the various types of HTHH are shown in 
Table 3.26. The numbers obtained from a Monopolies and Mergers Commission 
report investigating a proposed merger between Fresenius and Caremark, two 
commercial HTHH providers, are also shown. These were an estimate of the 
current home care market in the whole of the United Kingdom, mostly obtained 
from commercial providers and are discussed in Section 3.2.5.1.6
Table 3.26: Numbers Of Patients Receiving HTHH




Monopolies & Mergers 
Commission report data 
for 1997[43] (UK)
actual normalised* actual normalised**
Antibiotics for cystic 
fibrosis




29 33 597 990 490
Antivirals for HIV 22 25 50 83 283
Home TPN 204 234 271 449 322
Desferrioxamine 99 114 159 264 450
Enzymes for 
Gaucher*s disease
11 13 6 10 94
‘divided by 87 multiplied by 100
** 167-11 who did not provide HTHH = 156 94/156=60.3% , therefore divided by 60.3 multiplied by 100, does  
not take into account the fact that som e non-responders may not provide HTHH
“ Not accurate to normalise numbers from Trust survey because they include tertiary providers with very large 
numbers of patients.
If the proportion of HAs purchasing HTHH from the Keele study [42] are 
accurate then these numbers will be significantly underestimating the true
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numbers. It is still not possible from these data to determine accurately the total 
number of patients who are receiving HTHH in England. In some cases the HAs 
contract for the service themselves and were able to give accurate numbers of 
patients, under their care, for whom they purchase HTHH. In this case the Trust 
and/or commercial supplier will have also included these patients in the 
responses to their questionnaire. In other cases the Health Authority have little 
or no idea of the numbers of patients in their area receiving HTHH. These 
patients will also be accounted for in the responses from providers. There is no 
co-ordinated approach to providing home infusions and therefore obtaining 
accurate information on the numbers of patients is almost impossible. If the 
NHS have no idea how many patients are being treated and how much is being 
spent on HTHH at any point in time it seems unlikely that they are aware of the 
cost effectiveness and quality of the care being provided (see sections 3.2.5.2.2 
and 3.2.5.2.5).
3.2.5.1.5.1 Correlation Between HA, Trust and Commercial Home Care Company 
Surveys -  Number o f  Patients
The largest numbers of patients being treated at home according to the Health 
Authorities were cystic fibrosis patients receiving antibiotics but the results from 
the Trust survey show that the largest numbers according to the hospitals are 
receiving infusions of chemotherapy (Figure 3.25). This is probably because the 
HAs do not fund home chemotherapy under EL(95)5 [41], as prior to 1995 the 
Trusts and not the GPs were supplying patients so there was no money for this to 
top-slice from GP prescribing budgets. In 5 out of the 8 regions none of the HAs 
said they had any home chemotherapy patients (Figure 3.23c). This highlights 
one of the problems with the provision of HTHH in England under EL(95)5 [41]. 
Health Authorities were only able to use money top-sliced from GP prescribing 
budgets to purchase HTHH and therefore any HTHH that was not being 
prescribed by GPs is not included in the Health Authority contracts.
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Figure 3.25a: Actual Numbers of Patients Being Treated with Home



















In all but one region the total number of patients receiving home infusions was 
larger from the Trust survey than from the HA survey. This supports the finding 
that Trusts are providing HTHH which is not being funded for and purchased by 
the HA under EL(95)5 [41]. In appears that in the West Midlands the HAs must
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be contracting directly with commercial providers for many of their patients. In 
this region it is only home chemotherapy infusions where the number of patients 
specified by the Trusts is greater than those specified by the HAs (Figure 3.23c).
The discrepancy between the numbers of patients being treated by Trusts and the 
numbers given by the HAs show that although some packages of care are being 
purchased for patients through the HAs, there are also many patients being 
treated with home infusions whose therapy is being paid for out of Trust funds. 
This poses further questions such as
a) Is the quality of care the same for both groups of patients?
b) Why are these packages of care all not being purchased through the same 
contract, as there may be economies of scale in purchasing in this way?
c) Why are HAs not purchasing packages of care for all patients covered by 
EL(95)5?
d) Has EL(95)5 caused inequity of care?
Due to the nature of the therapies used and conditions treated with home 
infusions many of the patients were under the care of hospital doctors on 1st April 
1995 and hence receiving their therapy through arrangements made by the 
Trusts. It seems absurd that the purchasing of HTHH by HAs is based on 
whether the GP was willing or not willing to take on prescribing for home 
infusions prior to 1995. The introduction of a single mechanism of purchasing 
and providing care for home infusion patients would seem a sensible approach.
From the synthesis of these data it appears that the Trusts are choosing to treat 
patients with home infusions which are not covered by HA contracts. This is 
also apparent from the other therapies being administered in the domiciliary 
setting that were specified by Trusts but not by HAs (Section 3.2.5.1.6.1). The 
data from the Monopolies and Mergers Commission Report [43] supports this 
showing that the NHS provides the following percentages of the home care 
market in 1997 HPN 14%, antibiotics 50%, antivirals 76%, chelation 75%, 
chemotherapy 77% and immunoglobulins, Gaucher’s disease, infertility and beta 
interferon 0%.
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3.2.5.1.6 Validation Of Data With That Obtained From Other Sources 
These data correlated broadly with those obtained from other sources for 
antibiotics and HPN. The Monopolies and Mergers Commission report [276] on 
the proposed Fresenius, Caremark merger estimated from information received 
from commercial providers that 908 patients were receiving home antibiotic 
infusions in the UK in 1997 (Table 3.26). This compares with an estimate of 879 
for England from the Trusts survey, just for cystic fibrosis patients.
The 1997 Annual Report of BANS [277] estimated, “from incomplete 
information” that there were 250-360 patients receiving home TPN at the time of 
their survey. The British Association of Parenteral and Enteral Nutrition 
(BAPEN) estimated in 1994 [278] that there were between 250 and 300 patients 
receiving home TPN. The Monopolies and Mergers Commission gave an 
estimate of 322 patients in 1997. This compares with 449 (just in England) 
extrapolated from the data collected from the survey of Trusts or 234 
extrapolated from the HA survey. The reason for slightly larger numbers of this 
survey could be that a few Trust pharmacists might have included numbers of 
inpatients in their response. It was stressed during the telephone survey, in the 
accompanying letter and in the questionnaire itself that information was required 
only on home infusions.
The numbers for the North West region for the Health Authority survey are 
higher then those reported by Pilling [6]. In his report carried out a year earlier 
than this survey, 1995, the number of individual patient contracts for TPN, IV 
antibiotics, IV antivirals, IV chemotherapy and desferrioxamine were 
approximately 54, 55, 12, 8 and 2 respectively versus 59, 77 (just cystic fibrosis), 
10, 0 and 12 respectively from the 14 HAs in the North West region who 
completed this survey.
It appears from the commercial home care company survey that hospital Trusts 
commission most HTHH services from them. This is supported by the Trust 
survey but not by the HA survey.
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3.2.5.1.6.1 Other Home Infusions
The lists of other home therapies obtained from the three surveys it can be seen 
were very similar (Table 3.27). The Trusts listed infusions such as apomorphine, 
dopamine and aminophylline which were not mentioned by the HAs or 
commercial home care companies. EL(95)5 [41] has been interpreted differently 
by different Trusts and HAs. It can be seen from these data that some include all 
of these other therapies as being covered under the EL and others include some 
or all of the examples listed in EL(95)5 [41]. This is also shown by the fact that 
5 HAs have patients being treated at home with enzymes for Gaucher’s disease, 
not mentioned in EL(95)5 [41], whereas many Trusts are independently funding 
patients with home chemotherapy or antivirals for HIV, specified in EL(95)5 
[41] but not covered by Health Authority contracts.
Table 3.27: Other Home Infusions Being Provided
HA, Trust and  CHCC Trust and CHCC Trust and HA HA and CHCC

































3.2.5.2 Provision of HTHH
3.2.5.2.1 Correlation Between Trust, HA and Commercial Home Care Company 
Surveys
The question where do patients receive their therapy was put into the Trust 
questionnaire for two reasons. One as a validation to make sure that the 
respondents were answering questions about home patients and the other to find 
out what proportion of patients receive infusions at home and which visit the 
hospital to receive their infusions. This was a difficult question to answer as 
patients often come into the hospital to have their infusion set up and then go 
home whilst the drug is infused over a few days or a week. Many people 
interpreted this to mean where is the infusion set up, which is probably why the 
numbers for outpatients is higher than might be expected (Figure 3.8). For drugs 
which are infused once a day or less frequently such as antivirals for HIV and 
desferrioxamine it can be seen that some patients visit the hospital to have 
infusions, similar to the US infusion centre model described in Chapter 2.
In by far the majority of cases the patient or their carer administers the therapy 
themselves (Figure 3.9). When asked who provides various aspects of the care 
for these patients, it might be expected that the Trust questionnaire would be 
biased towards Trusts as providers of care.
It can be seen that where HAs contracted for or were aware of their patients 
receiving HTHH they were more likely to use a commercial provider than the 
Trusts (Figure 3.26). This raises questions regarding a conflict of interest when 
HAs pass the responsibility for contracting for HTHH on to the Trusts. If the 
Trust, has the facilities they are possibly more likely to provide the service 
themselves than contract with a commercial provider or put the service out to 
tender as required by European law for any contract worth over 93,896 ECU’s 
(approximately £60,000), total value of contract regardless of time period. There 
were some comments in the Trust survey about inadequacy of their current 
provider around lack of ability to respond to changes in therapy at short notice.
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It seems that few HAs or Trusts have carried out tendering exercises for 
purchasing HTHH (see results of commercial company survey, Section 3.2.4.3). 
This is supported by the findings of the Keele study [42]. The commercial 
providers are the largest suppliers of nursing care and equipment and supplies 
according to the HA survey and supply almost as many of the drugs as hospitals 
but according to the Trust survey all of these services are supplied much more 
commonly by the hospital than by a commercial provider. The commercial 
providers claim to have more contracts with Trusts than HAs. Information 
obtained from the commercial providers shows that 5 of the 6 companies provide 
nursing care either subcontracting or employing their own nurses. 3 companies 
have their own aseptic facilities for provision of the drugs, two subcontract this 
and one company said that the hospital or other organisation provide this part of 
the “package of care” (Section 3.2.4.3).















I T rust survey 
I HA survey
provider
In the Trust survey the only item that was more commonly supplied by a 
commercial provider than a hospital was children’s TPN and the equipment and
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supplies for both adult and children’s TPN. This is in line with the information 
obtained from commercial providers of HTHH. Many did not provide care under 
formal contracts but provided HTHH on a patient by patient basis mostly paid for 
through Trusts and occasionally through HAs. This method of purchasing raises 
further concerns regarding the monitoring of the quality of care supplied and 
patient outcomes. It seems unlikely that service specifications would be set up 
on an individual patient basis and anecdotal evidence suggests that they are not.
These surveys have revealed inequity of quality of care received by patients in 
different areas of the country. During the telephone survey (Appendix 22) many 
Trusts revealed that patients are given antibiotics as take home medication and 
are taught how to draw them up and administer them at home. One Trust 
(Survey no 182) reported that they currently had 220 cystic fibrosis patients with 
a bill of £90,000 per month on drugs alone and that they could not be able to 
cope with the workload of aseptically preparing the doses for their patients. 
Whereas other cystic fibrosis patients receive a “Rolls Royce” service in 
comparison with a trained home care nurse, ambulatory pump, aseptically 
prepared bags and a 24- hour call out service. It has been suggested by a 
commercial home care provider that after a spate of infections in patients 
administering their own intravenous antibiotics, the company is only then 
approached to tender for the service provision. More studies are required to 
quantify any difference in patient outcomes between patients receiving different 
level of care but work in the USA has suggested that cheaper care provision in 
the long run increases the overall cost of treating the patient [279].
From the Trust survey (Figure 3.9) it appears that hospital nurses including 
outreach nurses accounted for the largest proportion of nurses who administered 
therapy but for all groups of patients district nurses also featured. Both hospital 
outreach nurses and district nurses may visit the patient’s home to administer 
each dose. Commercial home care company nurses did not feature highly here. 
This is probably due to the bias of the Trust questionnaire as providers.
In contrast to the Health Authority questionnaire the Trust questionnaire revealed 
that most patients receiving home antibiotics for cystic fibrosis, chemotherapy
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infusions, antivirals for HIV and desferrioxamine received their equipment and 
supplies from the hospital but for HPN (for both children and adults) the major 
providers were the commercial home care companies. This again suggests that 
HPN is more often contracted for separately by the HAs.
The HAs were not asked who provides a 24 hour helpline for these patients but 
the response to the Trusts questionnaire shows that in all cases the hospitals most 
commonly provided this service followed by the commercial home care 
companies. Primary care provided 24 hour cover in a few cases for all groups 
except children receiving HPN. The commercial companies all said that they 
provide a 24 hour helpline. It may be the case that for clinical problems the 
hospital may provide emergency back up but for mechanical problems or those 
involving supplies it is the commercial provider.
3.2.5.2.2 Expenditure
3 .2 .5 .2 .2 .1  R esponse Rate
The expenditure by HAs on the various home therapies can be seen in Figure 3.5. 
The HA questionnaire did not provide detailed information on expenditure. It 
can be seen from Table 3.28 that the HA were more likely to give an idea of their 
expenditure than the Trusts. This may have been due to the fact that they were 
asked for less detailed information. It was however often the case that both HAs 
and Trusts were unaware of their expenditure and the Trusts commonly gave 
figures for only the drug costs. This suggests that there is little information on 
the cost effectiveness of home infusions being collected. If costs are not 
monitored, it seems unlikely that quality of care is being monitored and the HAs 
and Trusts cannot be monitoring the cost effectiveness of the HTHH that they 
currently purchase.
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Table 3.28, Responses re expenditure on HTHH
Percent* giving resp o n se  re expenditure
HA survey Trust survey
Cystic fibrosis 86.0% 51.2%
Chemotherapy 40.0% 38.5%
Antivirals for HIV 50.0% 57.1%
TPN 85.7% 50.0%
Thalassaemia 66.7% 50.0%
*Number giving response divided by number giving number ofpatients>0 multiplied by 100
3.2.5.2.2.2 Health Authority Survey
The results show a wide variation in expenditure on home infusional therapy. 
HAs were asked to give an approximate annual expenditure in wide bands as it 
was expected that exact figures might be difficult for a Pharmaceutical or 
Medical Adviser to obtain. 27 HAs gave no answer at all to the numbers of 
patients or the expenditure (see Section 3.2.4.1.1). It can be seen that antibiotics 
for cystic fibrosis were the lower cost higher volume infusions whereas TPN is a 
lower volume higher cost therapy. The wide range in expenditure on 
desferrioxamine is probably due to the demographics of the population as 
thalassaemia is endemic in Mediterranean countries and expenditure is related to 
the incidence within the immigrant population.
The unpredictability of the annual cost of HTHH to the HA was a problem that 
was raised in the qualitative data collected (Appendix 19), this was in contrast to 
the Trust survey where the problem of insufficient funding was raised by 23 
Trusts and unpredictability of funding by 5 (Appendix 24).
3.2.5.2.2.3 Trust Survey
Trusts were asked their annual expenditure on each category of home infusion 
and the number of patients. A very approximate idea of expenditure per patient 
per annum was calculated by dividing the number of patients by the expenditure 
(see Table 3.29). One Trust had a cystic fibrosis patient awaiting a heart/lung 
transplant on continuous home antibiotic therapy. The cost of the drugs alone for
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this patient amounted to over £80,000 per year (this patient was excluded from 
the data shown in Table 3.29). The range of cost for antibiotic infusions for 
cystic fibrosis and for chemotherapy infusions would be expected to be greater 
than that for desferrioxamine or TPN as there is a much greater variation in the 
cost of the drugs given. The cost of an adult TPN patient varied from £10,000- 
£60,000 per annum. It could be that the lower end of the range was due to a 
patient (or patients) only receiving TPN for part of the year or having bags two 
or three times a week instead of requiring them every day. Children’s TPN was, 
on the whole, more expensive than adult TPN probably due to the specific and 
varying requirement of a child’s nutrition compared to that of an adult who may 
well have standard bags and little variation in nutritional requirements.
It can be seen from Table 3.29 that the cost of treating patients with HTHH 
varies widely throughout the country. This would in part be due to different 
patients and patient groups possibly requiring very expensive therapy. However 
it is very unlikely that this accounts for all of the variation.
There may be some bias in the data on expenditure as it could be that Trusts 
whose expenditure was large were more likely to know what it was than those 
whose expenditure was small.
The Monopolies and Mergers Commission report on the proposed merger 
between Fresenius AG and Caremark Limited [43] shows that over the time 
period 1992 to 1997 for Caremark and 1994 to 1997 for Fresenius overall real 
price trends for home infusion therapy dropped. It also shows that Caremark’s 
average price of contracts with HAs is higher than that for Trusts. This is in part 
explained by large centres who had large numbers of patients and had exercised 
this buying power in negotiating contracts and whose patients due to the 
expertise of the centre were less costly for Caremark to service. The costs were 
excluded from the report to protect the interests of the companies concerned.
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Table 3.29- Expenditure By Trusts On HTHH












16 1,000-25,000* 4,707 3,038




12 1,111-10,500 4,515 3,536
HIV** 8 1,000-31,500 16,250 17,500




14 10,000-60,000 28,708 30,000
HPN children** 9 15,000-50,000 36,370 37,500




13 667-10,000 5,516 5,000
*One patient at £80K/year also excluded. **no figures stated that they were for 
drugs only rather than entire package of care?
These are broadly in line with the costs that Pilling [6] estimated of treating 
patients with HTHH in 1995/96. The figures in this report per patient per year 
were approximately £6,000 for IV antibiotics, £20,000 for antivirals, £3,000 for 
chemotherapy £35,000 for TPN and £14,000 for desferrioxamine.
3.2.5.2.3 Contracting/Purchasing HTHH Services
It is clear that the responsibility for contracting for the service, providing the 
service and monitoring the quality of the service provided, lies with different
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people in different areas. In many cases the Health Authority assume the Trust 
or commercial provider is responsible. EL(95)5 [41] clearly placed this 
responsibility with the Health Authorities.
It was difficult to interpret the answers to the question regarding whether HTHH 
was purchased as a separate contract or as part of a bulk contract by the Health 
Authority (Section 3.2.4.1.5). These data show that the majority of HAs contract 
for these services as a separate contract but over a quarter of respondents have 
added the money from top-slicing GP budgets in 1995 to their bulk contracts 
with the Trusts and passed on the responsibility for contracting for packages of 
care for these patients. This is in line with the findings of Short [42]. Both the 
HAs (5) and Trusts (2) commented that tertiary centres can cause problems with 
contracting mechanisms. This can particularly be a problem where a HA sets up 
a contract with a provider for all of their patients then they have a patient referred 
to a tertiary centre which may have their own contract with a different provider.
The Trusts were not asked specific questions regarding the commissioning of 
HTHH but the answers given regarding who supplies the drugs (Figure 3.11), 
nursing care (Figure 3.12), equipment and supplies (Figure 3.13) and a 24 hour 
help-line (Figure 3.14) all refer to commercial providers. It may be that the 
commercial company is entirely responsible for the care of patients at home or 
the hospital pharmacy and commercial company may be working in partnership 
to varying degrees. Some have formal partnership arrangements and others work 
closely with the company as the patients may frequently come in and out of 
hospital. There has been some conflict of interest in certain places where a 
hospital pharmacy department have bid for a contract and lost it to a commercial 
company with whom they then are expected to work, co-ordinating discharge 
arrangements and in some cases stepping in when the commercial company is 
unable to supply or respond quickly enough to changes in therapy (Box 2).
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Box 2:
“R ecently hom e TPN  p a tien ts  have been taken o ver  by  com m ercial com panies  
who have a less f lex ib le  approach  to form u lation  changes such that the ph arm acy  
departm en t p rep a re  bags when regim es have to be a ltered  a t very  short notice ”.
22 Trusts said that they did have patients who were receiving HTHH as part of a 
bulk contract prior to EL(95)5 [41]. In these cases the funding could not have 
been top-sliced from GP prescribing budgets and therefore it would have been 
difficult for the HAs to claw back this money from the Trusts to purchase a 
“package of care” for these patients. This is likely to be one of the reasons that 
many HAs do not contract separately for HTHH. It can be seen from these data 
that often ad hoc arrangements are in place for the different groups of patients 
receiving different therapies at home from local Trusts, Box 3.
Box 3
‘'The situation  is very com plex -diffuse an d  vague accoun tability  -very fragm ented. 
In short - a m ess!  ”
“I have been trying to f in d  out abou t cystic  f ib ro s is  pa tien ts  as 1 am  sure we have  
some. U nfortunately I  have n ot fo u n d  anyone who can an sw er these questions. This 
in itse lf  p ro b a b ly  indicates lack o f  any co-ord in a ted  a p p ro a ch ”.
Ten Trusts said that patients received home infusional therapy outside the scope 
of EL(95)5 [41]. One Trust stated that this depended on the interpretation of 
EL(95)5 [41], as the list of recommended drugs/treatments was not exhaustive 
and therefore all intravenous infusions administered at home came under 
EL(95)5 [41]. This again highlights the problems caused by different 
interpretations of EL(95)5 [41].
The Trusts were asked why their current home care provider was chosen (Figure 
3.16). Most said because of the quality of service (37) although only 18 Trusts 
said that they had an audit system in place to measure the quality of care received
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by these patients (see Section 3.2.4.2.13). The next most popular reason was 
convenience (33) followed by the fact that it was financially attractive (30).
Again very few measured value for money or quality of the service the patients 
were receiving for the financial outlay. 22 Trusts said patient acceptability was a 
reason for choosing their current provider but only 8 Trusts (Table 3.17) 
mentioned any kind of patient satisfaction survey when asked about how the 
service was audited.
Fewer than 20% of the Health Authorities had any future plans for the care of 
these patients. One Health Authority had decided to give the responsibility for 
organising care for new patients to the individual clinicians. This does not 
comply with EL(95)5 [41]. Another was thinking of giving responsibility to the 
Trusts and had decided to allow diversity or provision dependant on 
circumstances, two said the provision of the service was going out to tender and 
one Health Authority commented that an overall approach seems difficult due to 
the varied patients. None of the HAs gave any sign that they had a long term 
strategy for either continuing to care for the numbers of patients being treated 
with hi-tech therapies at home or for coping with and financing increased 
numbers of these sorts of patients. In the USA, both patients and payers 
(insurance companies etc) have demanded an increase in the provision of home 
care services. With increasing problems of antimicrobial resistance, hospital 
acquired infections and super-bugs in the hospitals in England [280], it is perhaps 
surprising that the promotion of high quality and cost effective home therapy 
which has been proven in the USA, and to a lesser extent in the UK (Chapter 2), 
is not being adopted and planned for [30].
None of the Health Authorities knew of any fundholding GPs who directly 
purchased HTHH. Pilling and Walley [6] note that there was confusion as to GP 
fundholder responsibilities for commissioning HTHH and suggested that due to 
the very small numbers of patients purchasing via consortia of GP fundholders 
would be more appropriate. The American Society for Parenteral and Enteral 
Nutrition (ASPEN) have published standards for home nutrition support the most 
recent update being in 1999 [214] with the aim of assuring sound and efficient 
home nutrition support care and assist organisations and health professionals in
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providing safe and appropriate nutrition care. The standards give examples to 
ASPEN’s multidisciplinary members of implementation of specific standards. It 
remains to be seen whether primary care groups (PCGs), will be responsible for 
purchasing HTHH and if so at what level.
Once PCGs attain Trust status they may have to contract for this service. They 
are being actively encouraged to enter into collaborative commissioning 
arrangements [281]. Pilling [282] predicts that PCGs and PCTs could become a 
catalyst for home care becoming the modality of choice in an effort between 
primary and secondary to care to maximise the efficiency of unified budgets. A 
Primary Care Trust could decide on a model of provision for all hi-tech therapies 
from a secondary care outreach service. Alternatively GPs may decide that they 
wish to care for patients whose only requirement is a course of intravenous 
antibiotics for example. If an appropriate package of care was available at short 
notice this might save a hospital admission. It is apparent from these data that 
GPs do not have any experience in this area. It is beginning to appear more 
likely from models emerging for the specialist commissioning of other services 
that some of these high cost, low volume therapies may well be contracted for on 
a regional basis [283]. It is recognised that the expertise for this does not rest 
within the PCG/Ts and the very small numbers of patients per PCT would mean 
commissioning on an individual PCT basis would not be viable unless a change 
in thinking led to a large increase in numbers of patients.
3.2.5.2.4 Collaboration With Health Authority And Primary Care Colleagues 
HTHH is an area of patient care at the primary/secondary care interface. Patients 
are in their home environment and often geographically closer to the GP than the 
hospital. Their GP is still expected to look after other ailments that the patient 
has whilst at home but may not be directly involved with the home infusion, 
especially since EL(95)5 [41] stopped GPs from prescribing these therapies on 
FP10 prescriptions. It can be seen from Figure 3.14 that primary care is involved 
in providing a 24 hour help line for these patients so good communication with 
all parties having a clear understanding of where their responsibilities lie and 
who to contact for advice is important. Only 10 (10.6%) Trusts had any shared 
care arrangements or guidelines for these patients and HAs reported very few
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shared care guidelines for home infusions (17.2% knew of a guideline for HPN, 
16.1% for home antibiotic infusions and 8.0% for home chemotherapy).
Concerns about hand over issues and patient selection were raised in the 
qualitative data from both the HA (14 comments) and Trust (11 comments) 
surveys. From these data it would seem that inadequate arrangements exist to 
ensure that the patient’s GP is kept fully informed of the patients’ treatment and 
where his responsibilities for the care of that patient lie.
30 Trusts (31.9%) said that there was some collaboration between the Trust and 
the Health Authority Prescribing Team. This question was asked as many of the 
HAs said that the Trusts dealt with HTHH and they were therefore unable to 
answer the questions. However the responsibility for contracting for HTHH 
should lie with the HAs (EL(95)5 [41]). This again suggests that the Trusts are 
providing HTHH which is not covered by EL(95)5 [41] and not contracted for by 
the HAs. Trusts that did have contact with their Health Authority 
Pharmaceutical Adviser mainly collaborated over contracts and particular 
problems which arose or to obtain funding for a new patient. One Trust had 
regular update meetings and clinical case conferences with the Health Authority, 
but this was far from the norm, which amounted to occasional telephone contact 
or meetings in most instances.
3.2.5.2.5 Quality Assurance of HTHH Service
It was apparent from the qualitative data obtained in response to the HA survey 
that HAs are unclear as to who is responsible for monitoring the quality of care 
received by patients receiving HTHH [284]. When these data were coded 
(Appendix 20) it can be seen that there were 12 comments regarding auditing the 
quality of patient care and 11 comments on how the HAs know whether they are 
getting value for money. No specific questions were asked in the HA survey 
regarding the clinical governance of HTHH but the number of HAs who 
independently raised this as a concern led to specific questions being asked on 
the subject in both the subsequent questionnaires. It is apparent that there is very 
little monitoring of quality of HTHH programmes currently in England. When 
the qualitative data received from the HAs was coded 14 comments showed 
ignorance/unfamiliarity with HTHH (Appendix 20). These findings are in line
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with those of Short [42] who found that the proportion of Health Authorities with 
monitoring mechanisms in place for their contracts for home chemotherapy, 
antibiotic and HPN were 76%, 56% and 47% respectively.
The answers that Trusts gave to the questions regarding quality assurance of the 
home infusion service are perhaps the most worrying of this study. Only 18 of 
the 94 (19.1%) responders replied “yes” when asked if there was an audit system 
in place to measure the quality of care received by these patients. Of those 18, 7 
did not specify how this was measured when asked, although one of these gave a 
telephone number of someone who might know, (no answer when called). One 
said “patient satisfaction” and 7 used questionnaires. The other two answers 
were “Depends what the individual Trust requires”, “May be some feedback 
from the Health Authority” and “Service assessed periodically”. Only 8 out of 
94 (8.5%) could specify a method of measuring the quality of care received by 
patients. This is particularly worrying in light of the fact that the qualitative data 
revealed 9 comments regarding the inadequacy of their provider’s service 
(Appendix 24). This contrasts strongly with the position in the USA (see 
Chapter 4).
EL(95)5 [41] was intended to introduce more competition into the home care 
market so that cost effective care would be provided. The Monopolies and 
Mergers Commission report [43] on the proposed merger of Fresenius and 
Caremark, two commercial providers of HTHH, found that the merger would 
lead to a reduction in competition and would particularly make it harder for the 
NHS to obtain value for money in purchasing parenteral nutrition for patients at 
home. If competitive tendering exercises are in place there is pressure for 
providers to provide HTHH at a competitive cost. If so few Trusts or HAs are 
monitoring the quality of service that is provided it is inevitable that quality will 
decrease along with cost.
More Trusts answered the question who specifies audit criteria. In 13 cases it 
was the Trusts. 4 Trusts said that commercial home care companies specified 
audit criteria, although when asked the same question no commercial companies 
claimed to specify audit criteria and 4 said it was the Health Authority. One said
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that patients and their carers specify audit criteria to measure the quality of the 
service they receive. When asked who measures the quality of care received by 
these patients 11 said that it was the Trust or provider unit, 4 said it was a 
commercial company, 2 said the Health Authority and 2 the patient/carer. It 
appears from these data that even when Trusts are specifying audit criteria 
themselves, and consider themselves to be responsible for audit, they are not 
carrying it out.
A similar situation existed regarding monitoring patient outcomes. This time 
even fewer (12) Trusts said there was an audit system in place to measure patient 
outcomes. 11 said that it was the Trust who specified audit criteria and 12 said it 
was the Trust/provider unit who monitors patient outcomes.
14 Trusts gave answers to the question “how is this achieved?” (Table 3.17). 
Some had audit programmes, both small occasional audits and more formal audit 
programmes, others had systems for long term data collection, or regular audit 
meetings. One said that the oncology survival rate/cancer cure was monitored. 
This is a fairly crude audit of the clinical outcomes of patients receiving home 
chemotherapy infusions. However it is better than the 76 (80.9%) responders 
who gave no answer. It seems that audit systems need to be put into place in 
order to ensure that patients being treated with home infusions are doing at least 
as well as those being treated as inpatient or outpatients. If this were not the case 
it would be unethical to treat patients with infusions in the domiciliary setting. 
These data suggest that very few Trusts have any idea whether patients being 
treated at home are faring any better or any worse than they would be if treated in 
the hospital or if their care was being provided by another provider.
Both HAs and Trusts purported to be providing HTHH because it improves 
patients’ quality of life. There was little evidence for this. They had chosen their 
current provider because of the quality of care provided but very few were 
measuring this at all and many of those that claimed they were, were doing it in a 
very superficial way or “by default”. The second commonest reason that Trusts 
had chosen their current provider was convenience, convenient for whom, the 
patient or the purchasers and providers of HTHH? 30 Trusts had chosen their
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current provider because they were financially attractive but they then failed to 
measure the quality of care received by the patient or patient outcomes. As was 
shown by Bimbaum et al [279] those providers that appear cheaper can end up 
being more expensive in the long term due to poor patient outcomes and higher 
incidence of complications. 14 Trusts said there was “no available alternative” 
which perhaps highlights the lack of competition in the current home infusion 
market referred to by the Monopolies and Mergers commission in their report 
[43].
Four out of six commercial providers knew of any HAs or Trusts with whom 
they had contracts having an audit system in place to monitor the service they 
provided or to measure the service provided against agreed service 
specifications. Only one company knew of any HA or Trust with systems in 
place to measure patient outcomes or benchmark the service provided against 
that of other providers. One company stated that they had initiated all of the 
audit systems in place with HAs and Trusts as they wished to differentiate 
themselves from their competitors on quality grounds.
3.2.5.2.6 Role of the Pharmacist
The areas where pharmacists presently have the greatest input into HTHH are 
pharmaceutical advice to the prescriber, supply of drugs, aseptic reconstitution 
and provision of formulation and stability information which is what might be 
expected, as they are traditional roles of the pharmacist.
3.2.5.2.6.1 Contracting
Although 63 of the 94 responders said that pharmacists were involved with 
setting up the HTHH programme and 59 said they were involved with setting 
service specifications very few were involved with market analysis (33) or 
contracting for the services (42.5) that many of them were themselves providing 
(Figure 3.15). It would have been interesting to ask how many Trusts had any 
service specifications for the provision of HTHH. The reason that pharmacists 
were not involved with setting them could be that none had been set. 8 Trusts 
listed other people who were responsible for setting service specifications, these
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included the HA, consultants, pharmacy managers, directorate managers, nurse 
managers and the business manager for nutrition.
3.2.5.2.6.2 Co-ordination and Communication
Pharmacists in the USA have had a major role in the co-ordination of the home 
care programme (Section 3.1.6). It appears from these data that the pharmacists 
main role in HTHH was communication with other health care professionals (83) 
and with patients and their carers (76). Only 60 said that they were involved 
with communication with other pharmacists which is surprising in a hospital 
pharmacy environment where there may well be a specialist pharmacist looking 
after nutrition, paediatrics or HIV for example and another pharmacist involved 
with aseptic dispensing. Patient selection was left up to medics in nearly all 
cases where the person responsible was specified. Only 35 Trusts said that 
pharmacists had any involvement in patient selection. This is in contrast to the 
situation in the USA where pharmacists have become heavily involved in patient 
selection, education and support (Section 3.1.6).
3 .2 .5 .2 .63  Education
An area where pharmacists often have a major role in the hospital environment 
generally is in education. Relatively low numbers of pharmacists were involved 
with education regarding HTHH, an area where a great deal of education of both 
patients and staff is necessary for safe and effective therapy. Only 5 Trusts said 
that pharmacists were “very involved” with competency assessment of the 
patient or their carer and 15 had “some involvement”. This was a task mainly 
left to the nursing staff or in a few instances to a commercial provider. The 
largest role that pharmacists had in education was that of educating other health 
care professionals (61). 43 Trusts said pharmacists were involved with the 
design of written information regarding HTHH and 42 were involved with 
training patients and their carers how to administer their medication at home.
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3.2.5.2.6.4 Supply
72 of the Trusts were involved with the supply of drugs and aseptic 
reconstitution and filling of infusion devices. If the Trust did not supply the 
drugs a commercial home care company most commonly supplied them.
Pharmacists in the USA have reported a strong involvement in selection of 
infusion device. This does not appear to be the case in England. 23 Trusts said 
that pharmacists were “very involved” with selection of infusion pump and 32 
had “some involvement”. Again where commercial companies were providing 
HTHH they were responsible for selection of infusion device and maintenance of 
pumps. Medical electronics and supplies departments of hospitals and specialist 
nurses were the other people responsible for maintenance of the pumps; there 
was little pharmacy involvement (19).
3.2.5.2.6.5 Quality Assurance
Quality assurance is another area where pharmacists have experience. The 
numbers involved with quality assurance of the provision of hi-tech health care 
to patients at home was disappointingly low.
24 Trusts were involved with quality assurance of the infusion pumps and only 
one Trust with no involvement gave an answer for who was responsible. This 
suggests that either no one is responsible or no one knows who is responsible. 
Pharmacists should be happy about the accuracy of delivery of infusion devices 
that they are filling for patients’ use at home. These data would suggest many 
have no idea who is taking responsibility for quality assurance of the pumps.
60 said that they were involved with compliance with regulations such as Good 
Manufacturing Practice. As 72 were supplying and aseptically reconstituting 
drugs or filling of infusion devices it would be expected that this number should 
be the same. Only 8 Trusts were “very involved” with quality assurance of the 
home infusion program and 33 had some involvement. Even fewer (40) had any 
involvement with ensuring that service specifications were complied with. 
Comments included “I do not know of anyone performing” and “no service
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specifications that I know o f ’. In the main there were not answers to the 
question who was responsible if the pharmacist was not. It seems that in many 
cases it is only the statutory monitoring of quality that is being carried out. It 
appears that it is easy to become caught up in the vital quality assurance of the 
product manufactured in pharmacy but very few organisations are taking a step 
backwards to look at the bigger picture and the quality of the whole package of 
care received by these patients and how this may affect patient outcomes.
32 .5 .2 .6 .6  Clinical
There was more pharmacy involvement with clinical matters. Pharmacists did 
have a role in giving pharmaceutical advice to the prescriber (86), providing 
formulation and stability data (83) and maintaining prescription records (78). 
These tasks were performed by Trusts even when a commercial company was 
supplying medication to the patients in their homes. 71 were also involved with 
choice of appropriate drug therapy and 43 were involved with documentation of 
a pharmaceutical care plan for the patients. More pharmacists had “no 
involvement” in selection of venous access device (73), documentation of a 
pharmaceutical care plan (47), interpreting laboratory tests (40), providing a 24- 
hour help line (60) and monitoring patient adherence (56) than had any 
involvement. Selection of venous access device was the domain of the medical 
and nursing staff although one Trust said that this was protocol driven.
3.2.5.2.6 . 7  Other Roles o f  the Pharmacist in HTHH
Other roles of the pharmacist in the provision of HTHH included general queries 
and advice regarding interactions, advice regarding terminal care and supply of 
diamorphine syringes, identification of other therapies that could be practically 
dealt with on a home care basis, negotiation with purchasers re EL(95)5 [41] 
budget, ordering of blood test etc, ordering and monitoring expenditure and 
billing other HAs via contract or Extra Contractual Referral and costing.
It is apparent that there are potential roles for the pharmacist in this area but in 
many places these have not been fully developed. Many pharmacists have the
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skills to train and educate patients and their carers and other health care staff, 
particularly in areas where they have more knowledge and experience than any 
other health care staff such as in handling cytotoxic medication and waste. They 
have developed skills in quality assurance of other services they provide both in 
quality assurance of products supplied and in validating processes used in 
manufacturing techniques. In order to hold a Medicines Control Agency 
“specials licence”, which many of these Trusts do, a high level of competency in 
quality assuring both product and process is required. Colleagues in the US have 
proved, more than a decade ago (2.3.7) that pharmacists can effectively co­
ordinate a home care service. They have an important role in patient selection, 
continuous quality improvement and quality assurance of the service and are 
often responsible for selection of infusion device and venous access device and 
therapeutic drug monitoring, in addition to the traditional roles of providing 
formulation and stability data and giving pharmaceutical advice to the prescriber, 
and supplying drugs in a ready to use form.
The shortage of hospital pharmacists in hospitals in England in recent years may 
be a contributory factor in the lack of pharmacist involvement in HTHH 
programmes [285].
Pharmacists in England have not realised the full potential of their role in the 
provision of HTHH and in many cases are the best placed healthcare professional 
to take on these new roles [286].
3.2.5.2.6.8 Level o f  Awareness o f  HTHH Amongst Staff Groups 
The level of awareness of various staff groups of HTHH as perceived by the 
hospital pharmacists, who responded to the Trust survey, is shown in Figure 
3.19. In all cases, except pharmacists, the highest peak is for a low level of 
awareness. The highest peak for pharmacists is for a moderate level of 
awareness. Doctors had the smallest numbers for a high level of awareness and 
most “don’t know” responses were for hospital managers. This could have been 
that it was the pharmacists responsible for aseptic manufacturing who were asked 
to complete the questionnaire and it might be that their pharmacy managers are
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more likely to be in touch with Trust managers. Some pharmacists commented 
that the staff involved with the care of these patients have a high level of 
awareness but others are completely unaware of the potential for treating patients 
with home infusions. It would be interesting to know whether there are different 
schemes going on within the same Trust for different groups of patients to 
provide HTHH which have no contact with each other. It seems probable that 
this is the case {Box 4).
Box 4
Pharmacy need to become involved in a Trust wide policy on home infusional 
therapy, rather than different areas doing their own thing and everyone 
pulling in different directions.
The situation is very complex -diffuse and vague accountability -very 
fragmented. In short - a mess!
Pm sorry it's such a mess! I ’ve collected information from three different 
specialties; paediatrics, chemotherapy/production, HIV all involved in hi- 
tech therapy.
3.2.5.2.7 Limitations Of This Study
Limitations have been discussed throughout this chapter. This information goes 
some way towards establishing the current situation with regard to HTHH and 
has highlighted the complexity of contracting mechanisms. Accurate 
information on the numbers of patients being treated with HTHH cannot be 
obtained, as there are so many contracting mechanisms in place and the number 
is also not static. This data would need be interpreted in conjunction with 
accurate demographic data of the incidence of need in the population at the time 
of the study to draw firm conclusions about geographical differences in the 
provision of HTHH. It is unlikely that all the geographical variation can be 
explained by demographics.
Some patients will be counted twice in the returns from Trusts, HAs and 
commercial providers. Theoretically if the HAs were aware of all of the HTHH
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they were purchasing then the returns from the Trusts and commercial home care 
providers should add up to the numbers of patients the HAs were commissioning 
care for. It can been seen from these data that this is far from the case.
All of the surveys reported required the respondents to spend time collecting the 
information. It may have been that the questionnaires were not always targeted 
at the most appropriate member of an organisation. It was also difficult to ask 
people for the same information twice to triangulate the data but some effort was 
made to do this with the Trust survey and the HA data was compared with that of 
Short [42] and the Monopolies and Mergers Commission Report [43].
Limited information was available, as the questionnaires needed to be short 
enough to ensure a good and therefore representative response rate.
3.2.6 Conclusion
These data have highlighted both the benefits of HTHH and some of the 
problems with the way it is purchased and provided in England under EL(95)5 
[41]. The complexity of contracting mechanisms has led to a service which is 
often fragmented. Different specialities are not working together to provide a 
high quality home infusion service for their patients.
This work supports the conclusions of Short [42] that EL(95)5 [41] has led to 
inequity in the provision of home infusions with some being contracted for by 
and paid for by the HAs and other patients relying on whatever service their local 
Trust can provide. It seems nonsensical that the way HTHH is funded and 
provided depends upon what prescribing of HTHH GPs were willing to take on 
prior to 1995. Most HAs have not invited tenders for provision of HTHH and 
commercial companies report that most of their work is from contracts with 
Trusts on a patient by patient basis. There are geographical differences in 
contracting mechanisms, in who is providing “packages of care” for these 
patients and on the numbers of patients being treated and indications for home 
infusions. There is also an apparent variation in cost and a lack of information as 
to how much is being spent on treating patients with home infusions.
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In light of the recent emphasis on clinical governance in the new NHS, the most 
worrying findings of this study were the lack of monitoring of contracts and lack 
of requirement for quality assurance of service provision/ outcomes monitoring 
or benchmarking. Pilling [6] recommended in 1995 that consultants and 
purchasers agree the most appropriate clinical outcomes data that should be 
provided to purchasers to enable them to purchase more effectively, but this is 
very rarely seen. This is in stark contrast to the situation in the USA where there 
are strict accreditation standards and benchmarking is a requirement laid down 
by purchasers. HAs have a poor understanding of a service for which EL(95)5 
[41] gave them responsibility. There is very little evidence as to whether the care 
received is cost effective and whether patients are fairing better or worse than 
they would be as inpatients. There is confusion as to whose responsibility 
monitoring the quality of care and patient outcomes is. Providers of HTHH have 
very little information to compare their service against that of others. What is an 
acceptable line infection rate, readmission rate etc?
This highlights the urgent necessity to build quality monitoring into contracts and 
to collect information on clinical outcomes of HTHH which can be used to 
define acceptable standards and improve patient care. This has been addressed in 
the United States but never in the United Kingdom where the systems for the 
provision of health care are very different. The commercial, political and patient 
forces are very different in the UK due to the differences in the way health care is 
funded. This means that different mechanisms have had to drive the quality 
agenda. The government has recently tried to address this by introducing clinical 
governance and to enforce it by setting up the Commission for Health 
Improvement [62]. These mechanisms seek to improve quality and learn from 
current best practice in all areas of health care within the NHS but these 
mechanisms do not appear to be providing an early focus or catalyst for change 
in the UK home infusion market.
This work has identified the need for sharing of information on outcomes of 
home infusion therapy and the processes leading to those outcomes. It is 
important, if providers are to compare information to identify their strengths and
234
weakness, that like is compared with like. In the United States an industry has 
developed around this but the tools used there do not easily fit with the health 
care systems of the United Kingdom. It was therefore decided that to facilitate 





4.1.1 The Quality Concept
The Japanese were the first to embrace the concept of quality as a philosophy for 
managing business organisations taught by quality management gurus such as 
Deming and Juran during the 1950s [287], Deming, taught statistical techniques 
of quality control. He argued that improved quality leads to decreased costs, 
increased profit and to the company staying in business. Juran also looked at the 
contribution of quality to reducing costs and introduced the “fitness for use 
concept” defining quality as product performance that leads to customer 
satisfaction. Crosby [287] introduced the “zero defect” concept. He believed in 
changing the culture and attitudes of an organisation to focus on prevention and 
producing everything “right first time”. He estimated that service companies 
spend about 40% of their operating costs on doing things wrong.
Techniques such as Statistical Quality Control, Continuous Improvement, Total 
Quality Management (TQM), Quality Function Deployment, Zero-Defect and 
more recently Business Process Reengineering (BPR) have over the past few 
decades had a huge impact on the management of organisations. There have 
been literally thousands of books written on these subjects and it is outside the 
scope of this research to study these management techniques.
TQM is about the continual improvement of quality through an organisation. 
Striving through the workforce to find new ways of improving quality. TQM 
also encompasses the optimisation of both internal and external operations and 
this is where the tool of benchmarking is commonly employed. BPR involves 
radically rethinking the way things are done. Its advocates claim that it can lead 
to huge leaps in performance through major organisational change [288]. It 
focuses more on thinking outside of the box, “don’t automate obliterate”, “don’t 
cement the cow paths”, Tom Peters [289].
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The Deming Prize, the American Malcolm Balbridge Award and the European 
Quality Award were all established to promote the importance of quality. They 
all require self-assessment by an organisation and demonstration of the 
successful use of benchmarking as a quality improvement tool.
BS 5750 was one of the first recognised quality standards in Britain developed 
from standards for defence procurement. It had shortcomings amongst which 
was that for world class competitiveness there had to be a common international 
standard. Pressure from the motor industry led to the formation of the 
International Standards Organisation (ISO) during the early eighties. The ISO 
9000 series standard was developed in 1987 by the ISO Technical Committee 
176. It encourages documentation of processes but has been criticised by 
companies such as Motorola (1988 winner of the Malcolm Baldridge Award) and 
Sun Microsytems for having no direct connection to quality of a service [288]. 
ISO 9000 is currently being updated to give a more rigorous standard based on 
the systems used by Ford, General Motors and Nissan.
4.1.2 History of Benchmarking
Benchmarking is recognised as a useful, if not new, tool used in quality 
initiatives such as TQM, BPR and process redesign [290, 291]. It aims to 
achieve leaps in performance and quality in an organisation by comparing 
current practices and processes with outstanding performance of others 
performing a comparable process (or ideally the “best of the best”) and through 
an understanding of the processes which lead to this superior performance 
adapting and developing current in-house processes.
Figure 4.1 shows the place of benchmarking as a tool in operations management.
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Figure 4.1, Where does benchmarking fit in as a tool for operations 
management?
(From a Benchmarking in Public Services Workshop, Bone and Robertson, 
London 3rd November 1998).
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The Xerox Corporation is credited with being the first in the Western world, in 
1979, to fully embrace the concept of benchmarking and use it to turn around 
their business. They found that their Japanese competitors were able to sell 
products for less than the price it was costing Xerox to manufacture, even though 
the quality of the Japanese products was twice as good as those manufactured in 
the United States. They decided to encompass quality improvement initiatives 
and change their processes by learning from the ‘best of the best’. They learnt 
from their competitors in Japan, within the same industry, but also from others 
working in other industries with the same problems, such as that of distribution
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where they formed a benchmarking partnership with L.L. Bean, a mail order 
company. Their success in winning the prestigious Malcolm Baldridge National 
Quality Award in 1991 inspired others to adopt the concept of benchmarking. 
The benchmarking experiences of Xerox were published by Robert C. Camp in 
1989 [292].
Benchmarking was being used in various forms long before the Xerox 
Corporation’s success. Codling [293] noted that there are records dating back to 
ancient Egyptian times pointing to the use of benchmarks in construction work. 
Loh [288] cites both Frederick Taylor’s work in the late 1800s on the application 
of a scientific method of business encouraging comparison of work processes 
and the common practice during the second world war of companies to “check” 
with other companies to determine standards for pay, work loads, safety and 
other factors as examples of benchmarking, in place well before the 1970s. 
Hamington [294] says benchmarking is one of the oldest improvement tools in 
the world stating how even the Bible’s Old Testament has many examples of 
how progress was made by studying what others were doing.
The Japanese were the first to realise the importance to business success of 
taking on the quality concepts taught by Deming and Juran [287]. The Japanese 
practice of shukko has been around for many years, it involves loaning 
employees to other organisations so that they come back with new and 
innovative ideas on changing processes within their own organisation. The word 
dantotsu means striving to be “best of the best” and is used in kaizen (continuous 
improvement).
Watson [295] outlined the historical development of benchmarking in 
manufacturing industry starting with the practice of reverse engineering, moving 
on to the Xerox model of competitive benchmarking of the late 70s, then process 
benchmarking, strategic benchmarking and finally global benchmarking.
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4.1.3 What is benchmarking?
4.1.3.1 Definitions
There are many definitions of benchmarking with various differences in 
emphasis depending upon what an industry is hoping to achieve from the 
benchmarking process. They all involve understanding current processes and 
adapting them for the better based upon learning from others.
The Xerox Corporation defines benchmarking as:
“A continuous, systematic process of evaluating companies recognised as 
industry leaders, to determine business and work processes that represent ‘best 
practices’ and establish rational performance goals. ” [294].
Watson [295] gives two definitions. The first is that of The Westinghouse 
Productivity and Quality Centre:
“Benchmarking is a continuous search for and application of significantly better 
practices that lead to superior competitive performance. ”
and the second developed at the APQC by the International Benchmarking 
Clearing House Design Steering Committee which represents a consensus among 
more than 100 companies:
“Benchmarking is a systematic and continuous measurement process; a process 
of continuously measuring and comparing an organisation’s business processes 
against business process leaders anywhere in the world to gain information 
which will help the organisation take action to improve it’s performance. ”.
The British Institute of Management in its publication Understanding 
Benchmarking, defines benchmarking as:
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“The process of identifying, understanding and adapting outstanding practices 
and processes from organisations anywhere in the world in order to help your 
own organisation to improve it’s performance.
This last definition uses the word “outstanding” rather than “best”, as what is 
best for an organisation depends upon its unique situation. The word “adapt” is 
used rather than “adopt” as benchmarking is not about observing outstanding 
processes and copying them, for an outstanding practice to work in another 
organisation it must be changed to make it effective. As Deming advised “adapt 
don’t adopt” [296].
When the Milliken Company won the Malcolm Baldridge Award Roger Milliken 
described benchmarking as “stealing shamelessly”. Motorola even used the code 
name ‘Bandit’ to identify its pocket pager project which was built by 
incorporating the best practices of many companies [288]. Unlike its 
predecessor, competitive analysis which incorporates such activities as reverse 
engineering where a company takes a competitors products, tests them and strips 
them down to find out how they have been manufactured, benchmarking is a 
fundamentally open process of sharing honestly rather than industrial espionage.
Various benchmarking organisations have developed their own version of a code 
of conduct for benchmarking studies; many organisations use The Benchmarking 
Code of Conduct of the International Benchmarking Clearing House [295, 297, 
298]. This aims to ensure openness and honesty during the benchmarking 
process and ensures that confidential information is used only for the purpose of 
a benchmarking study. These concerns over sharing of information highlight 
another advantage of not working with direct competitors; information can be 
freely shared without the risk of losing competitive advantage in the field.
Other definitions of benchmarking are more financially orientated such as that of 
Gondringer of the Association of Nurse Anaesthetists in the USA
“Benchmarking is an approach of reducing costs while improving productivity.
It is a process of organisations learning or measuring their organisation against
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the leaders in the industry to improve performance outcomes in a defined service 
area while keeping costs to a minimum. ” [299].
Tucker et al [300] noted that managers at Xerox tended at first to concentrate on 
comparative costs but as they became more knowledgeable about benchmarking 
they discovered that understanding practices, processes and methods is more 
important because these define the changes necessary to reach the benchmark 
costs. It can be seen from the above definition of benchmarking used in a health 
care environment that benchmarking in health care has not yet evolved as far as it 
has in manufacturing industry.
It is important that the difference between benchmarks and the process of 
benchmarking be distinguished. People often assume they are benchmarking 
when all they are doing is comparing benchmarks. This has tended to be the case 
with hospital league tables in the United Kingdom. The benchmarks are not 
homogenous and there is no examination of practices or processes or learning 
from the experiences of others. MacDonald [296] defines the term benchmark as 
a reference or measurement standard for comparison. It is important that 
benchmarks, performance indicators or outcome measures used in a 
benchmarking process are comparable and representative of better or best 
practice [44, 301]. Bullivant [290, 302] stresses that data is only part of the 
information you need for successful benchmarking. Watson in his 
Benchmarking Template (Figure 4.2) illustrates this. Equally important is the 
knowledge of how your own organisation works and the learning from others 
who are better. As Harrington puts it “don’t set benchmarks, do benchmarking” 
[294].
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Figure 4.2, Benchmarking Template
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4.1.3.2 Types of Benchmarking
Three types of benchmarking are generally recognised, internal, competitive and 
functional, although definitions vary. Codling describes three types of 
benchmarking, internal, external and best practice [293], whilst Camp defines 
internal, competitive, functional and generic process benchmarking [292].
Internal benchmarking is heralded by many authors of benchmarking textbooks 
as a good place to start benchmarking initiatives. It is often easier and cheaper to 
benchmark internally within an organisation (either at the same or another 
location) but it is unlikely that improvements will be as great as those achieved 
when benchmarking with external partners who think outside of organisational 
boundaries. The level of excellence achieved will be limited to that of the best 
performer within the organisation. Internal benchmarking has the advantage that 
data is often more easily available and directly comparable and is relatively easy 
and quick to implement the process adaptations.
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External benchmarking may be against competitors or partners from a 
completely different company or even industry. Camp [292] subdivides this into 
competitive and functional benchmarking. Competitive benchmarking has 
disadvantages of the fact that the companies are directly competitive and there 
are legal and ethical considerations which can make the open sharing of 
information difficult. There is also the worry of whether a competitor can be 
trusted not to impart misleading information.
Functional best practice benchmarking involves benchmarking against an 
organisation who have comparable processes but are not a competitor such as the 
L.L. Bean/Rank Xerox success, where Xerox learned from L.L. Bean’s packing 
process which was similar to their own but three times faster [300]. This type of 
benchmarking has the advantage that you can potentially become better than 
your best competitor by using ideas from outside of the industry.
One widely quoted case of how it is possible to learn from an external 
benchmarking partner outside of the industry is that of Bath Iron Works who 
carried out a benchmarking exercise with Disney World in Florida. They were 
able to learn from Disney’s world class maintenance routines for their air 
pneumatics systems within their animated characters [296]. This type of external 
benchmarking is more likely to lead to major innovation as Theodore Levitt 
found in his famous paper “Marketing Myopia” published in the Harvard 
Business Review in 1960.
Best practice benchmarking involves finding the undisputed leader in a process 
that is critical to business success, regardless of sector or location. This means 
the best for the organisation studied, for the process being examined, and this 
will not be the same for any two organisations looking for benchmarking 
partners. The only way to find the best for an organisation is to systematically 
plan and collect data on which company is the ‘best’ to benchmark against.
Generic benchmarking involves looking at a key business process which may be 
common to many industries such as pay roll generation. Benchmarking is
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conducted across various industries. These types of benchmarking activities are 
those that typically show breakthrough results [303]. An example of this was 
when a team at DuPont wanted to improve the manufacture of ammunition shells 
making them smoother and shinier and chose a cosmetics manufacturer who 
consistently delivered smooth shiny and by co-incidence ammunition shell 
shaped lipstick cases as a benchmarking partner [296].
4.1.4 Benchmarking As A Tool In Service Industries
The concept of looking at process and best practice and learning from others has 
been shown to be as applicable to service industries including health as to 
manufacturing industry [294, 303, 304] [305]. There are numerous examples of 
how benchmarking has led to breakthrough improvements.
TNT won both the 1994 UK Quality Award and the European Quality Award in 
1995. TNT use internal benchmarking in the form of Performance League 
Tables linked to various incentive programmes. They competitively benchmark 
themselves against their major competitors such as Parcelforce, Red Star and 
Interlink and used functional benchmarking against others providing similar 
services such as benchmarking their warehousing and distribution system against 
that of Cow and Gate [293, 294]. The benchmarking experiences of Post Office 
Counters, Royal Mail, the Australian National Roads and Motorists Association 
(NRMA), Leeds Permanent Building Society, Nationwide Building Society, 
Bradford Community Health NHS Trust, Leicester Royal Infirmary NHS Trust 
and benchmarking studies in the NHS from the Audit Commission are used as 
case studies by Zairi [294]. Codling describes how British Rail’s Network South 
East sought out “best practice” when trying to improve the cleanliness of their 
trains. At British Airways it took 11 people nine minutes to clean a 250-seat 
jumbo jet. British rail learned from British Airways cleaning process with the 
result that it now takes just eight minutes to clean a 12-coach 660-seat train 
[293]. General Motors used a service industry American Express as a 
benchmarking partner to gain new ideas on customer satisfaction rather than 
comparing themselves to another company in the manufacturing sector.
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4.1.4.1 Benchmarking in Healthcare
Initially the providers of healthcare throughout the world viewed TQM and other 
quality improvement principles as business management practices that were not 
applicable to their field but during the 1980s the quest for improved outcomes 
with limited resources made the healthcare industry look elsewhere for answers 
[306-308]. Other service industries had begun to adapt the manufacturing quality 
techniques for use in their industries and it was realised that adaptation to 
healthcare was not only possible but extremely useful, benchmarking being both 
process driven and customer orientated. Quality initiatives such as TQM and 
BPR have since been applied with varying degrees of success to health services 
[306, 307, 309]. The term Continuous Quality Improvement (CQI) has been 
adopted by many who have adapted TQM to the health care industry [134, 291, 
310].
The need to measure and monitor the quality of medical care has been 
extensively discussed. Hopkins [311] and Bullivant [290] both quote the World 
Health Organisation’s target 31 of it’s “appropriate health care and technology 
programme” that by 1990 all Member States should have built in effective 
mechanisms for ensuring the quality of patient care. A theme that was taken up 
in the UK in 1989 in the Government White Paper “Working for Patients” [312] 
which required that each health district have medical audit in place by 1991. 
“Caring for People” in 1990 and almost every other White Paper from the 
Government since has placed emphasis on quality issues the most recent being 
the emphasis on Clinical Governance in the 1997 White Paper “The New NHS: 
Modem and Dependable”, reiterated in the National Plan of July 2000 [5]. Joss 
et al [307] discuss the difficulties of applying TQM to the NHS, one of the major 
concerns being the definition of quality given the different perceptions and 
requirements of different groups of staff and the wide range of stakeholders in 
the NHS. 0vretveit [308] points out that whereas in most industries a quality 
service is one that provides customers satisfaction i.e. provides them with what 
they want, health services must provide people with what they need as well as 
what they want and do so at the lowest co st. Williams [305] noted in 1996 that 
in the NHS, benchmarking has started to become widespread, with both formal 
and informal benchmarking clubs and centrally driven initiatives. Outcomes in
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health are often not as simple to define or to measure as they might be in other 
industries. This coupled with the way the NHS is funded in Britain leads to 
further challenges in the adaptation of benchmarking to health provision.
Donabedian is an acknowledged guru of medical audit and quality assurance. He 
suggested in 1966 that the quality of care of patients could be audited in three 
dimensions - structure, process and outcome [311]. Structure involving the 
buildings, equipment and availability of appropriately trained staff, process 
referring to the activities of medical care and outcome referring to the change in 
the patient’s current or future health that can be attributed to a medical 
intervention. Many home infusion outcome measures have been built upon this 
principle [45, 46, 313] (described later in section 4.1.4.1.1.).
Benchmarking has been reported to be a useful and successful tool in CQI in 
health care in the USA [303]. The SunHealth Alliance (Charlotte, NC), has been 
active in promoting and facilitating benchmarking of health services [314, 315]. 
Bergman reports reducing average length of stay for pneumonia patients from 8.1 
to 6.7 days after comparing its processes with three other hospitals [314]. Mohr 
et al [304] describe how benchmarking can play an integral role in clinical 
improvement work and can stimulate wise clinical changes and promote 
measured improvements in quality and value. Lagoe et al [316] also report a 
reduction in length of stay after benchmarking their East coast hospital with 
similar hospitals on the West cost of the US. A 28% reduction in mean length of 
stay for total hip replacement and 17% reduction in mean length of stay for 
stroke and acute myocardial infarction were reported. Barnes et al [317] used 
benchmarking to streamline their processes for caring for coronary artery by-pass 
graft patients. They achieved reduction in costs and average length of stay whilst 
maintaining a stable mortality rate. Gift et al [291, 318] suggest that a 
collaborative approach to benchmarking in health care is successful having the 
advantages that it is economical, permits more organisations to take advantage of 
it’s potential and promotes much needed co-operation between health care 
organisations.
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Successful benchmarking projects have been reported in health care in the NHS 
[287, 290, 294, 298, 302, 319-321]. Lam [287] points out that clinical practice 
has remained a challenge for measurement and comparison and has not often 
been the subject of benchmarking but has tended to remain within the domain of 
clinical audit.
During early 1990’s in the UK, medical audit and clinical audit (which 
incorporates care given by other professionals as well as surgeons and 
physicians), became popular tools used to promote continuous improvement in 
the quality of patient care either directly or indirectly. It was recognised by 
many health care workers that objective measurement of baseline data before the 
implementation of a quality improvement programme allowed evidence for the 
benefit of that programme to be assessed.
The idea of using benchmarking in the NHS arose from discussions with the 
Patient’s Charter Implementation Group to fulfil the need for a systematic 
approach to assessing practice. It was recognised that all sites visited had mixed 
elements of very good practice and areas in need of improvement. A 
Benchmarking Club was launched in January 1993 sponsored by the NHS 
Executive. Ellis [319] points out that much of the benchmarking in the NHS has 
focused on organisational benchmarks such as targets set for the Patient’s 
Charter and are not specific to clinical practice.
In the UK there has been a tendency for outcomes to be service related rather 
than clinical. An example of this is the hospital league tables published by the 
government which were heavily criticised for not taking into account clinical 
outcomes. Length of hospital stay could be very short in one hospital but twice 
as many of their patients may be readmitted within a week than those of a 
hospital with a longer length of stay.
Lam [287] discusses the potential advantages of benchmarking over clinical 
audit. She argues that benchmarking is an ideal instrument for enhancing peer 
group learning in a non-threatening and flexible way. It allows dissemination of 
good practice with the understanding that no-one is best at everything and
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encourages open and shared learning in a structured way. Benchmarking can be 
used as a tool to facilitate structured comparison of process, practice and 
performance between units within an organisation or with other organisations, as 
long as units have a clear understanding of processes, clear criteria and respect 
privacy of their benchmarking partners. She points out that clinical audit tends to 
be conducted internally and is centred around learning how to improve next time 
whereas benchmarking is concerned with mapping best known practices 
wherever they occur and sharing learning in an open and structured way.
Bullivant [290] gives the following explanation of the relevance of 
benchmarking to health care “ In the hospital it is about getting the patient to the 
best treatment as quickly as possible, providing that treatment on the basis of 
knowing what works, and then getting the patient home or on to appropriate care 
as quickly as possible, consistent with their needs. It is about staff in the hospital 
and outside working together to achieve that care for patients, so for example it is 
about getting the patient, surgeon, anaesthetist, nurses and medical records to the 
theatre at the same time and it is about ‘creating’ the department for getting 
people home rather than ward nurse, medical records, pharmacy and ambulance 
service all thinking it’s not their fault if you stay in hospital another few hours or 
another night after being discharged by the consultant".
One of the most important considerations when carrying out a benchmarking 
exercise is ensuring that like is compared with like. If the benchmarks are not 
comparable then they will not help to identify best practice and therefore point to 
process improvement. This is a problem in health care. There has been a great 
interest in recent years in outcomes monitoring. The development of meaningful 
performance indicators, clinical and non-clinical outcomes and benchmarks is a 
difficult task and is in itself a fast growing discipline. It is easy to criticise 
indicators developed for the purpose of comparison but there is an argument that 
measuring something is better than nothing and certainly they act as a starting 
point for asking why there are differences between different organisations and 
why trends are occurring within an organisation. Used in isolation they are often 
meaningless but if used as a starting point they can help identify a problem or in 
the point to an area where practice can be improved. Eaton [322] warns that the
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use of benchmarking in the NHS will be widely adopted as laid out in the White 
Paper, The New NHS [4] and a recent Health Economics Report, Benchmarking 
and Incentives in the NHS. Benchmarking is widely used to monitor 
performance in social services and the Commission for Health Improvement and 
the Audit Commission will soon start to inspect against benchmarks of 
acceptable service level and cost. Eaton [322] notes that there is a lack of 
appreciation of the cost of implementing a performance management culture in 
the NHS.
4.1.4.1.1 Benchmarking and Outcomes Monitoring of Home Infusion Services 
The first standards for accreditation of home care were published by the JCAHO 
in 1988 [323] and included standards on specific areas of concern such as patient 
rights and responsibilities, patient care, safety management and infection control, 
home care record, quality assurance and management and administration [323].
It was soon recognised that accreditation of a home health care agency did not 
necessarily signify quality and in response to this the JCAHO Home Infusion 
Therapy Task force developed a set of clinical indicators that focused on 
outcome designed to lead to assessment and improvement of process.
Six indicators underwent alpha-testing in 1992. These were
• Unscheduled inpatient admission by type of therapy
• Discontinued infusion therapy by type of therapy
• Interruption of infusion by type of therapy
• Prevention and surveillance of infection by type of therapy
• Adverse drug reaction and
• Patient Monitoring and appropriate intervention [313].
Beta-testing of these same indicators was discontinued due to reasons unrelated 
to the quality or value of the indicators themselves. There was a need for broader 
performance measures and simpler methods of data collection and analysis.
Other organisations both commercial and non-commercial developed new 
performance measures with broader application to the entire home care market 
[271].
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In 1989, Barget and Zink [324] identified a need for the development of a 
method for evaluating the quality of care of patients receiving complicated home 
care procedures. They developed a clinical indicator tool based on absence from 
complications of intravenous therapy, patients’/carers’ knowledge of intravenous 
therapy and patients’/carers’ being able to demonstrate ability to manage their IV 
therapy. The tool served as a useful first step, it had weaknesses identified 
during piloting, one of which led to the addition to the tool of a measure of 
complications due to medication toxicity.
Segal [272] reviewed and compared (benchmarked) published studies looking at 
the economic, clinical and psychosocial outcomes of home infusion therapy. He 
pointed out that cost savings had not been reported in a systematic way from 
study to study (i.e. not comparing like with like) but overall the cost of home 
infusion therapy was lower compared to hospital treatment programmes. The 
overall direct charges to patients were often higher due to the fact that third-party 
payers may not cover the full cost of this type of treatment. The clinical 
outcomes were comparable to those achieved in hospital. Complications related 
to catheter care were common in home therapy but one study found that a larger 
proportion of patients using home infusion therapy could keep to their dosing 
schedule compared to hospital patients. Many patients were able to return to 
work or school but there were also a number of reports of patients refusing home 
infusion therapy. Levels of psychological stress were reported to be lower at 
home than in hospital in one study, although another study of TPN patients found 
that a high proportion of patients had psychological problems in adjusting to 
home parenteral nutrition. It was concluded that there was a marked bias 
towards the benefits of home infusion therapy as an alternative to hospital 
therapy but this should be interpreted cautiously due to the wide variation in the 
populations of patients studied, patient selection, study site and limitations in 
study design. A recommendation was made that research standards be developed 
for the evaluation of home infusion programs and a prospective study with clear 
definitions of direct and indirect costs and benefits be carried out.
By 1996 the home setting had become the accepted “norm” for many prescribed 
infusion therapies in the United States [135], Activities of health professionals
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were collectively monitored as “patient-focused functions” and the home care 
industry had begun to embrace the concepts of TQM and CQI. The challenge 
was managing change whilst maintaining quality [135].
Hamill [325] looked at measuring quality, outcomes, standards and costs in the 
home medical equipment (HME) industry. He emphasises the need for 
standardised assessments, methods and analyses performed on data and 
advocates the monitoring of clinical outcomes, service outcomes and patient 
outcomes with the aim of establishing a service benchmark that can be used to 
determine appropriate standards for providers and which can be used for internal 
quality improvement. The creation of a national reference database focused on 
the home health business is mentioned (called “HOMEcare databank” and 
sponsored by the National Association for Medical Equipment Services 
(NAMES)). Hamill also recognised the need among home care providers for a 
nationally standardised, reliable, valid patient satisfaction tool which would 
benefit both payers and providers. A tool was being developed by the Picker 
Institute with a grant from the Commonwealth Fund of New York.
McKeon [44] discussed his experience of benchmarking in Home Health Care 
Agencies pointing out that the key to benchmarking is understanding the 
composition of the benchmarks and making sure that like is compared with like. 
Cost per visit, the average number of nursing visits per day, and percentage of 
patients discharged to home health by Diagnosis Related Group are cited as 
examples of benchmarks used within the home health industry. They are 
generally available because they form part of the regulatory data collection 
process or because they can be extrapolated easily from data collected within the 
agency but do not provide good benchmarks because of their lack of 
homogeneity. McKeon points out that the home infusion industry has difficulty 
in defining common terminology and standards for the delivery of care and calls 
for the development of industry wide indicators that include common activities, 
activity attributes and measures. In the mean time he suggests the development 
of an activity-based management system, which would at least allow the 
development of agency specific standards to evaluate operational results with 
respect to strategic goals. The use of external benchmarking from outside the
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home care industry was advocated, the examples given were organisational 
rather than clinical in nature. Benchmarks should be relevant, easy to calculate, 
evaluate internal and external customers’ perceptions and support continuous 
quality improvement efforts. Classification by patient problem can be used to 
ensure greater homogeneity of benchmarks and results of patient surveys can be 
added to the performance measurement process. Use of the balanced scorecard, 
another tool developed in manufacturing industry and adapted for use in quality 
initiatives in health was suggested (described later in section 4.1.5.3.)
The importance of outcome standards was discussed by Seignemartin [45] citing 
the fact that infusions are given in alternate sites even campgrounds as one 
reason for needing to monitor outcomes along with cost containment, 
expectations of patients, accreditation and performance improvement. She 
defines an outcome indicator as a tool used to measure the result of the 
performance of a function and gives examples of five outcomes indicators 
developed in the setting of home infusions. These were a patient discharge 
survey, infection rate, adverse drug reactions, unscheduled readmissions to 
hospital and a log of interventions. It is pointed out that the challenge is not to 
collect information but to find standardisation for collection to enable 
benchmarking with other institutions and with national averages.
Rosenheimer [326] reports an infection control benchmarking exercise involving 
four home health agencies. Standard definitions for symptomatic urinary tract 
infections in patients with urinary catheters and for bloodstream infections in 
patients receiving intravenous therapy were agreed and identical data and 
methods for calculating infection rates were developed to ensure homogeneity of 
the benchmarks. The primary aim for each company was to collect baseline data 
about its infection rates and use these in the future to detect problems and trends. 
The secondary goal was to make infection control benchmarking between the 
agencies possible. Limitations in reporting incidence of blood stream infections 
were noted as one site had an extremely small number of device days so one 
infection resulted in a high incidence rate.
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Kunkel [46] looking at outcomes of home antibiotic infusions defined an 
outcome as an indicator of the results of a process which is related to the content 
and delivery of healthcare and is used to determine the best approach to that care. 
He notes that outcome data must be measurable but are not useful as indicators 
until they are transformed through analysis. From the financial perspective good 
outcomes are not enough, the extra cost of achieving the good outcome must be 
factored in using the concept of value. Kunkel divides outcomes in home 
antibiotic infusions into macro outcomes (organisational performance, clinical 
effectiveness, service quality, patient satisfaction, appropriateness of care, 
response to treatment and cost and efficiency) and micro-dimensions (adverse 
events, clinical success of therapy, readmission, interventions, functional status, 
patient/family well-being, achievement of therapeutic goal, cost). The most 
important question he recommends asking is “Do the benefits of tracking and 
analysis outweigh the costs of collection and analysis?”. It is suggested that tools 
for data collection are standardised and data element defined. Once the data have 
been validated they can be used for both internal and external benchmarking.
Bimbaum and Tang [279] developed a model for incorporating the cost of 
adverse outcomes into overall cost of home infusions for use by purchasers of 
home infusions. Using this model showed that vendors who appeared to be 
lower cost were actually higher cost when the cost of remedial care for adverse 
outcomes was taken into account.
In the USA during the 1990s benchmarking and performance measurement 
companies have emerged who collect data anonymise it and produce reports 
which compare outcomes with companies of similar case mix, load and size 
[273]. They specify criteria and definitions for the data collected to try and 
ensure that like is compared with like. In any industry there are companies who 
perform better than others. Cain [273] specifies what to look out for when 
choosing a performance measurement company and comments that the ability to 
not only measure yourself but also to compare yourself with other providers is 
very beneficial and allows identification of areas that need work. She gives an 
example of an increase in occluded venous access devices that required the use
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of urokinase and an improvement that was demonstrated after the 
implementation of a new flush technique and a needleless system.
With the introduction of Managed Care in the USA, companies seeking contracts 
not only need to be accredited but also the company is required to be involved in 
a national outcomes program [46, 273]. Outcome measurement is now a 
requirement of Medicare, JCAHO and NCQA (National Committee for Quality 
Assurance) accreditation and is increasingly becoming a requirement for all 
programmes. The American Society of Health Systems Pharmacists promote a 
“software solution for the entire home infusion office” called iv-ease Home 
Infusion designed to help organisations to meet the Joint Commission standards 
for home health care organisations. The commercial nature of performance 
measurement of home care companies in the USA has meant that there have been 
few published studies showing the development of benchmarks as performance 
indicators and it is difficult to obtain detailed information on data collected as it 
is no longer in the public domain. In England service specifications are often not 
set and contracts are not monitored [284] by purchasers. There are no 
performance measurement companies specialising in the home infusion market 
and there are no recognised performance indicators or benchmarks for the home 
infusions.
4.1.5 Methods o f Benchmarking
There are many ways to go about a benchmarking project. The method used 
must be adapted to suit the goals of the project being undertaken and the 
organisations involved. Benchmarking is a structured tool and although there are 
numerous different methods reported in the literature they all follow the same 
sort of approach, the Deming [327] plan, do, check, act cycle.
Given the success of Xerox in employing the benchmarking process the Xerox 
Ten-Step Benchmarking Process is probably the most often quoted (Figure 4.3) 
[292, 294, 303]. Camp and Tweet explain how the Xerox approach can be 
adapted to use within health care [303].
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Zairi [294] gives details of the processes developed for benchmarking in a 
variety of organisations. Kodak have a ten step benchmarking process which 
broadly follows the lines of the Xerox approach, the Post Office Counters 
method is a little different and is divided into process and documentation. The 
Australian NRMA have developed an international best practice model flowchart 
and Texas Instruments Europe have their own 10 step approach which is divided 
into the four phases used by Xerox of planning, analysis, integration and action. 
IBM has been a leader in quality concepts and IBM, Rochester won the Malcolm 
Baldridge National Quality Award in 1990. IBM, Havant’s four phases are 
organisation and planning, data collection, analysis and action with a 14-point 
flowchart demonstrating their benchmarking process. Rover simplified the 
competitive benchmarking process down to define five key stages, plan, 
investigation, measure and analyse, communicate findings, plan and implement 
action, review and calibrate.
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Figure 4.3, Xerox Ten Step Benchmarking Process
Phase 1 -Planning
1. Select a subject to benchmark
Determine the purpose 
Recruit the team 
Determine the measurements 
Determine the scope and constraints 
Obtain support of major stakeholders
2. Identify the best practitioner(s)
Prepare a list
Select the benchmarking partners
3. Determine the Data Collection Method 
and Collect the Data
Prepare a list of questions 
Answer the questions for your own 
operation
Search for data in existing studies 
Review processes for collecting new data 
Select process(es) and develop guidelines 
Determine who will conduct data gathering 
Review legal, ethical and protocol 
requirements
Collect data using process guidelines
Phase 2 - Analysis
4. Determine the Current Gap
Tabulate the data
Analyse data against the purpose of the study 
Determine the benchmark 
Determine the gap 
Determine the general reasons 
Determine specific drivers and practices
5. Project Future Performance
Identify assumptions used in projection 
Project the gap
Phase 3 - Integration
6. Communicate the Results of Analysis
Understand your audience 
Determine method of communication 
Organise your analysis 
Obtain acceptance from stakeholders
7. Establish functional goals
Identify current goals
Determine what changes could and should
be made
Revise your gap projection 
Obtain commitment to changes 
Revise functional goals
Phase 4 -Action
8. Develop action plans
Prepare action plans 
Organise your plan 
Obtain functional buy-in
9. Implement, plan and monitor results
Implement action plans 
Monitor results
10. Recalibrate benchmark
Identify appropriate time frame 
Repeat steps 1 -9.
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4.1.5.1 Selecting the process to benchmark.
It can be seen from all of the above processes that the first step is selecting the 
process to benchmark. There are various techniques employed to help decide a 
subject area. The criteria for selecting the subject are that it should be of 
strategic importance to the business and improvement in an area that will make a 
significant contribution to overall business results [293]. Codling [293] uses a 
series of five questions to identify processes to benchmark:
1. Which business are we in?
2. What must we do to remain in business?
3. What must we do to be really successful in our business?
4. Which single factor would make the most significant improvement to our 
customer/supplier/employee relationships?
5. Which areas, if improved, would make the most significant contribution to our 
bottom line results?
Management’s task is to gain consensus on which processes should be selected.
A common sense approach is required alongside any system used to help identify 
an area where benchmarking could have the greatest impact.
Critical success factors are those characteristics, conditions or variables that have 
direct influence on customer’s satisfaction with the output, product, service of 
specific business processes and, hence are critical to the success of the entire 
business. They represent measurable or observable aspects of business 
processes, which when performed well, result in the continuing growth and 
success of a business. In short, they are the critical few factors that have the 
most impact across the entire business system [295] MacDonald shows a method 
whereby critical success factors can be correlated with critical processes so that 
those processes which by their improvement would have greatest impact on the 
critical success factors can be identified for benchmarking [296]. Bullivant uses 
a table of critical success factors against barriers to success; it is easy to express a 
commitment to critical success factors but do nothing to make them happen. 
Success will not be achieved until the barriers have been removed [302].
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The European Foundation for Quality Management (EFQM) has developed a 
model for identification of key processes or practices to be benchmarked. It 
involves a scoring system based on five sets of criteria known as ‘enablers’ 
followed by four criteria that address the ‘results’ obtained as a consequence of 
the use of these ‘enablers’ [294, 296].
Zairi [298] gives an example of Ramirez and Loney’s work using critical factors 
of TQM to check whether the philosophy of TQM was transferable to the UK 
NHS.
4.1.5.2 Defining the process.
One of the next steps is to make sure that the way the organisation works and the 
current processes used are fully understood. This involves process analysis and 
is extensively discussed by Hunt in relation to reengineering [328]. It is 
important to find out what really happens not what people say happens or think 
should happen. What people do and what they say they do are almost never the 
same [288] so it is important to observe a process when mapping it for the 
purpose of a benchmarking study. Bullivant [290] starts by defining the 
boundaries of the activity and clarifying the desired outcome of the activity to be 
benchmarked. The next step is to map the current process (process mapping). 
This can be done using process flowcharts, flow diagrams, cause and effect 
(Ishikawa) diagrams, Pareto charts, or more complex methods such as CASE 
tools and simulation tools [328, 329].
The subject of process mapping in health care is addressed by Corbett [330] who 
points out that the first obstacle in benchmarking is understanding how work is 
currently performed. She advocates flowcharting current processes to build a 
frame of reference to use when talking to benchmarking partners. First a simple 
six to ten box linear flowchart is drawn to outline a process. A connection chart 
can be used to show how different departments interact then a cross-functional 
flowchart to show who is working together at each stage of the process. Other 
information can be added to this for example, the length of time each process 
takes justification of the cost of procedures, customer satisfaction and copies of
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relevant policies and procedures. Areas that seem to be the source of 
inefficiencies can be broken into microlevel charts so that the process may be 
followed more closely. Flowcharts can also be used to identify what is going 
well so that these processes can be retained when the process is redesigned.
4.1.5.3 Benchmarking Methods Used in Healthcare
An example of a benchmarking model used for a benchmarking process in health 
care is the Baxter Benchmarking Model (Figure 4.4) incorporating 15 essential 
steps to successful benchmarking and divided into the preparation phase and the 
benchmark analysis phase.
Figure 4.4, The Baxter Benchmarking Model
Preparation Phase 1. Define goals
A British example is that of Leicester Royal Infirmary who have developed their 





3. Choose what to measure
4. Commit resources
6. Identify sources of data
7. Collect data
8. Translate data to common format
9. Identify best level of achievements, that is, the
benchmark
10. Identify differences between your organisation
and the benchmark
11. Identify factors driving the differences
12. Verify the results
13. Present the results and conclusions
14. Agree on action steps
15. Form task forces to implement action steps
260
Figure 4.5, T h e  B en ch m a r k in g  P ro cess  a t L e ice ster  R o y a l 
















Plan next cycle of benchmarking
It can be seen from the examples given above that the general structure of a 
benchmarking process varies little, but once this is broken down further there is 
huge variation in the way the steps are achieved and indeed achievable in 
different industries.
McKeon uses benchmarks, performance indicators and the balanced scorecard as 
a way of evaluating organisational results and continuous quality improvement 
efforts (Figure 4.6). The balanced scorecard developed by Kaplan and Norton is 
a way of enabling management to see the breadth and totality of company 
operations rather than focusing on the attainment of financial goals [288]. 
McKeon argues that in the past, too much emphasis has been placed on financial 
indicators as benchmarks and he suggests using the balanced scorecard which 
encompasses the internal and external customer, clinical and financial results, 
process improvement and activities designed to expand the agency. Elements 
which are out of balance can be identified and corrected and decisions can be
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made to consider how all the pieces interrelate [44]. Performance measures can 
be used to benchmark both internally and externally but he stresses the 
importance of understanding the composition of benchmarks and ensuring 
homogeneity.









4.2 Development of a Benchmarking Tool for the Home Infusion Industry 
in England.
4.2.1 Select a subject to benchmark
This work has so far established from questionnaire surveys that the market for 
home infusions in this country is highly complex with a heterogeneous group of 
patients with varied diagnoses receiving different therapies via different 
mechanisms which are being commissioned in a variety of ways.
The Health Authority questionnaire identified, mostly in the qualitative data 
collected, concerns about the lack of monitoring of the quality of care received 
by patients or even a basic monitoring of adherence to service specifications 
[284]. Further questions regarding monitoring of the quality and patient 
outcomes of HTHH in the Trust and commercial home care provider surveys 
raised further concerns in that in many cases service specifications had not been 
set [331]. This was particularly true when the home infusion service was being 
provided directly by a NHS Trust and was not being purchased via the HA under 
EL(95)5 [41] mechanisms. Commercial providers of HTHH reported that they 
most often contracted directly with NHS Trusts and that this was often on a one- 
off, ad-hoc basis with little or no monitoring of the service they provided by the 
purchaser.
Using grounded theory this research has identified the urgent need for a tool to 
be developed to facilitate quality monitoring, help set service specifications and 
benchmark home infusion services to learn from the processes of those achieving 
the best results. Effective and thorough monitoring of quality is the first step, 
which leads to continuous quality improvement usually via audit, used to 
improve internal outcomes and then benchmarking to achieve “best practice”.
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4.2.2 Aim
The aim was to develop a tool which could be used for this purpose.
An outline of the development of the benchmarking tool is shown in Figure 4.7
and will form the basis of this chapter. A copy of the tool developed is enclosed
in Appendix 25, on a compact disk, in Microsoft Access ® Version 97,
Windows® 98.
4.2.3 Determine the Purpose
The purpose was to develop a tool which could be used;
by purchasers to
• facilitate cost-effective purchasing and ensure added value. It has been 
shown that providers who submit lower cost tenders for contracts but provide 
a lower quality service cost more due to the treatment of complications [279]
• set reasonable minimum service specifications to achieve higher goals in 
quality of care received by patients and to ensure equity of care for patients 
across the country in line with the government’s agenda [2-5, 61, 62]
• allow monitoring of contracts and adherence to service specifications.
• achieve clinical governance targets by using data for continuous quality 
improvement [62]
• compare the cost and clinical outcomes of home infusions with those of 
treating patients as inpatients to ensure that patients do at least as well at 
home
and by providers to
• compare outcomes and performance indicators with others to determine 
differences and to learn from the processes employed by others how to adapt 
their own practice to achieve better outcomes for patients
• identify trends in both clinical and non-clinical outcomes which can be used 
to identify and address problem areas
• identify training needs.
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• make treatment decisions such as which patients on which drugs do best with 
which sorts of infusion device and which IV access device
• improve information given to patients when they commence therapy by 
looking at the most common problems patients have contacted health 
professionals about and adapting information provided to suit patients’ needs
• improve communication between health care professionals about a patient by 
having all information collated and accessible to those who need it
• evaluate the impact of education/staff training/patient training and changes in 
process.
Much if not all, of the data required to do this is currently collected. It is stored 
on paper, often in prose, in different departments or organisations. The idea of 
developing a database was to store the information in a way that would allow it 
to be used to improve patient care. Both from collating the data so that it is 
available to all staff looking after the patient and by learning from the data by 
using it in continuous quality improvement and clinical governance initiatives.
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Figure 4.7, Development of the Benchmarking Tool
Identify subject to benchmark 
(questionnaire surveys)






Identify the best practitioners
>  Develop quality indicators and outcomes as <  
benchmarks
Define to ensure like is compared with like <
Data currently 
collected
Develop a data collection method <
Incorporate into 
benchmarking
Design a tool to analyse data <
Redesign
Collect data to pilot data collection method
Feedback from staff involved in pilot
Validate benchmarking tool
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4.2.4 Determine the Constraints
A difficulty always evident when looking at home infusions as one entity is that 
the patients, their diagnoses and therapies are diverse and outcomes that are 
important in one group e.g. maintenance of or increase in weight in a HPN 
patient, are not as relevant to other therapies. The same can be said for specific 
indicators of outcome of antibiotic treatment in cystic fibrosis patients such as 
respiratory function tests. Therapy or diagnosis specific indicators of clinical 
outcome are perhaps more valid than general home infusion indicators and would 
be the next stage in development of this tool.
These differences in patients and their therapies also means that the processes 
involved in their care can be very different, for example a TPN patient will 
almost certainly commence their therapy in hospital but a patient receiving a 
home chemotherapy infusion may well never be admitted as an inpatient and 
receive all of their training, care and support in outpatients or in a specialist 
cancer unit. A cystic fibrosis patient receiving antibiotics may be under the care 
of a district nurse, or a home care company nurse or an outreach nurse from the 
hospital or a combination of these. Information required about these patients will 
be different but there are common themes and so a tool was developed to monitor 
common performance indicators and benchmarks.
From piloting the benchmarking tool it was found that one of the major 
constraints to benchmarking and outcomes monitoring of home infusions in 
England is that the data are stored separately by different individuals using 
different mechanisms. Information is initially stored by the GP in both written 
and electronic notes, then by the hospital specialist in hospital records. Different 
departments in hospitals keep separate records such as pharmacy, physiotherapy, 
and laboratories, and similarly home care companies and others that they contract 
with keep separate records about patients. It was found that even within one 
home care company there are often multiple records for one patient regarding 
different aspects of their care. The storage of information is centred around the 
providers rather than being centred around the patient. It is currently almost
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impossible to collate all of the information stored about one home infusion 
patient. It is hoped that this will improve with the introduction of one NHS 
number for patients and the drive to achieve computerised patient records which 
can be accessed at different levels by all health care professionals looking after a 
patient. The potential year 2000 problem caused many hospitals to install new 
computer systems with greater compatibility between systems and greater access 
to patient records. The recent NHS Plan [5] has reinforced the push towards 
electronic records and electronic prescribing in both primary and secondary care.
All performance indicators and benchmarks have limitations and should be used 
with these in mind. A tertiary centre may well be treating patients with poorer 
prognoses to start with who may be more susceptible to blood stream infections 
or other complications. It is beyond the scope of this work to refine outcomes 
incorporating further factors to make them more specific to particular patient 
groups. At present there is very little or no data to compare. The benchmarks 
will need to be refined to ensure that like is truly compared with like.
4.2.5 Review the Literature
The literature was reviewed (3.1 and 4.1) in order to learn from the experience 
of others in benchmarking services, to determine indicators that have been 
successfully used in outcomes monitoring of home infusions and to identify “best 
practice”, not only from home infusions but wherever best practice occurs, for 
example incidence of line infections may be better in an inpatient setting.
It was found that benchmarking of health services in general and more 
specifically benchmarking of home infusion services is far more developed in the 
USA than in the UK. In the UK clinical audit has been widely adopted as the 
means for continuous quality improvement but has limitations in that it only 
measures, usually small, improvements internally and does not pick up the fact 
that the outcomes when compared with others may be completely unacceptable. 
Using benchmarking, processes can be changed by learning from what has been 
demonstrated to provide the best outcomes elsewhere.
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Although benchmarking has been adopted to some extent in the NHS [287, 290, 
294, 298, 302, 319, 320] the only benchmarking of the provision of home 
infusions in the UK that was found was in the provision of home parenteral 
nutrition. Mughal and Irving [7] found an inverse relationship between catheter- 
related sepsis and the treating team’s experience with HPN. Richards et al [213] 
compared the results of 56 studies, 37 from the USA and the rest from Europe, to 
look at the patient experience of home parenteral nutrition. They reported a 
weighted average catheter sepsis rate of 0.34 episodes per catheter year, a 
weighted average catheter occlusion rate of 0.071 episodes per catheter year, an 
overall rate for central vein thrombosis of 0.027 episodes per catheter year and a 
range of 0.12-0.61 episodes per catheter year of metabolic problems. It is 
important to recognise that in these studies it was difficult to determine whether 
like was being compared with like.
It was concluded from the literature review that in the USA benchmarking of 
home infusion services has proved a useful tool in improving patient outcomes 
and that some of the experiences in the USA may help in developing a 
benchmarking tool for use in the USA. The review of the literature confirmed 
that no such tool has been developed for use in the very different health care 
system in the UK.
4.2.6 Identify and Map the Processes
The researcher mapped current processes used in the care of home infusion 
patients using standard or agreed operating procedures, guidelines or protocols 
and observed the process from the decision that a patient may be suitable for 
home infusion therapy to administration and follow up in the home. Information 
was elicited from staff involved in the processes.
The first area mapped was that of contracting (Figure 4.8). A contracts manager 
and Pharmaceutical Adviser of the local Health Authority helped to map the 
processes involved. This process is specific to South and West Devon Health
269
Authority, although most HAs would adopt a similar approach as instructed by 
EL(95)5 [41].
The second process mapped was from the point of view of a person co-ordinating 
the provision of the home infusion from the patient being in hospital to their 
maintenance on infusion therapy in their home. There are numerous models for 
this process involving many staff from secondary care, primary care and 
commercial providers. It was impossible to map all of the models used and 
therefore one model was chosen as an example. This was the model where a 
home care company nurse co-ordinated the process. This involved one person 
communicating with all others involved and included all of the necessary steps in 
discharging a patient to their home and maintaining them on a home infusion
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Need for service 
(Trusts)
Bid for funding from 
Health Authority if 
likely overspend
Set service specifications for 
whole ELf95)5 contract
Send invitations to tender to companies 
who have previously approached the Health 
Authority.
Would not refuse if best or 
necessary treatment based 
on consultant’s decision but 
would restrict scope of 
patient treated etc
Offer 3 year contract with requirement to feed back 
results of patient satisfaction surveys to Health 
Authority every 6 months
Review service specifications annually. Facility to 
increase price in line with inflation annually (contract 
specifies daily dose price fo r  each type of therapy with a 
range for antibiotics)
Review offers Health Authority Contracts Dept, Pharmacist and other specialist 
staff e.g. dietician, oncologist with aim of increasing quality and reducing cost 
(large varia tion  in o ffers e.g. da ily  f o r  T P N  va ried  by £70/day, d id  n o t choose  
cheapest as w an ted  a  ded ica ted  nurse)
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Figure 4.9 maps this process which can be divided into
• Patient selection and suitability of home environment
• Training of patient/carer and other healthcare professionals
• Organisation of equipment, delivery etc
• Co-ordination and communication
• Patient discharge and support and
• Continuing care.
The processes mapped were used in the initial development of the benchmarking 
tool which will be described in 4.2.10.
4.2.7 Identify the best practitioners
This project has highlighted the fact that very little information is being collected 
on the quality of any home infusion services in England. The information that is 
collected is not routinely shared or used to improve practice within an 
organisation. Most clinical information is still stored as hand-written notes 
which makes manipulation of the data difficult.
There has been little or no information published in the UK on benchmarking the 
provision of home infusions other than TPN. Mughal and Irving [7] published 
their study in 1986 and Richards et al [213] systematically reviewed the literature 
in 1997 as previously discussed. St Marks Hospital in London and Hope 
Hospital in Salford are two major tertiary centres who both provide TPN to large 
numbers of patients at home. They have been comparing empirical data such as 
incidence of line infections and catheter occlusion rates for some years [332]. 
Hope Hospital have published papers including information regarding their line 
infection rate and these are one of the few sources of benchmarks available in 
England [209, 333, 334]. It has also been reported that North Staffordshire 
Hospital has designed and validated outcome measures for a home IV service for 
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There is some information available from the USA on line infection rates [335] 
and incidence of other problems in home infusions such as number of out of 
hours calls, however the data is often now collected commercially and is not in 
the public domain [30], It can be seen from the Table 3.1 which compared 
catheter sepsis rates in patients receiving home parenteral nutrition that most of 
the data from the USA is from the late 1970s and early 1980s. The health care 
system is very different to that in the UK but, if the outcomes achieved are better 
than those being achieved in England, the processes and practices adopted in this 
country need to be examined and lessons learned from our colleagues across the 
Atlantic. Presently there is a dearth of information from England on the quality 
and outcomes of home care programmes. Much of the published information 
states that complication rates are low but these are rarely quantified [336]. 
Melville et al [30] working in paediatric gastroenterology at Great Ormond 
Street Hospital, London, compared catheter survival and sepsis rates in the same 
20 patients receiving TPN in the hospital and the home care setting. They found 
a significant reduction in the rate of sepsis and a similar improvement in line 
survival at home compared to hospital.
4.2.8 Develop quality indicators and outcomes as benchmarks and define 
them.
The literature on outcomes monitoring was studied particularly looking at 
outcomes developed in the home infusion industry (2.3.4.1.1) and potential 
complications of IV therapy [337]. In order that extra work was minimised the 
benchmarks were developed from data already routinely collected and the 
benchmarking tool was designed with the purpose of minimising data entry.
Outcomes cannot be directly altered but are a function of structure (relating to for 
example organisation, personnel, management, equipment, records) and process 
(how these are used). By changing or developing aspects of structure and 
process outcomes may be altered. Structural, process and clinical outcomes are 
all useful benchmarks and should be included in a benchmarking tool.
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4.2.9 Clinical Outcomes
(N.B. Before reading further go to Appendix 26, this will take you through 
opening the database in Appendix 25 and gives working examples which will be 
referred to through the remainder of this chapter.)
From the literature and local experience a list of clinical problems associated 
with home infusions was drawn up [30, 114, 337-340]. This list was sent to 
other providers of home infusions in England both commercial and non­
commercial for comments and was adapted based on comments received (Table 
4.1).
Table 4.1, Definitions of Clinical Problems Stored on the Database
Problem Definition
allergic reaction characterised by such symptoms as itching, rash and shortness 
of breath
anaphylactic shock characterised by such symptoms as swelling, constriction of 
bronchioles, heart failure and circulatory collapse
blood stream infection where a recognised pathogen is isolated from a blood culture 
which cannot be related to an infection at another site (making 
the assumption that no culture would be done without symptoms).
catheter migration movement of tip of catheter to site other than that which was 
intended and where it was originally placed
catheter occlusion 
complete type A
unable to flush line or draw back any blood, unblocked by flushing 
without the need for urokinase, alcohol etc
catheter occlusion 
complete type B




unable to flush line or draw back any blood, line remained 
blocked despite all attempts to clear it, had to be removed and 
replaced
catheter occlusion partial one way blockage, or blockage which prevents normal infusion of 
fluid
depression Either patient complains of depression or symptoms of 
depression or this is observed by staff
extravasation leakage of drug/infusate outside of the vein
therapeutic failure therapeutic failure e.g. therapeutic failure of an antibiotic, 
temperature not resolving after 48 hours treatment, infection not 
responding to antibiotics
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infusion phlebitis grade 0 No pain, erythema, swelling, induration or palpable venous cord 
at or around IV site
infusion phlebitis grade 1 Pain at IV site, no erythema, swelling, induration or palpable 
venous cord
infusion phlebitis grade 2 Some erythema, swelling or both at IV site, no induration or 
palapable venous cord
infusion phlebitis grade 3 Erythema and swelling at IV site, induration and palpable venous 
cord less than or equal to 3 inches above the IV site
infusion phlebitis grade 4 Erythema and swelling at IV site, induration and palpable venous 
cord greater than 3 inches above the IV site
local infection at entry site characterised by inflammation, redness, puss at entry site
none no problems
other Please specify in box below.




Symptoms that may be related to line placement
symptom of disease state patient complaining of a symptom/problem likely to be related to 
the underlying disease rather than therapy
thrombophlebitis thrombus formation at iv entry site
Any database is only as good as the quality of the data entered into it. In order to 
ensure homogeneity of the data collected it was important to have unambiguous 
definitions of clinical problems to ensure that like was compared with like. 
Definitions which had been successfully employed in previous studies were used 
where possible such as those developed for assessing the degree of infusion 
phlebitis in patients receiving infusions of amiodarone developed by Hilleman et 
al and used by Cahill [341] and Stonehouse [342].
These definitions are shown on the screen when the problem is chosen from the 
list in the database (Appendix 25, Clinical Evaluation Form) so that all operators 
are aware of the definitions (Working Example 1, Appendix 26).
Incidence of adverse drug reactions has been a common outcome measured in 
home infusion therapy since Barget and Zink [324] noted that it was a necessary 
addition when developing their clinical indicators in IV home care in 1989. The
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classification published by Wills and Brown [343] seemed a useful subdivision 
of adverse drug reactions in the home care environment particularly as it 
separates chemical reactions from delivery and pharmacological adverse events. 
It should be noted that this classification has not been extensively used and itself 
has limitations. The major limitation for the purpose of its use as an outcome 
measure in this project is that it does not indicate severity of the adverse drug 
reaction. After an initial pilot of the database the definitions were adapted to be 
more user friendly and specific to home infusions (Table 4.2). Adverse drug 
reactions needed to be included as a separate field as it was thought that it was 
useful to also record the result of adverse drug reactions such as degree of 
infusion phlebitis rather than recording this solely as an adverse drug reaction 
related to the delivery mechanism being used. The nursing staff found this 
separation easier to work with. The following definitions of severity were 
developed in conjunction with the staff piloting the database.
• Mild -minor discomfort to patient
• Moderate- requiring treatment to overcome
• Severe-necessitating withdrawal of the drug or dose limiting
• Serious -fatal, life-threatening, disabling, incapacitating or which result in 
prolonged hospitalisation (Committee on Safety of Medicines and Medicines 
Control Agency definition).
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Table 4.2, Definitions of Adverse Drug Reactions
A dverse drug reactions Definition
Adverse drug reaction Type 
A -augmented
Type A (augmented) reaction: Pharmacologically predictable, dose related, 
improves if medicine withdrawn, common e.g. diarrhoea with chemotherapy
Adverse drug reaction Type 
C -chemical
Type C (chemical) reaction: Due to irritant action of drug, related to drug 
concentration e.g. extravasation, pain at the entry site owing to irritant action 
of drug or excipient, contact dermatitis
Adverse drug reaction Type 
D -delivery
Type D (delivery) reaction: Caused by method of administration or nature of 
formulation, improves if medicine withdrawn or method of delivery changed 
e.g. particles in injections causing thrombosis or blood vessel occlusion, 
infection at entry site, owing to the opening of a port of entry for bacteria.
Adverse drug reaction Type 
H -hypersensitivity
Type H (hypersensitivity) reaction: requires activation of immune system, 
improves if medicine withdrawn e.g. rash with antibiotic
Adverse drug reaction type 
O -other
Type 0  (other) Includes adverse drug reactions associated with a micro­
organism, withdrawal reactions, reactions which occur only in those who are 
genetically predisposed, reactions which cause irreversible genetic damage 
(carcinogenic, genotoxic or teratogenic or reactions whose mechanism not 
understood.
Information regarding unplanned stopping of the infusion or unplanned visits to 
the patient or the patient to the hospital and unplanned admissions to hospital 
were all found to be important negative outcomes to record. They show 
increased morbidity and increased cost of treating the patients. The database can 
be used to link these outcomes to other factors to see for instance whether they 
are more commonly related to a particular type of infusion device, method of 
administration or method of training the patient. Definitions for these were 
developed with nurses involved with follow up and continuing care of patients 
receiving home infusions are shown in Table 4.3.
By virtue of the way that this information is stored on a Microsoft Access® 
database performance indicators can be developed from any combination of the 
data input and those included are just examples of the way the data can be used 
(see section 4.2.13).
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Table 4.3, Definitions related to unplanned interruption of infusions, visits 
and hospital admissions




unplanned home visit by 
health care professional
visit by health professional to patient in home environment at 
request of the patient or due to unforeseen problems arising
unplanned or extra visit to 
outpatients or ward
visits not scheduled in advance but due to problem with home 
infusion that patient is unable to solve over the telephone or 
requires reassurance of visit to health care professional
infusion stopped before 
planned end of course 
Type A - ADR
infusion ceased or changed prior to end of planned course due to 
adverse drug reaction
infusion stopped before 
planned end of course 
Type B -  therapeutic 
failure
infusion ceased or changed prior to end of planned course due to 
therapeutic failure, e.g. failure of infection to resolve
infusion stopped before 
planned end of course 
Type C -drug admin 
problems
infusion ceased or changed prior to end of planned course due to 
drug administration problems
hospital readmission as 
an inpatient due to 
condition deteriorating
medical decision to readmit patient due to deteriorating medical 
condition/need for other forms of hospital care
hospital readmission due 
to inability to cope with 
/lack of desire to continue 
home infusion
decision made by patient carer or professional staff that home 
infusion not safe or effective or in the best interest of the patient
The following indicators were developed and are made up from both process and 
clinical indicators of performance of a home infusion program within the 
limitations already discussed.
a) Incidence of all clinical problems by type of therapy.
b) Incidence of infusion phlebitis (divided by grade) by type of therapy and type 
of intravenous access device.
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c) Incidence of all clinical problems by intravenous access device and 
benchmarking centre
d) Incidence of all adverse drug reactions (divided into sub-categories) by type 
of therapy.
e) Incidence of catheter occlusion by type of therapy and type of intravenous 
access device.
f) Incidence of contacts by patients /carers by therapy group subdivided by 
main subject of contact.
g) Proportion of out-of-hours contacts over all contacts by patients and carers by 
therapy group.
h) Information provided to patients/carers by therapy group subdivided into 
categories of information given.
i) Incoming and outgoing contacts by therapy type for specified categories of 
information.
j) Incidence of patient/carer enquiries regarding infusion device by type of 
device and therapy group, 
k) Incidence of unplanned patient visits, interruption or stopping of infusion and 
hospital readmissions by therapy type.
4.2.10 Data Collection Method and Piloting
A Microsoft Access® database (Appendix 25) was used to collect and manipulate 
data. This software was chosen because it is a readily available Windows®-based 
programme which is part of the Microsoft Office Pro® package. Many users are 
familiar with the other software in this package (such as Microsoft Word® and 
Excel® and PowerPoint®) and there are many shared operating systems which 
will make it familiar to many users, even if they have no previous experience of 
operating a database. Conventions such as being able to operate buttons by 
clicking the mouse on them or by typing the underscored letter were programmed 
into the database for ease of use.
The database was designed so that it would as far as possible, resemble 
information already collected on paper. User friendly forms were set up with
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buttons allowing a user with no understanding of Access to enter and manipulate 
data by a menu driven system.
4.2.10.1 Main Menu
The main menu (Figure 4.10) form is programmed to open when the database is 
first opened. It allows the user to choose whether to add information about a new 
patient onto the database or to amend or add to existing information stored about 
patients. There is also a button which allows the user to report on current data 
stored in the database.
Figure 4.10 Main Menu
H I Eile Edit ¥ ie w  Insert Farms! R ecords I o o ls  Window Help - I g l x l
Home Infusion 
Benchmarking Database
F a  a now pafeantyou 
patent delate before j»ou can  
e rtt t  any othet nJomabcnMain Menu|
C h o o se  from the following
Add to or am m end record of existing patient
C h o o se  a  report to v iew  or print
FSiST 1 '■ : —~ •, ■ ----- ■  -| | | | | | |
4.2.10.2 Patient Details
The form “Patient Details” collects details specific to the patient which are 
unlikely to change during the course of the therapy, such as name, address, date 
of birth etc (Figure 4.11). The database was designed so that this information is 
only ever entered once and is automatically completed in other forms which refer 
to it by the computer. Any piece of information known about the patient such as
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name, telephone number or date of birth can be used to find the record of the 
appropriate patient using a find patient button (pair of binoculars).
The patient’s hospital number (or ID number used by a commercial company) is 
used as a primary key to identify patients in all data and for future data 
manipulation. The database will not allow a primary key to be duplicated as it is 
used as a unique identifier. If there are patients in different hospitals with the 
same hospital number the primary key will have to be altered to also include 
benchmarking centre. With the introduction of NHS number, it will only be 
possible for one patient to have each number and it would be recommended that 
this number be used to identify the patient.
Figure 4.11, Patient Details Form
Microsoft A c cess  - [1 Patient details]





—  ' »





--------------------------- - 1 Concurrent d !se a se s7 5 h e n n fo ^ |
F — J
HBH
1 Record: l<  1 « 1 1 18 ► of 18
Form View mmmmmmmamamnmMmmmIW W !
*NB See copy of database on CD (Appendix 25), to scroll down to bottom of 
page and to see drop-down lists.
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To allow ease of data entry drop down list were used so that an entry could be 
selected from a list rather than typed in each time. This also ensures greater 
accuracy of data manipulation and for grouping of the data, for example the 
diagnosis of “rectal cancer” could be written in a number of ways such as 
“cancer of the rectum” with varying accuracy of diagnosis but if all were entered 
differently the computer would be unable to recognise them as one diagnosis and 
group them as such for the purpose of data analysis. It would also be possible in 
this field to use read codes to store data. These are commonly used both in 
primary and secondary care in order to group patients by diagnosis. There have 
been problems in the use of read codes. Clinicians have not been consistent in 
read code allocation and particularly in general practice it is common for a group 
of practitioners to agree on a limited set of read codes for use in their system. 
MIQUEST a software package which extracts clinical data from various GP 
software packages has highlighted these differences. See Working Example 2, 
Appendix 26.
It is vitally important to ensure that patient confidentiality is maintained and that 
the law relating to data protection is followed when storing details of patients in 
an electronic format. The patient details included in the database (Appendix 25) 
are fictitious. The database is password protected (password “homeinfusion”) 
and this password protection could be used to allow access to different levels of 
information to different staff if the database was networked. When the database 
was piloted some real information was input but access to the information was 
firmly restricted to the patient’s doctor and two research nurses. Two passwords 
were required to obtain access to the database.
The database is able to function without all fields being filled in but there are 
some fields on which it relies to sort data and relate it to other information stored 
in the database. Irrespective of the computer programming there are some fields 
that it would be illogical not to complete as they are part of the minimum 
information required such as the name of a drug on a prescription or a patient 
identifier. If the fields that the computer requires are not completed an error 
message is shown and the form where the data is being input cannot be saved. It 
was found on first piloting the database that this became an irritation for the staff
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inputting the data as they had to guess which fields these were. These fields on 
the forms were subsequently coloured yellow so that it was easy for staff to 
identify what data they were missing.
4.2.10.3 Add To Or Amend Patient Records Form
Once the patient details have been entered or a patient previously entered into the 
database has been selected a further menu allows the user to select information 
that they wish to enter (Figure 4.12). Use of this form is covered in Working 
Example 2, Appendix 26.
Figure 4.12, Menu 2, Add To Or Amend Patient Records
^  Microsoft A ccess  - [Menu 2 2 : Form] w i  iri I
Eile Edit y iew  Insert Format R ecords Io o ls  W indow tjelp
Add to or am mend patient's records









iy Access Device 
Despatch 
Back to Mam Menu
|  Record: H I  < l P ^ 1 > | H | > - | o f  1
Form View 1 1 1 1 1 1 1
4.2.10.4 Patient Discharge and Selection
The database collects very simple information on patient discharge. It should be 
noted that patients on home chemotherapy infusions, for example, might not be
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admitted to hospital at all. The patient discharge screen is shown below (Figure 
4.13) and is used to record suitability of home environment.
Figure 4.13, Discharge And Patient Selection
A  Microsoft A ccess - [FDischarge]
| Eila Edit View Insert Fermat Records Ioo ls \flfmdow Help
iDischarge and Patient Selection













D ate rew e< n o^ !orn ?h efap v
Date disharged fiom hospital
Number of days in hospital poor to
1 Record: l < l  < 11 ! » ' ! ■ 1 of 1 (Ffcered)
Formvtow
It is assumed that there is a robust system in place for patient selection and that 
patients who are entered onto the database are deemed suitable for home care and 
meet any criteria laid down in the patient selection procedure. The success of 
home infusion programmes is dependent upon good selection criteria being 
strictly adhered to [112, 128, 157, 160, 193]. Monitoring of patient compliance 
with administration of the therapy and adherence to the procedure that they are 
taught throughout treatment is also important in achieving desired outcomes of 
treatment [158].
Information collected on this form could be used to monitor how quickly patients 
are discharged after referral for home infusion and number of days in hospital 
prior to discharge. These data may then be related to incidence of complications,
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further patient/carer training requirements or readmission rates (Working 
Example 3, Appendix 26).
4.2.10.5 Venous Access Device
The next form records information regarding the intravenous access device(s) 
used (Figure 4.14). Including information in the database, such as diagnosis, 
intravenous access device, type of drug therapy and pump used is important in 
ensuring that like is compared with like. The incidence of replacement of 
intravenous access devices in patients receiving their infusion through a 
peripheral cannula is not comparable with that of those patients receiving their 
infusion through a central line. The data collected in this form might be used to 
identify which staff groups have lower incidence of catheter related 
complications associated with catheter that they have placed or may identify a 
problem with the technique of a particular member of staff. There have been 
papers published which suggest that members of staff with a dedicated role in 
placing intravenous access devices may have better outcome than hospital 
doctors due to improved technique [344, 345]. From data collected on this form 
the numbers of days a catheter remained patent can be calculated.
The number of catheter days for a patient can also be calculated from this form 
and used as a denominator for comparisons of line infection rates etc. This is 
calculated using the DateDiff function which counts the number of days between 
the “date venous access device put in” and the “date removed”. See working 
example 4, Appendix 26.
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Figure 4.14, Venous Access Device
A. Microsoft A ccess - [FIvAccess]
] Eile Edit View Insert Farmat Records Io o ls  Window Help
Add New Record |  Enter mote Mormadon on this patient 
PabentHospitaINo
Back to main menu
PatientFirstName
PatientS irName
Patient* date of Uth
batch number
Date venous access device put in





The Training Record Form (Figure 4.15) allows information to be obtained on 
the number of training episodes required by patients on particular therapies and 
the time spent by various members of staff on training. An average can be 
calculated and used to estimate cost of this part of the service in a managed care 
situation when tendering for contracts. This serves as a record of particular 
problems a patient may have encountered in learning to administer their own 
therapy or look after their line and can be used by healthcare professionals to 
ascertain where the patient has previously experienced difficulties when they are 
advising the patient by telephone, in the hospital or on a home visit.
The Training Record also records whether the carer was present at training 
sessions and who taught the patient that particular technique. Again this could be 
used to identify staff training needs and learn from best practice. (See working 
Example 4).
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Figure 4.15, Training Record
Microsoft A ccen  • [FTraining2]
Eile Edit Yisw Insert Ffirmat R ecords Joo ls Window Help











The prescription record (Figure 4.16) was based upon a prescription used by one 
provider of home infusions (Appendix 27) and was designed to look exactly the 
same to allow ease of data entry. This meant that the form had, in effect, been 
piloted and included all of the necessary information. The prescription could be 
completed on the database, printed off and signed by the doctor to act as the legal 
prescription, or signed order for the drug. This is why a print button has been 
incorporated into this form (Working Example 5, Appendix 26).
The prescription allows queries to be performed (records searched, grouped and 
counted) by drug therapy, start date, prescribing doctor, type of infusion device, 
intravenous access device and length of course.
Length of course can also be used as a basis to calculate number of infusion days 
for reports and performance indicators. If the infusion is stopped early for any 
reason the length of course on the prescription is overridden by the “number of
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days therapy if infusion stopped early” field from the Clinical Evaluation form 
(Figure 4.17). It is important to know the number of infusion days or catheter 
days. For example one line infection in a patient receiving a home infusion for 7 
days is not the same as one line infection in a patient receiving a home infusion 
for 100 days.
Figure 4.16, Prescription Record
b b h b b o b d b d
I H  Eile Edit View Insert Form at H ecords lo o ts  W indow Help - I f f l xl
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I Hospital consultant
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Addre ss  d G P l
Address d  GP 2
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I o Home Care Company Limited.
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1 » | M | » . |  o f  l  (Filtered)Record: H I  < I I 
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*NB See copy of database on CD (Appendix 26), to scroll down to bottom of 
page and to see drop-down lists.
4.2.10.8 Clinical Evaluation Form
This form was designed from one already being used by another home care 
company. It is used to record details of the patients’ visits to hospital or a visit 
made to the patient in their home. It records patient observation which could be 
plotted in a graph within the database to show trends such as weight gain in a 
TPN patient. When this form was piloted in a cancer centre it was commented 
that it would be useful if the database was able to calculate body surface area
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from height and weight so this was incorporated. The body surface area is 
calculated from the patient’s height and weight using the Du Bois and Du Bois 
formula (S = W0 425 x H0725 x 71.84; where S = body surface area cm2; W = 
weight in kg; H = height in cm) reference.
Time spent with the patient was important for commercial billing purposes but 
also in predicting costs for contracts and for reducing unnecessary patient visits. 
Number of unplanned visits made outside office hours can be calculated from 
clinical data input onto this form. It may also be used to monitor the effect of 
changes in practice put in place to minimise out of hours visits. The clinical 
problem section was used to record problems in medical terminology rather than 
the way the patient explained the problem as is recorded in incoming 
information. This data was used to calculate some of the outcomes which have 
been more commonly monitored in the Unites States e.g. incidence of line 
infection.
It was decided that adverse drug reaction classification should be recorded 
separately in future because it was sometimes not known whether a problem was 
related to the drug or not. During the pilot a category of “suspected line 
complication” was included as staff commented that it was difficult always to 
know whether a problem was related to the line or not. This could be categorised 
under adverse drug reaction as a Type D-delivery caused by the method of 
administration.
This form was also used to capture data on unplanned stopping of infusion, 
unplanned or extra visits to the hospital or to the patient in their home and 
hospital inpatient admissions.
The length of therapy if treatment stopped early is important as it can be used to 
recalculate the number of infusion days, rather than using the originally intended 
length of course recorded on the prescription form. (See Working Example 1, 
Appendix 26).
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Figure 4.17, Clinical Evaluation
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4.2.10.9 Incoming Information (Patient/Carer Contacts)
Patient or carer contact was thought to be important to record. A high incidence 
of patient contact may reflect an approachable, friendly staff rather than a high 
number of problems; this highlights the care needed in interpreting the data. 
Recording details of the subject of patient calls may help to identify information 
required by patients before discharge or help in development of the training 
programme. The categories used for incoming problems are shown in Table 4.4.
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Figure 4.18, Incoming Information
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A primary and secondary problem category were included as a patient may, for 
example, be experiencing pain caused by a line problem or may be querying 
quantity of supplies because of a delivery problem. (See working Example 2, 
Appendix 26)
Table 4.4, Categories Used to Classify Incoming Information from Patients 
or Their Carers














A record of who gave what advice to the patient when was also considered useful 
for a co-ordinated approach from the healthcare professionals looking after a 
patient and also for monitoring the categories of information given Figure 4.19. 
Again this could help in identifying gaps in training or written information given 
to the patient and their carer and could identify staff training needs if related to 
the staff or staff groups responsible for training the patient. Another example of 
how this information could be used is in relating the frequency of outgoing 
information regarding pumps to the type of infusion device used from the 
prescription record. Infusion devices that patients had less problems using could 
then be chosen if appropriate or extra information on the use of the device could 
be provided. The categories of outgoing information from the hospital, home 
care company or primary care professional are shown in Table 4.5
Table 4.5, Categories Used to Classify Incoming Information from Patients 
or Their Carers
Category ID Category outgoing info
1 Delivery
2 Advice re Pump
3 Consumables
4 Equipment e.g. fridge
5 Advice re line care
6 Advice re drug administration
7 Other
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Figure 4.19, Outgoing Information
Microsoft A ccess - [F Outgoing info]
£ile  Edit y ie w  insert Format R ecord s I o o ls  W indow Help
Outgoing Information
Add Hew Record Enter more information on this patient Back to Mart Menu
Patients date of birth
contact made date 
time




category of information given 
deiais of information given!
1 » of I (Filtered)
4.2.10.11 Other Forms For Data Collection
Two other forms were included which were not piloted in the evaluation these 
were to record despatch of infusions and quality control Figure 4.20 and
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Figure 4.21. It has already been noted that information regarding home infusions 
is stored in disparate places and it was found when piloting the database as a data 
collection method that the information regarding quality control of the infusions 
and despatch is not readily available by the same people who have access to 
clinical information.
The idea of the database is that it could be networked so that information from all 
staff caring for home infusion patients can be collated including that from 
different departments of a hospital such as the ward, outpatients, pharmacy, 
outreach nurses, commercial providers and primary care. Levels of security 
could be incorporated to give delivery staff and others access to information that 
would be useful to them and allow them to input certain information.
Figure 4.20, Despatch Check Form
Microsoft A ccess - [FDespatch]
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Figure 4.21, Quality Control of Infusion Form
Microsoft A ccess • [FQualityControl]
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4.2.11 Design a Tool to Analyse the Data
The data was analysed using queries and reports incorporated into the Access® 
software. It was necessary to manipulate the data for the reports. In order that 
data is comparable between centres an attempt was made to calculate the 
incidence of the measures used such as complications of catheter occlusion or 
blood stream infection. Frequency of complication per number of catheter days 
was calculated so that centres can compare their rate of complications per 
number of days the patient had a catheter in situ. Some studies compare rates of 
an incident per number of infusion days, however, all the time the patient has a 
catheter in-situ even if it is not being used for an infusion there is the potential 
for drug delivery related adverse drug reactions. It is possible to calculate 
incidence both by number of infusion days and by number of catheter days from 
the information stored in the database. Incidence of clinical problems has been 
calculated per 100 catheter days in the example reports given.
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A problem arises that one patient may in a very small number of cases have more 
than one catheter in-situ at the same time. If a patient has two catheters in situ 
for 7 days should this count as 7 catheter days or 14? It was decided after some 
discussion with staff looking after home infusion patients that the risk of 
complications from each line was additive and therefore the number of days 
should in the above case be recorded as 14 rather than 7. The queries were set up 
to incorporate this so that in the above example 14 catheter days would be used 
in calculating the incidence for the report.
Select queries were used to select the required information and calculated fields 
were incorporated to calculate incidence. In order to calculate the number of 
catheter days select, make table, update, append and delete queries were used. 
Functions such as “I lf ’and “DateDiff ’ were used to calculate the number of 
infusion days and number of catheter days.
Number of infusion days can be calculated by taking the largest length of 
infusion from infusion 1 and infusion 2 and returning this unless “number of 
days treatment if infusion stopped early to the nearest day” was completed on the 
“clinical evaluation/visit” form in which case this should be returned as the value 
for number of infusion days.
A problem was encountered whereby one patient may have many prescriptions 
and those many prescriptions may be associated with many records of “clinical 
evaluation/visits” (a many to many relationship). If the infusion stopped early 
section was filled in on the “clinical evaluation” form the computer had to be told 
which prescription this referred to so that the correct value was overridden. 
Clinical evaluations may also occur outside of the time that the patient is actually 
receiving the infusion. It has been assumed that in this case the infusion stopped 
early field would not contain a number of days because there would be no 
ongoing infusion to stop early. The start date of the infusion plus the number of 
infusion days was used as a time period over which the patient was receiving this 
infusion. The computer was programmed to search the prescription records to 
find the appropriate prescription using a complex set of greater than and less than
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commands for date and time.
It can be seen from the above that the number of infusion days is reliant on the 
prescription so that every time a patient has a prescription this needs to be 
entered onto the database. If, for example, a patient is receiving a 14 day course 
of an antibiotic infusion and two prescriptions each of one week in duration are 
written both must be entered onto the database and the start date of the second 
must be 8 days after the start date of the first, it cannot be the original start date 
of the course.
One idea to overcome these sorts of problems was to incorporate the concept of a 
treatment episode which for chemotherapy or antibiotic infusions would seem 
logical. It was very difficult to define an episode in terms of fields input so that 
the computer was able to identify one episode from another. Patients receiving 
TPN or desferrioxamine infusions do not fit these categories. Is a break in the 
infusion of one or even two days the end of an episode? It would be for an 
antibiotic infusion but what happens when a TPN patient has three bags a week?
The reports incorporated as examples later in this chapter (4.2.13) start by asking 
the operator the time period over which they wish to report. If the start date 
chosen is after the “date catheter put in” date then the chosen start date is 
returned and similarly if the “date catheter removed” date is after the end date the 
end date is returned. For catheters that have been put in but not taken out today’s 
date is returned as date removed for the purpose of the calculation. It is therefore 
very important to make sure that data input is up-to-date before running reports. 
As with any database the output is only as good as the quality of the data input.
By using the number of catheter days rather than the number of infusion days the 
incidence of some complications may appear to be lower than those reported in 
some of the literature. This makes it difficult to compare like with like, hence 
the need for clear definitions. Williams et al [28] give an incidence of catheter 
related sepsis per number of patient months receiving TPN, it appears that this 
has been calculated using duration of catheter placement in months but they do 
not define a month making it difficult to compare this to other data which is
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given in terms of days, although this can be extrapolated to a year and divided by 
365 to give an estimation. If all benchmarking partners are using the same tool 
then calculations will be made from the same data ensuring that data is 
manipulated in the same way, and assuming integrity of the data input, 
comparisons will be more accurate although this will not account for external 
factors such as case-mix already discussed.
Comparing incidence such as a complication per 100 catheter days can be a 
problem because in a centre whose number of catheter days is low one incidence 
of a complication could skew the incidence significantly when comparing it to 
data of another centre with far more patient catheter days. Patients who did not 
have a catheter left in situ (i.e. they had a new catheter placed each time they had 
an infusion administered) were excluded from the analysis in the reports shown 
in the database.
A further adaptation required was discovered on piloting the database. This was 
the need to include a field asking whether this was the first time that the clinical 
problem had been recorded. Initially on the “Clinical Evaluation/Visits” form 
the nursing staff were recording the same problem on each occasion that they 
saw the patient so that a centre who saw the patients with clinical problems 
regularly appeared to have a very high incidence of problems but in fact they 
may well have been just providing better care or more support for their patients.
4.2.12 Validation of the tool.
It was almost impossible to develop the benchmarking tool without having any 
real data to put into it, as it was only then that many of the problems of logic in 
the relational database were highlighted. It was difficult to determine the 
relationships between each of the tables. The relationships formed are complex 
and are shown in Figure 4.22. The mapping of the processes was used to 
develop relationships in a database in a logical manner. A difficulty arose where 
circular relationships were the only logical way to relate tables but this causes 
problems for the database in that when running queries it does not know which 
way to go around the relationship.
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The piloting, feedback and subsequent redesign of the database was almost a 
continuous, circular process and has therefore been discussed in the development 
of the tool. Two home infusion centres contributed data, one was a cancer unit 
of a NHS Trust and the other was a commercial home care provider. The 
database was piloted in these two different settings to ensure that it would 
function successfully in both models of providing home infusions.
As the reports were designed each report was validated by calculating the 
expected output from the raw data held in the tables of the database. Further 
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The number of patients entered into the database during piloting was small and it
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is probable that further problems may emerge as more data is entered. It takes 
many months to build up a picture of one real patient and even longer to come 
across all the many scenarios which may emerge. The small amount of data 
incorporated here is one of the main limitations of this work.
It is often computer programmers who develop these sorts of programmes and a 
major problem with these is the programme is designed around the software 
rather than the software being designed around it’s application. This is purely 
because the computer programmer generally has a far greater understanding of 
the software than they have its application. This programme has been designed 
around the provision of home infusions and some of the programming now needs 
to be improved. Further development was limited by the researcher’s ability to 
programme more complex aspects of the database.
A manual explaining the importance of completing fields and how the computer 
has been programmed to calculate certain outcomes would be the next step after 
the design of the software has been finalised by further testing. A small help 
section could also assist users to overcome the majority of problems they might 
encounter.
4.2.13 Reports
Reports are accessed via the main menu “reports” button, which is linked to the 
report menu form (Figure 4.10). This gives the operator the opportunity to 
choose a time period over which they want the report run. The finish date 
defaults to today’s date but this may be overridden. Four example reports have 
been programmed in. The data used in these reports is fictional, as much more 
data would have to be input before an incident of some of the rarer events would 
occur.
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Figure 4.23, Report Menu
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The first is an empirical report showing overall incidence of clinical problems by 
benchmarking centre and is presented as a graph (Figure 4.24) (see Working 
Example 6, Appendix 26).
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Figure 4.24, Report 1, Incidence of Clinical Problems per 100 Catheter Days
by Benchmarking Centre
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This obviously needs to be broken down further into, for instance, the report that 
shows incidence of infusion phlebitis by grade and benchmarking centre (Figure 
4.25) which gives a much better comparison (providing that the same definitions 
have been used to grade infusion phlebitis). (See Working Example 7, Appendix 
26).
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Figure 4.25, Report 2, Incidence of AH Grades of Infusion Phlebitis per 100
Catheter Days by Benchmarking Centre
Microsoft A ccess  - [PBDT3 : Report]
j Eila Edit View Io o ls  Window {Help
! _ f e g - a ] p [ D B B | > « > »  H g o s e j y - I P ~ f l ’ l <3) 1
j m
Incidence of All Grades of Infusion Phlebitis per 
100 Catheter Days By Benchmarking Centre
Centre 3 Centre 4
Start Dale
| Page: i i L i j r — t j j m i  j j
Incwwj
□  infusion phlebitis 
grade 4
■  infusion phlebitis 
grade 1
■  infusion phlebitis 
grade 0
It may not however be useful to compare incidence of clinical problems without 
specifying which type of intravenous access device was used as incidence of 
complications is affected by this [339]. The next example report (Figure 4.26) 
shows incidence of clinical problems reported by intravenous access device (See 
Working Example 8, Appendix 26).
The reports included in the database are just a very small number of examples of 
reports that can be programmed into the database. The combination of these 
types of reports can be used to highlight differences in benchmarking centres and 
to identify best practice. Each separately stored field can be queried and shown 
against any other field held in the database so that there are almost an infinite 
number of hypotheses that these data can be used to test. Once the data is stored 
in this way it then becomes possible to use it when new questions arise. It should 
be noted that all of this information is already collected but because of the way it
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is recorded and stored it is not currently used to improve patient outcomes and 
the quality of care they can expect to receive.
Figure 4.26, Report 3, Number of Clinical Problems Per 100 Catheter Days 
By Intravenous Access Device and Benchmarking Centre
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The database also makes it very easy to access a history of patient details; an 
example of this is given which lists a summary of all of the prescriptions that 
have been written for a particular patient (Figure 4.27). (See Working Example 
9). The same could be done to print out a summary of communication with the 
patient or clinical problems before a visit to that patient or before an outpatient 
appointment. Clinical monitoring could be shown as trend graphs for measures 
such as blood pressure, temperature and weight and different reports could be 
specific to measure outcomes of different patient groups such as respiratory 
function test for cystic fibrosis patients or pain scores for patients receiving 
infusions for pain relief. It is possible to separate patients by diagnosis but
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would require far higher numbers of patients to be input into the database to 
achieve meaningful comparisons.
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The database would require further piloting and more advanced programming if 
it were to be made available for general use. One centre that piloted an early 
version of the database continued to input data for their own benefit after the 
period of the pilot so that they had easy access to their patient information as a 
central resource.
The situation that has occurred in the United States is that providers provide 
information to a commercial benchmarking centre who collate it and compare it 
to other similar providers, matched for case mix, size of population and size of 
company. Payers require this information when the providers tender for 
contracts.
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4.2.14 Discussion and Future Work
The limitations of this database as a tool for benchmarking home infusion 
providers have been discussed throughout this chapter. This work has shown 
that it is possible to develop a benchmarking tool which achieves the purpose 
outlined in 4.2.3. A patient centred database has been designed that can be used 
by providers of home infusions to compare outcomes and performance 
indicators, to identify trends and problem areas, to monitor the effect of changes 
to the service, improve patient education and to improve communication between 
health care professionals. Data collected and manipulated appropriately can then 
be used to aid purchasers in identifying cost effective care packages, setting 
service specifications, monitoring of contracts against specifications, setting and 
achieving clinical governance targets and ensuring that home infusion therapy 
provides acceptable outcomes.
This work represents the very first stage in development of such a tool. It is not a 
fully functioning tool ready for use. In order to take this further the skills of a 
computer programmer would have to be employed. There are obvious 
limitations of the programming and further technical work is required to develop 
a fully comprehensive software tool. Similarly the development of the tool 
would require far more real patient data to be entered and the outputs validated to 
ensure that the database functioned effectively. Refinements in the relational 
nature of the database and the way data is stored, manipulated and entered are 
needed. It is envisaged that a software package would have to be, probably 
commercially, developed to bring it to a standard required for day to day use. 
Further discussion of this is outside the scope of this work.
This work has shown the necessity for such a tool to be developed using a 
constant cycle of design, piloting, feedback and validation and this methodology 
would need to be employed in further refinement of the tool. The clinical 
definitions, performance indicators and benchmarks would need validation to 
ensure that like is being compared with like and also that appropriate conclusions 
were being drawn from the data. To validate the use of the tool as a whole it 
would have to be shown ultimately to improve patient outcomes. This would
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involve ensuring that the tool was used to challenge current practice and 
constantly learn from best practice, implementing process adaptations to achieve 
better outcomes.
Feedback from clinicians was positive during the piloting but to gain full benefit 
from the benchmarking tool involves a complete change in the way clinicians 
work. Training of staff would be a very important part of implementing 
benchmarking of home infusion services. It is not only important that the data is 
input in an accurate, comprehensive and timely way but also that once stored in 
the database the information is used to stimulate critical appraisal of the 
processes employed and to adapt best practice to improve patient outcomes.
Achieving buy-in from the staff is very important. They must see that this is a 
way to improve the quality of care that they deliver to patients. In the USA the 
motivation for home infusion providers to carry out benchmarking is that 
insurers and payers require this information before they will purchase care and 
often will require that the providers outcomes fall in the upper end of the range. 
In the UK, clinical governance initiatives supported by the Commission for 
Health Improvement (which aims to identify and share good practice) may 
provide the motivation for home infusion providers to benchmark services. The 
Department of Health has, in recent years, tried to encourage learning from best 
practice with the introduction of their beacon scheme [346]. There is limited 
competition in the home infusion market in the UK but in the commercial 
company survey one commercial provider of home infusions specified that they 
wished to benchmark their service against that of others to demonstrate the high 
quality of the service they provide which will help them to make sales.
Using the experience of other industries in employing benchmarking techniques 
it would be necessary for some sort of discussion forum to be established for 
sharing ideas, comparing benchmarks, developing better and more meaningful 
benchmarks and learning from best practice.
There remains much work to be done in developing valid indicators of 
performance to use as benchmarks. In the USA, where benchmarking of home
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infusion providers is well established the indicators are not standard despite 
attempts by the JCAHO to develop a set of indicators which underwent alpha 
testing in 1992 (4.1.4.1.1). Collecting data and storing it together in discreet 
fields in the database facilitates the development of better more useful 
benchmarks.
In order for a benchmarking tool such as this to achieve maximal benefit to 
patient care it would have to be networked so that all NHS health professionals 
and commercial providers have access to all the information they need to provide 
best quality care for the patient. The development of the NHS net is bringing us 
closer to the aim of having all information stored about a patient in the NHS 
being held together and being accessible to those who require it to benefit patient 
care. It is intended that it will eventually be used in empirical benchmarking of 
health care organisations. The current situation remains that patient information 
is stored around the organisations and departments providing the care and not 
around the patient. It is hoped that eventually a tool such as has been developed 
here would be compatible with a patient centred database where all the health 
information regarding that patient is stored. First steps towards linking general 
practices and community pharmacies with electronic prescribing were announced 
in the NHS Plan [5] and pilots will start this year with the aim of making this a 
reality by 2004.
A first step would be for those involved in home infusions to monitor defined 
patient outcomes and establish the processes that lead to those outcomes.
Sharing of information will lead to identification of good practice and facilitate 
improved patient care by learning.
With the formation of PCTs it seems that unless commissioning of home 
infusions is done in a collaborative way the small numbers of patients will mean 
that there is a risk that service specifications will not be set, outcomes of 
individual patients are unlikely to be monitored and the quality of care received 
by patients receiving hi-tech health care at home is unlikely to improve.
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5 Overall Discussion
This chapter draws together the main discussion points from Chapters 2, 3 and 4 
to make overall conclusions and recommendations regarding the management of 
hi-tech health care in the community setting. The work has highlighted both 
opportunities and major barriers to the provision of high quality care, with ever 
more hi-tech therapies closer to patients’ homes. This is in line with the 
government white paper “Our Healthier Nation” [3] and the NHS Plan [5].
5.1 Sharing the care of patients on hi-tech/specialist drug therapies 
AIM 1
To establish the current situation in England regarding the implementation of 
shared care arrangements under EL(91)127 [19] and subsequently under 
EL(94)72 [21] and to identify models which had been successful or otherwise.
AIM 2
To evaluate and critically analyze one example of an initiative intended to 
implement and facilitate shared care between primary and secondary care 
practitioners in South and West Devon.
Shared care guidelines have become widely adopted in various forms throughout 
England but the numbers in each Health Authority area were small at the time of 
this study (average of six per Health Authority area in 1996/7), section 2.2.5.1.2. 
They were generally found to cover a limited range of therapies where there has 
been contention about where prescribing responsibility should lie, (Section 
2.2.5.1.2)
Many of the available shared care guidelines have been produced on the subject 
of higher cost therapies and Health Authorities have often facilitated their 
introduction (2.2.5.1.3). It is likely that gaining agreement about where 
prescribing responsibility should lie, with the backing of the Health Authority, 
through a shared care agreement, has ensured that resource for prescribing these 
high cost therapies is vired to the appropriate budget, i.e. ensuring the money 
follows the patient. An example of this would be erythropoietin prescribing
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(Appendix 5). The Health Authority survey showed that in areas where GPs 
have agreed to prescribe under a shared care agreement, funding to cover the cost 
has been allocated via mechanisms, such as high cost drug contingency reserves, 
into their budgets. Conversely in areas where there has been agreement that 
prescribing should remain in secondary care money already spent on prescribing 
erythropoietin in primary care has been top-sliced from primary care prescribing 
budgets and vired back to secondary care (Appendix 5 and Section 2.2.6.1.5.1).
Although this may be a motivating factor in producing shared care guidelines it 
is interesting that the survey of a sample of GPs showed that when GPs were 
asked what they would most like guidelines developed for it was not the high 
cost drugs that they most frequently requested (Appendix 10 and section 
2.2.6.2.5). The drugs were relatively low cost and those which a GP is unlikely 
to prescribe for large numbers of patients, such as disease modifying agents used 
in rheumatoid arthritis, methylphenidate and atypical antipsychotics. It seems 
from this work that GPs value shared care guidelines for their clinical direction. 
Drugs such as the DMARDs are potentially very toxic and it may be that GPs 
like to have guidelines for prescribing and monitoring such therapies because by 
following the shared care guidance their actions are likely to be more easily 
defensible if legally challenged. The GPs surveyed were happier to take on 
prescribing of these drugs when a shared care guideline was available (section 
2.2.5.2.4.). This finding supports that of Home et al [347] who found that "... 
GPs’ concerns about lack of knowledge to discharge their clinical responsibility 
fully in relation to prescribing seemed genuine”.
Drugs such as methylphenidate [348], rosiglitazone [349] and donepezil [350] 
have recently become the subject of NICE guidance. The guidance on 
methylphenidate [348] gives recommendations as to when it should be prescribed 
and who should initiate the treatment. It recommends that GPs may share care 
with a child psychiatrist or paediatrician under a locally produced shared care 
guideline. It will be interesting to see whether such guidelines in the future will 
contain less clinical information which will be available as part of the NICE 
recommendation and focus more on defining the respective responsibilities of GP 
and specialist. If NICE continues to define suitability for shared care in this way
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it is likely that there will be an increase in the number of shared care guidelines 
available. This will be driven by the fact that compliance with NICE guidance 
will be audited. Audit may be a condition of commissioning arrangements, it 
may be part of clinical governance arrangements and the Commission for Health 
Improvement will be looking for compliance with NICE guidance during it’s 
inspections of both primary and secondary care providers.
The Health Authority and GP surveys showed that respondents perceived that 
both the shared care guidelines themselves and the process for development of 
these guidelines have contributed to improving communication between primary 
and secondary care physicians. However both HAs and GPs commented that 
hospital specialists still often fail to recognise the ethical and emotional dilemma 
that GPs face when asked to take on prescribing of hi-tech therapies. They still 
assume that a GP will take over prescribing hi-tech therapies and tell the patient 
that this will be the case (Appendices 5 and 11). This then puts GPs in a difficult 
position. This finding supports that of Mailey et al [106, 347] and was 
recognised by the Royal College of Physicians in their recent Working Party 
Report: Prescribing of Costly Medicines [22] where it was recommended that 
prescribers in secondary care take into consideration the anxiety that those in 
primary care may have about prescribing certain new medicines. It would have 
been useful to survey the secondary care consultants as well as the GPs in South 
and West Devon in order to determine the success of the guidelines from their 
point of view and to ascertain whether the perceived misconceptions of 
consultants were real. This work is currently being undertaken in South and 
West Devon by the Shared Care Working Group [351]. The work of Home et al 
[347] would suggest that the views attributed to hospital doctors by GPs in this 
survey are reasonably accurate.
During the period of this research most of the guidelines were developed by 
committees facilitated by Health Authorities. Health Authority, hospital and less 
frequently, community pharmacists were heavily involved in drawing up, getting 
agreement on and implementing the guidelines (section 2.2.5.1.3). Membership 
of the committees was very similar throughout the country. The role of the 
Health Authority in the reorganisation of the NHS has changed since 1996/7.
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Health Authorities have taken on a more strategic role and are responsible for 
performance management of PCGs and PCTs [5, 352] Health Authorities will 
shortly be abolished in Wales and there will be fewer of them in England [353].
Since the introduction of PCGs and some PCTs there have been new committees 
or groups formed often referred to as Drug Interface Groups or joint primary and 
secondary care Drug and Therapeutics Committees. These link into, or in some 
instances have replaced, existing Area Prescribing Committees and Drug and 
Therapeutics Committees. They provide a forum to discuss interface issues 
around prescribing usually between a secondary care provider and the main 
PCGs and PCTs associated with them. Representation on the groups is similar to 
the older Health Authority committees but there may be greater potential for 
agreement on shared care issues at a more local level. It seems that future 
commissioning arrangements will specify where prescribing responsibility for 
certain drugs lies, now that purchasing responsibility sits within primary care. 
Delegating decisions to a local level has benefits but may also lead to duplication 
of effort in the development of shared care guidelines and potential problems 
when a GP practice refers patients to a number of secondary care providers each 
of whom have different shared care agreements.
The “traffic light” system mentioned by some Health Authorities in the survey 
(Appendix 5) has become more widely adopted as it is a relatively simple system 
and gives a clear indication of agreement reached between primary and 
secondary care as to where prescribing responsibility should lie. This 
categorisation may also aid the commissioning process as funding can be 
allocated to appropriate budgets.
The perception of cost and workload shifting from secondary to primary care 
were found to be major barriers to the acceptance of shared care by GPs. It 
appeared from this work that GPs would be willing to take on more complex 
treatments in the community if the resource to support this was in place 
(Appendix 11). This will always be an issue in a NHS which has been plagued 
by resource constraints from the outset [354] and where the innovations in
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therapeutics and technology discussed here are adding substantially to cost 
pressures to the NHS as a whole.
Primary care prescribing budgets have only relatively recently become cash 
limited for all GPs, particularly for non-fundholding practices, (abolished with 
the introduction of PCGs in April 1999). Doctors employed by hospital Trusts 
are not bound by the same Terms of Service as GPs [355] and Trusts have a 
statutory responsibility to operate within budget. This has lead, in the past, to 
GPs sometimes inappropriately taking on prescribing responsibility for drugs 
such as prostacyclin or octreotide because the local Trust does not have the 
resource to pay for it. This is in conflict with the General Medical Services, 
Terms of Service which state that GPs must render to their patients “all necessary 
and appropriate personal medical services of the type usually provided by general 
medical practitioners” [355]. Work in the South East of England [347] found 
hospital doctors to be “quite candid in their financial motivation for asking GPs 
to prescribe specialist medicines”.
Responders to both the Health Authority and GP questionnaires expressed a hope 
that unified budgets may solve some of the problems of perceptions of cost 
shifting (Appendices 5 and 11). PCGs budgets are now based on unified baseline 
allocations for hospital and community health services and family health 
services, general medical services and prescribing costs [356] which has made it 
easier to allocate resource to the appropriate sector but indicative budgets still 
exist. Performance against budget such as prescribing incentive schemes in 
primary care are still based on performance against these indicative budgets. The 
resource available for service developments is minimal and tends to be directed 
towards achievement of national targets set by the Department of Health such as 
waiting list initiatives, the milestones contained in National Service Frameworks 
and the implementation of NICE guidance. Although it is a government aim to 
bring high quality, hi-tech care into the community, it is unlikely that resource 
will be allocated to these developments until there are national targets set for this. 
The most likely way that these targets will be set is through NICE technology 
appraisals.
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It appears that there is a lack of supporting infrastructure for training of staff such 
as GPs, district nurse and practice nurses to enable them to take responsibility for 
hi-tech medicines in the community. An example of this is the recently 
introduced drug for rheumatoid arthritis, etanercept (Enbrel®, Wyeth), that could 
be given in the community setting, but it is unlikely that GPs will be happy, at 
least initially, to take on clinical responsibility for the prescribing of such an 
agent and if this is the case, will nursing staff based in the community be 
expected to administer the drug? The pharmaceutical industry has looked for 
ways to get around the short-comings of the NHS by providing specialist trained 
nurses “free” with the drug, an example of this is for the administration of 
lanreotide (Somatuline LA®, Ipsen) in the patient’s home. This is not ideal as it 
allows the pharmaceutical industry to decide on the appropriate levels of training 
their staff should receive, staff will be working outside of Trust policies and the 
company may withdraw the service at any time. More formal agreements of this 
type may come into being as a result of the current debate on partnerships 
between the NHS and private sector to provide NHS care.
It may be that as community services are moved into primary care through the 
formation of new PCTs, a role of specialist community nurses will develop with 
skills in administering hi-tech or complex therapies, in training patients, trouble­
shooting and liaising with specialists in secondary care. This may be through a 
community-based “consultant” nurse. Alternatively the model of outreach care 
may be developed further or, as happens currently with HTHH, expertise may be 
purchased from the private sector.
It is apparent from this research that there is currently no satisfactory mechanism 
that can be called upon when a GP does not feel qualified to prescribe some of 
these complex hi-tech therapies on which the patient may be stabilised for long­
term treatment (Section 2.2.6.2.4). If the hospital specialist continues to see the 
patient this could block outpatient appointments for new patients being referred. 
There is also a practical problem of geography. Currently it seems that patients 
living in rural areas or remote from a tertiary provider receive an inferior level of 
care to those patients for whom it is not inconvenient to get to the specialist
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centre for follow-up. This inequity is what the present government is trying to 
eliminate from the NHS.
Prescriptions issued from hospitals that can be dispensed in community 
pharmacies {FP10(HP)s} have been used in some situations in an effort to 
overcome this. Electronic prescribing may facilitate this in the future where a 
hospital specialist could prescribe for a patient electronically and the patient 
could collect their prescription or have it delivered from their local community 
pharmacy. Similarly e-pharmacies which were welcomed in the NHS Plan [5] 
and Pharmacy in the Future, Implementing the NHS Plan [357] might mean that 
a delivery of the drug, prescribed by the hospital specialist, could be made 
directly to the patients home. The introduction of repeat dispensing also 
announced in the NHS Plan [5, 357] could facilitate repeat dispensing of hospital 
generated prescriptions. It may be appropriate that in the future repeat 
dispensing is linked to the availability of clinical results such as the system used 
in hospitals for the dispensing of clozapine (Clozaril®, Novartis) prescriptions 
which may only be dispensed if the results of a blood test are favourable [358].
These solutions however do not overcome the problem that the condition of 
patients on these complex and often high cost therapies should be adequately 
reviewed before further supplies of a drug are given. This may be facilitated in 
the future by video-linked consultations. These have already proved successful 
in linking rural minor injury units to large accident and emergency departments 
tapping in to the expertise of the accident and emergency consultants [359].
They have also been used successfully for dermatology consultations from where 
a GP and patient use video-conferencing facilities for specialist consultations 
[360] but may not be suitable for all specialties.
The Crown report [109] considered extending prescribing rights to other health 
professionals and recommended the concept of a “dependant prescriber”. These 
recommendations could be extended for these hi-tech therapies so that GPs could 
prescribe as “dependant prescribers” on the recommendation of a hospital 
specialist under a shared care arrangement, with a fast track mechanism for 
referral back to the specialist for any queries or problems which may arise.
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Similarly specialist nurses or pharmacists could continue therapy initiated by a 
hospital consultant under strict criteria as “dependant prescribers”. An example 
of this would be continued prescribing by a hospital outreach nurse of domase 
alpha in cystic fibrosis. The advantage would be that the nurse would be able to 
review the patient’s condition against a set protocol before sanctioning the next 
prescription but would refer straight back to the specialist if there was any 
irregularity or cause for concern. In instituting such a mechanism it would be 
important to ensure that patients treated under this arrangement achieved clinical 
outcomes comparable to those of patients who were cared for entirely by a 
hospital specialist.
The success of shared care guidelines already produced has demonstrated that in 
certain circumstances where cost shifting and work load shifting issues are 
resolved, the implementation of good quality, locally agreed guidelines with 
local ownership has allayed many of the concerns of GPs about prescribing 
complex treatments (section 2.2.6). The GPs surveyed felt that prescribing 
within the terms of the guidance should be more easily defensible medico- 
legally, although there have to date been no test cases to confirm this. If the 
clinical guidance is of high quality, clearly defining the responsibilities of the 
consultant and the GP, and primary care staff receive adequate training many 
GPs are happy to take on these new responsibilities. This has been shown to be 
the case in South and West Devon where there are now 21 guidelines available 
which are regularly reviewed and updated and are posted on the Health Authority 
website (www.sw-devon-ha.swest.nhs.uk/HaTeams /Prescribing/sharedcare/ 
intro.htm).
5.2 Hl-tech Health Care at Home Under EL(95)5 
AIM 3
To establish the current position in England on the purchasing and provision of 
HTHH under EL(95)5 [41].
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AIM 4
To evaluate the effectiveness of EL(95)5 [41] in the delivery of HTHH to 
patients with an emphasis on the role of the pharmacist.
This research found that for hi-tech therapies requiring more complex 
administration techniques such as intravenous infusions, there are still many 
barriers that prevent patients receiving appropriate care (sections 3.2.4.1.8 and 
3.2.4.2.16). The work has highlighted major inequalities throughout England.
An example is the treatment of cystic fibrosis patients. Some patients have their 
infusions made up in a controlled aseptic environment, with strict quality control 
measures in place, in special devices or with infusion pumps, which accurately 
deliver a drug at a set rate and can even provide a history of the infusion 
parameters. They may have a visiting specialist nurse and 24 hour call out 
arrangements. However, other patients are supplied with a bag of needles, 
syringes and vials of a drug and are taught to reconstitute and administer the drug 
themselves with minimal support (section 3.2.4).
This research found that EL(95)5 [41] did little to introduce competition into the 
home care market in England. In line with the findings of Short and Norwood 
[42] it has established that very few Health Authorities have set up competitive 
tendering exercises to purchase care for patients requiring HTHH. Most continue 
to roll over existing contracts or arrangements without review (section 3.2.5.2.3). 
This is probably due to the relatively low numbers of patients in any one Health 
Authority area meaning that contracting arrangements for HTHH are a low 
priority.
The care of patients with HTHH was found to be organised on an ad hoc basis, 
by hospitals or Health Authorities with responsibility for commissioning this 
care. Some large tertiary centres have negotiated their own contracts with 
commercial providers to provide home TPN, for example, and this has led to 
problems when the Health Authority responsible for the patient has a different 
contract (Appendices 19 and 24). This research and that of others [213] has also 
identified the fact that there is a higher incidence of patients receiving home
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infusion therapies such as TPN in patients who live closer to the tertiary centres, 
a further inequality (Section 3.2.5.1.2).
When HTHH is purchased by Health Authorities or NHS Trusts it was found that 
service specifications are not always set and when they are, monitoring of 
compliance with the specifications is scant. The most worrying finding of this 
research was the lack of almost any formal monitoring of patient outcomes 
(Section 3.2.6). Some large tertiary providers have begun to monitor certain 
outcomes and have started to share information on these with other centres to 
learn from best practice [361]. However this does not apply to the majority of 
patients receiving HTHH in England. Specialist commissioning teams at a 
Health Authority level who have little understanding of the clinical outcomes 
often have responsibility for managing these contracts on a day-to-day basis.
If EL(95)5 [41] had encompassed all HTHH and not just that being prescribed on 
FP10 prior to 1995 then it’s impact may have been greater. As it is, many Health 
Authorities have not made provision for an increasing number of new patients in 
diverse therapeutic groups requiring HTHH and so HTHH services have 
developed in a very fragmented way. Hospital Trusts were found to be unaware 
of the extent of HTHH being provided by different specialties within the Trust 
(Appendix 24). If Trusts and Health Authorities are unable to identify which 
patients are being treated with home infusions, let alone how much it is costing 
them, it is difficult to see how they can ensure cost effectiveness and that all 
patients receive a comparable and acceptable level of care.
It is evident from the situation in the USA [134] and other countries such as 
Canada [117-120], Japan [33, 34] and Italy [126] that more patients could be 
treated in the home setting. Although hospital at home schemes for older people 
and those who have had orthopaedic surgery or hysterectomies does seem to 
have been accepted in England [362-366], hi-tech infusions in the home care 
setting may be underused [37]. The differences between England and other 
countries can, to some extent, be explained by different treatment modalities, 
such as not using TPN in AIDS and cancer patients [38] and less use of 
intravenous route of administering antibiotics [190]. However a major factor
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must be the way the health service is funded in this country. The pressure from 
patients and payers (purchasers) of health care to reduce hospital length of stay 
differs from that in the USA. Although the overall efficiency of bed usage in the 
NHS is increased by treating patients with hi-tech health care at home the overall 
cost to the NHS is increased [37]. Closing beds is the only way that an overall 
cost reduction can be realised [40]. However perhaps greater use of HTHH 
could free up some beds and reduce the need for some of the current investment 
in increasing inpatient beds.
With the current emphasis on clinical governance [62], to ensure quality of care 
is high, it seems inconceivable that there are so few mechanisms in place to 
monitor the outcomes of patients receiving HTHH. This is a comparatively 
expensive form of treatment with for example one home TPN patient costing in 
excess of £30,000 a year. However, service specifications are rarely set and 
there appears to be limited, if any, follow up to ensure that even minimum 
standards are being met (section 3.2.5.2.5). It has been shown that the number of 
complications of treatment is inversely related to the experience of the centre 
providing home TPN [7] and yet the service received by many patients is on an 
ad hoc basis, often from a district general hospital with no previous experience of 
providing home infusion therapies. Little account is taken of the fact that an 
apparently expensive provider of HTHH can prove more cost effective in the 
long term due to fewer complications of treatment [279].
The formation of Primary Care Trusts with full commissioning responsibilities 
for their smaller populations will mean that the numbers of patients requiring 
these therapies will be even smaller than those in Health Authority areas and 
ensuring high quality, cost effective care of these patients may be even less of a 
priority unless purchasing consortia are formed for this type of commissioning, 
or care is purchased at a regional specialist commissioning level. This has been 
considered for drugs such as prostacyclin for primary pulmonary hypertension 
where the number of patients in a typical Health Authority area would be very 
small but the cost of treatment is high [367].
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This research found that very few Health Authorities were planning for the future 
growth of treating patients with hi-tech drugs and therapies in the community 
setting (section 3.2.4.1.6), even though it has been shown to be safe, effective 
and cost effective in diverse groups of patients [9, 11, 25, 127-132], Studies 
have shown that both the quality of life of patients and their families is improved 
[216, 236, 237, 249, 272]. In a health service where resources are so limited it 
seems that treating patients in the community negates the need to pay costly hotel 
charges for patients and decreases the risk of contracting hospital acquired 
infections. Greater numbers of patients can be treated for the same resource, 
increasing efficiency, although the overall cost to the NHS is unlikely to 
decrease. This is an ongoing problem in the NHS as technologies advance then 
there is a cost associated with providing treatments that were unavailable in the 
past. Increasing life expectancy is not only associated with increasing costs to 
the NHS, but a corresponding decrease in the proportion of the population 
contributing to tax revenues. Health Authorities in their new strategic role need 
to plan allocation of finances and resources to support an increase in numbers of 
patients receiving HTHH.
There are various options available in training nursing staff to support patients 
receiving hi-tech therapies in the community. As with shared care of hi-tech 
drugs, existing or new community staff could be trained in the care of central 
lines and use of hi-tech administration techniques, perhaps with consultant 
nursing specialists to advise and provide support. There could be increasing 
numbers of outreach staff from hospitals or specialist outreach staff could 
support community staff, a model which has been shown to work effectively in 
Oxford [25]. Alternatively partnerships with commercial providers may 
developed further in a model where the NHS buys in specialist care for these 
patients. For this to be successful more competitive tendering would have to take 
place with close monitoring of contracts to introduce greater competition into the 
home care market. Although this was an aim of EL(95)5 it has so far not been 
achieved.
The NHS is beginning to embrace new technologies and these could make 
HTHH safer and more cost effective in the future. As with hi-tech medicines,
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video conferencing could be put in place to reduce the number of visits to 
patients in their homes. Some home care providers are developing this 
technology for use in the UK home care market [368]. In time training videos 
will be available in an interactive form on the Internet with staff being available 
to answer questions online. In the USA ambulatory pumps are already being 
programmed via telephone lines and data about infusions are being transmitted 
back to health care professionals for checking and interpretation [369, 370]. It 
must however be remembered that emotional support is an important part of 
patient care and patients receiving home infusions have been found to value 
interaction with and reassurance from both health professionals and other 
patients in the same position as themselves [236]. This support is also vital to 
carers who may be taking on a large part of the responsibility for looking after 
the patient, for coping with the hi-tech devices and coping with the illness of a 
loved one.
5.2.1 Role of the pharmacist
The pharmacist has an important role to play in the co-ordination and provision 
of HTHH in the USA and to a lesser extent in the UK. Pharmacists in the UK 
tend to take on more traditional hospital roles. Some community pharmacists 
have become involved in the provision of HTHH [268] but this is not currently 
where their experience lies and it is more appropriately a role for hospital 
pharmacists or those employed by commercial home care providers. Community 
pharmacists and primary care pharmacists may have a future role in medicines 
management initiatives under Pharmacy in the Future -  Implementing the NHS 
plan [357]. The problems with recruitment of staff into hospital pharmacy over 
recent years [371] have inhibited the development of the role of the pharmacists 
to taking on more responsibility for the management of patients receiving 
HTHH. There are examples where pharmacists have had a dedicated role and 
this has proved successful [269]. Most pharmacists who returned the 
questionnaire had at least some involvement with co-ordinating the home care 
programme however it must be remembered that there may be some bias in that 
pharmacists with more involvement with HTHH programmes may have been 
more likely to complete and return the questionnaire than those who had little
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involvement. It would seem that the pharmacy department is well placed to co­
ordinate a home care programme providing services to more than one specialty in 
the hospital. This has been a major role of pharmacists in the United States. 
However from the data gathered it was apparent that clinical pharmacists in 
hospitals often specialise and often set up a programme with just one group of 
patients in mind (section 3.2.4.2).
Pharmaceutical Advisers to Health Authorities were found to play a major role 
when contracts have been tendered for in providing some clinical and 
pharmaceutical expertise (section 3.2.4.2.18). It is unclear with the changing role 
of Health Authorities who will provide this role in the future. Where service 
specifications are set both Health Authority Pharmaceutical Advisers and 
hospital pharmacists are likely to have been involved. A future role may develop 
along the same lines as the USA with pharmacists playing an important role in 
continuous quality improvement and outcomes monitoring of HTHH services.
5.3 Benchmarking 
AIM 5
To develop a benchmarking tool for use by providers of home infusion therapy to 
monitor quality of care and improve patient outcomes (Chapter 4, Development 
of a Benchmarking Tool for the Provision of Home Infusions).
A major finding of this work was the general lack of robust mechanisms for 
monitoring HTHH services and leading on from this the lack of continuous 
quality improvement processes. The final part of this work sought to 
demonstrate the possibility of monitoring quality and outcomes of HTHH in 
England by the development of a tool which could be used in benchmarking 
home infusion services in order to identify, and learn from, best practice.
It is vital that patient outcomes are monitored and that those centres with greatest 
experience and with lower complication rates share through benchmarking their 
experiences, giving advice on procedures and processes that should be followed 
to allow others to achieve comparable outcomes. It is unacceptable that within
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the NHS learning is not shared. Learning must be shared in an open way even 
when commercial providers are contracted to provide care on behalf of the NHS. 
An organisation with a memory [372] goes one step towards the NHS learning 
from critical incidents and errors and the philosophy of beacon sites [373] has 
started to create a culture of learning from best practice within the NHS. 
However, neither of these initiatives appears to have impacted on the provision 
of HTHH under EL(95)5 (section 3.2.5.2.6.5).
Now that technology exists whereby information can be easily stored, 
manipulated and used to identify best practice and improve patient care, many 
would suggest that it is inexcusable not to do so. Electronic communication and 
access to data can be used to make communication easier and more timely but 
this is not current practice in the NHS. It can be seen from the benchmarking 
programme developed in this study, that storing information around a patient 
rather than a provider is relatively simple to achieve and could lead to better 
communication and learning from current best practice. The use of a model such 
as this in the provision of HTHH would require investment in both hardware and 
software which was compatible across primary care, secondary care and 
commercial sectors. When security issues around patient data are resolved NHS 
net could provide the vehicle for doing this.
A major step towards a wider culture of benchmarking would be to develop a 
robust set of quality or outcome indicators. Information from different centres 
must be comparable if it is to be used for this purpose and so the first step would 
be to identify a set of benchmarks and then define them to ensure that like is 
compared with like. Difficulties in achieving this have been demonstrated the 
USA where a set of indicators underwent alpha [313] then beta testing but were 
not developed further [271]. Insurers and other payers eventually drove home 
care providers to register with commercial benchmarking organisations which 
developed their own benchmarks and indicators. Examples of some crude 
indicators have been included in the demonstration tool (Appendix 25) but would 
require significant refinement for future use.
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A factor that is difficult to overcome is ensuring that complications are not 
effectively double counted or centres are not presented negatively for 
maintaining close contact with the patient and keeping better records. A centre 
that diligently records all contact with patients and all potential problems can 
easily appear to be performing badly compared to a centre who do not keep such 
detailed records. It is vital to ensure that like is compared with like and that 
indicators are interpreted and rather than being used as face value. They should 
be used to ensure that relevant questions are asked and can be answered 
satisfactorily.
Advantages of the use of a tool similar to that in Appendix 25 would be that all 
staff involved in the care of a patient at home would have access to up-to-date, 
accurate information. This would lead to decreased risk of error or omission 
caused by lack of timely information or poor communication between health 
professionals and ancillary staff, delivery drivers etc. The patient would receive 
consistent information from all involved in their care and data could be used to 
monitor quality of care and patient outcomes. The database could subsequently 
be queried for the purpose of audit, demonstrating compliance with service 





I. The situation in 1996/7 was that shared care guidelines had been adopted 
to a limited degree in most areas of the country to resolve interface 
prescribing issues.
II. Shared care guidelines were found to have been produced, in general, for 
higher cost and hi-tech therapies where there has been contention over 
where prescribing responsibility should lie.
ID. Successful models were those where there was local ownership of the
process of developing the guidelines from both primary and secondary 
care.
IV. Processes which improved communication and collaboration between 
primary and secondary care both in the agreement of the guidelines and in 
their implementation were the most successful, particularly where the 
guidelines clearly defined respective responsibilities of the clinicians 
involved.
V. Major barriers to the successful implementation of shared care initiatives 
were the perception of cost shifting and workload shifting from primary 
to secondary care, lack of recognition that clinical responsibility is not 
separable from prescribing responsibility, poor communication, and 
problems caused by the practicalities of sharing care with a tertiary 
provider.
6.1.2 Recommendations
I. Further shared care guidelines for complex specialist initiated therapies
should be developed to facilitate prescribing in the community setting.
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II. The process for agreeing guidelines should be one that encourages 
communication and agreement at the primary/ secondary care interface.
III. Mechanisms should be put in place to enable local prescribing of 
complex or hi-tech therapies whilst allowing tertiary (or secondary) care 
specialists to maintain overall clinical responsibility.
6.2 Hi-tech Health Care at Home
6.2.1 Main Findings
I. The incentive, found in other countries, to discharge patients from 
hospital in order to reduce hotel costs by providing HTHH is not present 
in England due to differences in the way the NHS is funded.
II. Considerable variation occurred throughout England regarding 
mechanisms in place for the purchasing and provision of HTHH under 
EL(95)5 leading to inequitable service provision.
ID. EL(95)5 did little to introduce competition into the home care market as
most HAs have not put the provision of these services out to tender and 
have no plan for future provision or development of this model of health 
care delivery.
IV. Service specifications are rarely set and patient outcomes or quality of the 
care are seldom monitored.
V. By directing HAs to top-slice primary care prescribing budgets but not 
secondary care budgets to provide HTHH, EL(95)5 caused provision of 
HTHH to become fragmented.
VI. NHS Trusts were found to have an uncoordinated approach to providing 
HTHH across different clinical specialties.
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VII. Pharmacists currently play a central role in the provision of HTHH in
England but experience in the USA has shown that their expertise could 
be used further, particularly in taking a professional lead of continuous 
quality improvement and outcomes monitoring.
6.2.2 Recommendations
I. A plan is required for introduction and development of HTHH in a more 
co-ordinated manner across the NHS.
II. A system should be introduced whereby all HTHH is purchased via the 
same mechanism, perhaps through groups of purchasers, such as 
consortia of Primary Care Trusts.
HI. Service specifications should be set and compliance closely monitored.
Quality of care and patient outcomes should be continuously reviewed 
and improved upon. A quality-monitoring tool is required to facilitate 
this.
IV. Greater use should be made of the clinical skills of pharmacists to
improve the quality, co-ordination and monitoring of HTHH services.
6.3 Benchmarking Hi-tech Health Care at Home
6.3.1 Main Findings
I. A benchmarking tool was developed which shows the possibilities of
-  storing data regarding patients receiving HTHH
-  improving communication between health care professionals and the 
patient
-  allowing monitoring against service specifications
-  focusing continuous quality improvement initiatives
-  providing benchmarking data
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-  identifying staff training needs.
n. Development of more robust quality or outcome indicators would require
a wider pool of patient data and substantial further work. The 
benchmarking tool could be used to establish, test and validate these.
6.3.2 Recommendations
I. It is recommended that a database be professionally developed 
incorporating the features outlined above.
II. Wider use of such a programme through its incorporation onto NHS net
would provide an excellent way of generating a sufficient database to 
allow the benefits to be fully realised. Commercial providers would need 
access to this facility.
HI. A robust set of quality or outcome indicators for HTHH should be
developed and agreed to allow benchmarking of home infusion services.
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7 Presentation and Publication of results
Data from this project has been presented at both national and international 
conferences and published in both British and American journals.
Information from the Health Authority survey on the current position regarding
i L
HTHH in England was presented orally at the 25 Anniversary, Clinical 
Pharmacy and Pharmaceutical Care International Meeting, Barcelona, June 4th- 
6th 1998.
Results of both the national survey of Health Authorities and the local survey of 
South and West Devon GPs on shared care was presented orally at the 3rd 
National Prescribing Centre Conference for Health Authority Advisers, Hinkley, 
18,h-19th June 1998.
An interim analysis of the data obtained from the Health Authority questionnaire 
was presented as a poster at the British Pharmaceutical Conference, Eastbourne,
| L  f l .
September 8 -11 1998 and published in a Pharmacy Practice Research 
Supplement to the Pharmaceutical Journal [284] (Appendix 28). More 
questionnaires were returned after this was published.
A poster showing the combined results of the Health Authority, Trust and 
Commercial provider surveys on HTHH was presented at the American Society 
of Health Systems Pharmacists Section of Home Care Practitioners Home, 
Hospice and Long Term Care Conference, Chicago, 31st July -  2nd August 1999 
and a paper was subsequently published in the American Journal of Health 
Systems Pharmacy [331] (Appendix 29).
An analysis of the role of the pharmacist in HTHH from the Trust questionnaire
thwas presented as a poster at the British Pharmaceutical Conference, Cardiff, 13 - 
15th September 1999 and was also published in a Practice Research Supplement 
to the Pharmaceutical Journal [286] (Appendix 30).
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The benchmarking tool developed was demonstrated at a workshop of the first 
UK inter-disciplinary Home Care Conference, At Home ’99, Advances in 
Treatments at Home, London, 10th-12th November 1999.
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APPENDIX
Pharmacy Office, 
Mount Gould Hospital, 





I am a pharmacist working in Plymouth and am researching the current position in the 
United Kingdom on ‘shared care’ and ‘hi-tech health care at home’. The work is for an 
M.Phil. project registered with the University of Plymouth and sponsored by the NHS 
Executive.
My aims are to find out, for shared care
• which areas have shared care committees
• who is represented on them
• what different areas have managed to achieve (with or without a committee)
• what are the future goals in the area of shared care
• which aspects of shared care have been successful
• which aspects have been difficult or unsuccessful
and for hi-tech healthcare at home
• to what extent patients are being treated in their homes with ‘hi-tech’ therapies
• who is currently providing the various aspects of their care
• to what extent are primary care professionals involved with their care
• whether there are geographical or demographic trends in ‘hi-tech’ home care in England
• how much is being invested into the caring for these patients at home nationally
I will be sending this questionnaire to medical and/or pharmaceutical advisors of all of the 
Health Authorities in England. The information I receive will be used with other 
information on demographics, expenditure etc to see if there are any correlations between 
the data you provide and other factors.
* V M °
Dear Colleague,
I intend to publish an analysis of the information I obtain in a relevant health journal. The 
data will be combined so that data from individual health authorities will not be 
identifiable. I will be happy to send responders a summary of my findings.
If you would like more information about my study or these questionairre please contact me 
(01752-272588).
The questionnaire will take approximately x minutes to complete. If you are unable to 
complete the questionnaire please pass it on to someone else who may be able to.
Thank you very much for your help.
Yours faithfully
Jill LOADER (Miss) 
Research Pharmacist
CONFIDENTIAL | Survey number | |
Shared Care And Hi-Tech 
Health Care At Home 
Questionnaire
\The questionnaire will take approximately x minutes to complete. If you do not know the answer to a 
question just leave it blank and go on to the next one. If there is someone that I can contact who might 
jknow any missing answers please give a contact name and telephone number.
I'To complete the questionnaire please write in the boxes provided, delete yes or no as required or tick 
the appropriate box. If  more than one answer applies please tick all appropriate boxes. If you feel an 
answer might need an explanation, please feel free to add additional comments.
Thank you
Please return in the stamped addressed envelope to: 
Miss Jill Loader, Pharmacy Office, Mount Gould Hospital, Mount Gould Rd, 
Plymouth PL4 7QD 
S  01752-272588
What is your job title? (please tick)
Medical Advisor a
Pharmaceutical Advisor □




Do you have a shared care committee or equivalent in your area? (please ring) yes/ no
Question 2
If yes, which professional groups are represented on the committee? 
If no, go to question 4 (tick as many boxes as necessary)
General Practitioners
Health Authority Consultants in Public 
Health
Health Authority Medical Advisers
Health Authority Pharmaceutical 
Advisers





















a) When was the shared care committee formed? (year)
b) What was the subject of the first guideline it ageed?
c) When was it produced? (year)
a ,
CONFIDENTIAL | Survey number
Question 4
Do you h ave a shared care guideline in your area for the following drugs/ conditions?  
fitick as many boxes as necessary)
jrug/condition agreed and in u se informally agreed
arythropoetin □ □
cyclosporin □ □
alpha interferon □ □
aeta interferon □ □
nethotrexate a □
lo m e  antibiotics □ □
lorne parenteral nutrition a a
io m e  chem otherapy □ □
anteral feeding □ □
anticoagulants □ □
j is e a s e  modifying drugs 
-heumatology
□ □




cystic fibrosis □ □
epilepsy □ □
jsychiatric disorders □ □
erminal illness □ □











































Which aspects of shared care have been successful in your area?
Question 6
Which aspects of shared care have been difficult or problematic?
Question 7
\ny further comments you would like to make about shared care?
ection 2
Hi-tech health care at home
uestion 1
d w  m any patients under the care of your Heath Authority currently receive hi-tech health care at hom e, 
accord ance with EL(95)5, in the following groups?
num ber over  
th e  p a st 3
y ea rs  current expenditure  
(including num ber March ’9 6 -  
current) April’97
Patients with renal failure receiving CAPD
C ystic fibrosis patients receiving intravenous or 
nebulised  antibiotics
C ancer patients receiving intravenous 
chem otherapy a g e n ts
HIV patients receiving intravenous or nebulised  
anti-infectives ••
P atients receiving TPN or various typ es of 
sp ecia lised  enteral feed
T hallassaem ics receiving desferrioxam ine
Other, e g  antibiotics for other conditions, asthm a  
patients, p le a se  specify .
luestion 2
/h o  is currently resp on sib le  for contracting for ‘h i-tech  h om e therapy*?
[uestion 3
10 you know of any fundholding G P s in your area  w ho directly purchase hi-tech health care at
om e for their p atien ts?  (please ring) y e s /  no
so  p le a se  specify  for which condition, from w hom  do they purchase this care and for how  
lany patients._______________________________________________________________________
Question 4
Who provides the following to the patients receiving home care in your area? (Please tick as many as 
necessary)
nursing services drugs Other equipment/ 
supplies
commercial home care company a □ □
acute trust a □ a
community trust □ a a
combined acute/community trust a a a
combination of the above, please a a a
other organisation, please specify Q a a
-  •
Question 5
Does the health authority have future plans for the care of these patients? (please ring) yes/ no
If yes, who do you plan to contract with (please tick)
• commercial home care company □
• hospital trust □
• community trust □
• combination of the above, please specify a
• other, please specify □
lestion 6
lich aspects of ‘hi-tech healthcare at home* have been successful in your area?
[uestion 7
Vhich a sp e c ts  o f hi-tech health care at hom e h ave b een  difficult or problem atic in your area?
Question 8
:urther com m ents on hi-tech health care at hom e
Please tick if you would like a summary of the results obtained from this questionairre 
Your name and address (if you would like to give it)___________________________
Thank you for spending the time to 
complete this questionnaire
Please return in the stamped addressed envelope to: 
Miss Jill Loader, Pharmacy Office, Mount Gould Hospital, Mount Gould Rd,




Mount Gould Hospital, 






I am a pharmacist working in Plymouth and am researching the current position in the United Kingdom on 
‘shared care’ between primary and secondary care and ‘hi-tech health care at home’. The work is for an 
M.Phil. project registered with the University of Plymouth and sponsored by the NHS Executive.
My aims are to find out, for shared care
• which areas have managed to develop and implement shared care guidelines
• who is involved with drawing up and agreeing the guidelines
• whether a specific committee has been formed to facilitate the introduction of shared care
• what are the future goals in the area of shared care
• which aspects of shared care have been successful
• which aspects have been difficult or unsuccessful
and for hi-tech healthcare at home
• to what extent patients are being treated in their homes with ‘hi-tech’ therapies
• who is currently providing the various aspects of their care
• whether there are geographical or demographic trends in ‘hi-tech’ home care in England
• how much is being invested into the caring for these patients at home nationally
I will be sending this questionnaire to medical and/or pharmaceutical advisers of all of the Health 
Authorities in England. The information I receive will be used with other information on demographics, 
expenditure etc to see if there are any correlations between the data you provide and other factors.
I intend to publish an analysis of the information I obtain in a relevant health journal. The data will be 
combined so that data from individual health authorities will not be identifiable. I will be happy to send 
responders a summary of my findings.
The questionnaire will take approximately 10 minutes to complete. If you are unable to complete the 
questionnaire please pass it on to someone else who may be able to.
Thank you very much for your help.
Yours faithfully
^  s
* Y U °
Miss Jill Loader, Research Pharmacist
CONFIDENTIAL | Survey number | | |
Shared Care and Hi-tech 
Health Care at Horne 
Questionnaire
The questionnaire will take approximately 10 minutes to complete. If you do not know the answer to a 
question just leave it blank and go on to the next one. If there is someone that I can contact who might 
know any missing answers please give a contact name and telephone number.
To complete the questionnaire please write in the boxes provided, delete yes or no as required or tick 
the appropriate box. If more than one answer applies please tick all appropriate boxes. If you feel an 
answer might need an explanation, please feel free to add additional comments.
Thank you
Please return In the stamped addressed envelope to:
Miss Jill Loader, Research Pharmacist, Pharmacy Department, 
DerrifOrd Hospital, Plymouth, PL6 ?D H .
«  01752-2725? ?
Section 1
Shared Care
1. Do you have any guidelines in your area for sharing the care of patients between primary and 
secondary care? yes/ no
If yes, for which drugs/conditions? (tick the appropriate box)
drug/condition agreed and in use informally agreed being developed
erythropoetin □ □ □
cyclosporin a □ □
alpha interferon a □ a
beta interferon □ □ □
domase alpha □ □ □
donepezil a □ a
riluzole □ □ □
home antibiotics □ a □
home parenteral nutrition □ □ □
home chemotherapy a □ a
enteral feeding a □ a
anticoagulants a □ a
rheumatology □ a □
diabetes □ a □
AIDS/HIV □ □ □
infertility □ □ □









2. Who is responsible for agreeing and implementing shared care guidelines?
• a shared care committee Ql
• a trust drug and therapeutics committee a
• a health authority prescribing committee □
• other, please specify Q
3. Which professional groups are represented on the committee?
General Practitioners □ Local Medical Committee 
Representatives
□
Health Authority Consultants in Public 
Health
□ Local Pharmaceutical Committee 
Representatives
□
Health Authority Medical Advisers a Trust Consultants □
Health Authority Pharmaceutical 
Advisers
a Trust Pharmacy Representatives a
Contracting Managers/Administration 
Staff
a Other, please specify 
(in box below)
a
4. Which aspects of shared care have been successful in your area?
5. Which aspects of shared care have been difficult or problematic?
6. Any further comments you would like to make about shared care?
Section 2
Hi-tech health care at home
1. How many patients under the care of your Heath Authority currently receive hi-tech health care at 
home, in accordance with EL(95)5, in the following groups?
current approximate annual expenditure
number (will remain anonymous)
(approximately) under £50- £100- over
_______________  £50K £100K £200K £200K
• Cystic fibrosis patients receiving
intravenous or nebulised a n t ib io t ic s ________________________________________________
• Cancer patients receiving intravenous
chemotherapy agents ________________________________________________
• HIV patients receiving intravenous or
nebulised a n t i - i n f e c t i v e s ________________________________________________
• Patients receiving TPN or various types
of specialised enteral f e e d ________________________________________________
• Thallassaemics receiving
desfemoxamine ________________________________________________
• Other, eg antibiotics for other conditions,
asthma patients, please specify. ________________________________________________
2. Is ‘hi-tech health care at home’ as specified by EL(95)5 contracted as part of a bulk contract 
with a provider or as a separate contract by your health authority?
3. Do you know of any fundholding GPs in your area who directly purchase hi-tech health care at 
home for their patients? (please ring) yes/no
4. Who provides the following to the patients receiving home care in your area? (Please tick as 
many as necessary)
nursing services drugs other equipment/ 
supplies
commercial home care company a □ □
acute trust □ a □
community trust □ □ □
combined acute/community trust □ a a
combination of the above, please 
specify
□ □ a
other organisation, please specify □  a  a
5. Does the health authority have future plans for the care of these patients? (please ring)
yes I no
6. Which aspects of ‘hi-tech healthcare at home’ have been successful in your area?
7. Which aspects of hi-tech health care at home have been difficult or problematic in your 
area?
8. Further comments on hi-tech health care at home
What is your job title? (please tick)
Medical Adviser a
Pharmaceutical Adviser □
Other, please specify □
Please tick if you would like a summary of the results obtained from this questionnaire 
Your name and address (if you would like to give it)___________________________
Thank you for completing this questionnaire!
Please return in the stamped addressed envelope to: 
Miss Jill Loader, Research Pharmacist, Pharmacy Department, 






In November 1991 the NHS Executive produced guidance 
on the responsibility for prescribing at the hospital/general 
practitioner interface in the form o f EL(91)127. It 
reinforced the basic premise that the doctor who has 
clinical responsibility for the patient should prescribe and 
focused on the concept o f shared care, emphasising the need 
for proper hand over procedures from hospitals to make 
sure that the general practitioner was properly informed 
and could monitor treatment and adjust dose if  necessary 
based on a protocol for treatment.
As a result of this guidance the South and West Devon, Cornwall and Isles of Scilly Shared 
Care Working Group was formed and has been working on the development of such shared 
care guidelines. The first few of which you should have received.
I would be very grateful for some feedback from you about the locally agreed guidelines and 
the concept of shared care. All information gathered will be treated as strictly confidential. 
The survey number on the top of this form will be used purely for a second mailing to non- 
responders. The data collected will be used to compare GP opinions on shared care with 
those of Health Authorities for a MPhil project sponsored by the NHSE.
This brief questionnaire should take less than 5 
minutes to complete.
Many thanks for your help!
Please return in the stamped addressed envelope provided to:
Jill Loader, Research Pharmacist, Plymouth Post Graduate Medical School,
Pharmacy, Level S , Derriford Hospital, Plymouth. PL6 ?D H
pilot- '
Section 1
Some questions about your experience of the locally agreed shared 
care guidelines.
Question 1
Have you ever seen a shared care guideline produced by the South & West Devon, Cornwall &
Isles of Scilly Working Group? (tick the appropriate box)
□  I have used one or more of the guidelines
□  I have seen a guideline but never used one 
Q  I have never seen one
Question 2
If you have read the guidelines, do you think the information they contain is 
(tick one in each row)
□  very useful Q  not very useful Q
a  too complex □  not complex enough □
Q  too long □  not long enough □
Question 3
a) If you are asked to prescribe specialist drugs initiated by a secondary care colleague of which 
you have little experience, do you
a  generally prescribe it 
Q  ask the hospital consultant to prescribe it
□  prescribe it only if the patient would have difficulty obtaining supplies otherwise
□  prescribe it, providing you have a recommendation from the hospital in writing 
Q  prescribe it if there is a shared care guideline
Q  prescribe it only if the request is accompanied by sufficient clinical information
□  other, please specify  ............................................................................................
Question 5
What drugs/diseases would you most like to have a shared care guideline for? (please specify 
below)




Some questions about your views on the concept of shared care.
Question 1
Please tick the most appropriate box for each statement
strongly agree undecided disagree 
agree
• Shared care is a useful idea so primary and Q  Q  Q  Q
secondary care clinicians are aware of their
respective responsibilities when sharing the care of 
a patient.
• Shared care is the development of something that □  □  Q  Q
has been going on for years.
• Shared care is about transferring care from □  □  □  □
secondary into primary care.
• Shared care guidelines empower GPs to prescribe Q  Q  □  Q
more complex medication.
• Shared care guidelines give GPs the opportunityto □  Q  Q  Q
opt out of sharing the care of a patient for whom
they do not feel qualified to prescribe.
• Shared care is about cost shifting to primary care. □  □  □  □
• The shared care working group is able to suggest □  □  □  □
that a drug is unsuitable for prescnbing in pnmary 
care.
• The concept of shared care is a medico-legal Q  □  □  □
problem.
• Shared care guidelines give GPs the opportunityto □  Q  Q  Q
opt in to sharing the care of a patient for whom they














Have you any further comments regarding shared care?
I would like a summary of your findings. (Please tick) n
Thank you very much for your time.
Please return in the stamped addressed envelope provided to:
Jill Loader, Research Pharmacist, Plymouth Post Graduate Medical School,
Pharmacy, Level 5 ,  Derriford Hospital, Plymouth. PL6 ? D H
APPENDIX
CONFIDENTIAL Survey No • i  *. • j
— :------------------------------------------------------------------------------------------
Shared Care Survey
The NHS Executive produced guidance on the responsibility 
fo r  prescribing a t the hospital/general practitioner interface 
in the form ofEL(91)127.
EL(91)127
•  reinforced the premise that the doctor who has clinical 
responsibility fo r  the patient should prescribe
•  focused on the concept o f shared care
•  emphasised the need fo r proper hand over procedures 
from hospitals to ensure the GP was fu lly informed
•  highlighted the need fo r protocols which the GP could 
use to monitor treatment and adjust doses if  necessary.
Following this guidance the South and West Devon, Cornwall and Isles of Scilly Shared Care 
Working Group was formed and has been working cm the development of such shared care 
guidelines. You should already have received a folder containing the first agreed guidelines.
I would be very grateful for some feedback from you about the locally agreed guidelines and 
the concept of shared care. All information gathered will be treated as strictly confidential.
The survey number cm the top of this form will be used purely for a second mailing to non- 
responders and to send out a summary of my findings where requested. The data collected will 
be used to compare GP opinions cm shared care with those of Health Authorities, obtained from 
a national survey, for a MPhil project sponsored by the NHSE.
This brief questionnaire should take less than 
5 minutes to complete.
Many thanks for your help1
I *
Please return in the stamped addressed envelope provided to:
Jill Loader, Research Pharmacist, Plymouth Post Graduate Medical School,
Pharm acy, Level 5 ,  Derriford Hospital, Plymouth, PL6 £ D H .
Section 1
Some questions about your experience of the locally agreed shared 
care guidelines.
Question 1
Have you ever seen a shared care guideline produced by the South & West Devon, Cornwall & 
Isles of Scilly Working Group? (tick the appropriate box)
□  I have used one or more of the guidelines 
a I have seen a guideline but never used one 
Q J have never seen one
Question 2
If you have read the guidelines, do you think the information they contain is 
(tick one in each row)
a) □ very useful a
b) Q too complex a
c) □  too long a
Question 3
a) if you are asked to prescribe specialist drugs initiated by a secondary care colleague of which 
you have little experience, do you generally: (tick one or more)
□  prescribe it
a ask the hospital consultant to prescribe it
a prescribe it only if the patient would have difficulty obtaining supplies otherwise
□  prescribe it providing you have a recommendation from the hospital in writing 
Q  prescribe it if there is a shared care guideline
□  prescribe it providing it is not too expensive
a prescribe it only if the request is accompanied by sufficient clinical information 
a other, please specify...............................................................................................
Question 5
What drugs/diseases would you most like to have a shared care guideline for eg. risperidone, 
DMARDs ?(please specify below)
of some use U  not veryuseful
about right Q  not complex enough
about right □  not long enough
Section 2
Some questions about your views on the concept of shared care,
Question 1
Please tick the most appropriate box for each statement
strongly agree undecided, disagree 
agree
• Shared care is a useful means of defining the Q  Q  Q  Q
respective responsibilities of primary and secondary
care physicians.
• Shared care is the development of something that □  □  □  □
has been going on for years.
Shared care is about transferring care from □  Q  Q  □
secondary into primary care.
Shared care guidelines empower GPs to prescribe Q  Q  Q  Q  
more complex medication.
• Shared care guidelines give GPs the opportunity to □  Q  Q  Q
opt out of sharing the care of a patient for whom
they do not feel qualified to prescribe.
• Shared care is about cost shifting to primary care. Q  Q  Q  Q
• The shared care working group is able to suggest Q  Q  Q  Q  
that a drug is unsuitable for prescribing in primary 
care.
• There are unresolved medico-legal problems when □  □  □  □
sharing the care of a patient with a secondary care
colleague.
• Using shared care guidelines gives GPs the Q  Q  Q  Q
opportunity to opt in to sharing the care of a patient
for whom they do feel they have the experience to 
prescribe.
Have you any further comments regarding shared care?
I would like a summary of your findings. (Please tick) n
Thank gou very much for your time.
Please return in the stamped addressed envelope provided to:
Jill Loader, Research Pharmacist, Plymouth Post Graduate Medical School,




Thank you very much for agreeing to help code this qualitative data obtained from a 
questionnaire survey of Health Authorities in England. The questionnaires were completed 
by either the Pharmaceutical Adviser, Medical Adviser or Contracts Manager of the Health 
Authority. The response rate to the questionnaire was 87%. I enclose a copy of the 
questionnaire sent out and copies of the original answers, in hand written form will be
available to you at the meeting. The following are the answers to Section 1, questions 4, 5 &
6 .
Abbreviations:
GP = General Practitioner, HA = Health Authority
Qualitative Comments Regarding Shared
Survey Number 1
4 Successful Joint approach between GPs/Trusts and HA.






6 Further comments Not sure what you mean by 'shared care'. We have generic guidelines 
for GPs who are asked to prescribe specialist initiated drugs.
3 and 8 (2 people completed the survey for this HA)
3) The committee has been useful in providing clear guidance to GPs on 
drugs are appropriate for primary care prescribing and giving a clear 
around transfer of care. 8) It's hard to say, some protocols developed but they 
don't seem to see the light of day.
5 Difficult 3) Often contentious debate between the HA and Trust consultants around the
evidence base for the drugs under discussion. Has raised difficult issues around 
funding. Getting consultants from our 5 Trusts(!) to all agree to a shared care 
protocol. 8) Getting the consultants to understand that prescribing and clinical 
responsibility are attached, not separable.
6 Further comments 3) We prefer the term "Transfer of Care" rather than "shared care" -
(if a GP is accepting responsibility for drugs discussed within the 






Development of a traffic light system where; red = hospital only 
prescribing, amber = initially hospital-only for specified period. Transfer 
of care after initial period with appropriate shared care arrangements in 
place and agreement of GP, green = prescribe in primary and secondary 
care.
5 Difficult Development of specific guidelines/protocols for individual preparations.
A 'generic' framework setting out information to be included is currently 
being prepared.
6 Further comments Shared care is not about cost-shifting but about ensuring that
responsibility for prescribing is consistent with clinician responsibility and 
establishing appropriate transfer of care arrangements. Development of 
a shared care protocol/guidance is not in itself a shared care agreement. 
Shared care must be agreed by a clinician and GP on an individual basis 






Within the current climate no area of shared care is easy - the GPs are 
revolting! The DTC for this HA has not so much developed guidelines 
for shared care as put forward advise as to whether or not to prescribe 
(and who should prescribe - consultant or GP) and made relevant 
suggestions as to what to expect from a share care agreement.
Although one of the Trusts in this area have put together a series of 
shared care guidelines - they are not too successful. The emphasis is on 
empowering GPs to look at whether to take on prescribing and if so to 











4 Successful Working with th e .................. (neighbouring) HA generally.











Anything expensive! Also areas such as beta interferon where the local 
consultants don't wish to use the drug.
Survey Number 24
4 Successful Helps transfer of prescribing responsibility - GPs feel more comfortable.
5 Difficult Persuading consultants of need to write them.
6 Further comments -
Survey Number 25
4 Successful Unsure
5 Difficult Seen as a cost shifting exercise and so not fully developed
6 Further comments Not always done on appropriate drugs.
Survey Number 26




Bureaucratic policies. Who will 'pay' for the drug. GPs view shared 









6 Further comments 
Survey Number 30
Home Parenteral Nutrition
4 Successful We successfully produced a document outlining process and the drugs 
concerned.
5 Difficult We have been unsuccessful in implementation. The committee was not 
seen to be "high-powered enough". Trust chief pharmacists seem unable 
to implement formulaiy management at hospital level. Anything which 








The areas in which shared care has worked are either; a) Those already 
in place before 1995 ie EPO in dialysis patients b) Those introduced as 
a consequence of EL(95)5.
Virtually all other areas but especially neurology/psychiatry drugs.
Developing shared care guidelines is an important part of this Authority's 
approach to the managed introduction of new drugs and technologies.
Survey Number 32
4 Successful Not much.
5 Difficult
6 Further comments
Consultants don't know what GPs need to know to take on clinical 
responsibility.
Survey Number 33
4 Successful Agreeing a policy for defining shared care drugs and criteria for 
developing "shared care" policies.
5 Difficult
6 Further comments






All, GPs see it as cost shifting. Really we are in the early stages of 
development of shared care guidelines. We may introduce a traffic light 
system for prescribing like they are doing in .......... HA.
Survey Number 35




Often identifying the need for protocols. Attitude is often "I am a 
consultant, so do as I say and prescribe drug x because the hospital 
cannot afford it!"
Survey Number 36





4 Successful Constructive discussion. Understanding of problems facing GPs by 
consultants.
5 Difficult Prescribing outside product licence. Shared care vs cost-shifting.
6 Further comments Care can really only be "shared" when GP’s have the ability to alter 







4 Successful Development and agreement on the principles and recommendations as 
to how shared care prescribing should be undertaken.
5 Difficult Ownership, developing specific guidelines for drugs/conditions.
6 Further comments
Survey Number 40
4 Successful Gaining joint agreement from GPs on the key drugs for hospital only 
prescribing and top slicing GP budgets to pay for the change. (100% GP 
fundholders in HA)
5 Difficult Gaining joint agreement with other HAs so that approaches are 
standardised for Trusts. Communicating the facts (eg funding will follow 
from GPs to Trusts, FP10(HP)s will avoid need for patients to get 
supplies from hospital) to Trusts and consultants in particular.
6 Further comments Clinical and prescribing responsibility can not be separated. Must 
therefore TRANSFER rather than SHARE these aspects of care 
between primary and secondary care. There will always be a need to 
update positions as clinical knowledge advances and GPs gain confidence 
and become increasingly competent to prescribe.
Survey Number 41
4 Successful Diabetes
5 Difficult with high cost drugs GPs suspect they are being asked to ‘share care’ merely
to fund the medication. Often this is correct.
6 Further comments
Survey Number 42
4 Successful Although I have not seen any written guidelines areas such as diabetes 
and asthma appear to work well.
5 Difficult Increasingly problems with renal transplant patients eg. cyclosporin and 
epo. GPs also increasingly reluctant to prescribe GnRH analogues for 
prostate cancer.
6 Further comments True shared care in some instances is very difficult to achieve with 
respect to prescribing. Frequently what you are talking about is 
TRANSFER of responsibility to GP as opposed to shared responsibility. 
The whole area of shared care seems to have become caught up in the 
"core - non core" political debate.
Survey Number 43
4 Successful Process involved in setting up guidelines to be tested by audit. Not yet 
done (!)
5 Difficult
6 Further comments Through good communication setting up of guidelines developed so far 
has worked well with hard work.
Survey Number 44
4 Successful In all areas where guidelines are in place they have been welcomed from
primary and secondary care.
5 Difficult Difficulty with fundholding practices in transfer of prescribing due to lack
of understanding on their part of what is and what is not agreed.
6 Further comments_____________________________________________________________________
Survey Number 45
4 Successful Very few implemented successfully.
5 Difficult Most
6 Further comments It's a political fudge to resolve a mismatch of resources.
Survey Number 46
4 Successful For whom? It is really difficult to answer this properly (phone). [Very complex 
issue. Shared care means different things to different people. Looking cynically it has been quite a 
success for the hospitals instead of truly sharing care what happens is that the hospital consultant 
decides what should be prescribed and asks the GP to prescribe it. This is an unsubltle form of cost 
shifting. We have about six shared care guidelines based around conditions such as diabetes, asthma, 
hypertension where the aim is to make sure everyone is doing the same thing. As it makes sense that 
they should be. This ensured that patients are receiving equitable care. The hospital doctors and GPs 
can then follow the guideline and know where they stand and who is responsible for what.]
5 Difficult All o f it!






4 Successful We have some shared care protocols and we have a pilot running in
which the GP drugs budget has been top-sliced and money is given to 
the consultants to provide drugs which should be consultant prescribed.
(Copy of guideline attached - but wasn't!)




5 Difficult Cost shifting to primary care. Poor communications. Lack of
acceptance that GPs hold responsibility for prescribing. Issues of 
core/non-core services for GPs.
6 Further comments Need to overcome medicolegal responsibility. ?how? Use resources (ie
more resources) to support best clinical practice ie usually consultant 
prescribing. This is an area of interest for our HA -re virement. Please 
ring for further info. [ Virement project giong on. Intention was to do a large 
project but this has been scaled down due to lack of funding to two practices 
running a pilot project. The aim is to make sure that the prescribing is done in 
the most appropraite place. If a GP feels that he does not have the clinical 
knowledge necessary to take on prescribing a high cost drug the Trust 
prescribes it and invoices the GP fund holder. This system has been used for
erythropoietin and growth hormone which are both on the high cost drugs list so 







EPO, cyclosporin, goserelin 
Growth hormone, IVF, Thalidomide
I am not convinced that it is working. It remains a cost-shifting exercise 
and fails to resolve the medico-legal problems with GP prescribing.
Survey Number 51
4 Successful
5 Difficult New drugs prescribed in secondary care and patient discharged without 
discussion between GP and consultant. Appears consultant gives no 




4 Successful Only get to know when there are problems!
5 Difficult Hospital doctors do not always communicate adequately and in an 
appropriate time scale with the GPs. GPs contact me complaining that the 
first they sometimes hear of a patient on these high cost drugs is when 
the patient requests a supply or in a brief letter from the hospital asking 
them to prescribe. Shared care in the true sense is often not really 
shared and often problematic.
6 Further comments Shared care guidelines are not always followed even when they exist. 
Shared care should be on an individual patient basis and on individual 
communication made between the secondary care doctor involved. The 
patient should not be told that a GP will prescribe unless the GP has 
already made an agreement to do so. Adequate patient specific 
information must be made available to the GPs to enable safe prescribing 
and monitoring - not just a data sheet copy! Shared care must be seen 
as being in the best interest of patients and not a cost shifting exercise - 





Most of the drugs mentioned here come from tertiary centres and the 
consultant from the centre discusses sharing the care directly with the GP 
concerned. There are some regionally prepared guidelines available.
HA does not really get involved.
Survey Number 55
4 Successful
5 Difficult Getting the concept accepted particularly by Trust consultants. Getting 







Regional protocols currently in use. Development of specific committee 
agreed 7/97 first meeting is in September 97.







4 Successful Very few, except now have our act together about new drugs.
5 Difficult Tertiary centres cause the problems most, especially communication on 
issues about prescribing responsibility. It doesn't really work.
6 Further comments We have guidance for GPs about how to accept shared care.
Survey Number 61
4 Successful new in post cannot comment
5 Difficult
6 Further comments
new in post cannot comment
Survey Number 62
4 Successful Can't comment - at very early stage of development.
5 Difficult
6 Further comments
Can't comment - at very early stage of development.
Survey Number 63
4 Successful epo
5 Difficult alpha interferon for hepatitis C. Infertility (too many providers - lack of 
policy especially re private IVF).
6 Further comments We would like to move towards TRUE shared care (not simply shifting 
the costs to GPs). Shared care will have prescribing in the most 
appropriate place for the patient and the therapy.
Survey Number 64
4 Successful Alpha/beta interferon, protocols have been written, prescribing is by a 
named consultant at the hospital and the service is managed by 
Caremark who deliver to patient's homes. This is therefore a 
home-based service and was the first service of this sort to be set up.
5 Difficult Treatment of cystic fibrosis as many of the antibiotics used are outside of 
licensed doses. We are looking to see if we can move prescribing back 
into secondary care (the funding for this will also move).
6 Further comments Much of the work of the therapeutics committee is aimed at the 
managed entry of new drugs. Shared care may or may not be 
appropriate depending on individual cases. We as a HA will support a GP 
who does not wish to take prescribing and therefore medicolegal 







clinical responsibility, communication between Trust and GP, financial 
arrangement
Survey Number 66
4 Successful Managed entry of drugs.
5 Difficult Compliance of Trusts and consultants and use of guidelines.
6 Further comments
Survey Number 67
4 Successful Too early to evaluate
5 Difficult Inconsistency among GPs about what prescribing they will accept. 
Inconsistency amongst Trusts about what drugs they wish to pass to 






6 Further comments I feel the whole issue of "shared care" needs to be revisited. I feel the 
term is being misused for written protocols which give a safety net for 
consultants when transferring patients back to GPs with a request to 
prescribe. My interpretation of shared care is an agreement between a 
consultant, a GP and a patient as to the most appropriate place for them 
to receive certain aspects of their care. On the whole this isn’t achieved 
by "shared care protocols".
Survey Number 69
4 Successful The development of arrangements for use of beta interferon in MS 
seemed to be quite successful.
5 Difficult Prescribing issues in mental health currently proving to be difficult. 
General reluctance to take on shared care for certain groups of mentally 
ill patients following publication of GMSC paper "Mentally Disordered 
People: Continuing Care in the Community". Fertility issues cause 
general problems because of the difficulty of private services.
6 Further comments General impression that hospitals (particularly tertiary centres) have not 
developed their views on shared care. Still there is a view that GPs will 
automatically take on the prescribing for all drugs regardless of the 
clinical responsibility issues. Good evidence for this is provided in Rob 







asthma guidelines development (so far)
1. Where it is motivated solely by drug price. 2. Defining what each 
share is, not just what is shared. 3. Evaluation
Motivation should, to my mind, be increased compliance with good 
practice. It often isn’t. Where it is, the investment in audit is usually 











Examples where difficulties arise usually relate to where prescribing is 






Borderline issues, enteral nutrition. (Hoped it would fit into the HTHH 
package of care but didn't). Agreement between GPs and local providers 
reached. Some GPs still not happy. Education issue as increase in 
secondary care use of enteral feeding especially post-stroke and GPs 
have not kept up with the advances.
Survey Number 74
4 Successful Difficult to say!
5 Difficult Money!!






First "hurdle"- assessment of effectiveness and cost effectiveness - 
insufficient data - time consuming. Response of Trusts when shared 




5 Difficult Reimbursement arrangement for GPs who take on the prescribing of 
particularly expensive drugs. We have a contingency fund to try and 
reimburse 100% of "high cost drugs" but this cannot be guaranteed at the 
time when GPs need to decide whether or not to prescribe.




6  Further comment
77
Erythropoetin, Growth Hormone
Where hospitals/consultants in different HA.
Survey Number 80
4  Successful Second line rheumatology drugs - good communication.
5 Difficult
6  Further comments
EPO now becoming hospital only, others may follow?
Survey Number 82
4  Successful beta-interferon
5 Difficult
6  Further comments
all others
Survey Number 81
4  Successful erythropoetin
5 Difficult clozapine






ALL -Trusts find it difficult to manage variation in GP’s willingness to 





6 Further comments not applicable
Survey Number 86
4 Successful Not been in post long enough to know!
5 Difficult Not been in post long enough to know!
6 Further comments Shared Care tends to be provider led. More involvement of primary care 
and greater emphasis on disease management may make shared care 
more effective.
Survey Number 87
4 Successful Many GPs have been happy to extend their knowledge and participate to 
a greater extent in their patients care, good working relationships have 
been formed.
5 Difficult Clinical responsibility. Financial difficulties ie inability to vire money from 
one budget to another. Medicolegal issues - prescribing responsibilities. 
Patients being "removed" from GP lists once their care has become too 
expensive or difficult. Many consultants seem to think that GPs should 
just do what they are told - this only damages the enthusiasm of those 
GPs who wish to participate.
6 Further comments I think that "shared care" is really only a delaying tactic to facing up to 
the rationing debate. In MANY cases there would not be an argument
about shared care if the drugs were inexpensive. It is an elaborate and 
time consuming way of trying to equip GPs to take on roles which hospital 






At the HA we do not really believe in the term "shared care" as regards 
guidelines or rules - we encourage dialogue between GPs and clinicians 
directly.
Survey Number 89
4 Successful Restricting therapy to appropriate patients. Ensuring that therapy is 
available for appropriate patients. Ensuring that therapy is monitored.
5 Difficult
6 Further comments





6 Further comments We have agreed guidelines with Trusts and specialists on several drugs 
but not shared care ie specialist will prescribe only. Need to define what 
you think shared care is to get an accurate response.
Survey Number 93
4 Successful Very few - still largely an exercise of cost-shifting on part of Trusts.
5 Difficult View of hospital consultant of "why should we have to discuss/agree this 
with GPs in advance. We just tell them and they should prescribe it"!!!
6 Further comments Unlikely to work properly until all funding from same pot.
Survey Number 96




Top slicing primary care budget to transfer EPO to secondary care. 




5 Difficult I was surprised that clozapine had been agreed. A number of GPs have been 
unhappy to take on prescribing usually for financial reasons. We are finding
it difficult to get the consultant rheumatologists to produce tight shared
care guidelines.
6 Further comments This questionnaire is not very well designed, many of the drugs overleaf have 
been discussed to decide whether they are shared care and decisions have
been made to keep them in tertiary care. This is not asked. You do not
know from your results whether the drugs have been discussed- perhaps





6 Further comments We have no formal shared care guidelines however informal ones are






Whole section not applicable as no shared care guidelines.
Survey Number 100
4 Successful Usually better communication. GPs are reimbursed through contingency 
reserve if drug is high cost and shared care prescribing has been agreed.
5 Difficult Shared care being used as a route primarily for cost shifting. Judgement 
as to whether to prescribe should be up to the individual GP based on 
clinical parameters though consultants sometimes exert pressure on GPs 
to prescribe when the GP is not happy to accept responsibility.
6 Further comments
Survey Number 101
4 Successful The process of developing agreed approaches to disease management 
between specialists and generalists (both GPs and non-specialist 
consultants) has opened communications between these groups on many 
fronts. It has provided a useful cornerstone to developing the input of 
professionals into Trust and HA management.
5 Difficult Trying to develop shared care around one drug - too focused and often 
'sides' develop with entrenched (usually financial) positions. Also the 
development of shared care which is very strongly led by secondary care 
(and usually GPs see no need for shared care) - the shifting of care 
from secondary to primary care sectors is not an appropriate basis for 
the development of "shared care"!!
6 Further comments We don't view it as a 'separate' entity but as part of an evidence based 
approach to commissioning, then allowing care to be delivered in the 




5 Difficult Agreeing contingency guidance for situations where GPs legitimately 




4 Successful GPs do take on the prescribing of "specialist" drugs but not with a formal 
shared care protocol.







Management of Hep C and the clinical responsibility and thus appropriate 
funding for: Riluzole, Domase alpha, alpha and beta Interferon ie the 
high tech drugs.
1. Arrangement of funding through contracts. Still an issue for Trusts 
cost-shifting to GPs even though a policy has been drawn up. 2. Ensuring 
that all of the parties are aware of the shared care ie communication
Survey Number 105
4 Successful See list.
5 Difficult
6 Further comments




5 Difficult Transfer to secondary care of clinical and prescribing responsibility.
6 Further comments Tends not to be shared at all! Simply moving costs to primary care.
Survey Number 107
4 Successful Where clinical responsibility either defined or funded as secondary care, 
or where there are agreed shared care arrangements - few problems.
5 Difficult Some difficulty shifting back clinical responsibility for 
immunosuppresants, particularly cyclosporin in organ transplantation. 
Tertiary centre reluctant because multiple purchasers.
6 Further comments We take a simplistic view that clinical responsibility either sits 
comfortably in general practice or it doesn't - in which case the 
consultant should retain clinical and prescribing responsibility. Shared 





5 Difficult Who has clinical and therefore prescribing responsibility. Mainly 
because this is centres around costs.
6 Further comments Often seen purely as a cost shifting exercise from secondary to primary 
care.
Survey Number 109
4 Successful Collaboration has improved communication and ensured equity of care.
5 Difficult Getting people to meet let alone try & agree. Trust staff particularly 
uncooperative.
6 Further comments Hospital attitude is a serious problem, they do not put forward proposals but 












4 Successful We have managed to separate the issue of shared care from funding. 
Shared care has been used in the past as cost-shifting. True shared care 
is necessary for specialist drugs irrespective of whether the GP pays or 
the HA via contracts.
5 Difficult
6 Further comments
Infertility - the HA will only fund one cycle of drug therapy.
APPENDIX
Coding of Shared Care Data by Hospital Pharmacists
10.30am Wednesday, 11th March 1998
Hospital Pharmacists: Susan Manktelow, Duncan Cripps, Victoria Bendall





Medicolegal - responsibility 4
Education - GP provided with information 5
Principle of Shared Care - What it means, how i t ’s interpreted 18
Shared vs Transfer of Care - any comments on transfer 6
Comment on generic guidelines - how to make a shared care protocol 7
Not used/not successful 6
Early stages - no data to comment on yet 4
Audit- comment on need to evaluate 3
Patient selection - who gets what 2
Framework - appropriate drug primary care prescribing, needs a protocol, drug 16
selection
Co-operation - communication debate, time practicalities, HA <$HA, primary care <=>










TPN 1 6-interferon 2
EPO 5 cyclosporin 2
EL(95)5 2 EPO 3
0-interferon 4 GnRH 1
donepezil 1 growth hormone 1
riluzole infertility 4
infertility 1 thalidomide 1
diabetes riluzole 2
asthma 1 a  interferon 1
cyclosporin 1 cystic fibrosis 1
GnRH analogues 1 mental health 2
a  interferon 1 enteral nutrition 1
enteral nutrition 1 clozapine 1
growth hormone 1 rheumatogy 1
second line rheumatology 1 high cost 1




Coding Shared Care Data Health Authority 
Questionnaire bv Health Authority Staff 5/5/98
successful difficult further
comments
joint approach GPs, Trusts, HAs 5 7
negative comments 11 5
positive comments 1 1
infrastructure/process 9 4 1
negative comment 2 2 1
specific drug 17 13 1
informar agreement 1 1
negative comment 2 1
positive comment 1
specific disease area 7 9 1
informal agreement 1
managed entry of drugs 3 2 1
positive comment 1
uncertain 2




positive comments 1 2
negative comments 5 1
cost see table 2
definition of shared care 2 9
usage/implementation 1 2
positive comments 1
negative comments 1 2 4
evidence based practice 3 2
clinical responsibility 2 13 9
positive comment 1





tertiary referrals 14 2
Coding of Heath Authority Questionnaire Shared Care Data 
Dartington 21/4/98
CO►ST I
successful difficult further comments I
cost shifting 4 16 11
cost (total) 1 7 2
cost irrelevant 1 0 1
cost effectiveness 0 1 °




cost shifting contingencies/top-slicing implemented 3
null 1
cost (total) null 1
cost irrelevant shared care implemented 1
null shared care implemented 1
total 7
Difficult
cost shifting null 12
unified budget suggested 1
contingencies/top slicing implemened 2
shared care implemented 2
1 cost (total) null 7
I cost effectiveness null 1
total 24
Further Comments
1 cost shifting null 6
shared care .................... 1
shared care implemented 3
unified budget suggested 1
1 cost (total) null 2
1 cost irrelevant null 1
null unified budget.................... 1
total 15 I
1 Total comments re cost 47 |
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• difficulty establishing guidelines etc
• lack of clear guidelines
• specific drug
• increased paperwork?
• Lack of leadership
• no comments
• too difficult (individual difficulties not specified)
• tertiary centre
• failure to obey guidelines
• evaluation/audit
• lack of education/knowledge/training
• reluctance to accept responsibility
APPENDIX




re Shared Care and Hi-tech Health Care at Home Survey
Thank you for your response to my questionnaire survey on the subject of shared care 
arrangements under EL(91)127 and hi-tech health care at home provided under 
EL(95)5 distributed last year. I received an outstanding 87% response rate from 
Health Authorities in England.
I have pleasure in enclosing the summaiy of findings from the survey that you 
requested. I have presented some of the findings of the survey at the NPC Conference 
in Hinckley and as a poster at the BPC Conference in Eastbourne this year [1],
Further surveys of general practitioners, regarding shared care, and Trusts and 
commercial home care providers, on the subject of hi-tech health care at home, have 
been completed. The data from these will be synthesised with those obtained from 
this survey to elucidate a broader picture of shared care and hi-tech health care at 
home initiatives in England. I hope to publish this in a relevant journal in the near 
future.




cc Professor Graham Sewell
1. Loader, J. and G. J. Sewell, The Current Position in England Concerning Home-based 
Ambulatory Infusion Provided Under EL(95)5. Pharmaceutical Journal, 1998. 261 
(Pharmacy Practice Research Supplement): p. R42.
Summary of Findings of Health Authority Shared 
Care and Hi-tech Health Care at Home Survey
JiO Loader, Research Pharmacist, Plymouth Hospitals NHS Trust & Post Graduate Medical 
School, University of Plymouth
Aims and Objectives
The main aim of the survey was to find out the current situation in England regarding the 
development of shared care guidelines under EL(91)127 and the purchasing and provision of 
hi-tech health care at home under EL(95)5 from a Health Authority perspective.
The objectives were to find out, for shared care
• which areas have managed to develop and implement shared care guidelines
• for which drugs/diseases
• who is involved with drawing up and agreeing the guidelines
• which aspects of shared care have been successful and which aspects have been difficult or 
unsuccessful
and for HTHH
• to what extent patients are being treated in their homes with "hi-tech* therapies
• which drugs are being used and for which conditions
• who is currently providing the various aspects of their care
• which aspects of HTHH have been successful and which have been difficult or problematic 
Method
• A questionnaire was designed using recognised questionnaire design techniques.
• Piloted in South and West region and design modified based on comments from the pilot.
• Distributed at Regional meetings of Pharmaceutical (and Medical) Advisers to the 100 
Health Authorities (HAs) in England.
• Non-responders followed up by telephone after 6 weeks and 10 weeks.
• The responses were recorded on a database to enable subsequent analysis of the results
• Qualitative data were coded independently by a group of health authority staffs a group of 
hospital pharmacists and a group of trust finance staff.
Results
87 of the 100 HAs in England responded to the survey.
Shared Care
81/87 (93.1%) had some kind of guideline for sharing care between primary and secondary 
care, this included some HAs who had generic guidance and others that had drug or disease 
specific guidelines.
Figure 1 shows the number of HAs with a guideline for the drugs/conditions specified on the 
questionnaire. Erythropoietin was the most common subject of a guideline with 74.7%
(65/87) of the HAs having a guideline formally agreed (41), informally agreed (17) or being 
developed (7). Other subjects of guidelines included growth hormone, psychiatric disorders 
and GnRHs.
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no of HAs with a  guideline
The mean number of guidelines per Health Authority at any stage of development was six. 
These were agreed and implemented by a variety of committees but mostly by a Health 
Authority Prescribing Committee (52). Ten HAs reported that there was a specific shared care 
committee. Representation on these committees was reasonably standard with most including 
GPs, Trust doctors and pharmacists and Health Authority Public Health doctors , Medical 
Advisers and Pharmaceutical Advisers as a minimum.
Comments regarding which aspects o f shared care had been successful included those 
regarding a specific drug or disease state, improved communication/collaboration between 
primary, secondary care and the HAs, the fact that there was a framework/infrastructure 
around sharing care, benefits with respect to the managed entry of new drugs and education of 
GPs.
Aspects which had been difficult or problematic included the perception o f cost shifting and 
funding in general, problems with specific drugs, clinical responsibility issues, problems when 
tertiary providers initiate therapy and communication/collaboration problems.
Hi-tech Health Care at Home (HTHH)
27 out of 87 (31%) were unable to answer any questions regarding the number of patients 
under their jurisdiction receiving hi-tech health care at home or provide information on the 
cost of their treatment.
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The percentage of HAs treating one or more patients with the following home therapies were 
TPN 54%, antibiotics for cystic fibrosis 46%, desferrioxamine 25%, antivirals for HIV 10% 
and chemotherapy 5%. Other hi-tech therapies being given at home included terbutaline for 
asthma, immunoglobulins, enzyme replacement for Gaucher’s Disease and prostacyclin. 
Commercial home care companies and acute Trusts were found to be the main providers of all 
aspects of HTHH (Figure 2).
Figure 2, Provision O f Services To Patients Receiving Hi-tech Health Care at Home 
60 T
■  nursing serv ices
■  drugs
■  other equipm ent/supplies
commercial acute trust community trust combined combination of other
company acute/community above
provider trust
Only 17 out of 87 (19%) HAs had any future plans for the care of these patients and none of 
the HAs knew of any fundholding GP who directly purchased HTHH for their patients.
Comments regarding the aspects of HTHH that had been successful included the fact that the 
HA has been able to shift the responsibility for contracting for HTHH on to the Hospital 
Trusts who some see as being better placed to contract for these services and that the 
contracting process enabled them to achieve better quality of care or cost effective care for the 
patients.
Difficulties included problems with the initial implementation of EL(95)5, funding of new 
patients, as there are no new monies available, problems with tertiary centres and extra- 
contractual referrals, and not knowing whose responsibility the monitoring, audit and 
evaluation of the service is.
Other comments centred around discussion o f cost shifting, clinical responsibility issues, 
defining shared care and convenience for the patient.
Discussion
Shared Care
The development of shared care initiatives have been slow throughout England. It can be seen 
from Figure 3 that there are not large variations throughout the eight regions on the number of 
guidelines in use. Various committees have responsibility for agreeing and implementing the 
guidelines but in the main they are Health Authority led and representation on the committees 
is similar throughout the country.
Shared care guidelines have mostly been developed for high cost drugs such as erythropoietin 
and cyclosporin. They have been successful in improving communication between primary 
and secondary care and have put in place an infrastructure for sharing care and for the 
managed entry of new drugs in some parts of the country. The implementation of shared care 
guidelines has perhaps been slowed by perceptions of cost shifting and transfer of work load
into primary care. GP concerns regarding clinical responsibility may become the main barrier 
once Primary Care Groups have developed to a level where a unified prescribing budget is a 
reality.
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Hi-tech Health Care at Home
This survey has highlighted the complexity of the current contracting procedure for hi-tech 
health care at home under EL(95)5. Some Health Authorities have invited tenders to provide 
the service, whilst others have either continued with arrangements in place before EL(95)5 or 
passed on the responsibility to the local Tmsts. From these data it appears that commercial 
home care companies have the largest share of the home care market in England closely 
followed by NHS Trusts. District nurses working for community Trusts are caring for patients 
receiving HTHH in some areas of the country. Intravenous antibiotics for cystic fibrosis and 
home TPN are the major infusions being provided in the domiciliary setting. It is unclear who 
is monitoring the quality o f service received by patients or patient outcomes.
The large number of HAs that were unable to answer any questions regarding patients under 
their jurisdiction being treated with hi-tech infusions in their homes is of concern given that 
the HAs were the bodies charged under EL(95)5 with the responsibility for purchasing 
“packages of care” for these patients. This might however be a limitation of the survey in that 
the questionnaire may not have been targeted at or passed on to the correct person within the 
Health Authority. The absence of monitoring of contracts or patient outcomes, highlighted by 
the qualitative data is worrying as this could result in poor patient care.
In order to establish the full picture regarding HTHH in England it is necessary to obtain 
information, not just from the purchasers but also from all providers of “hi-tech” home care, ie 
commercial home care companies and Tmsts. This is the subject of further work of this 
project.
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behaviour and learning disabilities 
methylphenidate 

































see also cyclosporin and 
immunosuppressants.
















































new cardiac drugs 1
What drugs/diseases would you most like to have a shared care guideline for?
Other comments
Drugs usually initiated in secondary care of which GPs have little experience 8 
New drugs 7
Expensive/high cost drugs 7
None/don’t want any more 6
Drugs which need monitoring 3
No views/don’t know 3
Already covered/happy with what’s available 
Complex drugs
Drugs with multiple side effects
Would rather secondary care prescribed the drugs
Yes
Should have individual one for each patient 1
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Transfer of workload including shared care guidelines should be 
properly funded. Local agreement in place = guideline->LMC/HA 
negotiating committee->price for work if money available can be 
purchased. LMC Neg Comm Member!!
13
transferring - most care is primary care 
19
It would be most convenient to have an A5 sized sheet attached to 
the specialist letter giving the guideline which would be kept in that 
patient's notes - rather than yet more paperwork needing yet more 
filing on yet more shelves that need to be put up somewhere etc etc
27
regret no time to complete this 
47
This is cost-shifting with no shifting of funds from secondary care 
into the primary care prescribing budget. We are personally 
critisised by consultants if we do not prescribe all these drugs when 
asked by consultants, our drug budget will be overspent and we 
will have to cut back in other areas.
61
shared care is never going to work happily until there is a shared 
prescribing budget!
62
It isn't just the prescribing it's the associated unwanted workload.
64
Excellent innovation - shared care guidelines. Redress 




















v nice questionnaire, simple, easy and clear 
70
We sometimes seek opinion of Health Authority Pharmacy 
Department Advisers ie Dr Shivaun Gammie
73
I remain unhappy about prescribing specialist drugs which I am 
unfamiliar with. We do not have enough patients on the drugs to 
become competent with their use. The guidelines may be the way 
forward. I will find out when I use them.
79
should not be about cost shifting 
81
The shared care guidelines should be available in electronic form - 
else they are far too cumbersome!
87
Any guideline should be 1. very concise if thought essential 2. not 
talk down to primary care team 3. refer to existing information 
sources eg BNF & Martindale 4. clearly define the primary care 
role desired by specialists 5. not be a means of transferring costs 
from hospital to primary care budgets 6. not be a way of making 
the primary care team soley responsible medicolegally.
112
Shared care is about much more than prescribing drugs.
Guidelines are seen as a way of getting GPs to write prescriptions 
for specialists.
129
Shared care seems an under the counter way of shifting costs from 
hospital trusts to primary care.




















Shared care guidelines sometimes seem like a convenient excuse 
for GPs not to prescribe perfectly reasonable drugs suggested by 
secondary care (who have no budget to prescribe them on an 









I suspect the guidelines are so long and turgid that few primary and 
even fewer secondary care doctors will refer to them regularly.
158
It's about transferring costs not care. To date it seems to have 
been a cost shifting exercise - not just for drug costs but the follow 
up bloods etc. We pay our staff from our own pockets to the 
tume of 30%. Consultants don't. Time to stop the budget 
boundaries I think. Also the psychiatrists are sending patients out 






'make' would be a better word than empower. I sincerely hope 
you don't intend to fill that folder!


















Due to pressure of work Dr xxxxx is no longer completing 
questionnaires.
271
Danger of cost-shifting from secondary to primary care without 
transfer of resources is that secondary care will continue to be 
underfunded - effectively subsidised by primary care funds, and 
that primary care funds will continue to be eroded putting more 
pressure on primary care budgets. If cost shifts are identified they 
usually only consider drug costs and ignore costs incurred by extra 
GP workload & nurse/phlebotomy/pathology handling 
results/dealing with problems or side effects etc. Is it any wonder 
primary care is becoming more stressful!
276
Note the consultant who has issued a consultant only drug (very 
expensive too) is still refusing to prescribe it himself (taking no 
notice of the guideline) - quite awkward for me.
277
Monitoring of drugs is not simple in general practice - it can be 
time consuming monitoring side effects.
286
Good communication with hospital doctors over individual patients 





Guidelines are long and repetitive. Punchy, short bulletin point 
cards would be easier to use.
362
More work for GP. Shifting cost to GP. More responsibility. More 
chance of litigation.














"Integrated care pathways" is the current buzz word, isn't it? Isn’t it 
all just bollocks? We’re haggling over whose budget it goes on 
involving incalculable committee time which has a finite cost and 
comes out of the various NHS budgets when, in they end, there is 
an overall health budget. This is a silly Tory game which just keeps 
getting sillier.
376
I am not confident about prescribing these medications and will, as 
much as possible, defer to the relevant consultant about 
interactions with the patient's other medication. I need the 
consultant to overview it; ie I am not happy about shared care and 
will avoid it as much as possible.
167
Methylphenidate - the patients are being seen regularly in 
secondary care and I see little point in the GP issuing the 
prescriptions, as we do not control the dosage/other therapies.
EPO - again, the patients are being monitored in secondary care, 
and I see little point in devolving to the GP apart from cost transfer. 
2nd line antirheumatics I see a much stronger case for monitoring 
and prescribing being undertaken in primary care, due to chronicity 
of prescribing, lack of resource in secondary care, and the number 
of patients taking these agents. Anticoagulation - seems entirely 
appropriate to be monitored in primary care.
53
Needs to be on a case by case basis and excessive burden of 
detailed paperwork is not appropriate. We are responsible for 
correctly prescribing and monitoring as recommended only.
215
empower GP’s to prescribe more complex medication - 1 hope 
not!
216
It is for me not an important issue that of taking the responsibility of 
prescribing. I think that cost is a driving factor (previously it did 
not mind).












Sony I am burnt out with questionnaires! I must get back to the 
patients.
355
Generally if a consultant recommends a treatment I prescribe that 
treatment whether or not I have experience in using that drug, for 
example, I have a liver transplant patient on tacrolimus - the tertiary 
care centre in London do not provide the regular presciptions for 
this, I do. I understand that signing the prescription is my 
responsibility but the monitoring of the doses and the disease is not 
I think there is generally still great confusion regarding the GPs 
responsibility for prescribing "specialist" drugs. If the GP 
INITIATES a specialist drug the responsibility for the monitoring/ 
further legal ramifications is clearly the GPs - but I do not think that 
this should be the case if the consultant recommends the drug in 
the first place. Unless the consultant is happy to develove 
responsibility I feel that the consultant should retain responsibility 
once he/she has prescribed the drug.
244
Shared care can become NO care with the patient a political pawn 
in the middle. Shared care is seen as a means of transferring work 
from secondary to primary care and the cost thereof.
15
cost shifting "inevitable" It is useful as it helps to keep one'updated 
about new treatments and best care for patients.
359
Transferring "dumping". Going on for years - "if you mean the 
activities of the committee". I wonder what you really think has 
changed. It is unlikely that this issue will ever be resolved, and 
given the small amount that it represents in the total budget of little 
significance other than medicolegal. I would rather see 
responsibility retained by the initiating prescriber. Let’s have a sea 
change in the wway we purchase and supply drugs!














Unfortunately the current guidelines came out too late for some of 
the drugs that I had already started to prescribe (after being 




Shared care working group are under pressure to get it into 
primary care. I do not see any reason why the hospital cannot 
prescribe the drugs concerned either on a yellow script ( I can't 
remember it's code) or through repeat dispensing through the 
hospital pharmacy - but then of course the hospital would have to 
pay for it!! and that's the whole point - it's all about buck passing 
and budget shifting.
121
Most times I am asked to prescribe by the hospital without proper 
notification or literature on the drug in question.
182
Shared care often means being placed in a situation of emotional 
blackmail by hospital to prescribe drugs you are not happy to 
prescribe, but the implication is if you don’t prescribe the patient 
will not get the treatment. All letters say that helping out is only 1 
or 2 patients a month but from every speciality this placea an 
increasing amount of work on GPs who are already working flat 
out and we cannot ration care by having waiting lists unlike our 
hospital colleagues. More work for GPs should produce more 
income to employ more GPs nurses to provide more appointments. 
GPs can not take on more and more work to help reduce hospital 
waiting lists.
234





















It is important that consultants abide by shared care guidelines and 
that consultants out of area abide by OUR shared care guidelines - 
this is NOT happening at present. If there is a gap between 
consultant care and GP care that must be budgeted - and primarily 
from the secondary care side until communication and agreement 
has been reached.
49
Each time we have new guidelines this increases the amount of 
specialist knowlegde a GP is expected to hold. Where will it end 
Will we do away with secondary care routine follow-ups?
206
At present consultants still recommend drugs to be prescribed with 
no regard for shared care protocol.
321
The issue of shared care is not just about clinical responsibility. 
There is a significant cost in terms of doctor, nurse and admin time 
associated with treatement currently this cost is NOTbeing met by 
the Health Authority.
44
My brain is too exhausted to cope with all this. Sorry.
166
transferring care and responsibility and cost, cost shifting and 
work load shifting. Would like more hospital care and more 
shared care NOT a generalised shift of responsibility, cost and 
workload.
105
One often feels normally pressurised into prescribing by hospital 
and/or patient. The PRESCRIBER has the legal responsibility 
even if hospital recommended.
304
I am on the Shared Care Guidleines Committee.
52
I didn’t sign up to shared care protocols.
Page 8 o f9
survey no 159
further comments Touch repetitive on the wording, ? more concise 
survey no 3 6
further comments Not completed as I have already completed one and returned it.
Page 9 of9
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re General Practice Shared Care Survey
Thank you for your response to my questionnaire survey on the subject of shared care 
arrangements under EL(91)127, sent out in May this year. I received an outstanding 
59% response rate from the General Practitioners in South and West Devon.
All of the comments you sent in have been anonymised and fed back to the South and 
West Devon, Cornwall and Isles of Scilly Shared Care Working Group.
I have pleasure in enclosing the summary of findings from the survey that you 
requested.




enc General Practice Shared Care Survey - Summary of Findings
GP Shared Care Survey - Summary of Findings
Objectives
Survey of all GPs in South and West Devon to:
• establish if the local procedure for the development of guidelines is successful
• establish whether the guidelines being produced locally are what the GPs want
• find out the opinions of local GPs on the “concept” of shared care
Method
• Designed questionnaire using recognised questionnaire design techniques.
• Piloted on 5 GPs and modified design based on comments from pilot
• Distributed by post with a stamped addressed envelope to all 371 GPs in South 
&West Devon.
• Second mailing sent eight weeks after first.
• Qualitative comments coded by a group with an understanding of the issues 
involved.
Results
After 2 mailings 18th May 1998 and 13th July 1998 received 218/371 back (59%).
86.7% of respondents had seen a shared care guideline (SCG) produced by the South 
and West Devon, Cornwall and Isles of Scilly Shared Care Working Group.
46.8% of respondents had used one or more of the guidelines.
The guidelines were considered to be of some use or very useful by 99.1% of the GPs 
who answered the question. Most thought the complexity and length were “about 
right” but 19% of those who answered thought the guidelines were too complex and 
29% thought they were too long.
If asked to prescribe a drug of which you had little experience by a secondary care 
colleague 96 respondents said they would prescribe it if a shared care guideline was 
available, 91 would prescribe it if they had a recommendation from the hospital in 
writing and 77 would prescribe it if the request was accompanied by sufficient 
clinical information. 38 would prescribe it and 36 would ask the hospital consultant 
to prescribe it. 24 would prescribe if the patient would have difficulties obtaining 
supplies otherwise and 22 if it was not too expensive.
The drugs and conditions that most GPs said they would like a guideline for were: 
antipsychotics*, drugs used in rheumatology*, methylphenidate*, fertility treatments, 
cyclosporin*, chemotherapy, methotrexate*, drugs used to treat impotence, drugs 
used in the treatment of drug and alcohol abuse and gold*.
*SCGs are available for risperidone, cyclosporin, methylphenidate, penicillamine, 
gold and sulphasalazine. They will shortly be available for olanzapine, methotrexate 
and hydroxychloroquine.
The views of the GPs on the concept of shared care are shown in the graph.
S C G s give G Ps the opportunity 
to  opt in if they feel they have 
the  experience to prescribe
unresolved medico-legal 
problem s when sharing care 
with a  secondary care colleague
working group able to suggest 
drug is unsuitable for prescribing 
in primary care
cost shitting to primary care
S C G s give G Ps opportunity to 
op t out if they don t feel qualified 
to  prescribe
S C G s em power G Ps to prescribe 
m ore complex medication
transferring care from secondary 
into primary care
developm ent of something that's 
b ee n  going on for years
useful m eans of defing respective 
responsibilities of primary and 
secondary  care
Further comments included concerns over responsibility transfer from secondary to 
primary care (16), unresourced workload shift (9) and no organised mechanism for 
transfer o f funding for the drugs (10). There were also some negative comments 
regarding the concept o f shared care generally (9).
Discussion
The local procedure for developing SCGs appears to be successful. Most GPs in 
South and West Devon have seen a guideline and nearly half of the respondents had 
used one. The guidelines produced so far are generally considered useful and about 
the right complexity and length. Six o f the top 10 requests GPs had for guidelines 
have been worked on by the group and will shortly be available to local GPs. The 
respondents are happiest to prescribe a drug o f which they have little clinical 
experience if  a SCG is available.
The views o f GPs on the concept of shared care were diverse. More GPs felt that 
SCGs give them the opportunity to opt in to sharing the care of a patient for whom 
they do feel qualified to prescribe (159) than to opt out if  they do not feel qualified to 
prescribe (116). The largest number o f GPs agreed with the statement that the 
working group is able to suggest that a drug is unsuitable for prescribing in primary 
care and the largest number disagreed that SCGs empower them to prescribe more 
complex medication. The statement that the most strongly agreed with was that 
shared care is about cost shifting to primary care. Concerns about the shift o f 
workload, responsibility and cost came through from further comments made by the 
respondents.
Thank you very much for your help in completing the questionnaire.
□ no answer
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CONFIDENTIAL _ Survey number
Hi-tech Health Cafe at Home 
Questionnaire
This questionnaire will take approximately 15 minutes to complete. If  you do not know  
the answ er to a question just leave it blank and go on to the next one. If  there is 
somone that I can contact who might know any missing answers please give a contact 
nam e and telephone number.
To complete the questionnaire please write in the boxes provided, delete yes o r no as  
required or tick the appropriate box. I f  you feel an answer might need an explanation, 
please feel free to add additional comments.
Thank yo u
1. Do you have the facility for aseptic reconstitution and filling of ambulatory infusion devices in 
your pharmacy department? (delete as appropriate) yes/no
If yes, do you have an MCA “Specials” licence? (delete as appropriate) yes/no
2. Is your pharmacy department involved with the treatment of patients with hi-tech health care at 
home covered by EL(95)5? (delete as appropriate) yes/no
If no, who would provide the care for patients in the table listed overleaf?
Thank you for your help, your answer is an important part of this survey, please 
post the questionnaire back to me in the envelope provided.
If th e  a n sw e r  to  (2) 
w a s  y e s ,  p le a s e  
c o m p le te  th e  ta b le  
for e a c h  o f  th e  
fo llo w in g  g ro u p s  o f  
p a tien ts .
cu rren t
nu m b er
o f
p a tien ts
(approx)
ap prox  
annual 
ex p en d itu re  
(to the 
nearest £25K)
w h ere do  
p atien ts  
receive their  
drug  
therapy?
w h o  a d m in isters  
th e  th erap y?
w h o  is  
re sp o n s ib le  for  
training th e  
patien t?
(T here m a y  b e  m o r e  
than  o n e  a n sw e r  to  
e a c h  q u e s tio n )





















.c y s t ic  f ib r o s is  
a tie n ts  rece iv in g  
itra v e n o u s  
n tib io tic s
.c a n c e r /h a e m a to lo g y  
a tien ts  rece iv in g  
itra v e n o u s  
h em o th era p y  a g e n ts
. HIV p a tien ts  
jc e iv in g  in tra v en o u s  
n ti-in fectiv es
a d u lts  rece iv in g  
>tal p arenteral 
utrition
ch ild ren  rece iv in g  
>tal parenteral 
jtrition
th a lta s sa e m ic  
atien ts rece iv in g  
asferrioxam in e
-
p a tien ts  r e ce iv in g  a 
an tin u ou s in fu s io n  
: a n tico a g u la n t  
ea tm en t










who provides a 24 
hour helpline?














eg. hospital pharmacy, 
commercial homecare  
company
company, primary  
care team
4. W hich a sp e c ts  o f h i-tech health  care at h om e h a v e  p harm acists in your Trust b een  involved  
with?
role 1 very _ s o m e  ! no involvem ent
\ involved involvem ent j (please state who is
: \ responsible)
CONTRACTING
• setting-up the hi-tech health care at home 
program □ □ □ .............................
• costing the program □ □ □ .............................
• market analysis
a □ □ .............................
•  contracting for hi-tech health care at home □ □ □ .............................
•  setting service specifications □ □ □ ............ ..............
CO-ORDINATION AND COMMUNICATION
• co-ordinating the home care program □ □ □ .............................
• with other pharmacists eg in nutrition team □ □ □ .............................
• with other health care professionals □ □ □ .............................
•  with a commercial home care company □ □ □ .............................
• with patients and their families
□ □ □ .............................
• patient referral for inclusion in the home care 
program □ □ □ .............................
• patient selection □ □ □ .......................
EDUCATION
•  d esig n  o f written inform ation for th e patient 
on h o m e infusion therapy
□ □ □ .............................
•  educaton/train ing o f patien ts and their carers
□ □ □ .............................
•  education/training gif o th er health care staff
□ □ □ .............................
•  co m p eta n cy  a s s e s s m e n t  o f patient/carer
□ □ □ .............................
SU PP L Y
• supply o f dru gs e g  antibiotics, heparin etc
□ □ □ . . . .
•  a sep tic  reconstitution  o f drugs, TPN and  
filling of infusion d e v ic e s , syrin ges □
□ □ . . . .
• se lec tio n  o f appropriate infusion pump
□ □ □ . . .
•  m ain ten a n ce  o f infusion pum ps □ □ □ . . .
•  providing oth er item s su ch  a s  infusion  
pum ps, fr id ges e tc
□ □ □ . . .
role very  
| involved
so m e  
involvem ent j
no involvem ent 




• quality a ssu ra n ce  o f hom e infusion program □ □  ■ • ' □ .............................
•  ensuring com plian ce with serv ice  
specifications
□ □ □ .............................
• ensuring com plian ce with appropriate 
regulations, gu id elin es, GMP e tc
□ □ □ .............................
•  quality a ssu ra n ce  o f infusion pum ps
□ □ □ .................... ..........
CLINICAL
•  pharm aceutical a d v ice  to prescriber
□ □ ..........................................................................
•  ch o ice  of appropriate drug therapy
□ □ □ ..........................................................................
•  selection  o f v e n o u s  a c c e s s  d ev ice
□ □ □ ..........................................................................
• providing formulation and stability data □ □ □ ..........................................................................
• docum entation o f pharm aceutical care plan □ □ □ ..........................................................................




• clinical monitoring o f the patient □ □ □ ..........................................................................
• interpretation o f laboratory te s ts
□ □ □ ..........................................................................
• moni:oring o f patient com plian ce/ad heren ce
□ □ □ ..........................................................................
• providing a 2 4  hour help line
□ □ □ ..........................................................................
other roles of th e  pharm acist in hi-tech health  
ca re  a t  home (please specify)
□ □ □ ..........................................................................
5. Do ary [atients outside the scope of EL(95)5 receive home infusional therapy? (de le te  as  
appropriate)
If yes, for which drugs/conditions?
6. Are the patients listed in the table in question 3
fully fu n d ed  by m o n ies  from EL(95)5 □
or is their ca r e  funded  by th e Trust/provider unit? □
Further c o m m en ts  regarding funding
7 . W hy w a s  your current h o m e  care provider ch o sen  to provide care for this group o f patien ts?
quality o f  their s e r v ic e  □  financially attractive □
c o n v e n ie n c e  Q  no available alternative Q
patient accep tab ility  □  other, p le a se  sp ecify  □
8 . D o you  h a v e  an y  g u id e lin es  for sharing the care o f th e se  patients b etw een  primary and  
se c o n d a ry  ca r e?  y e s /n o
If y e s ,  p le a s e  g iv e  d eta ils
9 . Is th ere  an y  audit s y s te m  in p lace to m easure th e  quality of care received  by th e s e  patients  
and patient o u tc o m e s ?  y e s /n o
If y e s , w h o  s p e c if ie s  audit criteria and monitors patient o u tco m es?
health  authority com m ercial h om e care com pan y □
trust/provider unit Q  other, p le a se  sp ecify  Q
10. In which group of patients has home infusion therapy worked best and why?
11. W hat a re /h a v e  b een  th e barriers in providing infusion therapy at h om e in your area?
12 . W hat is th e  major rea so n  that your Trust provides hi-tech health  care at h o m e?  (please tick 
the appropriate box)
• to im prove patient independence/quality of life □
• to red u ce  treatm ent c o s ts  □
• to free-u p  hospital beds/outpatient b ed s □
• other, p le a s e  sp ecify  □
13. Is th ere  a n y  collaboration betw een  the Trust and th e H ealth Authority Prescribing T ea m  e g  
pharm aceutica l ad v iser  on  is su e s  regarding hi-tech health  ca re  at h om e?  y e s /n o  
If y e s ,  p le a s e  sp ecify
14. W hat, in your opinion, is the general level of a w a r en ess  o f h i-tech health ca re  at h o m e in your 
hospital a m o n g st
low m oderate high d o n ’t know
• n u rses
□ □ □ □
• p h arm acists
□ □ □ □
• d octors
□ □ □ □
Any other com m ents you would like to make or explanations of your answ ers?
Your n am e and  a d d r e ss  (if you  would like to g ive  it)
Job  Title______
N a m e of Trust
P le a s e  tick if you  w ould  like a  sum m ary o f the resu lts obtained  from this questionnaire Q
Thank you for commoting this questionnaire.
Please post it back to me even if you have been unable to complete all of the
questionnaire!
P lease return in the stam ped addressed envelope to:
Jill Loader, Pharm acy Office, M ount Gould Hospital, M ount Gould Road,
Plym outh, PL4 7QD. ^ 0 1 7 5 2 -2 7 2 5 8 8
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Devon PL6 8DH 
United Kingdom
Tel 01752 272588 
1* November 1997
Tel 01752 763402 
Fax 01752 763431
Dear Colleague, Dr Graham SewellReader in Biomedical Sciences
Thank you for agreeing to complete this questionnaire. Your time is greatly appreciated.
As discussed on the telephone, I am a pharmacist working in Plymouth and am researching the current 
position in the United Kingdom on ‘hi-tech healthcare at home’ under EL(95)5. The work is for a M.Phil.
project registered with the University of Plymouth, under the supervision of Dr Graham Sewell, Reader in 
Biomedical Sciences. The project is sponsored by a “Developments in the Organisation of Care Project 
Grant” from the NHS Executive.
EL(95)5 instructed Health Authorities to make provision through their contracts to support patients at home 
whose treatments included the delivery o f drugs together with other products and equipment needed to 
administer them, typically provided as packages o f care, such as TPN, intravenous antibiotics and 
chemotherapy. Prescribing o f these services by general practitioners was stoppedfrom Ist April 1995.
My aims are to find out
• how many Trusts are providing home infusional therapy and for how many patients
• which drugs are being used and for which conditions
• who is providing the drugs, supplies and nursing care
• why the above where chosen to provide the care
• whether there are audit systems in place to measure the quality of patient care received by these patients 
and patient outcomes
• what are the barriers to providing home infusional therapy
• in which patients has home therapy worked best and why
• what is the role of the hospital pharmacist in the provision of hi-tech health care at home
The information I obtain will be used with that obtained from similar questionnaires to Health Authorities and 
commercial home care organisations to establish the current position in the UK with regard to home infusional 
therapy. I intend to publish an analysis of the information I obtain in a relevant health care journal. The data 
will be combined so that the data from individual Trusts will not be identifiable. I will be happy to send 
responders a summary of my findings.
Please fill out the questionnaire even if you contract with a third party to provide services for these patients. 
If you do not feel that you are the most appropriate person to complete this questionnaire please pass it on to 
someone who may be able to help.
Many thanks in advance for your help.
Yours faithfully
0\U  [LUCW
Jill LOADER (Miss), Research Pharmacist
T h e  Q u e e n ’s 
A n n i v e r s a r y  P r i z e s
fO ft HlCMSK AMO PURTI«R EfHICATtOM
1994
CO N FID EN TIA L Survey number
Hi-tech Health Care at 
Horne Questionnaire
This questionnaire will take approximately 20 minutes to complete. If you do not know the answer to a 
question just leave it blank and go on to the next one. If there is someone that I can contact who might 
know any missing answers please give a contact name and telephone number.
To complete the questionnaire please write in the boxes provided, delete yes or no as required or tick the 
appropriate box. If you feel an answer might need an explanation, please feel free to add additional 
comments.
Thank you
Thank you for your help, your answer is an important part of this survey, 
please post the questionnaire back to me in the envelope provided to: 
Jill Loader, Research Pharmacist, Pharmacy Department, 
Derriford Hospital, Plymouth, PL6 ?DH. 8 0 1 7 5 2 - 2 7 2 5 ? ?
Question 1 ©(It’s OK it gets easier after this!!)
Please answer the following questions for the groups of patients under the care of your 
Trust treated with hi-tech health care at home. (There may be more than one answer to 
each question).
1. Current number of patients
(approx)
2. Where do patient receive their 
drug therapy? eg as outpatient, at 
home
3. Who administers the therapy?
eg patient, hospital outreach nurse, 
district nurse, nurse from commercial 
company
4. Who is responsible for training 
the patient?
eg hospital nurse, hospital pharmacist, 
commercial company
5. Who provides the drugs?
eg hospital pharmacy, community 
pharmacy, commercial home care 
company
6. Who provides the nursing 
care?
eg district nurse, hospital outreach nurse, 
commercial home care company, hospital 
nurse
7. Who provides equipment and 
supplies?
eg. hospital pharmacy, commercial home 
care company
8. Who provides a 24 hour 
helpline?
eg on-call hospital doctors, pharmacists, 
nusres, commercial home care 
company, primary care team
9. Approx annual expenditure for 
total package of care for all 
patients in this group (to the
nearest £10K)
NB. If you only supply part of this service 















adults receiving children receiving thallassaemic patients receiving a other, please 
total parenteral total parenteral patients continuous infusion specify




Which aspects of hi-tech health care at home have pharmacists in your Trust been involved with?
role very some no involvement
involved involvement (please state who is
responsible)
CONTRACTING
• setting-up the hi-tech health care at home 
program
□ a □ ............................
• market analysis a a □ ...........................
• contracting for hi-tech health care at home a a □ ............................
• setting service specifications a □ □ ............................
CO-ORDINATION AND COMMUNICATION
co-ordinating the home care program a a a
with other pharmacists eg in nutrition team a a a
with other health care professionals □ □ a
with a  commercial home care company □ □ a
with patients and their families □ a a
patient selection a a a
EDUCATION
• design of written information for the patient 
on home infusion therapy
a □ □ ............................
• education/training of patients and their carers □ a □ ............................
• education/training of other health care staff a □ □ ............................
• competency assessm ent of patient/carer a □ □ ............................
SUPPLY
supply of drugs eg antibiotics, heparin etc □ a a
aseptic reconstitution of drugs, TPN and 
filling of infusion devices, syringes
□ □ □
selection of appropriate infusion pump □ a a
maintenance of infusion pumps □ a a
QUALITY ASSURANCE
quality assurance of home infusion program □ □ a
ensuring compliance with service 
specifications
□ a □
ensuring compliance with appropriate 
regulations, guidelines, GMP etc
a a a
quality assurance of infusion pumps a a a
role very some no involvement
involved involvement (please state who is
responsible)
CLINICAL
pharmaceutical advice to prescriber □ a a
choice of appropriate drug therapy □ □ □
selection of venous access device □ □ a
providing formulation and stability data □ □ □
documentation of pharmaceutical care plan a □ a
maintenance of prescription records □ a □
interpretation of laboratory tests a □ a
monitoring of patient compliance/adherence a □ □
providing a 24 hour help line □ a a
other roles of the pharmacist in hi-tech health 
care at home (please specify)
□ a a
Question 3
Do any patients outside the scope of EL(95)5 receive home infusional therapy eg. apomorphine 
for Parkinson’s Disease? (delete as appropriate) yes/no
If yes, for which drugs/conditions?
Question 4
Are there any patients under the care of your Trust who were receiving hi-tech health care at 
home prior to EL(95)5 and continue to do so as part of a bulk contract eg chemotherapy? (delete 
as appropriate) yes/no
If yes, please specify
Question 5 ©(You’re doing really well, nearly finished!)
Why was your current home care provider chosen to provide care for this group of patients? 
quality of their service □  financially attractive □
convenience Q  no available alternative Q
patient acceptability □  other, please specify □
Question 6
Do you have any guidelines for sharing the care of these patients between primary and secondary 
care? yes/no
If yes, please give details_______________________________________________
Question 7
Is there an audit system in place to measure the quality of care received by these patients?
yes/no
a) If yes, who specifies audit criteria? 
health authority q
trust/provider unit a
commercial home care company Q
b) Who measures the quality of care received? 
health authority q
trust/provider unit a
commercial home care company Q
other, please specify a other, please specify a
c) How is this measured? Please specify.
Question 8
Is there an audit system in place to measure patient outcomes? yes/no
a) If yes, who specifies audit criteria 
health authority a
trust/provider unit a
commercial home care company Q
other, please specify q
b) Who monitors patient outcomes?
health authority q
trust/provider unit □
commercial home care company Q
other, please specify Q
c) How is this achieved? Please specify.
Question 9
in which group of patients has home infusion therapy worked best and why?
Question 10
What are/have been the barriers in providing infusion therapy at home in your area?
Question 11
What is the major reason that your Trust provides hi-tech health care at home? (please tick the 
appropriate box)
•  to improve patient independence/quality of life a
•  to reduce treatment costs Q
•  to frse-up hospital beds/outpatient beds a
•  other, please specify Q
Question 12
Is there any collaboration between the Trust and the Health Authority Prescribing Team (eg 
pharmaceutical adviser) on issues regarding hi-tech health care at home? yes/no
If yes, (tease specify
(Questitn 13
Wlhat, ii your opinion, is the general level of awareness of hi-tech health care at home in your
Ihospita'amongst
low moderate high don’t know
* nunes □  □  □  □
«• phamacists □  □  □  □
<• docors Q  □  □  □
«• trus managers Q  Q  Q  Q
©(You made it!! Congratulations.)
Any other comments you would like to make or explanations of your answers?
Your name and address (if you would like to give it)
Job Title
Name of Trust
Please tick if you would like a summary of the results obtained from this questionnaire Q
Thank you for completing thie questionnaire.
Please post it back to me even if you have been unable to complete all of the 
questionnaire!
Please return in the stamped addressed envelope to:
Jill Loader, Pharmacy Department, Derriford Hospital, Plymouth,
PL6 8DH. 801752-272588
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Survey no | | 1 1
Trust Telephone Survey
Date 1 Date 2 Date 3
1. Does your Trust have a pharmacy department? yes/no
If no, from where does your Trust obtain it’s pharmaceutical supplies?
Go to question 5.
2. Do you have the facility for aseptic reconstitution/filling of ambulatory infusion 
devices in your pharmacy department? yes/no
If no, who does this for you?
Go to question 5.





3. Does this unit have an MCA “Specials” licence? yes/no
4. Do you have a manufacturing unit that has an MCA “Specials” licence? yes/no
Survey no
5. Are there any patients under the care of your Trust treated with hi-tech health care 
at home in accordance with EL(95)5 eg. antibiotics for cystic fibrosis patients, TPN, 
HTV, Thallassaemics? yes/no
6. Not under EL(95)5 eg ceredase for Gaucher’s Syndrome, apomorphine for 
Parkinson’s Disease? yes/no
7. Do you ever aseptically reconstitute drugs or fill infusion devices for treatment of 
patients at home? yes/no
8. If yes to 5 or 6 or 7, would you fill out the questionnaire? yes/no
Telephone no












Speak to a 
pharmacist
Speak to aseptic 
services 
pharmacist
Any input into care 
of HTHH patients?
Where does your 
pharmacy service 
come from?
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I am a pharmacist working in Plymouth and am researching the current position in England on ‘hi- 
tech healthcare at home’ under EL(95)5 [1]. The work is for a M.Phil. project registered with the 
University of Plymouth, under the supervision of Graham Sewell, Professor of Pharmacy and 
Pharmacology. The project is sponsored by a “Developments in the Organisation of Care Project 
Grant” from the NHS Executive.
I have completed national surveys of Health Authorities and NHS Trusts to establish the current 
situation in England with regard to the purchasing and provision of “hi-tech” health care at home 
(HTHH). The aim of this survey of commercial home care providers is to complete the national 
picture by finding out what is provided and to what sorts of patients by the commercial sector.
The findings of this project will be published in an appropriate scientific journal and may be 
presented at conferences. The data collected from this survey of commercial home care providers 
will be synthesised with that collected from Trusts and Health Authorities to gain an 
understanding of the overall picture regarding the purchasing and provision of HTHH in England. 
It should be stressed that no company, Health Authority or Trust will be identified in any 
publication or presentation of the findings of this project
It is hoped that this work will raise the profile of home infusional therapy in England so your help 
in completing the enclosed survey would be greatly appreciated. If you have any questions 
regarding the project or completing the questionnaire please do not hesitate to contact me.
Yours sincerely
Jill Loader, Research Pharmacist
1. NHS Executive, EL(95)5 Purchasing Hi-Tech Health Care for
Patients at Home. Letter, 1995. Leeds.
Survey no
Commercial Home Care 
Company Survey
EL(95)5 instructed Health Authorities to make provision through 
their contracts to support patients at home whose treatments 
included the delivery of drugs together with other products and 
equipment needed to administer them, typically provided as 
packages o f care, such as TPN, intravenous antibiotics and 
chemotherapy. Prescribing o f these services by general 
practitioners was stopped from 1st April 1995.
The aim of this survey is to establish the current situation in England regarding the purchasing, 
provision and monitoring of hi-tech health care at home (HTHH) under EL(95)5. Synthesis o f the 
data collected with that collectedfrom national surveys o f Health Authorities and NHS Trusts will 
enable the current situation with regard to HTHH in England to be elucidated.
No company will be identified in any publication or presentation of the
findings of this project
Thank you for your help.
Please return in the stamped addressed envelope provided to:
Jill Loader, Plymouth Post Graduate Medical School, c/o Pharmacy
Department, Derriford Hospital, Plymouth, PL6 8DH
Question 1
Do you provide an entire package of care for patients being treated at home with hi-tech infusions 
covered under EL(95)5 such as home TPN? (delete as appropriate) yes/no
If no, do you provide a package of care for these patients jointly with a hospital or other 
oiganisation? (delete as appropriate) yes/no
I f  no to both please specify what kind of service you provide.______________________________
Question 2











• Nursing care □ □ □
• Patient training □ □ □
• Education of other health care professionals □ □ □
• Aseptic reconstitution of drugs/filling of 
infusion devices
□ □ □
• Provision of equipment such as fridges, 
pumps etc
□ □ □
• Provision of disposables □ □ □
• Delivery to patient’s home □ □ □
• 24 hour help-line □ □ □
[ • Waste disposal □ □ □
• Maintenance of pumps etc □ □ □
• Other, please specify □ □ □
Question 3
Approximately how many treatment doses per day do you supply to patients being treated with 
home intravenous infusions in England?
Under 10 per week CJ
10-30 per week O
30-60 per week C.J
60-90 per week O

















1. intravenous antibiotics for cystic fibrosis □ □ □ □
patients
2. intravenous chemotherapy agents for patients □ □ □ □
with cancer
3. intravenous anti-infectives for HIV patients □ □ □ □
4. total parenteral nutrition (TPN) □ □ □ □
5. intravenous desferrioxamine for Thallaesaemics □ □ □ □
6. continuous intravenous anticoagulant treatment □ □ □ □
7. intravenous antibiotics for other conditions □ □ □ □
8. intravenous terbutaline for asthma □ □ ' □ □
9. intravenous prostacyclin □ □ □ □
lO.intravenous immunoglobulins □ □ □ □
11. subcutaneous beta-interferon □ □ □ □
12.enzyme replacement for Gaucher’s disease □ □ □ □
13.intravenous Iloprost □ □ □ □
14.intrathecal baclofen (for relief of spasticity as a □ □ □ □
result of spinal cord disease)
15.intravenous calcium gluconate infusions (for □ □ □ □
ricketts)
16. methotrexate for arthritis □ □ □ □
17.0ther, please specify □ □ □ □
Question 5
How many Health Authorities/Trusts do you currently have contracts with either for individual patients or 











When you tender or bid for a contract who specifies service specifications? (tick as appropriate)
Health Authority □  I
Trust
Other, please specify □
Question 7
Are you aware of any Health Authority or NHS Trust with whom you have a contract having an audit 
system in place to 
(delete as appropriate)
• monitor the service you provide? (delete as appropriate) yes/no
• measure patient outcomes? (delete as appropriate) yes/no
• measure your service against the agreed service specifications? (delete as yes/no
appropriate)
• benchmark your service against that of other providers? (delete as appropriate) yes/no
If yes to any of the above, please give details___________________________________________





Please return in the stamped addressed envelope provided to: Jill Loader,
Plymouth Post Graduate Medical School, do Pharmacy Department, Derriford
Hospital, Plymouth, PL6 8DH.
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2 No No TPN and Intermate separate contract, everything else bulk.
3 No No The HA Medical And Prescribing Adviser contract for the service with our 
local Trust pharmacy department.
5 No No separate contract for patients previously being treated through primary 
care. Trusts contract as part of bulk contract for new patients.
6 Yes No We do not contract separately for hi-tech therapy.
16 No No unsure
17 No No HA contracts with combination of acute trust and commercial home care 
company
21 No Yes Performance management team contract for hthh
23 No No CAPD as bulk, others individually.
24 No No HA contract
25 Yes No
26 No No Responsibilityiven to trusts, HA holds budget.
27 No No In most cases we have put it back into secondary care as part of a bulk 




31 No Yes Separate contract with secondary or tertiary care provider who usually 
sub-contract.
32 No No
33 No No don't know
34 Yes No Part of a bulk contract with several providers
35 No Yes
36 No No
37 Yes No Bulk contract with main provider.
38 No No
39 No No
40 Yes No Part of bulk contract with acute provider
41 No Yes Up to 97/98 separate contract. Trust answer separate contract by the HA.
42 Yes No Because of question 1 this is dealt with as part of a bulk contract should 
any particular issue arise.
43 No No
44 No Yes
45 No No sub-contracted to provider
46 Yes No Bulk, Trust contracts out.
47 No No TPN via provider, tube feeds via gp and Caremark
48 No No Both - CAPD fluids as part of the contract with Provider Trusts. Drug 
regimens by a commercial home care company.
49 No Yes
50 No No Handled by Birmingham consortium very little known in Sandwell.
51 No Yes
52 No No Part of a consortium contract involving 3 HAs. Block contracts or in 
contracts with the host speciality hospital
54 Yes No For first year HA had separate contract then gave the money to the Trusts 
who are now responsible for contracting for hi-tech health care at home. 
Think that three Trusts are doing it themselves.
55 No No All Trusts (acute and community) contract directly with providers. 
Numbers not known.
56 No No CAPD fluids via Black Country Consortia - separate contracts for TPN/IV 
antibiotics as and when required
59 No Yes TPN is a separate contract. Intravenous drugs contracted for via sub-
contracting arrangement with Trusts.
60 No Yes As a separate cost per case contract at one of our providers
61 Yes No yes
62 No Yes Separate contract by HA - the service was tendered.
63 No No We have a small Caremark contract but the bulk of EL(95)5 money was 
for renal dialysis - this was blocked back to the Trust who now contract for 
supplies. This also happened for HIV drugs.
64 No Yes
65 No No
66 Yes No Bulk contract to provider.
67 No Yes Separate contract by HA except CAPD which is done by the Trusts
68 No No both
69 No Yes
70 No No neither, responsibility devolved to main providers of routine care
71 No No Provided as part of bulk contract with a provider, except for 3 exceptions, 
therefore cannot fill above in any detail.
72 Yes No
73 No Yes Separate contract between HAs and companies involved.
74 No No Most of funding is through bulk contracts with some providers, (eg £30K 
to Community Trust for Hi-tech equipment & feeding). Other individuals 
are treated with separate contracts direct to the provider (eg Caremark or 
Derbyshire Ambulance Service).
75 No No A contract within a contract
76 Yes NO Part of the main contract
77 Yes No Bulk (I think) (not sure)
80 Yes No I assume it is a bulk contract with the provider.
81 Yes No
82 Yes No bulk contract with provider
84 Yes No Incorporated within acute contracts.
85 Yes No Part of contrct with provider.
86 No No ?
87 No Yes Forms part of separate contracts.
88 Yes No Part of bulk contract now.
89 No Yes This patient is still under a separate contract. All others are included in 
standard Trust contract.
90 Yes No
93 No No Dealt with individually - some are within block contracts ie cf packages of 
care, others as ECRs ie Ceredase & TPN
96 No Yes
97 No No
,98 No No we contract with Trusts to provide a service - they sub-contract but could 
do it in house if they wanted to.
99 No No
100 No Yes
101 No Yes Separate contracts with Trusts and suppliers outside the NHS.
102 No No For 1998/99 it will be an addendum to bulk contracts - thereafter probably 
included.
103 No No Both
104 No Yes Separate contract by our HA
105 No Yes
106 No No Both - Part of District Contract with Salford Royal Hospitals for TPN; spot 
purchase for rest.
107 No Yes
108 No Yes As above -separate contract.
109 No Yes
111 No Yes HA Caremark
112 No Yes
113 No Yes
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Good quality service provided. Healthcare at Home service has improved care of patients 
previously getting TPN from Caremark.





8 further comments The main issue is that of sharing the risk, small numbers of patients therefore variation in 
likely spend.
survey no 3
6 successful Contracting with our acute Trust has been successful in that they are the specialist unit 
for cystic fibrosis/TPN etc and have a good working knowledge and good working 
relationship with us at the HA. Using Trust contract has kept costs down.
7 difficult
8 further comments
Problems have risen around new patients being entered onto the contract, eg whether the 










8 further comments Difficult to answer any of these questions in our circumstance - 1 assume it has been 





8 further comments I'm not involved in this at all. There was no GP prescribing for these products and 
therefore no need to implement the EL as such. Local Trust deals with these patients.







6 successful Passing the responsibility on to others!
7 difficult
8 further comments
No cost control at the moment Evaluating the service provided by the commercial 
company.
survey no 23
6 successful Renal services.
7 difficult
8 further comments
Immunoglobulins. Original setting up for EL(95)5.
survey no 24
6 successful Remained with previous provider - continuity of care for patients.
7 difficult Not sure we are getting best value for money.
8 further comments Dilemma - is the hassle of tendering process and possible disruption to patient care worth 
the p>ossible financial saving?
survey no 25
6 successful All - now vired money to hospitals for immunoglobulins.
7 difficult
8 further comments
Deciding what is hi-tech' health care.
survey no 26
6 successful Trust pharmacist negotiates health care at home contract. They know the patients' 
needs, consultant requests etc. Can arrange knowing individual needs of patients supplier 
to suit these needs.
7 difficult Before trust arranged, we were told at the last minute and didn’t have time to arrange 
p>rop>erly. Also initially contracted with one company and felt they gave p>oor value for
8 further comments
survey no 27
6 successful ?cystic fibrosis
7 d ifficu lt Cancer therapies. Moving back to secondary care as recommended in the report
'Purchasing Hi-tech Health Care for Patients at Home" by Mark Pilling and Tom 
Walley, University of Liverpool, Department of Pharmacology and Therapeutics,
8 further comments The report mentioned in question 7 concluded that 1. formal structures for monitoring
contracts need to be introduced at purchaser level 2. that from 1997/98 purchasers 
should place their contracts with NHS Tertiary centres 3. That the NHS Tertiary centres 
should have overall responsibility for patients at home ensuring they receive the most 






Two ongoing contracted providers a) Commercial Home Care Company b) tertiary acute 
trust One person has care specifically tailored using GPs, local trust and tertiary centre.
survey no 30
6 successful Purchasing direct from the Acute Trust let them develop their service.




6 successful Local secondary care units have co-ordinated TPN services very well.















No-one really seems to know much about it but as part of the bulk contract doesn't seem 
to be any problems. Initially implementation of EL(95)5 was a nightmare.













6 successful - Identification of patients receiving therapy. - Appreciation by HA managers of the 
problems involved with such patients.
7 difficult Difficult for provider units to give accurate data (numbers & costs). Ongoing monitoring 
of budget allocation.
8 further comments A shambles when first introduced (at national level). Difficult to know which therapies to 
include/exclude. No extra funding from DoH. Provider units have found other ways to 












6 successful Smooth changeover in responsibilities.
7 difficult
8 further comments
Identifying patients in the first place when legislation came in.






Trust answer Transitions from GPs have been seamless. Discussions with provider Trusts 
progressing value for money.










8 further comments The prescribing department deals with data generated from PACT. We therefore have no 
data on hi-tech health care at home. Please contact Rob Little, Director of Finance, 












6 successful CAPD successful.
7 difficult desferrioxamine, TPN





Works satisfactorily. GP prescribes feeds. Caremark deliver feeds and equipment. Costs of 
equipment agreed in contract with Community Trust.






Continuity of care to the patients.
survey no 49
6 successful care of cf patients, looking to develop this service
7 difficult identifying precise costs, agreeing standards of service and best practice - as in a need to 
ask provider for ’standards".







6 successful TPN formerly supplied by a commercial home care company. Local acute trust has been 
awarded this service providing good quality service at lower cost.
7 difficult
8 further comments
Continuing financial pressures in CAPD fluid with increasing pool of renal patients.
survey no 52
6 successful The consortium approach has been successful - sharing the risk particularly as we are a 
small authority.
7 difficult Funding of equipment for enteral feeds. Continuing cost pressures as more ’hi-tech' drugs 
become available. (Getting information initially - now OK)
8 further comments The Regional Specialities Consortium will complete this on behalf of the 3 HAs it covers 















One home TPN patient threatened to use the whole budget when treatment initiated. 
Predicting the use of the budget is impossible due to small number/amount of patients with 







6 successful So few patients it's difficult to assess.
7 difficult
8 further comments








7 difficult A child on TPN from Great Ormond Street Hospital, for this patient we haven’t been able 
to contract with the company of our choice.
8 further comments Tendering for hi-tech health care is a good process to follow, communication with the 
relevant stakeholders is crucial to the success of such a service.
survey no 63
6 successful Because of the low volume of demand there have been no problems.
7 difficult 1. Internal problems within HA (FHSA/HA mergers, staff changes etc) have made 
continuity difficult - even locating the right budget line from one year to the next! 2. 
The money top sliced from the GP budgets for HTV drugs was relatively low. This was 
blocked back to the Trust but was insufficient for the demand in 1995/96. This was a
8 further comments Our view was that it was appropriate in most cases to allocate the EL(95)5 money that 
was top sliced from the FHSA and given to the HA to the relevant Trusts and allow then 
to arrange the supply function either in-house or via a home care provider. The pressure 
to develop hi-tech home care comes from within the Trusts and should be included in 

























interferon alpha/beta- see earlier
65
We have directly sub-contracted with our Trust to provide the services to our local 
patients.
Patients outside of our HA, new patients, potential wastage, audit
66
Since devolving to the Trust and Home Care Companies there are few problems. 
Very few problems.
67
No patient complaints following contract changes 
None
68
TPN patients have been a problem when sent out before nutritional requirements were 
stable enough - in a couple of situations, the Trusts rather than the commercial company 
have had to act as supplier due to the specific patient requirements.
We have recently moved to Caremark (Fresenius since the take-over) for our 
beta-interferon patients which, although this comes out of a different budget (ie not 
EL(95)5), seems to work very well. Our local Trusts are keen to keep as many of the 
hi-tech responsibilities themselves although the additional services offered by the home 
care companies seem to make them a more cost-effective option. Having been keen to 
support the Trust involvement in these areas as we have so few patients - this may
69
A new system was implemented to reduce the delay between Trusts applying for funding 
and the HA authorising treatment This has proved very successful in enabling both the 
HA to keep control of the budget and the Trusts to provide a faster, more effective
There have been no problems with supplying patients with hi-tech health care. There 
have been some minor inconveniences with attempting to find out from the Trusts how 
effective certain treatments have been.
Many of the original problems in establishing the current level of service were associated 
with the inaccuracy o f the baseline information provided to HAs to manage the original 
transfer from FP(10) to HCHS funding. This was coupled with the growth in the use of 
these types of delivery processes which is increasing at a faster rate than HCHS funding 
growth. HA felt that they had been given a raw deal in managing the changeover when 

























Got it off our agenda without effort
Potential savings for not accrue to us and difficult platform from which to develop i t  
1. What was the purpose of EL(95)5 2. Has it been achieved
71
None to my knowledge.
72
Staffing difficulties at acute Trust HAs meant they cannot provide service for community 
patients in some instances. Often too many people involved in discussing a particular 
patient eg. Consultant, Trust Managers, several people at the HA leading to delays in
Difficult to find answers to all questions. There seems no single person in the HA with an 
overview on the subject
73
TPN - as it is the major aspect of HTHH that concerns the HA, it has been successful.
Other aspects of HTHH insignificant
No particular problems. When EL(95)5 was introduced helped by the commercial 
companies. Trawled GP PACT catalogue, tracked down individual patients. This was a big 
job but not a difficulty.
74
We found that contracting through Trusts was more successful than attempting to 
contract directly with suppliers. Trusts have closer contact with the patient, more idea of 
their requirements & better economies of scale for the tendering process. Our role has 
been to monitor that process. We have obtained standard approx. costs from provider 
organisations to benchmark and ensure that we are getting a value for money, high quality
Setting up a contract outside of the tertiary provider has proved time-consuming. We 
had to write up a contract and agree it and then change it as the tertiary provider changed 
the treatment regime of the patient.
Our ideal model of service would involve the Trusts sub-contracting services for identified 
individuals on our behalf (see response to question 6). We would like sight of the 
contract and the tendering process to ensure that it was fair and high quality. We would 
compare the cost of the service with standard basic costs for that service to ensure value
75




6 successful Trusts are now responsible for the provision of those services who have the expertise and
knowledge to provide the best care. This is regarded as a success in itself













8 further comments New patients coining through as ECRs Has been difficult to monitor.
survey no 82
6 successful





8 further comments 
survey no 85
6 successful Smooth transition from old arrangements to new arrangements.
7 difficult Sorting out the funding arrangements. Ensuring providers obtain value for money by
putting the contract out to tender.
8 further comments It is not high on the current agenda at the moment hence the rather vague answers given
previously.
84
Savings realised through transfer from commercial 'niche-market' organisations to NHS 
providers without loss of quality of care.
ALL- particularly where providers have wished to increase patient nos. receiving HTHC 
eg desferrioxamine
80
No obvious problems because no communication from Trusts.
Potentially all of it! Who should be monitoring this? Are other areas of the country 
different with respect to HA monitoring?































Reviewing desfenal supply change from Caremark -> acute Trusts as providers 
Approval of new patients via ECR process - how can these be turned down??
89
The transfer of responsibility to the Trusts - BUT I don't know what they are doing. So 
far no complaints but no monitoring in force (to my knowledge).
90
93
Specification for services. Moving to local providers. 
Being involved early enough.
96
Contracts seem to work well. Tender exercise earlier this year involved quality 
specifications ( and not the cheapest option)










We had no problems during the transfer year and all seems well (with the exception of 
equipment) now.
When community trusts are involved we sometimes have problems with funding of 











Removing high-tech prescribing away from GPs to the care of specialists responsible for 
the patient






The services are better 'commissioned' than supplied as previously via GP prescription.
We have been able to develop specifications for service, know exactly what we have to 
budget for, and can develop new services as needed (eg. liquid oxygen)
Some difficulties in getting standard service spec agreed between Has, especially for supply 
from tertiary centres (who obviously cannot meet each and every HAs requirements).
The way it was done was very poor (by DoH) and put patients at risk o f potential service 
cessation. Lots of time needed to sort it out initially (and way out of proportion to the 
importance of HTHH in most advisers workload).
survey no 102
6 successful
7 difficult Devolving the budget, which accounted only for patients currently receiving care by 1
April 19% in a way that accounts for future use eg TPN costs doubled in one year but not 
because of policy changes just because 3 more HA residents went on to TPN.
8 further com m ents
Page 12 of 14
survey no 103
6 successful
7 difficult The fact that the money was top-sliced from GPs budgets and then was lost into the
system. There is no money ring-fenced for hi-tech healthcare.
8 further comments
survey no 104
6 successful 1. Competition - therefore reduction in cost but a more integrated service. 2. GPs no




6 successful TPN provision, HIV drugs
7 difficult Grey areas of prescribing eg iv immunoglobulin and iv albumin
8 further comments
survey no 106
6 successful undertook recently a tender for TPN with Manchester Children’s and Adult Services.
7 difficult Getting hospital providers to own budget and take responsibility for discharging  patients
and for the home care arrangements.
8 further comments
survey no 107
6 successful Good cost containment through competition. HA holds the budget for those transferred





7 difficult Limited number of suppliers. Providers (ie Trusts) can contract with who they like, no
responsibility as such to check quality or value for money.
8 further comments Should have included enteral tube feeding.
survey no 109
6 successful
7 difficult Audit, monitoring. Attempts to increase patients receiving care at home was ****ately
realised eg for rheumatology.
8 further comments Apologies for the blanks. PS. Pharmaceutical Adviser deals with hi-tech she is on
maternity leave.














New in post so info difficult to get 
112
Cost reduction for some services
The paper chase and lost expenditure when TPN patients have gone into hospital -waste 
TPN bags.
113
Multiple Sclerosis - beta interferon, TPN, cystic fibrosis 
Nil
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Coding of Qualitative HTHH Data
Meeting Dartington, 23/10/98 10am 









3. Tertiary Centre experience/involvement
a good 2
b bad (causes problems) 5
4. Ignorance/unfamiliarity 14
5. Audit of quality
a how do we know value for money 11
b patient care 12
6 . Patient criteria/ hand over issue
a clear 3
b unclear 14
7. Comparison with previous service (ie before EL(95)5)
a better than before 22




9. Not blank but haven’t made a comment which contributes anything
Coding of Qualitative HTHH Data
Meeting Dartington, 23/10/98 10am 









3. Tertiary Centre experience/involvement
a good 1
b bad (causes problems) 2
4. Ignorance/unfamiliarity 6
5. Audit of quality
a how do we know value for money 0
b patient care 0
6 . Patient selection/ hand over issue
a clear 2
b unclear 11
7. Comparison with previous service (ie before EL(95)5)
a better than before 10









































Triangulation Of Trust Data -Comparison Of Information Obtained In Written 





Telephone survey Written Survey Same
person
303 Unlicensed aseptic unit Have patients on 
home chemotherapy via Graseby pumps 
who come in once a week. Buy the 
syringes from Caremark.
2 cystic fibrosis patients and between 1 
and 3 chemotherapy patients, drugs 
provided for both by hospital pharmacy 
as dry powders. 10 HIV patients some 
treated at home some in HIV day case 
unit CHCC supplies home patients and 
hospital pharmacy supply patients who 
come to the day unit.
?
37 Have an aseptic unit. Some haematology 
patients have ceftazidime made up so that 
they can go home during the day. No 
HPN. G-CSF and flushes drawn up, 
cytarabine syringes so patients come into 
hospital for one of the doses each day and 
have the other at home. All have a 24 
hour expiry as isolators not in Class D air. 
Medax bags at end of use.
3 haematology/cancer patients at any 
one time receiving chemotherapy 
infusions supplied by hospital pharmacy. 
No other patients specified.
yes
116 Have an aseptic unit and have applied for 
a licence. No home TPN patients or 
antibiotics but occasionally make up 
chemotherapy in Baxter Intermate infusers 
for patient to start in the hospital then take 
home.
2 cystic fibrosis patients supplied by 
hospital pharmacy dispensary. 4 cancer 
patients, infusers supplied by company.
1 thalassaemic patient supplied by 
hospital pharmacy. 1 other- paediatrics 
receiving antibiotics for eg meningitis 
once a day administered by outreach 
nurse and supplied by hospital 
pharmacy.
yes
96 Aseptic unit do not have a pharmacist who 
has day to day input Make up 
chemotherapy for a couple of patients 
5FU, fludarabine etc. looking to take on
HTHH. Pharmacist a t......supply with
chemo. Will answer the relevenat parts of 
the questionnaire and pass on to .....
4 cystic fibrosis patients under joint care 
organised by ...(another Trust), drugs 
supplied by Caremark.
0 chemo patients
4 thalassaemic patients supplied by 
hospital pharmacy.
no
283 Unlicensed aseptic unit No-one at the 
moment, have had a number of people in 
the past TPN, cystic fibrosis antibiotics, 
HIV ganciclovir, desferral. Have also 
supplied special insulin dilutions, epidurals 
for terminal patients and terbutaline 
infusions.
Cystic fibrosis 0 patients, sometimes 1- 
3. Chemotherapy 0 patients sometimes 
as continuation of inpatient treatment 
HIV 0 -  very occasionally 1. TPN adult 
0 -  have treated patients for up to 9 
months. Other home epidurals 
occasionally. All supplied by hospital 
pharmacy.
yes
244 Unlicensed aseptic unit Have patients on 
home chemotherapy via Graseby pumps 
who come in once a week. Buy the 
syringes in from Caremark.
2 cystic fibrosis patients and 1-3 chemo 
patients supplied by hospital pharmacy. 
10 HIV patients some at home some 
come to HIV day case unit Commercial 
company supply home patients and 
hospital pharmacy day case unit 
patients.
?
53 Have an aseptic service. Minimal input, 
about 1 patient per year who they provide 
with 1-2 weeks of HPN and supply heparin 
syringes before the care is taken over by 
Caremark (Fresenius).
1 chemotherapy patient who receives 
therapy in outpatients. 1-2 adult HPN 
patients supplied by hospital 
pharmacy/commercial home care 
company.
?
233 Unlicensed aseptic unit. Had 1 TPN 
patient who died ages ago. Have home 
antibiotics eg ganciclovir but a commercial 
company deal with it. haematology 
patients come to ward to receive drugs.
Chemotherapy occasionally at home but 
rare provided by hospital. 2 
thalassaemics receiving desferrioxamine 
from hospital pharmacy.
no
118 Licensed aseptic unit. Have 65 home care 
patients, provide TPN to patients all over 
the country even in Scotland. Hope in 
Manchester are the other people who 
supply a lot of home TPN. BANS survey 
think register is now held at GOS (or 
maybe Birmingham Childrens or Hackney 
Childrens) we used to have it.
65 TPN supplied by commercial home 
care company.
yes
300 Unlicensed aseptic unit It is a rare 
occurrence. Have one patient currently on 
intermittent courses of cytarabine 
subcutaneously and he has been taught to 
give himself twice daily injections for a 
week repeated roughly every month.
Have a patient who has ganciclovir at 
home, she comes to the hospital 
once/week and picks up a weeks supply. I 
think the district nurse goes in and inftises 
it Most of the TPN etc is based at 
Sheffield. Have had HPN in distant past 
for scleroderma patient
1 HIV patient supplied by hospital 
pharmacy.
1 other -  Occasional subcutaneous 
cytotoxic therapy at home, self- 
administered, supplied by hospital 
pharmacy.
yes
92 Have a licensed aseptic unit and make up 
gancictovfr, foscamet and amphotericin for 
HIV patients.
12 HIV patients supplied by hospital 
pharmacy.
?
322 Unlicensed aseptic unit Have TPN 
patients at home but we do not make it up 
ourselves a commercial company does it
6 cystic fibrosis patients supplied by 
hospital pharmacy. 4 TPN patients 
supplied by a commercial company.
yes
271 Unlicensed aseptic unit Satellite oncology 
pharmacy, some patients have 24 hour 
pumps. We have one shared patient with 
....(another Trust). We used to sort out
the TPN but.....do it now because it got
too complex for the doctors and 
pharmacists here. Have the odd cystic 
fibrosis patient who does their own 
antibiotics at home. Do not provide much 
of a CIVAS service. Will fill in the 
questionnaire and then pass on to the 
oncology pharmacist to complete.
20 chemotherapy patients supplied by 
the hospital pharmacy.
?
258 Pharmacists and technicians counsel 
patients with pumps for chemotherapy, 
mostly 5FU. It is dealt with through 
pharmacy. Oncology. Manufacturing unit 
make up ganciclovir etc
27 home chemotherapy patients with 
Walkmed pumps supplied by hospital 
pharmacy.
yes
178 Unlicensed aseptic unit Yes do have 
HTHH patients. 1 home TPN which we 
make ourselves and 2 which are looked 
after by Central Homecare. Occasionally 
have home iv antibiotics which are dealt 
with by a commercial home care company.
2 children’s TPN provided by 
commercial company. Cannot answer 
on cystic fibrosis patients with home 
antibiotics which I know goes on in the 
hospital but I have no involvement.
?
17 Manager -only have a few patients. We 
organise the service but subcontract it out 
to a commercial company. Looked into 
being a provider as have specials licence 
for TPN. If had patients may supply the 
bags. Have supplied Caremark with TPN.
2 cystic fibrosis patients and 1 HIV 
patient supplied by commercial company 
or hospital pharmacy. 1 child on HPN 
organised by GOS. 1 patient on 
immunoglobulin supplied by commercial 
home care company.
yes
174 Aseptic unit -  unlicensed. Patients who 
have TPN at home are managed by Hope 
Hospital in Manchester. Have 
thalassaemics who are funded from 
region.
3 chemotherapy patients supplied by 
hospital pharmacy.
yes
321 Unlicensed aseptic unit working under 
Section 10 exemption. Have cystic fibrosis 
patients on antibiotics but currently this is 
mostly provided by Caremark. Have one 
domicfllary TPN patient under the care of
....... (another Trust), feeds come from
Caremark and are organised by
....... (another Trust) Patients on home
treatment for CMV we make up their 
ganciclovir in our cytotoxic suite. 3-4 
patients are having adjunct continuous 
chemotherapy, 5FU. Make up 7 days 
supply in house. Also do 2-3 days of 
vincristine and doxorubicin. Have looked 
at doing the cystic fibrosis antibiotics 
ourselves but funding issues are a 
problem.
12 cystic fibrosis patients supplied by 
commercial company and hospital 
pharmacy. 0 chemotherapy patients at 
present supplied usually by hospital 
pharmacy, no HIV patients currently 
sometimes receive therapy in 





Survey No 1 Region A&O Pharmacy ®  Send questionnaire 0
Comments Principal Pharmacist, Preparative Services Central Pharmacy.
___________Yes, do have input into hi-tech healthcare at home, will answer questionnaire.___________
Survey No 2 Region A&O Pharmacy O  Send questionnaire 0
Comments Pharmacy provided from Ipswich Hospital. Do some antibiotics for cystic fibrosis patients.
Sent both survey no 2 & 12 for Ipswich Hospital asking him to pass on the appropriate 
___________one. S eelZ  ___________________________________________________________
Survey No 3 Region A&O Pharmacy 0  Send questionnaire S3
Comments Divided into 2 trusts - Norfolk Mental Health and James Paget Healthcare Trust
James Paget - Have a pharmacy and make up antibiotics for children to use at home. 
Outreach children's nurse Marion Steward. Senior technician aseptic services Judy 
Ovenstone. Advised to send questionnaire to David Todd, Director of Pharmacy. Sent
___________with note._______________________________________________________________
Survey No 4 Region A&O Pharmacy 0  Send questionnaire S I
Comments Pharmacy open part-time. Pharmacist available on bleep through switchboard. Asa
pharmacy do not have anything to do with the care of these patients but district nurses do 
provide some services. Oxford Community Trust who share a boarder have developed 
their service and have good IV trained community nurses to support these patients at 
home. Pharmaceutical care from acute trust. So sometimes district nurses from this trust 
asked to help with care of eg iv antibiotics for orthopaedic patients. Will try to answer 
___________questionnaire. Have you spoken to Beth Taylor - survey of hospital at home?___________
Survey No 7 Region A&O Pharmacy 0  Send questionnaire 0
Comments Pharmacy manager. Have 2 HIV patients supply ganciclovir, foscamet W in answer 
_________questionnaire. ________________________________________
Survey No 12 Region A&O Pharmacy 0  Send questionnaire 0
Comments' Sent with 2 as same pharmacy supply both Trusts. Have not spoken to G. Hanson (who 
___________looks after aseptic reconstitution), spoke to Chris Galloway who has both 2 & 12.________
Survey No 14 Region A&O Pharmacy 0  Send questionnaire 0
Comments One patient on home TPN and one on desferrioxamine. Win answer the questionnaire. 
___________(Also provide services for 33) therefore sent her two questionnaires.__________________
Survey No 15 Region A&O Pharmacy 0  Send questionnaire 0
Comments Have recently had one home TPN patient for about a month. Made up the tpn but do not 
___________have a civas service. AH cf patients come under Papworth. Will answer questionnaire.
Survey No 17 Region A&O Pharmacy 0  Send questionnaire 0
Comments Manager - only have a few patients. We organise the service but subcontract it out to a 
commercial company. Looked into being a provider as have specials licence for TPN. If 
had patients may supply the bags. Have supplied Caremark with TPN. Going to China for 
 _________ 3 weeks will complete on return.______________________________________________
Survey No 25 Region A&O Pharmacy 0  Send questionnaire 0
Comments Technical Services Pharmacist. Couple of home TPN, dealt with by Caremark/Fresenius.
Occassionally fill CADD pump for chemotherapy but no civas service. Will complete 
__________ questionnaire.________________________________ ___________________________
Survey No 27 Region A&O Pharmacy D  Send questionnaire 0
Comments No pharmacy but have a pharmacist Give intravenous antibiotics to patients at home.
Have specially trained nurses to put in central lines and community nurses to look after the 
patients in their homes. The nurses usually go in to the patients home and administer the 
drug but occasionally a patient is trained to give it themselves. The community nurses 
work very closely with infection control and microbiology. Don't send patients home to 
other districts where they can not be monitored. There is a specially allocated ward in the 
hospital for these patients. Pharmacist attends consultant ward rounds and has clinical 
input. Initially had large input into the scheme when setting up protocols etc, now leaves it 
up to the specialist nurses who are very competant. Why don't you come and visit? 
______  Yes, I’ll fill in the questionnaire.
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Survey No 28 Region A&O Pharmacy ®  Send questionnaire ®
Comments Aseptic unit at the Churchill Hospital. Limited amount of patients. Have done
desfenrioxamine and do home TPN but service is stopping because the HA are not paying 
___________ for it. Will answer questionnaire._____________________________________________
Survey No 30 Region A&O Pharmacy - ®  Send questionnaire ®
Comments Have a contract with Central Homecare to supply these services. Will try and fill in the 
___________questionnaire.___________________________________________________________
Survey No 31 Region A&O Pharmacy ®  Send questionnaire ®
Comments Supply 23, do have aseptic suite, supply children with home antibiotics, have a hospital at ■ 
___________home scheme. Will fill in questionnaire._______________________________________
Survey No 36 Region A&O Pharmacy ®  Send questionnaire ®
Comments Very small aseptic unit, no licence. Occasionally make items for patients to use at home 
eg. desferrioxamine pump, cytarabine in CAOD pumps as part of 5/10 day regimen, . 
___________CVADD - doxorubicin, vincristine for 4 days. Will fill in questionnaire_________________
Survey No 37 Region A&O Pharmacy ®  Send questionnaire ®
Comments (spinal injuries etc) Aseptic unit. Some haematology patients have ceftazidime made up 
so that they can go home during the day. No HPN, gCSF and flushes drawn up, 
cytarabine syringes so patients come into hospital for one of the doses each day and have 
the other at home. Al have a 24 hour expiry as isolators not in Class D air. Med ax bags at-*
___________ end of use. Will answer questionnaire.__________  ______________________
Survey No 40 Region N&Y Pharmacy ^  Send questionnaire ®
Comments Aseptic unit. Kay Marriot ext 3509. Have had home TPN in past. Do not have many AIDS 
patients, sometimes IV antibiotics but often given once daily at the hospital in paediatrics. 
Unit not licenced use Kabimix standard regimen or if patient needs something else try to 
___________ base on a Pharmacia regimen so that stability OK Do not make up own formulations.
Survey No 41 Region N&Y Pharmacy ^  Send questionnaire ®
Comments Yes cystic fibrosis patients have home iv antibiotic therapy but everything including the 
. drugs and nursing care comes from Newcastle. Do make up cytotoxics in an unlicenced 
aseptic unit. Mostly fludarabine and the nurse goes out to the patient's home to give iL
___________Will fill out questionnaire.___________________________________________________
Survey No 43 Region N&Y Pharmacy ^  Send questionnaire ®
Comments Aseptic unit at St Luke's Hospital. Make up a weeks worth of antibiotics for cf patients and 
draw up saline. Technicain will ask John Suddo, Pharmacist to answer questionnaire. In a 
___________Warfarin clinic at the moment._______________________________________________
Survey No 45 Region N&Y Pharmacy ®  Send questionnaire ®
Comments Aseptic service. 5FU infusions, no HPN, abs for cf, have done a one-off ganciclovir. Will 
___________answer questionnaire._____________________________________________________
Survey No 46 Region N&Y Pharmacy ®  Send questionnaire ®
Comments Aseptic service. Home TPN, Northumberland patients get supplied from Newcastle, RVI 
with homecare but planning to start a service from Wansbeck General Hospital. Win 
___________complete the questionnaire based on the plan if it is of any interest.___________________
Survey No 48 Region N&Y Pharmacy ®  Send questionnaire ®
Comments Just started a hospital at home scheme this month still waiting to find out full scope of
service but brought in to facilitate early discharge. Also have paediatric patients at home. 
Send questionnaire and he will try to find out if there are any of these patients being treated 
___________at home._______________________________________________________________
Survey No K ) Region N&Y Pharmacy ^  Send questionnaire ®
Comments Minimal input. Some patients go home on ivs and the pharmacy supply the drugs but just 
on a TTA or outpatient prescription, not aseptically prepared. The patients administer the 
drugs themselves and are taught to do this by the nursing staff. Would like to aseptically 
dispense these items but there are no resources available to set up such a facility. Would 
like to go down this route but funding and staff levels do not permit. Quality issue. Medical 
audit is earned out from individual directorates and pharmacy are getting more involved in 
  this. Would be interested to see questionnaire, will answer anything relevant.
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Survey No 53 Region N&Y Pharmacy ®  Send questionnaire ®
Comments Aseptic service. Minimal input about one patient per year who they provide with one-two 
weeks of home TPN and supply heparin syringes before the care is taken over by 
___________ Caremark (Fresenius). Will answer.__________________________________________
Survey No 57 Region N&Y P h a rm a cy®  Send questionnaire ®
Comments Aseptic service with licence. No input usually but occasionally fill CAOO cassettes for 
___________chemotherapy patients. Will answer questionnaire._____________________________ '
Survey No 58 Region N&Y Pharmacy ®  Send questionnaire ®
Comments Aseptic service. Bit of home chemotherapy, no home TPN, no iv antibiotics, no
desferrioxamine, have made up ganciclovir for the odd patient. Will complete questionnaire 
as long as not too long and you don't want i  back in a rush! Aseptic Dispensing Services 
___________ Manager_______________________________________________________________
Survey No 61~ Region N&Y Pharmacy ^  Send questionnaire
Comments Maria Hogg, yes we have a pharmacist designated to home antibiotics for mostly cystic 
fibrosis and AIDS patients ( In on Thursday, Sally Allen ext 22689). TPN is dealt with 
through the Royal Victoria Infirmary. Sally Allen 6/11/97. We provide antibiotics and 
arrtivirals for hospitals all over the region. Have a licenced aseptic unit. Large hospital in 
Cleveland, Cumbria supplies some hospitals and there is a big centre in Leeds, either 
Seacroft or St James’ who have lost a contract to a commercial company in the last six 
months. Chemotherapy, mostly 5FU in intemates is also made up, Stephanie Klyne is the 
pharmacist responsible for that in the aseptic unit Make it up for Freeman Group of 
Hospitals. Cant understand why they didnt mention it. Send two questionnaires and she
___________will fill out one and ask Stephanie Klyne to fill out one._______________________ ______
Survey No 64 Region N&Y Pharmacy Send questionnaire ®
Comments Aseptic suite, pharmacist off sick. Senior tech -1 patient on home TPN for the whole 9
years that I've been here. Originally came from Manchester and has recently had a change 
in fromulation advised by Manchester. Is sure that David Young the pharmacist will fill out 
___________ a questionaire. Sent with note._______________________________________________
Survey No 66 Region N&Y Pharmacy ^  Send questionnaire ®
Comments Aseptic dispensing but no licence. Possibly have one TPN patient who is looked after by 
someone else, HI check. Cystic fibrosis patients have home IV antibiotics but the 
pharmacy do not reconstitute them they just disoense them and the patients make them up
___________themselves at home. Win try to answer questionnaire.______________________ ______
Survey No TO Region N&Y Pharmacy ®  Send questionnaire ®
Comments Supply desferrioxamine but the district nurses go in to the patients homes and make up 
syringe and give it. No TPN, no antibiotics but do have a clinical trial going on at the 
moment sponsored by Lilly giving gemcitabine as an infusion at home. The pharmacy 
make it up and the patients are trained and looked after by a nurse specialist from a private 
company who goes in to the patients home to administer the drugs, have treated children 
on an outpatient basis with ceftriaxone in the past but they tend to come into the hosital on 
___________a daily basis. Will answer questionnaire._______________________________________
Survey No 72 Region N&Y Pharmacy ^  Send questionnaire ®
Comments John Harwood, Pharmacist Aseptic Services 4812/4833/4807
Yes have patients on HTHH but do not supply the drugs, mainly TPN patients, speak to 
our nutrition team pharmacist Paul O'Brien. A commercial company have been contracted 
to supply the care, they have had a trial of 3 different companies and he thinks that one has 
just won the contract, ask Paul (01482 674411). Paul O'Brien - yes have one home TPN 
patient at the moment but have had six patients go through the process, care provided by a 
___________commercial homecare company. Will fill in a questionnaire._________________________
Survey No 73 Region N&Y Pharmacy ^  Send questionnaire ^
Comments Do lots of HTHH. Met him in Antwerp last year. Send the questionnaire. Went to 
___________Homecare *96, what was Homecare *97 like, any good? Any other conferences?_________
Survey No 74 Region N&Y Pharmacy S  Send questionnaire ®
Comments Aseptic unit. No current patients. One cf patient on TPN supplied by Caremark and cf 
antibiotics supplied by Caremark. W e supply initailly if the patient has been in hospital. 
Have a paediatric pharmacist who liases with the homecare nurse and consultant. Had 
____________ one potential home TPN patient but they died. Will fill in the questionaire._______________
Survey No 76 Region N&Y Pharmacy ^  Send questionnaire ^
Comments No home TPN, few home antibiotics for cystic fibrosis patients give one-two weeks of abs 
_________ at home. Also do weekly infusions of 5FU. Licenced unit, will answer questionnaire.
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Survey No 78 Region N&Y Pharmacy ®  Send questionnaire 0
Comments Do have aseptic unit but not of the best standard. Thinks region will soon dose it down.
No home TPN. Make up syringes of antibiotics for a couple of cystics. Will answer 
___________questionnaire.___________________________________________________________
Survey No 79 Region N&Y Pharmacy» 0  Send questionnaire 0
Comments Aseptic suite, es have several patients, no TPN but gCSF goes out into the community.
Do not standardly do antibiotics but have a manufacturing unit which sends out 
___________intermates, don’t know much about that but will try and find out.______________________
Survey No 80 Region N&Y Pharmacy 0  Send questionnaire 0
Comments Also Phil Deedee, TPN and David Ogwen, HIV. Do paediatric and adult tpn and antivirals..
Cockrigde in Leeds deal with the chemo patients. Will by and fill in the questionnaire and 
___________pass it around to other pharmacists to fill in the appropriate parts.____________________
Survey No 82 Region N&Y Pharmacy 0  Send questionnaire 0
Comments Pharmacist just left job. Do home chemotherapy, make up syringes in unlicenced aseptic 
___________unit. (Do civas, tpn and chemo for inpatients). Will try and fill in questionnaire.__________
Survey No 83 Region N&Y Pharmacy 0  Send questionnaire 0
Comments 2 patients on home TPN hospital pays commercial companies to provide this one is
through Kabi and the other through another company. One was initiated at Leeds and one 
at Hope Hospital, Salford. Over the past two years have had 4-5 cf adults receiving 
antibiotics at home and about the same number of children, Have filled CADD and 
Walkman bags and Graseby pumps VADD and Cytaribine on an intermittent basis using 
Graseby pumps. Have approval to buy two more pumps to use in palliative care, have 
treated 4-5 palliative care patients with medtronic pump - implantable reservoir, DN fills and 
patient controlled. Diamorphine and bupivicaine +/- clonidine. Do you know anything about 
Abbot pumps as anaesthetist has seen rep for these and we want to talk to someone who 
__________ might know their advantages/disadvantages for home use? ISOPP in Exeter._______
Survey No 85 Region NT Pharmacy 0  Send questionnaire 0
Comments Pharmacy at Basildon Hospital. Yes we supply home TPN, community paediatric nurses 
deal with home antibiotics for children. Speak to Peter Croot ext 3162.
Spoke to Robin Miller at Southend (129) he does compounding for this Trust too. Will
__________ anwer their questionnaire.___________________________________________ .
Survey No 88 Region NT Pharmacy 0  Send questionnaire 0
Comments Not really. Have done desferrioxamine at home for an anaemic patient. Send questionnaire.
Survey No 90 Region NT Pharmacy 0  Send questionnaire 0
Comments Have a compounding unit but not licenced. Do make up ganciclovir ring ext 8395. Have 
got loads of patients on ganciclovir but contracted to Charing Cross. Do some home 
chemotherapy in Baxter or CADD pumps we provide 14 days in a 50ml syringe and the 
nurses inject it into the pump. Donl do much HPN. No antibiotics, have one patient on 
  deferral via a Baxter pump at 5mI/hr which is filled every couple of days.________________
Survey No 92 Region NT Pharmacy 0  Send questionnaire
Comments Have a licenced aseptic unit and make up ganciclovir, foscamet and amphotericin for HIV 
___________patients.________________________________________________________________
Survey No 96 Region NT Pharmacy 0  Send questionnaire 0
Comments Aseptic yes but gone home! Do not have a pharmacist who has day to day input. Makeup 
chemotherapy for a couple of patients 5FU, fludarabine etc. Looking to take on HTHH. 
Pharmacist at Essex County, Tracey Chapman, supply with chemo. Will answer the 
__________ relevant parts of the questionnaire then pass on to Tracey Chapman._________________
Survey No 97 Region NT • Pharmacy 0  Send questionnaire 0
Comments Preparative Services Unit Manager. No iv abs or tpn but do make up chemotherapy in 
ambulatory bags in the pharmacy department, usually vincristine or doxorubicin. Will 
 answer questionnaire.. ________________________ ___
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Survey No 98 Region NT Pharmacy 0  Send questionnaire 0
Comments Phoned Dl to ask who to speak to-> Sue Patey, Pharmacist. Sue Patey 12/11 Do mostly 
home TPN through a commercial company. Tendering process for 3 year contract. 15 
months left before retender. Do some but very few home abs and chemo because we are 
a tertiary centre and prefer the local hospitals to take this on. If the patient is under the 
host purchaser we are more likely to do it, otherwise run into problems when other places 
___________have other contracts.
Survey No 99 Region NT Pharmacy 0  Send questionnaire 0
Comments All hospitals in the Trust have pharmacy departments. Hammersmith (A) - occasionally do 
home tpn, no home abs, no chemo. Speak to Gerda Viedge, pharmacist. 0181 3834711. 
Gerda Vddge 13/11 When patient goes home on tpn dietician, doctor & pharmacy arrange 
for their care to be taken over by a home care company either Baxter or Healthcare at 
Home. Sometimes make up syringes of chemotherapy for patients to take home. Karen 
Hamling, more senior production pharmacist. (Boyfriend Loader)
Charing Cross (B) - 0181 8461869. Nicola Hooper, senior Pharmacist, Aseptic Services. 
Have one desferrioxamine patient Provide HIV service for the Cheisea and Westminster 
(see 90) as they do not have a licenced unit (speak to Azeem Ahmed there). A little home 
chemo, patients start using Baxter infusers on the ward and then continue at home. Make 
up methotrexate syringes for National centre for trophoblastic disease, cycles every 2 
weeks, either the patient comes in as an outpatient or the DN gives it at home.
Acton Hospital no aseptic.
Queen Charlotte's Neonatal & Maternity Hospital (C), have a very small unlicenced aseptic 
___________ uniL Beryl ext 33915._______________________ _
Survey No 1®D Region NT Pharmacy 0  Send questionnaire 0
Comments No aseptic, speak to Alex Denby 01895 828595. Have a few patients on ganciclovir
arranged through Baxter at Mount Vemon. Send questionnaire to transplant pharmacist 
  Bhulesh Vadher. Sent with note._____________________________________________
Survey No 103 Region NT Pharmacy 0  Send questionnaire 0
Comments Aseptic unit at Oldchurch Hospital,ext 3446.
1 home TPN looked after by Trust nutrition team. 1 deferral patient looked after by gp. 
___________Make tpn for Caremark -12 patients at the moment______________________________
Survey No 109 Region NT Pharmacy 0  Send questionnaire 0
Comments Broomfield Hospital Pharmacy, Licenced aseptic unit, sometimes have home TPN, Don't 
___________know about chemo, Walkmed infusions? will find out. Send questionnaire.____________
Survey No 111 Region NT Pharmacy 0  Send questionnaire 0
Comments Watford pharmacy no aseptic. Have a lady on ceredase or cerezyme buy service from 
Caremark, all we do is organise the prescriptions.
Mount Vemon -> speak to Dr David Melzac, 01923-844474->Do home chemotherapy 
infusions. We have a Baxter unit on site who make infusers of 5FU etc. The pharmacists 
have a lot of clinical input, there are three oncology pharmacists. Andrew Hood would be a 
___________good person to ask but on holiday. Send me the questionnaire and Nl pass it on to him.
Survey No 114 Region NT Pharmacy 0  Send questionnaire
Comments Senior Pharmacist Prepartive Unit Aseptic. One patient having desferral, we made it up 
for a while now we buy it from the Royal Free. No home TPN these patients would be 
___________under the care of the teaching hospitals._______________________________________
Survey No 116 Region NT Pharmacy 0  Send questionnaire 0
Comments Have an aseptic unit and have applied for a licence. No home tpn or abs but occasionally 
make up chemotherapy in Baxter intermate infusers for patient to start in the hospital then 
___________take home._____________________________ ________________________________
Survey No 117 Region NT Pharmacy 0  Send questionnaire 0
Comments Have a licenced aseptic unit and make up home chemo (mostly 5FU) and ganciclovir. 
___________Jenny pharmacist 3069.____________________________________________________
Survey No 118 Region NT Pharmacy 0  Send questionnaire 0
Comments Licenced aseptic unit. Have 65 home care patients. Provide tpn to patients all over the 
country even in Scotland. Hope in Manchester are the other people who supply a lot of 
home TPN. BANS - British ArtificaB Nutrition Survey think the register is now held at 
GOS (or maybe Birmingham Childrens or Hackney Childrens) we used to have it. Will 
 answer questionnaire. ___  _________________ _________________
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Survey No 120 Region NT Pharmacy ®  Send questionnaire ®
Comments Did have patient on home TPN for 1 year, died last week, we supplied the TPN on a
weekly basis. Home antibiotics meetly for paediartics Also some home chemo. District 
nurses or community outreach nurses care for the patients, take gentamicin levels etc. 
Aseptic suite is being rebuilt so get supplies from another licenced unit at another 
___________ hospital. Will send back questionnaire if it's OK With the Pharmacy Manager.___________
Survey No 123 Region NT Pharmacy Send questionnaire ^
Comments Licenced aseptic unit. Nicola Holt Principal Pharmacist/ Acting Head of Dept also does 
___________ paediatrics, send to her. Spoke to Helen Morgan.________________________________
Survey No 124 Region NT Pharmacy ®  Send questionnaire ®
Comments Technical Services. TPN in manufacturing unit, Antibiotics in CIVAS. No cutrrent home 
TPN but are in the process of arranging for a child to go home. No antibiotics at the 
moment but do home desferral. Have 60 patients from other hospitals that they supply with 
desferral and 12 TPN patients from other hospitals. Win distinguish between patients that 
___________ belong to our Trust and those that belong to others in the questionnaire.____________ .
Survey No 125 Region NT Pharmacy ^  Send questionnaire 0
Comments Danny Murphy, TPN pharmacist. Whitechapel 20 desferral patients, TPN ->
Caremark/Fresenius so don't make ft. St Bartholomews have patients on ganciclovir in 
___________ intermates and other antibiotics. Will answer questionnaire.________________________
Survey No 126 Region NT Pharmacy ®  Send questionnaire ®
Comments Aseptic service. Spoke to Dl send to Caroline Websteer G1 Pharmacist. Mostly make up ** 
___________ 5FU for patients at home.___________________________________________________
Survey No 129 Region NT Pharmacy 0  Send questionnaire ®
Comments Principal Pharmacist Technical Services
One patient from this Trust on home TPN. Basildon and Thurrock Compounding unit 
used. Use Pharmacia regimens. £ TPNs at 85 now diong 6-7 which Kabi wholesale from 
___________ there. Will answer questionnaires for 85 and 129 as provides the service to both Trusts.
Survey No 131 Region NT Pharmacy ^  Send questionnaire ®
Comments Judith Dl, speak to Judy Keene, Acting Chief Pharmacist/ Head of Production 0171 
8866121 direct line (back from leave on 19/11/97). Have had patients on HPN and 
ganciclovir but have none at the moment. TPN patients have died. We buy in ganciclovir 
from Healthcare at Home. We used to make up the TPN. Distribution was taken over by 
Healthcare at Home. The paediatric pharmacist has a lot of clinical input Will answer
___________questionnaire.____________________________________________________________
Survey No 133 Region NT Pharmacy ^  Send, questionnaire ®
Comments Pharmacy, Basildon Hospital. Community paediatric nurses go to patient's home and
administer antibiotics. Will answer and discuss questionnaire with Robin from Southend 
___________who also provides aseptic services to this Trust._________________________________
Survey No 135 Region NT Pharmacy ®  Send questionnaire S
Comments Could you post us a letter asking what you want to know? Send questionnaire to Tony 
Murphy, Principal Pharmacist with note. Aseptic unit no current home patients but have 
___________had 1-2 in past___________________________________________________________
Survey No 139 Region NT Pharmacy ®  Send questionnaire ®
Comments Aseptic. Chrissie Cock 0181 5655883. Ring pm 13/11/97. Have the odd patient.
Sometimes buy in the services of Caremark for TPN etc. Paediatrics we make up in the 
___________unit and the paediatric team look after them._____________________________________
Survey No 142 Region NW Pharmacy ®  Send questionnaire ®
Comments Aseptic but under refurbishment. Home TPN is made up by Caremark. Small involvement 
in their care. Surgical and Medical Units are split aseptic is based in the surgical unit so 
although they may have some input with surgical patients they have none with medical 
patients. Monitor biochemistry, discuss with consultant 2 desferral patients dealt with by 
________ Caremark, very little input with these. Will anwer questionnaire. ___
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Survey No 143 Region NW Pharmacy 0  Send questionnaire 0  ^
Comments Aseptic, no licence but upgrade in process. Caroline Boardman deals with the cf patients.
Buy in care for them.
Caroline Boardman - EL(95)5 2 cf patients received IV antibiotics through Caremark.
Pharmacy now order on behalf of the patients. Also had two patients on ganciclovir at the 
time. Looking to start making up their own eg ceftazidime for cf, costing to make a bid to 
the purchaser as an alternative to purchasing from Caremark. Some cf patients are trained 
to make up and give their own antibiotics with support from a paediatric outreach nurse.
___________ Have two patients on ceredase but they make it up themselves.______________________
Survey No 145 Region NW Pharmacy 0  Send questionnaire 0
Comments Have a licenced unit but ganciclovir is made up in an unlicenced aseptic unit Unusual to
have patients being treated at home. No HPN, one patient on ganciclovir will find out if any '
___________ others. Send questionnaire._________________________________________________
Survey No 146 Region NW Pharmacy 0  Send questionnaire 0
Comments Aseptic unit. In the middle of a licence application, when have it will competitively tender to 
provide the service. At present Caremark, Fresenius do it. Most important is cf antibiotics 
there are quite a few and a few TPN patients. There are two districts under one HA the 
other district is Blackburn.
Have also had a project running for 11 years for terminal care. Make up vast numbers of 
diamorphine syringes for patients to use at home (200-300/month) Have 48 hours expiry.
Pharmacist educates groups ie they now do not ring until they have tried the oral route, they 
sort out laxatives, antidepressants etc first and then ring in advance of needing the 
prescription with starting doses of 100mg not 10mg. Cover whole area. Have a large 
advisory role. Work very dosely with the gps in the area. District nurses love it, they also *' 
send out a spare label to stick in the patient's notes when the syringe is used to record 
what has been given, make up all sorts of things. Try to discourage three items in a 
___________ syringe. Will answer questionnaire.___________________________________________
Survey No 149 Region NW Pharmacy 0  Send questionnaire 0
Comments Aseptic unit, Pam Harris - but going on maternity leave so send questionnaire to Debbie 
Jones, Senior Pharmacist. Buy in HTHH from commercial company, Caremark,
___________ Fresenius. Have cf patients being treated at home with antibiotics.____________________
Survey No 154 Region NW Pharmacy 0  Send questionnaire 0
Comments Have a licenced Baxter unit here at Christie's make up 5FU etc for Infuser B and Meric 
___________ pumps. Patients come to the hospital every fortnight to collect._______________________
Survey No 155 Region NW Pharmacy 0  Send questionnaire 0
Comments Aseptic at Wirral Hospital NHS Trust 199. Arrowe Park 0151-334115 ext 2832. Have the 
odd patient who has chemotherapy at home with a pump. Have cf patients with antibiotics 
___________ and TPN._______________________________________________________________
Survey No 158 Region NW Pharmacy 0  Send questionnaire 0
Comments Have 2 home TPN patients. Make up TPN in a licenced unit. Send questionnaire.
Survey No 161 Region NW Pharmacy 0  Send questionnaire 0
Comments Yes have 2 patients on HPN made up in a licenced unit Send questionnaire.
Survey No 165 Region NW Pharmacy 0  Send questionnaire 0
Comments We have a few patients. Some through EL(95)5 but there is arguement over whether cf 
patients are covered by this. An exception was made after April 1995 about numbers and 
the HA stepped back and tried not to pay. 1 child is having iv antibiotics under EL(95)5 
and Caremark provide the antibiotic in a bag. There are another 2 patients who get the 
antibiotics from their gp and make them up themselves and 3^4 who get antibiotics from 
the hospital but they have to make them up themselves. We are a district general and the 
nearest tertiary centre for cf is in Manchester. A consultant comes up from Manchester 
every 2 weeks for a clinic. The pharmc'ists do have some input but not really on choice of
__________ drug or dose more the practical management of problems that arise._________________
Survey No 168 Region NW Pharmacy 0  Send questionnaire 0
Comments Aseptic unit but not licenced. Have a tot of patients on home TPN - Caremark.
Community liason pharmacist deals with these. No home chemotherapy but do have cf 
patients receiving iv antibiotics at home. Home patients _ Booth Hall speak to Soni Bhatt.
___________10 HPN paediatric, Caremark just provide the bags. Send a questionnaire.___________
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Survey No 171 Region NW Pharmacy 2  Send questionnaire 2
Comments Aseptic unit. Make up antibiotics for cf patients to use at home in the unit and give them a 
___________7 day expiry as we have no licence. Patients who need home chemotherapy go to Christies.
Survey No 172 Region NW Pharmacy • 2  Send questionnaire 2
Comments Aseptic unit. One patient treated with ganciclovir at home using an eclipse device. Make 
up in an unlicenced unit. (Spoke to Jeanette but she's going on maternity leave so send to 
___________ Lynn)._________________________________________________________________
Survey No 174 Region NW Pharmacy 2  Send questionnaire 2
Comments Aseptic unit - unlicenced. Patients who have tpn at home are managed by Hope Hospital . 
___________in Manchester. Have thallasaemics who are funded from region._____________________
Survey No 176 Region NW Pharmacy 2  Send questionnaire 2
Comments No aseptic unit. Not many patients having home care but those who do arrange with
Caremark to look after them. Have had patient receiving intensive antibiotics at home and 
also a tpn patient that Caremark dealt with. Quite a lot of input from pharmacy staff. Will 
___________answer questionnaire._____________________________________________________
Survey No 177 Region NW Pharmacy 2  Send questionnaire 2
Comments Acting Sterile Production Manager. Licenced aseptic unit Have 2 home TPN patients. 
___________TPN is made up in the unit. Don't have anything else._____________________________
Survey No 178 Region NW Pharmacy 2  Send questionnaire 63
Comments Unlicenced aseptic unit. Yes do hane HTHH patients. 1 home TPn which we make
ourselves and 2 which are looked after by central Homecare. Occasionally have home iv 
___________antibiotics which are dealt with by commercial home care company.___________________
Survey No 180 Region NW Pharmacy 2  Send questionnaire 2
Comments Licenced aseptic unit. Make up home TPN and also ceredase infusions.
Survey No 182 Region NW Pharmacy 2  Send questionnaire 63
Comments Unlicenced aseptic unit. Do home gemcitabine for non-small cell lung cancer and
ganciclovir post-transplant (give it a 5 day expiry). Have 220 adult cf patients, more than 
we can cope with. Will now only acccept cf patients as adult at 18 rather than 16 which 
was the age in the past, shame becausedont build up such a close relationship with the 
patients when you don't get them until 18. Occasionally make up antibiotics for someone 
who is critically ill but able to stay at home. Could not cope with the work load to make 
them up for all these patients for their regular treatments. Have a large region to cover so 
transport would also be a difficult problem. Spend £90,000/month on the drugs bill for cf
_______ patients already. I think we provide a poor aseptic service but I'll fill in the questionnaire..
Survey No 184 Region NW Pharmacy 63 Send questionnaire 2
Comments Unlicenced aseptic unit. Don't have any patients currently being treated at home. Did have 
one tpn patient for a short time. Have also done ganciclovir and vincristine/adriamycin or 
___________vincristine/mitozantrone as a 4 day infusion as part of the VAD regime.________________
Survey No 186 Region NW Pharmacy 2  Send questionnaire 2
Comments Unlicenced aseptic unit. Occasionally have paediatric patients who have home
antibiotics. Hospital at home nurses take drugs that are made up in the unit to the patients 
home. They are given a 3 day expiry. It's mostly cf patients and occasionally for 
meningitis. Caremark do the home TPN I think and patients who need chemotherapy 
___________come in to the day case unit to have it._________________________________________
Survey No 187 Region NW Pharmacy 2  Send questionnaire 2
Comments Unlicenced aseptic unit. Do home TPN for one patient but it is generally catered for by
Hope Hospital. Home ivs for paediatrics, the home care sisters go in on a daily basis to the 
___________patient's home to administer.________________________________________________
Survey No 191 Region NW Pharmacy 2  Send questionnaire 2
Comments Unlicenced aseptic unit. Hope Hospital in Salford deal with the home TPN and have TPN 
compounding unit. Christies have a Baxter chemo unit and deal with that. We have one 
___________lady who we make up a desfemoxamine cassette for.________ __________ _________
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Survey No 192 Region NW Pharmacy 0  Send questionnaire 0
Comments Unlicenced aseptic unit. Only have one HIV patient who collects his foscamet from us 
___________once/week.______________________________________________________________
Survey No 194 Region NW Pharmacy 0  Send questionnaire 0
Comments Unlicenced asepic unit. Had a TPN patient who was referred to Caremark and we had no 
input. We have an asthmatic patient on aminophylline. CF patients reconstitute and 
administer the antibiotics at home themselves. The respiratory nurse looks after them. 
___________Pharmacists really only have an input when they are admitted.________________________
Survey No 195 Region NW Pharmacy 0  Send questionnaire 0
Comments Unlicenced aseptic unit. Don't have anyone right now. Have had someone on vancomycin • 
___________at home over the last two weeks. John-tech____________________________________
Survey No 207 Region S&W Pharmacy 0  Send questionnaire 0
Comments Have a licenced aseptic unit. Make up terbutaline infusions for 7 patients. Had one tpn 
___________patient but Caremark do it, don't even know if it is still current.________________________
Survey No 208 Region S&W Pharmacy 0  Send questionnaire 0
Comments Aseptic. Have had patients at home treated on an ad hoc basis. Fill the bags of Walkmed 
pumps for chemo patients and McMllan nurse sorts out the pump. Don't make up any 
antibiotic infusions, community paediatric nurse trains patients to draw it up themselves.
May even go through GP. Desferriaxamine, diamond black fan - patient chooses to come inr’
___________for treatment, father consultant, mother gp._______  ______________________
Survey No 212 Region S&W Pharmacy 0  Send questionnaire 0
Comments Sterile manufacturing unit. Sue Harding/Adele Jones job-share. Make up terbutaline in
intermate devices. Just started. Hope to take on TPN but Caremark do it now. Have been 
___________asked to do deferral but at the moment the patients come in to have 'it administered._______
Survey No 214 Region S&W Pharmacy 0  Send questionnaire 0
Comments Unlicenced aseptic unit No input. 1 anorexic man had TPN at home. Had 50 days TPN 
before fit enough for surgery. Aseptic unit made it up and he came in on a couple of days 
a week for a review of his condition and to collect One chemo patient has 4 days of 
vincristine/doxorubicin made up. Don't know of anything else. Paediatrics and chest
___________patients with long term infections have antibiotics at home but manipulate them themselves.
Survey No 219 Region S&W Pharmacy 0  Send questionnaire 0
Comments Licenced aseptic unit. Provide HTHH.
Survey No 220 Region S&W Pharmacy 0  Send questionnaire 0
Comments Occasionally have an oncology patient who wants to go home for a while but is on TPN, the
bed is usually kept for them and we make up 3 bags for example to allow them to go home
but they can come back in any time that they feel ill. Have patients on Baxter infusers or 
Graseby pumps, VADD regime. Have one patient on desfenrioxamine but don't do any
___________home iv antibiotics._________________________  ______________________
Survey No 222 Region S&W Pharmacy 0  Send questionnaire 0
Comments Licenced Manufacturing Unit separate from the pharmacy at Queen Alexandra Hospital.
Bob Lucas, Pharmacist yes, the number varies. Now supply 1 adult on home TPN , make 
up the bags and the flush syringes. Also provide TPN for other hospitals, sometimes 
people can not cope with the demand or do not have licenced facility so can not give long 
enough expiry.Jacky Collett the nutrition nurse co-ordinates the home patients and takes 
responsibility for implementing and setting up home care as we are purely a manufacturing 
unit with no association to the pharmacy. Major companies still get involved like Baxter, 
Kabi, Fresenius, Unicare, Health Care at Home. Have some cf patients receiving iv 
antibiotics. St Maryd deal with chemo speak to Tracey Evans. Do have home 
chemotherapy. We make up but it is all dealt with by the oncology/haematology nurses at 
___________QA._____________________________________ ________________________
Survey No 223 Region S&W Pharmacy 0  Send questionnaire 0
Comments Unlicenced aseptic unit. Had 1 TPN patient who died ages ago. Have home antibiotics eg 
ganciclovir but a commercial company deal with it. Heamatology patients come to the ward 
___________to receive d ru g s ._______________________________________________________
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Survey No 224 Region S&W Pharmacy 0  Send questionnaire 0
Comments Aseptic unit. Paul Evans Haematolgy Pharmacist ext 2596. Have 3-4 patients and
negotiate on an individual basis with Caremark for each patient I for example a patient 
needs to finish a 10 day course of antibiotics like ceftazidime and they have the last 4 days 
at home they will make K up in the pharmacy but any long term patients such as cf patients 
or the 1 -2 Gaucher's Disease patients are dealt with by Caremark. I think we have one 
__________ TPN patient being looked after by Plymouth and the HA pay directly for that, PHT sort it out.
Survey No 225 Region S&W Pharmacy 0  Send questionnaire 0
Comments see pilot
Survey No 227 Region S&W Pharmacy 0  Send questionnaire 0
Comments Lesley Woodhouse need to speak to her qun sent 4/12/97(A) Aseptic unit Do have 
patients on home IV rehydration electrolyte fluids, home antibiotics, TPN and make up 
bags for Walkmed pumps for home epidurals.
Jacky Davies (6). Have a satellite pharmacy in the Radiotherapy/Oncology Dept that make 
up chemo. Make up chemo for Health Care at Home. Do quite a bit but most people they 
■______ supply live in the Bristol area.________________________________________________
Survey No 228 Region S&W Pharmacy 0  Send questionnaire 0
Comments Unlicenced aseptic unit ext 4450 Have one home TPN patient in Jersey who has been
___________feeding for 15-16 years. Fly it over from Southampton.____________________________
Survey No 229 Region S&W Pharmacy 0  Send questionnaire 0
Comments No aseptic. Not involved in the supply. TPN is supplied by a commercial company
ordered through the District Nurse budget. Mr Brian Cope is the nurse responsible for the 
DNs 330236. Pharmacy have no involvement with TPN patients as commercial company 
contact patient on discharge and they are usually discharged from the acute Trust. We are 
the point of contact if there are any pharmaceutical problems with patients receiving 
chemotherapy at home but nurses just go in and drw up sraihgt forward injections 
otherwise the patient goes to the hospital. Community Services Pharmacist based in a 
Pharmacy in a Health centre with another pharmacist running the shop. Have 4 community
___________hospitals._______________________________________________________________
Survey No 230 Region S&W Pharmacy 0  Send questionnaire 0
Comments Have some HTHH patients will complete questionnaire.
Survey No 232 Region S&W Pharmacy ®  Send questionnaire 0
Comments Unlicenced aseptic unit. The Health Commission contract directly with Caremark. 4 TPN 
patients 3 attend the hospital nutrition clinic one is dealt with by Hope Hospital and the only 
___________input is that the Health Commission pay the bill._________________________________
Survey No 233 Region S&W Pharmacy 0  Send questionnaire 0
Comments Licneced aseptic unit Home TPN patient supplied by BRI. Would supply ganciclovir at 
___________home but have no need for it at the moment____________________________________
Survey No 234 Region S&W Pharmacy 0  Send questionnaire 0
Comments Unlicenced aseptic unit. No HPN. Have some home chemo in intermate devices which 
the DN goes out to change. Have taken over from Oxford in supplying these patients.
Have patients on home iv antibiotics but think they make them up themselves the 
___________dispensary deal with it Spoke to Ewan covering for Lindsay._______________________
Survey No 235 Region S&W Pharmacy 0  Send questionnaire 0
Comments Licenced aseptic unit. Have a couple of patients on algluterase. 1 is made up in the 
___________aseptic unit, the other the patient makes up for themselves._________________________
Survey No 237 Region S&W Pharmacy 0  Send questionnaire 0
Comments
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Survey No 238 Region S&W Pharmacy 0  Send questionnaire 0
Comments Donl have any patients at the moment Have had iv antibiotics, ganciclovir and one TPN 
patient A company, Baxter or someone supplied it We are not a licenced unit and at the 
moment have no unit as work is being done. We buy what we need from Portsmouth. 
___________ Spoke to Senior Tech Alison Thomas.
Survey No 244 Region ST Pharmacy 0  Send questionnaire 0
Comments Unlicenced aseptic unit. Have patients on home chemotherapy via Graseby pumps who - 
___________come in once a week. Buy the syringes in from Caremark.__________________________
Survey No 250 Region ST Pharmacy 0  Send questionnaire 0
Comments No home TPN patients. Paedatric ward sends patients home on iv antibiotics but we donl' * 
make them up. Have a paediatric home care team. Nurses go in to administer the 
___________ antibiotics. Have one patient on desferral and we get Central to make that up.___________
Survey No 256 Region ST Pharmacy 0  Send questionnaire 0
Comments Primarily cf patients on antibiotics but we do not make them up. Send us a questionnaire 
___________and we'll see if we think that we have any information useful to you.___________________
Survey No 257 Region ST Pharmacy 0  Send questionnaire 0
Comments Unlicenced aseptic unit No HPN. Have patients on CADD pumps receiving 5FU for 7 
days. Also have a desferrioxamine patient Send questionnaire and HI pass it on to a 
___________ colleague who knows more about it than I do.___________________________________
Survey No 258 Region ST Pharmacy 0  Send questionnaire 0
Comments Pharmacists and technicians counsel patients with pumps for chemo mostly 5FU. It is all 
dealt with through pharmacy. Oncology (A) Mrs Roselyn Shakespeare-Miller, Senior 
Tech, Howard Rogers Pharmacy, Samaritan Ward, 8th Floor, New Guy’s House, Guy’s 
Hospital, SE1 9RT. Send 2 questionnaires and I will pass the other to the most 
appropriate person in the Manufacturing Unit (B), they make up ganciclovir etc. St 
Thomas' - no HTHH from here Paul Tunstall at Guy’s is trying to set up a home ganciclovir 
___________ program.________________________________________________________________
Survey No 259 Region ST Pharmacy 0  Send questionnaire 0
Comments Aseptic unit. Have patients who come in onceAveek for pump change for their 5FU but that 
___________ is all.______________________________________________________
Survey No 261 Region ST Pharmacy 0  Send questionnaire 0
Comments Aseptic unit. Have no HPN. Once years ago had a nurse who was terminally ill and did it 
for a short time for her. We have a pilot project giong on in our cancer centre where 
nurses are sent out to give chemo to patients at home. There is a Homecare team for 
paediatric oncology and they sometimes have 4 days of cytarabine. Have patients with 
5FU pumps who come in to the cancer centre once/week to have them changed. 
___________Pharmacists do have a clinical input before the drug leaves the dept, check bloods etc.
Survey No 262 Region ST Pharmacy 0  Send questionnaire 0
Comments Small aseptic. Had one patient on doxorubicin/vincristine 4 day infusions.
Survey No 263 Region ST Pharmacy 0  Send questionnaire 0
Comments Presently unlicenced aseptic unit but hope to get one soon. Have 3 adults on HPN and 
one child. We are just about to start a second child. We also have cf patients with 
antibiotics etc. We do not make them ourselves but use a commercial company and the
___________Royal Free make it up for the company._______________________________________
Survey No 267 Region ST Pharmacy 0  Send questionnaire 0
Comments Aseptic. No home chemo. Home TPN supplied by Caremark. Home antibiotics supplied
___________by Lily. Don't make up any ourselves. Sometimes dispense iv antibiotics on a TTA.
Survey No 269 Region ST Pharmacy 0  Send questionnaire 0
Comments Unlicenced aseptic unit. Had a child on TPN. Buy in ready prepared bags and make 
additions.
Page 11 o f 15
Survey No 271 Region ST Pharmacy 0  Send questionnaire 0
Comments Unlicenced aspetic unit. Satellite oncology pharmacy, some patients have 24 hour pumps. 
We have one shared care patient with St Georges. We used to sort out the TPN but St 
Georges do it now because it got too complex for the doctors and pharmacists here. Have 
the odd cf patient who does their own antibiotics at home. Do not provide much of a 
___________CIVAS service. Will fill in quesionnaire then pass to oncology pharmacist to complete.
Survey No 275 Region ST Pharmacy 0  Send questionnaire 0
Comments Deal mostly with Mantal Health and Learning disabilities. Have a hospital at home scheme 
and pharmacist visits to assess pharmaceutical needs. Send questionnaire and I'll show it 
___________to Beth and ask if we have any input._________________________________________
Survey No 282 Region ST Pharmacy 0  Send questionnaire 0
Comments Aseptic unit. Have a number of patients on 5FU at home. ECF Regime. Occasionally 
__________ have a HPN patient, only had 2-3 ever.________________________________________
Survey No 283 Region ST Pharmacy 0  Send questionnaire 0
Comments Unlicenced aseptic unit. No-one at the moment, have had a number of people in the past 
TPN, cf antibiotics, HIV ganciclovir, desferral. Have also supplied special insulin dilutions, 
___________epidurals for terminal patients and terbutaline infusions.___________________________
Survey No 286 Region ST Pharmacy 0  Send questionnaire 0
Comments Unlicenced aseptic unit, nil pumps for 7 day continuous infusions of chemotherapy but 
just supply the drugs. Chemotherapy nurses have all the other input, counselling patients 
etc. Have had a couple of TPN patients I think but pharmacy did not get involved. I will try"
__________ and find out who did it. Send a questionnaire.__________________________________
Survey No 287 Region ST Pharmacy 0  Send questionnaire 0
Comments Make up 5FU pumps in a licenced manufacturing unit. Pharmacy have a lot of input.
Survey No 292 Region South Th Pharmacy 0  Send questionnaire 0
Comments Aseptic unit being refurbished. Only have continuous chemotherapy. Will complete 
___________questionnaire.___________________________________________________________
Survey No 297 Region ST Pharmacy 0  Send questionnaire 0
Comments Do the odd chemotherapy pump for VADD regime. Have problems with or air handling unit 
___________so cant do TPN etc at the moment.___________________________________________
Survey No 300 Region Trent Pharmacy 0  Send questionnaire 0
Comments Unlicenced aseptic unit. It is a rare occurrence. Have one patient curmetly on intermittent 
courses of cytarabine subcutaneously and he has been taught to give himself twice daily 
injections for a week, repeated roughly every month. Have a patient who has ganciclovir at 
home, she comes to the hospital once/week and picks up a weeks supply. I think the DN 
goes in and infuses it. Most of the TPN etc is based at Sheffield. Have had HPN in 
___________distant past for scleroderma patient.___________________________________________
Survey No 302 Region Trent Pharmacy 0  Send questionnaire 0
Comments Mansfield Community Hospital. Yes we do home iv antibiotics. We don't have any
manufacturing facility. We started an intensive home support scheme a month ago. There 
are currently 10 patients being looked after in their homes either referred from hopistal or 
by their gp. The pharmacist visits them. Nurse make up the antibiotics in the patients 
___________home. Pharmacist gives advice. Send questionnaire._____________________________
Survey No 303 Region Trent Pharmacy 0  Send questionnaire 0
Comments Make up antibiotics for cf patients etc in licenced part of pharmacy. Use a commercial 
___________homecare company to supply TPN.___________________________________________
Survey No 304 Region Trent Pharmacy 0  Send questionnaire 0
Comments Aseptic unit. Most HTHH is from tertiary referral centres in Manchester or Leeds. Did 
make up algluterase for 3-4 months to allow time for Caremark to sort out taking over. 
___________Summer symposium BAPEN July next year, will you present your work?______________ _
Sun’ey No 307 Region Trent Pharmacy 0  Send questionnaire 0
Comments Yes have intensive home nursing service. Don't get involved with the supply. Do iv 
__________ antibiotics at home and iv fluids for rehydration.
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Survey No 308 Region Trent Pharmacy ®  Send questionnaire 0
Comments Unlicenced aseptic unit. Most of the HTHH patients would be looked after by the DRI. We
do supply desferral for paediatrics. We have a nutrition sister but the DRI would take over
___________if needed HPN._________________________________________________ _________
Survey No 309 Region Trent Pharmacy • ®  Send questionnaire ®
Comments Yes we do it. Yes HI fill in the questionnaire.
Survey No 312 Region Trent Pharmacy D  Send questionnaire 0
Comments No pharmacy but have a pharmacist. Yes we operate a hopsital at home service.
Antibiotics etc are probably made up in the patient's home or bought ready prepared. Nova 
Pharmaceuticals prepare in their manufacturing unit, provide ready prepared chemotherapy 
syringes. Fosse Trust provides nursing input, gp generally looks after the patient. 
___________Leicestershire DG Hospitals provide guidance to the gps.___________ ________
Survey No 315 Region Trent Pharmacy W  Send questionnaire ®
Comments No TPN or antibiotics but we do CADD pumps for chemotherapy in a licenced aseptic unit.
Survey No 317 Region Trent Pharmacy ®  Send questionnaire ®
Comments Unlicenced aseptic unft. Occasionally make up iv antibiotics for patients to use at home.
Use Caremark for other things such as desferal. Have 1 -2 TPNs that either Caremark or 
another company deal with. Chemotherapy we provide from the lab. The ECF regime that
___________we used to do seems to have died a death recently. ______________________
Survey No 318 Region Trent Pharmacy ^  Send questionnaire ®
Comments Unlicenced aseptic unit. Have one patient on HPN which we get from Clinitec, Baxter's 
division. We do the additives and package it off to the patient. Chemotherapy use Baxter 
___________infusers and CADD pumps forSFU.______________________________________ ___
Survey No 321 Region Trent Pharmacy ®  Send questionnaire ®
Comments Unlicenced aseptic unit working under Section 10 exemption. Have cf patients on
. antibiotics but currently this is mostly provided by Caremark. Have one domiciliary TPN 
patient under the care of Sheffield, feeds come from Caremark and are organised by the 
Northern General. Patients on home treatment for CMV we make up their ganciclovir in 
our cytotoxic suite. 3-4 patients are having adjunct continuous chemotherapy, 5FU. Make 
up 7 days supply in house. Also do 2-3 days of vincristine and doxorubicin. Have looked 
___________at doing the cf antibiotics ourselves but funding issues are a problem.________________
Survey No 322 Region Trent Pharmacy ^  Send questionnaire ®
Comments Unlicenced aseptic unit. Have TPN patients at home but we do not make it up ourselves a 
___________commercial company does_it._______________________________________________
Survey No 323 Region Trent Pharmacy ®  Send questionnaire ®
Comments Licenced aseptic unit but make up home iv antibiotics for cf patients as a special in 
unlicenced unit. Sometimes we make them up and other times we use a commercial 
___________company.______________________________________________________________
Survey No 327 Region Trent Pharmacy ®  Send questionnaire ®
Comments Aseptic unit. Just do home TPN which we make up ourselves in a licenced unit.
Survey No 330 Region Trent Pharmacy Send questionnaire
Comments Aseptic unit. No HPN, one patient on 5FU infusion via a graseby pump. Have some cf 
patients whose parents are trained to make up and administer antibiotics. No iv additive 
service in operation. Ganciclovir and ceredase patients come to the ward for 
administration. Couple of patients on HPN prescribed and provided by other hospitals.
__________ May be 3-4, HA pays._______________________________________________
Survey No 332 Region Trent Pharmacy ^  Send questionnaire ®
Comments Unlicenced aseptic unit. Yes do it for odd patients. We make it up ourselves at the 
__________ moment but are about to dose for three months for thre aseptic facilities to be upgraded.
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Survey No 335 Region Trent Pharmacy E  Send questionnaire E  
Comments Chemotherapy aseptic unit. No HPN. 1 lady on 5FU infusion.
Survey No 337 Region WM Pharmacy- E  Send questionnaire E
Comments Aseptic unit. Yes we do have patients. Send the questionnaire l*m in a meeting at the 
___________moment.______________________________________________________________'
Survey No 338 Region WM Pharmacy E  Send questionnaire E
Comments Unlicenced aseptic unit Have the odd home TPn patient dealt with by Caremark and use . 
___________ready made Baxter's antibiotics for cf patients. Mike, Pharmacist, Yvonne cytotoxics._____
Survey No 341 Region WM Pharmacy E  Send questionnaire E
Comments Unlicenced aseptic unit. Donl have anyone at present Have the occasional patient on 
___________chemotherapy via Baxter infusers and we provide that_____________________________
Survey No 342 Region WM Pharmacy E  Send questionnaire E
Comments Aseptic unit Have the odd one. Desferrioxamine for a sickle cell patient and probably 
some home chemotherapy. Send the questionnaire to Brian Hebrown, Principal 
___________ Pharmacist._____________________________________________________________
Survey No 344 Region WM Pharmacy E  Send questionnaire E
Comments Unlicenced aseptic unit Make up 7 day 5FU pumps in the unit. Have ask) done HPN in 
___________the past. Will fill in chemo bit and then pass on to Sharon Ford to answer about the TPN.
Survey No 349 Region WM Pharmacy E  Send questionnaire E
Comments Aseptic unit = isolators. None at the moment. Had 2 patients on HPN Caremarfc supplied 
___________everything.______________________________________________________________
Survey No 352 Region WM Pharmacy E  Send questionnaire E
Comments Make up chemo but everyone comes in to the hospital to have it administered. Sometimes 
people have doxorubicin/vincristine in Walkmed pumps. They come in to the hospital to 
have it started and stopped. They are given written information about what to do in case of
___________problems and a contact number.___________ . ______________________________
Survey No 355 Region WM Pharmacy E  Send questionnaire E
Comments Aseptic unit. Do iv antibiotics for cf adults and children. All HPN is dealt with in 
___________Manchester._____________________________________________________________
Survey No 359 Region WM Pharmacy E  Send questionnaire E
Comments Unlicenced aseptic unit. Have 2 patients on HPN, one patient who has brittle asthma we 
make up colomycin for nebutisation amd terbutaline for infusion. We also make up 
___________methotrexate syringes for sub-cutaneous use in a child weekly.______________________
Survey No 362 Region WM Pharmacy E  Send questionnaire E
Comments Unlicenced aseptic unit. Andrea Foster. We do make up bags for a HPN patient. We do 
___________not supply antibiotics etc.___________________________________________________
Survey No 363 Region WM Pharmacy E  Send questionnaire E
Comments Unlicenced aseptic unit. No HPN. Few antibiotics for children on the hospital at home 
___________scheme. Also have a desferal patient_________________________________________
Survey No 365 Region WM Pharmacy E  Send questionnaire E
Comments Unlicenced aseptic unit. Did have a patient on HPN a while ago and would offer the
service. Currently provide no antibiotics but there is interest in this and we are looking into 
it. Don't really advocate home chemo but do syringe drivers and elastomeric devices on an
___________ad hoc basis.____________________________________________________________
Survey No 367 Region WM Pharmacy 1—1 Send questionnaire E
Comments No pharmacy but have a pharmacist.
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Survey No 368 Region WM Pharmacy ®  Send questionnaire ®
Comments Licenced aseptic unit. Rarely provide ganciclovir or desferal for use at home. About
___________once/year.______________________________________________________________
Survey No 371 Region WM Pharmacy ®  Send questionnaire ®
Comments Caroline Hamilton. We have 2 hospitals in Sellly Oak and it is all done at the Queen
Elizabeth site. Speak to Jo Humphries-> 3 patients on HPN. Looked after by the clinical 
nurse specialist Lynn Colodjiavaney. Buy from Caremark, Fresenius. IV antibiotics for cf 
are dealt with by Harlands Hospital which is a different Trust. We also do chemo for 
patients at home speak to Jim Baker -> Unlicenced aseptic unit, not yet submitted for
___________inspection. Make up chemo for patients to use at home in our unit._____________
Survey No 373 Region WM Pharmacy ^  Send questionnaire
Comments Aseptic unit. Had one patient on home chemotherapy to finish a course. Do have a home 
chemo nurse. Do not use oumps as the delivery system, have very minimal input.
___________Patients generally attend the outpatient clinic.___________________________________
Survey No 374 Region WM Pharmacy ®  Send questionnaire ®
Comments Unlcenced aseptic unit but opening new premises at the end of March. Do have patients 
who have desferral in home pumps but might change this because don't have the stability 
data. Also provide continuous 5FU for oncology, provide syringes of 5FU for Graseby 
drivers.
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74 4 £1,000.00 for pharmaceuticals only (?other costs)
79 70 £170,000.00
83 8 £150,000.00 1 pt £80,000 
total estimated
cost £50,000 pa on drugs alone.
Note: 1 patient on continuous antibiotics awaiting 
heart/lung transplant, total cost of drugs alone 
approx £80,000 pa
3 patients on regimes containing meropenem 
therefore cost of drugs alo
116 2 £10,000.00 less than? drugs only
123 130 £400,000.00
146 3 £15,000.00
165 6 £10,000.00 of which hospital £6000-£8000. Hospital 
pharmacy normally provides vials and diluents but 
on occasion we have supplied ready to use 
prefilled syringes. If Gp supply then they only 
provide vials and diluents.
171 8 £15,700.00 drugs only, current year projected.
219 2 £10,000.00
227 1 £25,000.00
230 2 £3,500.00 £3-4000 on iv antibitoics alone
244 2 £3,000.00 Drugs only about £500 per 2 week course, an 




323 47 £100,000.00 (Pharmacy 10% only)
332 3 £10,000.00
355 32 £60,000.00 drugs/on call
Expenditure On Chemotherapy, Trust Questionnaire
Survey no 
1




74 4 £5,000.00 for pharmaceuticals only (?other costs)
83 8 £60,000.00
116 4 £10,000.00 less than? drugs etc
117 6 £63,000.00
174 3 £8,000.00
208 5 sorry do not know equipment costs. Drug 
costs less than £10,000 but this could change
223 £25,000.00 only 5FU continuous infusions
228 5 £10,000.00
234 2 £10,000.00 approx
258 27 £30,000.00 approx
261 12 £300,000.00 approx £30 per bag
271 20 £70,000.00 drugs and equipment
292 10 £20,000.00 drugs
323 £20,000.00 home
373 1 £160.00 Supply chemotherapy only. 
Course now complete.
999 14 £50,000.00
Expenditure On Anti-virals For HIV, Trust Questionnaire












Expenditure On Home Parenteral Nutrition (HPN) For Adults, Trust
Questionnaire
Survey no No of patients expenditure explanation
1 8 £250,000.00
3 1 £10,000.00
53 2 £20,000.00 cost varies - pharmacy cost for TPN only £20,000pa
72 5 £80,000.00
103 1 £32,500.00 approx £30,000-£35,000
177 2 £100,000.00
208 2 Drug costs about £400
219 2 £60,000.00
227 1 £60,000.00 Part service of TPN
228 1 £10,000.00 excludes transport costs and equipment used by 
patient
230 1 £35,000.00
282 1 £100 per day of TPN
303 4 £130,000.00





Expenditure On HPN For Children, Trust Questionnaire
Survey no No of patients expenditure explanation
1 3 £90,000.00
98 12 £700,000.00 approx
219 1 £30,000.00
230 1 £35,000.00
287 2 £80,000.00 approx 40,000 per patient
327 1 £25,000.00
332 1 £15,000.00 £10-20K
337 5 £220,000.00
362 2 £100,000.00
Expenditure On Desferrioxamine For Patients At Home, Trust Questionnaire





79 10 £32,000.00 Desferral TTOs and desferral syringes in 
outpatients approx = £32,000 drug cost




230 1 £500.00 drug alone
250 1 £2,000.00
317 15 £10,000.00 for one patient on homecare pack, considerably 




352 1 £2,196.00 so far!
999 1 £10,000.00
Expenditure On Other Home Infusions, Trust Questionnaire
Survey no specify No of patients expenditure explanation
12 aglucerase 1 £22,248.00
17 immunoglobulin 1 £50,000.00
28 home iv antibiotics 60 £20,000.00 drugs, ancillaries not 
costed.
72 Gaucher*s Disease/Ceredase 1 £30,000.00
72 immunoglobulin 1 £20,000.00
79 G-CSF 12 £52,000.00 G-CSF at home approx 
£52,000 drug cost not inc 
technical support and 
preparation of syringes
98 Cerdase 1 £120,000.00 approx
98 home CAPD 38 £500,000.00 approx
116 antibiotics - paeds eg 
meningitis once daily
0 £10,000.00 less than?
131 2 x Gaucher's Disease 
receiving Cerezyme 1x 
chronic liver pt receiving 
antibiotics
3 £500,000.00 drugs only
194 patient receiving 
aminophylline infusion
1 £30,000.00
230 iv immunoglobulins, lloprost 2 £8000 Sandoglob 
£60,000 lloprost
283 home epidurals -occasionally
332 2-3 oncology patients receive 
line Iocs for home use
£0-1 OK
359 Child methotrexate -arthritis 0 £4000 - not clear if this is for
the adult on terbutaline or




Trust Survey: H T H H  worked best, barriers and other comments
Survey no: ll
worked best TPN more predictable and history of pharmacy involvement.
barriers Unco-ordinated as an entity eg Nutrition team deal with TPN, Dialysis unit 
deal with dialysis etc
further comments jno
Survey no: 7




further comments Dear Jill
Many thanks for sending the questionnaires. Trust provides 
community services but the Trust has no pharmacy of it's own. 
Pharmaceutical supply and advice is provided by the Ipswich Hospital 
NHS Trust (acute hospital).
The majority of patients who have home infusional therapy, have treatment 
initiated at the Ipswich hospital with link nurses etc based at the hospital 
monitoring patients in the community. Supply of advice and drugs are 
provided by the appropriate specialist pharmacists at the Ipswich Hospital 
NHS Trust. I have therefore passed on one questionnaire to the most 
appropriate pharmacist at the hospital.
Allington Trust may provide district nursing care etc, to support the care 
provided by the acute unit. From discussions with various staff at 
Allington Trust I gather the role of staff in hi-tech health care at home is 
limited, training has begun on intravenous antibiotic administration by 
district nurses. The pharmacy input is therefore very limited and tends to 
be reactive rather than a proactive role. We hope this will develop 
gradually.
The information I can provide is therefore limited. If I can provide further 
information please contact me on 01473 703606/5/4.
I wish you all the best with your research.
Best wishes
Survey no: 3l
worked best chemotherapy - regimens where patients had to sit in hsopital while the 




worked best |HIV - possibly because of their interest in self-medicating at home
barriers |fmancial support
further comments




further comments As a DGH we don’t treat many of these patient groups. The two patients 
we have are entirely managed by a commercial home care company, the 
main pharmacy input being in the setting up of the contracts and basing 










Survey no: _ .. 27l
worked best iv antibiotic patients, organised system, good communication, follow-up, 
records, support for pt/carers and PHCTs
barriers No real barriers - just sheer volume of patients at times for 2 woman home 
iv team to cope with.
further comments This isn't a very easy questionnaire to complete as I work for the 
community Trust and cover all the acute hospitals so provide iv therapy 
broadly so it’s difficult to answer questions that are specific. Please ring 
me if you need further information as I don't think this questionnaire does 
our service justice.
I was very involved in the early stages of setting up the home iv service 
from this hospital - esp in formulating protocols. Since then I have had to 
take a step back due to lack of time - but Jill, the doctors and 
microbiologists and I liase closely.
Survey no: 28l
worked best
barriers Complexity of drug regimens - tds and qds regimen impossible for a 








barriers '  ........................ - " ................. ' — 1i
further comments !
j




further comments r _ ..is a Community Trust with mostly rehab and 
psychistric beds. There is a palliative care ward but they do not do any hi- 
tech treatment at home.
Survey no: T7l
worked best 1) "ECF" Regime chemotherapy (21 days continuous 5FU)
2) Barts Regime (48 hours continuous 5FU)
Patients carrying on near normal life, not tied to large infusion volume 
IMED.
barriers ! ■ - 1 - - I
further comments
Survey no: 4 si
worked best All patients prefer to be treated at home. So far there has been no major 
problems, service has been well received.







program not up and running yet, cannot answer the questions in the 
questionnaire.
Survey no: 1—  . 53
worked best
barriers
. . .  ..  . _
_ j
further comments Very rarely have patients on home therapy. Usually TPN patients for a 
few months. Recently home TPN patients have been taken over by 
commercial companies who have a less flexible approach to formulation 
changes such that the pharmacy depatment prepare bags when regimes 






worked best cystic fibrosis - no other group known
barriers
further comments Only area the pharmacy is routinely involved with is cystic fibrosis - pts 
make up the drugs themselves though we do have the facilities but not the 
funding. TPN patient known about though no other details. Best of luck 
with the study.
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Survey no: . 72l
worked best Nutrition.
Well managed team approach.
barriers Finanace limited by purchaser.
further comments
Survey no: 74
worked best Too little real experience to answer properly - it works for both (limited) 
groups of patients.
barriers
further comments As I said when we spoke on the phone our experience of home iv therapy is 
very limited - please analyse the answers with this in mind!






worked best Chemotherapy delivery has been successful. Caremark delivery of 5FU is 
reliable. Haematology patients receive chemotherapy prepared in-house, 
always commenced in hospital. Assessment of these patients is thorough.
barriers { covers a larfe rural population, therefore delivery of products 
prepared in-house is difficult - transport could be more efficient!
Some child cystics are known to be poor compliers but are unwilling to be 
inpatients, therefore some improvement in selection and training may lead 
to better compliance.
further comments I feel the pharmacy department is supllying hi-tech care to cystics ’on 
demand' without the back-up systems in place - similarly demand for 'one- 
off epidural infusion at home is increasing, without sufficient liason (in my 
opinion) between district nurse/GP/hospital consultant re role and 
responsibility.
Survey no: . . 88
worked best
barriers
further comments All our TPN patients are referred to St Mark's. Most oncology patients go 
to the Hammersmith, we do not use home chemo just day care.
We have a collaborative care team who administer antibiotics etc at home. 
Our HIV patients go to St Mary's.
We have a sickle cell centre in Brent.
Survey no: 90
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Survey no: 9?l
worked best HIV patient - patients empowered and good compliance in this group.
barriers None
fu rther comments 1_ J
Survey no: 9fil
worked best I
barriers being unable to find out what is currently happening
fu rth er comments The situation is very complex -diffuse and vague accountability -very 
fragmented. In short - a mess!
Survey no: 98
worked best Home TPN - enables patient to leave hospitaland achieve some measure of 
normal life.
Home CAPD for same reason.
barriers No problems with purchasers re TPN, CAPD but there may be problems 
in home environment. Ability of carer to cope, support available in 
community.
fu rth er comments Please note: we are a tertiary referral centre with a number of purchasers. 
If  possible we refer patinets back to secondary centre - who may then 
institute a home care package themselves. For those purchasers who do 
not wish for our TPN package we charge a nursing element only.
Survey no: 99l




worked best Motivated transplant recipients (especially cystic fibrosis transplants).
barriers Timing, patient competence, monitoring.








fu rth er comments
—i
J
Survey no: m l
worked best (ancology patients - convenience/clinical indication/patient acceptability
barriers
fu r th e r  com m ents
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Survey no: 116l
worked best Chemotherapy only used at present. Can be used at home without keeping 
patient in hospital and essentially blocking bed.
barriers None
fu rther comments really sorry it's taken so long - good luck with your research, Marie.
Survey no: ...........  1171
worked best All patients seem happy with treatment apart from problems with the flow 
rates - common to all patients. . . ,
barriers cost, suitable suppliers
further comments
Survey no: 118
worked best Only do on TPN patients - works well because got dedicated team to teach 
patient, patients chosen for home care using strict protocols.
barriers mainly financial
fu rth er comments This is probably difficult to understand. We are a speciaist tertiary 
referral centre for GI disease therefore only see TPN patients that are 
suitable for home care. Wehave about 65 patients on home care TPN at 
present but they are not from local area. The hospital treats people from 
all over the country.
Survey no: 1231
worked best cystic fibrosis - our only group. We have large numbers of patients 
therefore familiarity with the system we have set up.
barriers In the past the response time of the homecare company has been a problem 
as need for antibiotics is not planned.
fu rth er comments Some answers incomplete as only recently taken over role of Acting Head.
Survey no: 1241
worked best The two areas we have particularly been involved with are TPN and 
Thallassaemia. TPN Has worked best because otherwise patients would 







Funding from the local HAs not available for all patients wanting home 
therapy and problems where a block contract does not cover sufficient 
patients. Where we are the tertiary provider some secondary providers 
anly being prepared to work with Caremark. This HAs also arisen where 
we are supposed to be providing care for paediatrics but a paediatric 
lospital will only work with Caremark.




We have a small number of our own patients on home care but also 
prepare TPN, Desferal, HIV treatment and antibiotics for patients based at 
Dther hospitals, either as direct contracts or through Health Care at Home. 
Fhe answers in brackets refer to patients based at other hospitals, the plain 
>nes are our own patients.
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Survey no: n il
worked best Gaucher's - frequency of treatment once a fortnight.
barriers Cost of HIV patients.
further comments I'm sorry it's such a mess! I’ve collected information from three different 
specialties; paediatrics, chemotherapy/production, HIV all involved in hi- 
tech therapy. Where involvement is different I've put which specialty. If 
no comment it is all or the remainder. I hope it is of use.
Survey no: __  133
worked best . _ **
barriers
further comments Dear Jill
We have decided that will include Trust in his 
questionnaire therefore I have not completed the form. ■ and 
. NHS Trust will be dealt with together.
Survey no: 142I
worked best Thallassaemics, because good communication/co-operation between 
haematologists and pharmacy.
barriers Poor communication between surgeons and pharmacy for home TPN.
further comments -
Survey no: 143
worked best Cystic fibrosis patients can receive treatment at home, less disruption to 
school
barriers Main barrier to us preparing iv antibiotics has been production unit 
facilities - now undergoing ugrade so we should be able to prepare in 
house so long as funding given. Bid is going to purchaser for us to prepare 








None of our patients receive hi-tech care at home. They are under the care 
Df specialised centres eg Christie Hospital who will then provide this 
>ervice.






thallaesaemics,cystics and TPN does work well.
EL(95)5 left grey areas such as diamorphine which IS hi-tech health care. 
Dear Jill
the Terminal Care service offered by our hospital started about 10 years 
ago when a lady was started on a syringe driver on a ward then wanted to 
go home for her last few days. Our transport agreed to deliver to her home 
daily, our aseptic unit was already running 7 days a week and the-staff all 
agreed that it was a very worthwhile product to provide.
This proved very successful for the patient and her relatives, but also 
created a very positive perception with the district nurses.
The IV additives service started in Burnley in 1972 and HAs developed 
over the years so that we now prepare almost 60000 units each year. This 
established the practice of pharmacists intervening and advising in the 
parenteral use of medicines almost from that time. I also develqped an 
interest in terminal care so that when the next requests arrived, I became 
involved in the development of the therapy.
This escalated over the next few years and in an attempt to validate the 
need for the service I started to enquire from the Gps the patient's clinical 
details, sometimes an equally effective and less intrusive approach was 
available ans acceptable, at the same time adjunct therapy could be 
discussed. As this developed, many GPs took on board the ideas and 
suggestions and became much more confident with very high doses (we 
have prepared and supplied lOOOOmg/day of diamorphine for one patient - 
yes 1 Ograms!) so that we are now often only involved in the difficult cases 
when our opinions are sought about symptom control and adequate 
analgesia. Communications with most GPs are now excellent with the 
community nurses involved as well.
The current level of service is for about 250 syringes each month for 
between 3 and 12 patients each day. The syringes are prepared daily and 
delivered to the patient’s home or nursing home each day by hospital 
transport. We obtain FPlOs for the legal nicety to supply, but cannot 
obtain any funding whatsover, costing the hospital at least £40000 each 
year.
The failure to include any services outside their small range of experience 
by personnel not at the 'sharp end' has, and will in the future, severely 
restrict and curtail any advance in patient care in this area.
We have tried every avenue to obtain external funding, all to no avail. 
Thankfully, the Trust Managers value this service to patients in their care 
and continue to provide the finance necessary, but this is coming 
increasingly more difficult.
What for the future?
I hope this gives a little insight into our service and provides what you are 
looking for. Please do not hesitate to contact me again.
Yours sincerely V ■ . . - .. ' _________________________________
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Survey no: L_ 1541
worked best Continuous 5FU for colorectal patients and ECF regimen, reduces the 
number of times a patient is required to attend clinics.
barriers depending on the area a patient lives, the district nurses may not be happy 
to change infiisors. Therefore the patient has to return to the hospital 
weekly.
further comments Due to the large number of patients being enrolled onto 5FU therapy it was 
inevitable that an infusor co-ordinator would be required. The service is 
not strictly speaking home care as the patients are required to collect their 







barriers Trusts pharmacy aseptic facilities are not licenced and there is no practical 
way of supplying the full back up support required by EL(95)5 from the 
Trust. This means that the Trust itself is unable to tender and outside 
organisations have to be involved.





fu rther comments Commenced home iv treatment for cf children in June 1993.
Survey no: 172








worked best TPN only at this Trust at the moment
barriers 24 hour support, patient selection




. . . . . . . .  . .
J
fu rther comments















Excellent for cystics via the home care paediatric sisters.
Yes. IV antibiotics for cellulitis/bacterial endocarditis due to lack of 
district nurse time and no real policy to state who provides ivs and -> 





. . .  194! —  . . . . _ — . .
cost factor






195------------ - ---——-------------------------------------------------------------------- ---- 1□
Pharmacy have never been asked to provide this
--------------- - ------------------------------------------------------------------.---------- 1
We are a small District General Hospital. Very few patients have hi-tech 





Chemotherapy, home TPN - these are our two main areas and we see them 
as successful on quality of life issues ie. patients spend less time in hospital
1. some patients prefer hospital treatment (health professionals within our 
Trust have chosen to have all their children's treatment at hospital even 
though they could have given it at home).
2. Non-awareness of possibilities of infusion therapies at home.
3. Difficulty of setting up on an ad hoc infrequent basis.
further comments We are a small Trust - therefore the possibilities of EL(95)5 are less for 
us.. One contracting organisation (healthcare at Home) were quite active in 
promoting their service during 1995 (their area manager did some nursing 
in this hospital) and we did supply them with pharmaceuticals but found in 
reality there were very few opportunities. It is possible that a less 
aggressive approach could slowly build up this area of work. All activity 
at the moment is "as and when" although at one stage we were about to put 
protocols/care plans in place for home TPN.
Survey no: 212.1
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Survey no: 7141
worked best Of the few patients treated at home, paediatrics probably gain most 
through children being at home rather than in hospital; parents are mosre 




Finances- need to set up working party to identify suitable patient groups;
design protocols; select patients; train pharmacy, nursing, medical staff
and patients; select commercial company (if appropriate); etc etc
fu rth er comments Pharmacy need to become involved in a Trust wide policy on home 
infusional therapy, rather than different areas doing their own thing and 
everyone pulling in different directions.
In order to succeed nedd a large and continued cash injection to set the 
process in motion and keep it working properly.
Survey no: 219
worked best TPN - patients are treated long-term and get into a routine. Also patients 
are well motivated and are generally quite well.
barriers Lack of knowledge/awareness by prescribers. limited HA funding.
fu rth er comments No!
Survey no: 777
worked best Home TPn was very successful - we have had several patients over the 
years. Home chemo has taken off really well. New service for DVT is 
just starting.
barriers Lack of nursing staff able to be released to set up practice.
fu rth er comments The home care system as such has only recently been set up for mainly 
haematology and starting medical patients with DVTs. Old systems are in 
place for home TPN (but we haven't any patients at present but have had 
up to 4 patients at a time in the past).
There are other pharmacists who have direct input into the group which 
was initially set up with a lot of support from the pharmacy/pharmacy 
management.
Survey no: m l
worked best chemotherapy patients on infusional 5FU - only having to attend hospital 
briefly once a week.
barriers Cost of devices has been a problem and workload but is now being 
resolved through negotiation with purchaser.
fu rth er comments We have just had one adult TPN patient transferred from another area 
which has been efficiently dealt with via Kabi Pharmacia and the Health 
Authority
Survev no: 721
worked best Cystic fibrosis - do not require hospital bed and can be with family. 
Electrolyte replacement- keeps patient at home.
barriers iCASH (OR LACK OF IT!)
fu rther comments


















Not sure how applicable your questionnaire is to the service that we 
provide - however hope it is of help._________________________
22S\
I am working in a Community NHS Trust covering the same geographical 
area as an Acute NHS Trust. All high tech provision is initiated in the 
acute Trust and the main input in the Comm Trust is via support from 
District Nurses/ health visitors
230
Don't know
Lack of facilities, staff, resources
Jill: These answers apply mostly to TPN as that’s where I have-’ 
involvement. We don’t have much to do with the other home patients. (I 
























fu rth e r  com m ents
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Survey no: ____  258
worked best n/a
barriers 1 We’ve had language barriers where interpreters have been called upon 
to aid explanation to patient/
2. Patients whose mental/physical state plus home environment have 
proved unsuitable.
further comments
i------- - ---------------------------------------------------------------------------------- -
I have based my answers purely on the service/treatment we provide to 
oncology patients therefore have excluded/not able to answer 
unappropriate questions. • - ~
1 apologise sincerely for taking so long to return your questionnaire. I had 
problems persuading other areas to find the time to fill it in. I've therefore 
retreived it. Unfotunately it's not complete.
Survey no: 26ll
worked best We only treat chemo patients with 5FU at home
barriers Money (with regards nurses giving chemo at home)
fu rther ciwnments The only patients I could think of were continuous 5FU pump patients who 
have bags filled weekly in Pharmacy but otherwise come in weekly to our 
cancer care centre for blood counts, line inspection etc. I can't think of any 
patients who administer drugs to themselves at home.
Survey no: 26?
worked best
■ “ " " ... " 1
1
barriers ' '■ ' ” 1_i
further comments We have no involvement and as far as we are aware no patients receiving 
high-tech health care at home. Chemotherapy is mainly provided by ,




further comments Only 5FU infusion pumps/devices are prepared for home use. We are 
unlicenced therefore patients return every seven days for a bag change 
which is changed by a chemo nurse.
Survey no: ? .d
worked best We only have experience of continuous infusional chemotherapy (5FU) 
and the occasional TPN patient, both seem to work well.
barriers No immovable barriers. Transport, nursing care, line care.
fu rth er comments
Survey no: 2831
worked best Home TPN -highly motivated patients. Cystic fibrosis antibiotics - 
motivated ward staff and paediatricians. Home epidurals - progressive 
lospice medical director with good links with hospiatl pain team consultant.
barriers  t̂ransport and delivery
fu rther comments These answers (as discussed) apply to * Hospital,
where I recently left from post of Senior Pharmacist Aseptic 
Services. They relate to my understanding at the time I left (end Feb 98) 
and have not (obviously) been discussed with htose now in charge.
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Survey no: 2871
worked best
barriers Funding issues with Health Authority.
fu rther comments Very difficult to answer questionnaire! We have different arrangements for 
different drugs and also different level of experience with individual care 
packages as we gradually taken them in house.
Survey no: .2921
worked best |Chemotherapy - Palliative Care with 5FU
barriers Cost of equipment
further comments 1
Survey no: 2 9 7
worked best
barriers
further comments We do not provide services at home for any patients.
Survey no: 3001
worked best Only had one patient who didn't want to be in hospital.
barriers Patient was keen to visist a friend outside the area which made continuous 
treatment difficult.
fu rth er comments Any patients from the area serviced by this hospital are seen and managed 
by the Teaching Hospitals in this area and the chemotherapy is managed by 
the local Oncology hospital and we have no involvement with these "hi- 
tech" treatments. This may well change ifTwhen we become a cancer unit.
Survey no: . .. .3021





worked best Home IV feeding.
HIV - feeding and antibiotics - surprisingly good.
barriers Delays from HAs accepting cost.
fu rth er comments








further comments Treatments are initiated in the acute Trusts in Sheffield and therefore 
clinincal decisions have been made before patients are taken on by our 
Trust, problems tend to be referred back to the original prescribers. The 
service works as a partnership between the trusts and the GP's. Our Trust 
pharmacy is asked for advice from time to time and HAs been involved in 
some nurse training.
Survey no: 31?!
worked best r  - .....................  -  ' - ii l
barriers
further comments Telephoned 16.2.98. As this is a community trust I am having difficulty 
answering the questions. Some of these things are provided by community 
pharmacies, for others the patient would have to go into hospital. There is 
no Pharmacy here and the Trust purchase care from acute trusts nearby. 
We have 12 community hospitals and they may have different 
arrangements. I'll try and get hold of some answers for you. "
Survey no: 3171




worked best Those who are young and motivated.
barriers jPolitical/financial primarily over who pays.
further comments Different parts of the services provided are co-ordinated by different staff 
and it HAs taken a bit of effort to get the answers!
Cytotoxics - currently there are no patients but our average for the last 12 
months HAs been 6/week. Cancer Unit accreditation HAs advanced audit 
etc in that area. Cystics have to catch up. We have in the past provided 
domiciliary narcotic analgesics for continuous infusion but this is now 










Medical staff- most do not consider the option and are unaware of the 
types of home care available. Those that are do not understand the process 
of arranging contacts between the home care companies and the relevant 
Has.
further comments The biggest problem is dealing with the HAs (often not our own) getting
them to agree to pay for the treatment and set up the contract with the 
home care company. Medical staff do not appreciate the complexity of this 
process - they agree to send a patient home on treatment in the morning and 
expect it to be provided the same afternoon._____________________ _____
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Survey no: 3231
worked best cystic fibrosis - already well established and a dedicated team available.
barriers providing 24 hour back up, providing fridges and transport - too expensive 
to do ourselves therefore need part of service provided by commercial 
company, try and decrease drag costs by providing short courses and 
cheap drags from hospital pharmacy as commercial companies charge a lot 
for this. Also save money by getting patient home quicker.
further comments
—  ■ — - ■ —i
ii
Survey no: 3271
worked best adult TPN - more stable patient
barriers cost! Complexity of managing system through internal market etc
further comments




further comments Providing hi-tech health care at home is an expanding field in this hospital 
especially for cystic fibrosis patients but as yet only represents a small 
number of patients. With the current programmes of care that are being 
developed, things are likely to take off in this area.
Survey no: 33 7 l ,
worked best we only have experience of the two groups identified. However we have 
managed to make both of these work despite occasional hiccups. BCH - 
based service works best (Desferal) due to easier communication.
barriers Ability of parents/families to cope.
Liason with other hospitals, particularly when patients transfer from 
paediatric to adult services. Large geographical area.
Purchasers NOT usually a problem!







worked best TPN - those on a stable regimen, long-term -> bulk orders and deliveries. 
Cytos - those involving a 7 day infusion to save beds.
barriers Cytos - transfer of funding to enable bed or day case savings to be used to 
purchase 7 day disposable pumps.
further comments Services indicated are not provided as "hi-tech health care at home" as such 
see Q13 but are types of home treatment under the caree of this hospital 
therefore have been included. Hope this is of some use.
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Survey no: w l
worked best Only had 3 TPN patients.
barriers Prior to EL(95)5 and even since - takes time to sort out financial aspects - 
agree budgets etc. Our first home TPN patient had to stay in hospital 
several months till sorted. Complicated by fact that he emigrated to 
another country then came back to Britain when foreign health insurance 




Survey no: ! 3<5?l
worked best Haematology myeloma patients having Doxorubicin/Vincristine 4 day 




worked best we only do one group
barriers funding
further comments Currently an MSc is auditing the home IV service should this study prove 
valid then permanent measures will be put in place.
Survcv no: L _ _  3591
worked best We have not been providing these services for very long but at present all 4 
services are success stories.
barriers -lack of funding from the HA
-difficulties in arranging delivery times and days.
fu rther comments
Survey no: 362
worked best Home TPN, no success elsewhere due to lack of consultant specialist 
knowlege and funding issues.






As a Trust our only progress has been with TPN, out of necessity. 
Personally Home Care is woefully under- utilised because of the lack of 
infrastructure in the community and clinicain understanding that it is 
possible.
Answers to Question 2 refer to an individual patient planned for home TPN 
some years ago. Since then no patients have received TPN at home. 
Chemotherapy is only very occasionally given at home, and is treated on a 
'one off basis and arraned between the oncology nurse and pharmacy. 
There have been no such patients in the last year.
Apologies for the delay. I have been trying to find out about cystic fibrosis 
patients as I am sure we have some. Unfortunately I have not found 
anyone who can answer these questions. This in itself probably indicates 
lack of any co-ordinated approach. Thanks.______________________
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Survey no: f 36X
worked best chemotherapy or desferrioxamine by supplying patients with pharmacy 
filled elastomeric pumps.







worked best HIV patients allows them maximum independence and patients normally 
show good compliance.
barriers Increased cost of equipment, increased work for pharmacy in filling 
devices and problems with infusion devices.
fu rth er comments Our number of HIV patients has dropped off dramatically
Survey no: 10051
worked best No real problems with any group.
barriers transport is sometimes (rarely) unreliable.
further comments I
Survey no: 2222
worked best Parenteral home care
barriers financial
fu rther comments
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APPENDIX
Microsoft A ccess®  1997 SR-1 database. 
Saved as Read Only File on CD-ROM  




Worked Examples for Benchmarking Database
Instructions for use and worked examples.
The benchmarking tool is a Microsoft Access ® 1997 SR-1 database. It is designed so 
that users need to have no knowledge of Access to use the tool. It is however helpful to 
have an understanding of Microsoft Windows® software.
Opening the database
To use the database load the CD onto the CD drive o f your computer. Open Microsoft 
Access and a window will appear, choose “open an existing database” and OK. Find the 
CD drive and open the file “benchmarking home infusions.mdb”.
Password
A password is required to open the database, type in “homeinfusion” Note that the 
password facility would be very important when real patient data was stored and 
compliance with data protection laws and ensuring patient confidentiality would need to 
be assured. This database does contain some real patient data and some which is made 
up to illustrate a point All of the patient names and personal details are fictitious. 
The database will open on the Main Menu Form.
Troubleshooting
If at any stage you press a grey button and nothing happens go to “tools” and choose 
“database utilities” then choose “repair database”. You should then get a message to say 
that the database has been successfully repaired and you will be back at the Main Menu 
Form.
Worked examples
The database does not have a huge amount o f data in it and therefore in order to 
demonstrate some of its functions it is necessary at this stage to direct the user to some
data that will seem meaningful. The following worked examples are referred to in 
chapter 4 and should be worked through at the appropriate point in the text.
1. Example showing how definitions of clinical problems are shown for the user.
• go to the main menu
• choose “add to or amend record of existing patient”
• choose “Stuart Donnington” from the drop down list
• press the “choose what to amend” button (if this doesn't work go to tools database 
utilities and then repair database and start again then it should work)
• press the “clinical evaluation” button, this will take you to the first of 7 clinical 
evaluation forms completed for this patient
• under “clinical problem” in a yellow box it says “infusion phlebitis grade 0” . The 
box underneath gives a definition of this.
• Use the drop down box to select other clinical problems and notice that the definition 
underneath refers to whichever you have selected.
• Reselect “infusion phlebitis grade 0”
• Press the “back to main menu” button
2. Looking at patient details and choosing what data you want to enter for a 
patient
• go to Main Menu
• choose “add to or amend record of existing patient”
• choose “Anne Green” from the drop down list
• note the use of the fields on this fonn
• press the “choose what to amend button”
• note how the information entered on the first form is carried through to other forms
• choose “prescription”
• you will see that Anne Green has had one prescription for a 5FU infusion
• you may choose to add a new prescription in which case the patient details will 
already be filled in and you have to select the drug and fill in the rest of the details.
Do not start to do this as you must then complete all the appropriate fields.
• The next grey button allows you to “enter other information about this patient” 
pressing this takes you back to the menu where you can select other information that 
you wish to check or enter such as “incoming information”. You will see that Anne 
Green has three forms completed with incoming information. Use the arrows at the 
bottom of the screen to go through them.
• You then have the choice of entering more information on that form, choosing to go 
to further details about Anne Green or going back to the main menu to choose another 
patient, go back to “Main Menu”.
3. The discharge form
• go to Main Menu
• choose “add to or amend record of existing patient”
• choose “Stuart Donnington” from the drop down list
• click on “choose what to amend”
• click on “discharge” or press the character d on the keyboard
• you will see that Stuart Donnington has three completed forms for discharge, scroll 
through them using the arrows.
• The binoculars allow you to search forms for a particular date for example.
• You have the choice of entering or viewing more information for this patient or
returning to the Main Menu
• Return to Main Menu
4. The venous access device and training forms
• go to Main Menu
• choose “add to or amend record of existing patient”
• choose “Stuart Donnington” from the drop down list
• click on “choose what to amend”
• click on “IV access device ” or press the character v on the keyboard
• you will see that Stuart Donnington has three completed forms, scroll through them 
using the arrows.
• you will see that this patient has had one central line placed by a registrar, and two 
PICC lines both placed by consultant anaesthetists
• you have the choice of entering or viewing more information for this patient or 
returning to the Main Menu
• choose enter more information for this patient
• click on training or press the “t” key on your keyboard
• use the arrows to scroll through in the same way as before
• return to Main Menu
5. The prescription form
• go to Main Menu
• choose “add to or amend record of existing patient”
• choose “Stuart Donnington” from the drop down list
• click on “choose what to amend”
• click on “prescription” or press the character “p” on the keyboard
• you will see that Stuart Donnington has a prescription for 5-flurouracil as a 
continuous infusion over 14 days in saline.
• Return to main menu
6. Reports 1
• go to Main Menu
• select the “choose a report to view or print button” or press the “r” key.
• This will take you to the Report Menu
• Enter a start date- 01/01/97.
• The end date will default to today’s date but may be overridden
• Press the button “overall incidence of clinical problems by benchmarking centre” or 
the “o” key. This will give you a report shown as a graph.
Click on close to return to the Main Menu
7. Reports 2
• Go back to the report menu as described above then enter the same date and press the 
“incidence of infusion phlebitis by benchmarking centre” button or press the “p” key. 
This will give you a report shown as a graph.
• Click on close to return to the Main Menu
8. Reports 3
• Go back to the report menu as described above then enter the same date and press the 
“incidence of clinical problems by IV access device and benchmarking centre” button 
or the “o” key. This will give you a report shown as a graph.
• Click on close to return to the Main Menu
9. Reports 4
• Go back to the report menu as described above then enter the same date and press the 
“show all prescriptions for a patient” button or the “s” key.
• The computer will ask you to input your centre ID, type 3.
• Then you will be asked for the patient number, type BL00066
• This will give you a summary report of all the prescriptions in the database for that 
patient.
• Click on close and then cancel to return to the Main Menu
APPENDIX
C EN TRA L H O M EC A R E  L IM IT E D
Unit 6, Grove Park, Mill Lane, Alton, Hampshire GU34 2QG 
Telephone: (01420) 543400 Fax: (01420) 544588
Patient’s
Nam e ________________________________________










please use hospital stamp
Tel. N o. 
Nam e o f carer
Carer’s relationship
GP’s Nam e 
and Address
To C en tra l H om ecare Lim ited,
Please supply the following for the  above nam ed patient:
Tel. No. _  
Health Authority
Special Instructions










Please fax the completed form to Central Homecare 
and then post the top copy using the reply-paid 




Delivery Address (please tick one box and complete 
further information if applicable)
j  Hom e
j  Hospital_
j  Other
Doctor’s Signature Doctor’s Name Pharmacy (optional) Date
A B C 3 7 2 3 .1 0 /2 0 0 0
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The current position in England concerning home- 
based ambulatory infusion provided under EL(95)5
By J . Loader and G.jf. Sewell
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Figure 1: Provision o f services to patients receiving HTHH
The apparent lack of knowledge of 
hi-tech health care at home by the 
bodies charged with responsibility 
for purchase is of concern, as is the 
absence of monitoring of contracts. 
This could result in poor patient 
care
In tro d u c tio n  Treatm ent o f patients at home 
with intravenous therapies such as antibiotics, 
parenteral nutrition (HPN), chemotherapy and 
chelating agents has become widely accepted as 
a safe and effective model o f health care.1 Few 
problem s have arisen and complication rates 
have been shown to be low.2 Treating these 
patients at home offers benefits for hospitals 
through earlier discharge o f patients, freeing- 
up hospital beds and improved cost effective­
ness.3
EL(95)54 instructed health authorities in 
England to make provision through their con­
tracts to support patients at home whose treat­
m ents included the delivery of drugs together 
with o ther products and equipment needed to 
administer them, typically provided as packages 
of care. T h e  pharmaceutical advisers, medical 
advisers and contracts managers of health au- 
tho-ides were responsible for the implementa­
tion o f  EL(95)5 together with contracting and 
strategic planning for home-based patient care.
T h e  aim o f the project was to establish the 
current position in England on the purchasing 
o f hi-tech health care at home (H T H H ) by 
health authorities.
A questionnaire was designed to elicit the 
required information from health authority 
pharmaceutical advisers and medical advisers.
M eth o d s A detailed, fully referenced literature 
review was prepared and questionnaire design 
techniques studied.
Regional directories for 1997/98 listing all 
the health authorities, trusts and community 
health councils in each region were obtained 
from the N H S Executive.
A health authority questionnaire was draft­
ed, designed for administration to pharmaceu­
tical advisers, medical advisers or contracting 
managers of health authorities to determine: 
which disease states are included in H T H H  
programmes; to what extent patients are being 
treated in their homes with “hi-tech” therapies; 
who is currently providing the various aspects 
of their care and how much is being invested in 
caring for these patients at home nationally.
T h e  questionnaire was piloted at a regional 
m eeting of pharmaceutical advisers. A letter 
was enclosed asking for the recipient’s com­
m ents on the questionnaire’s content and de­
sign. These resulted in minor changes to the 
final questionnaire and distribution in person.
-fFromjhe:DepanmentifF.barmacy,Plymouth 
■ HospitaUNHS T T t^  arid Postgraduate Medical
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Between May and November 1997 the re­
searcher was able to attend regional meetings 
of pharmaceutical advisers. Questionnaires and 
prepaid return envelopes were distributed by 
the researcher, where possible, with an explana­
tion of the aims and objectives of the project.
Responses to the questionnaire were 
recorded on an Access database which was sub­
sequently used in the analysis of the results.
R esults Responses were received from 87 o f 
the 100 health authorities; 27 out o f 87 (31%) 
were unable to answer any questions regarding 
the number of patients under their jurisdiction 
receiving hi-tech health care at home or pro­
vide information on the cost of their treatment.
T he percentage o f health authorities treat­
ing one or more patients with the following; 
home therapies were: T P N  54%, antibiotics 
for cystic fibrosis 46%, desferrioxamine 25%, 
antivirals for HIV 10% and chemotherapy 5%.
O ther hi-tech therapies given at home in­
cluded terbutaline for asthma, immunoglobu­
lins, enzyme replacement for Gaucher’s 
disease, prostacyclin and beta-interferon.
Commercial home care companies and 
acute trusts were found to be the main 
providers of all aspects of H T H H  (Figure 1).
Only 17 out of 87 (19%) health authorities 
had any future plans for the care of these pa­
tients. One of the 87 health authorities knew of 
any fund-holding GPs who directly purchased 
H T H H  for their patients.
Respondents were asked open questions on 
which aspects of H T H H  had been successful 
and which aspects had proved difficult or prob­
lematic.
Comments regarding success included the 
fact that the health authority has been able to 
shift the responsibility for contracting for 
H T H H  on to the hospital trusts and the con­
tracting process enabled them to achieve better 
quality of care or cost effective care for the pa­
tients. Some health authorities see the trusts as 
better placed to contract for these services.
Difficulties included problems with the 
initial implementation of EL(95)5, funding of 
new patients, as there are no new monies avail­
able, problems with tertiary centres and 
extra-contractual referrals, and not knowing
whose responsibility the monitoring, audit and 
evaluation o f the service is.
D iscussion This survey has highlighted the 
complexity o f the current contracting proce­
dure for hi-tech health care at home under 
EL(95)5. Some health authorities have invited 
tenders to provide the service, while others 
have either continued with arrangements in 
place before EL(95)S or passed on the respon­
sibility to the local trusts. From these data it ap­
pears that commercial home care companies 
have the largest share o f the home care market 
in England closely followed by NHS trusts. 
District nurses working for community trusts 
are caring for patients receiving H T H H  in 
some areas of the country. Intravenous antibi­
otics for cystic fibrosis and home T P N  are the 
major infusions being provided in the domicil­
iary setting. It is unclear who is monitoring the 
quality o f service received by patients.
T he  apparent lack of knowledge o f 
H T H H  by the bodies charged under EL(95)5 
with responsibility for purchase is of concern as 
is the absence of monitoring o f contracts high­
lighted by the qualitative data. T his could re ­
sult in poor patient care. In order to establish 
the full picture regarding H T H H  in England it 
is necessary to obtain information from all 
providers of “hi-tech” home care, ie, commer­
cial home care companies and trusts. T his is 
the subject o f further work of this project.
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Antibiotic treatment accompanying surgery for 
appendicitis
By T. L. Rose, K. Hatfield, B. Hebron*, J. F. Marriott and K. A. Wilson
Introduction Reducing inappropriate an­
tib io tic  prescribing is currently  a major issue 
in th e  drive to  reduce the spread o f  an ti­
b io tic  resistance.1 Appendicitis is com m on, 
rarely associated w ith concurrent conditions 
and is o ften  complicated by infection. H ow ­
ever, accurate diagnosis is often made only 
after surgery  and any antibiotic treatm ent 
should  reflect this diagnosis.2 T h e  present 
study  describes an audit o f  antibiotic use as­
sociated w ith appendectomy.
Methods T h e  medical histories o f all pa­
tien ts w ho underw ent appendectom y be­
tw een April, 1997, and M arch, 1998, at C ity  
H ospita l N H S  tru st were reviewed re tro ­
spectively. D ata were directly  entered into a 
relational database for m anipulation and 
analysis. D ata were collected on duration o f 
in -p a tien t stay, histological diagnosis, an­
tibiotics adm inistered, including frequency, 
ro u te  and duration. Patients with co-m or­
bidity  were excluded from this analysis.
Results M edical histories from  146 patients 
w ere included for analysis. Following opera­
tion  40 had  histologically norm al appendix, 
64 non-perforated  acute appendicitis and 42
Pharmacy practice group, school o f pharmacy, 
Aston university, Birmingham; *City Hospital 
*NHS trust, Birmingham  *
Patients Numbers treated Antibiotic duration (days)
No Infected Stay IV Oral T T O IV Oral T T O
Normal 40 4(10) 4 23(58) 14(35) 8(20) 2 2 5
Appendicitis 64 6(9) 5 58(91) 36(56) 28(44) 3 2 5
Severe appendicitis 42 12(29) 6 41(98) 27(64) 27(64) 4 2 6
No =  number ofpatients; stay *  duration of hospitalisation (days); IV  =  intravenous; TTO  =  discharge medica­
tion. Figures in parentheses art percentages
severe appendicitis presenting as abscess 
formation, perforation and gangrenous ap­
pendix. T h e  results from the present study 
are summarised in Table 1.
Discussion As m ight be expected, the length 
o f hospital stay, duration o f IV  antibiotic ad­
m inistration and total period o f antibiotic 
cover correlate with the severity o f  the con­
dition. However, although similar infection 
rates were observed in those patients found 
to have a norm al appendix and those with 
acute appendicitis, patients in the latter 
group received m ore aggressive antibiotic 
therapy, notably by the IV  route. T h e  u n ­
derlying reasons for these findings are being 
explored currently in order to improve cost- 
benefits in this area o f practice.
M oreover, since the conditions de­
scribed are embraced by clear form ulary 
guidelines supported by medical m icrobiol­
ogists, it is suggested that postoperative an­
tim icrobial prescribing m ight be best ac­
com m odated by a dependent prescribing 
pharm acist in accordance with the recom ­
m endations m ade in the recent C row n re ­
port.5 Im plem entation o f  this latter concept 
m ight further improve antibiotic  prescrib­
ing, by facilitating conversion from  IV  to 
oral routes and reducing the total duration 
o f antibiotic course.
R e f e r e n c e
1. Resistance to antibiotics and other an­
timicrobial agents. HSC 1999/049. 
London: Department of Health, 1999.
2. Page et al. Antimicrobial prophylaxis for 
surgical wounds. Arch Surg 1993;128: 
79-88.
3. Anon. Crown review paves the way for 
pharmacists as “dependent prcscribcrs”. 
PharmJ 1999; 262:346-7.
The role of the pharmacist in the provision of hi-tech 
health care at home (HTHH)
By J . Loader *f and G .J . Sewell*f
Introduction In  the U nited States pharm a­
cists have developed an im portant role in the 
establishm ent o f  H T H H  schemes,'-3 espe­
cially in ensuring th a t quality and continuity 
o f  hom e health  care is consistent with that 
provided to  inpatients.2 T h e  U K  has been 
slow to im plem ent hom e infusion p ro ­
gram m es but, w ith pressure on hospital beds 
and increasing experience o f H T H H , it is 
becom ing accepted as a safe and effective 
m odel o f  health  care, although there is still a 
need for m ore descriptive studies.4 H T H H  
fits the  G overnm en t agenda, laid out in the 
recen t W h ite  Paper,s o f making health care 
easily accessible to patients, as close to hom e 
as possible. T h e  aim o f this study was to  de­
term ine th e  curren t place o f  pharmacists in 
the  provision o f  H T H H  in England. T hese  
data w ould identify areas where their role
"Plymouth Hospitals N IIS  trustffP l 
postgraduate medical school, Plym  ̂
university; f  department o f pharfn^im d t '  
pharmacology, Bath tmrvcnuty'
v .  . ' . ■'
could be extended o r modified to optim ise 
pharmaceutical care for H T H H  patients.
Method Lists o f  all N H S  trusts in England 
were obtained from N H S Executive region­
al directories. Ambulance, mental health 
and learning disabilities trusts were excluded 
from the survey. A questionnaire was de­
signed based on roles o f the pharmacist re ­
ported in the literature and from local 
experience o f  providing H T H H . It was p i­
loted by seven pharmacists with experience 
of H T H H . A telephone survey o f 349 trusts, 
over the period Novem ber to  December, 
1997, was carried ou t to establish which 
pharmacy departm ents were involved with 
H T H H  schemes. T h e  written question­
naire was sent to those with any involvement 
(167). Responses were recorded on an Ac­
cess database which was subsequently used 
for analysis o f  the results.
Results O ne hundred and five responses 
were received (63 per cent), o f  which 94 
were evaluable. T h e  roles which pharm a­
cists m ost frequently undertook in H T H H  
(>67 per cent) are listed in Table 1. T h e  a r­
eas where pharmacists had least inpu t were 
in m aintenance o f the infusion pum p (19.1 
per cent), competency assessment o f  the pa­
tient/carer (20.2 per cent) and selection o f  
venous access device (22.3 per cent). T h ere  
were 64 pharmacists (68.1 percen t) who had 
been involved with setting up a H T H H  
program m e, but only eight were “very in ­
volved” with m onitoring quality o f the 
H T H H  service while 32 had “som e involve­
m ent” and 44 said they had “no involve­
m ent” (nine did not answer and one 
answered “n /a”). Fifty-nine pharmacists had 
been involved with setting service specifica­
tions and 30 had “no involvem ent” (five 
gave no answer). Fewer (39) were involved 
with ensuring compliance with the  service 
specifications than setting them  and 44 had 
no input at all (11 did no t answer this ques­
tion).
Discussion In England hospital pharmacists 
apply to  H T H H  their traditional roles o f
R70 THE PHARMACEUTICAL JOURNAL (VOL 263) September 18, 1999
T h e  C o n f e r e n c e
T able 1: M o st  c o m m o n  areas o f  pharm acist  in v o lv em en t  in  H T H H  program m es
Number of pharmacists giving response 
Very Some in- No in- No Total 
involved volvement volvement answerRole of the pharmacist
'  (a) (b) (a+b)
Pharmaceutical advice to prescriber 58 26 7 3 84(89.4%)
Co-ordination and communication 41 41 9 3 82 (87.2%)
with other health professionals
Providing formulation and stability data 62 19 10 3 81 (86.2%)
Maintenance of prescription records 55 21 13 5 76(80.9%)
Co-ordination and communication 19 56 15 4 75 (79.8%)
with patients and their families
Supply of drugs 55 15 21 3 70(74.5%)
Aseptic reconstitution of drugs and 54 16 19 5 70 (74.5%)
filling of infusion devices/syringes
Choice of appropriate drug therapy 32 37 22 3 69(73.4%)
Co-ordinating the home care program 25 38 26 5 63 (67.0%)
Setting up the HTHH program 35 28 26 5 63 (67.0%)
providing advice, specialist knowledge, 
com m unicating with patients and o ther staff 
and in providing drugs. M ore than ha lf o f 
the pharmacists giving a response had no  in­
volvem ent in quality assurance o f the hom e 
care program m e even though 64 were in­
volved w ith setting up the programme. T his 
contrasts m arkedly with the US situation.1' 3 
I t  has been shown that this role o f m on ito r­
ing  quality  has no t been taken on by health 
authorities as purchasers o f  H T H H .6 W ith
the recent emphasis on clinical governance, 
pharmacists w orking in H T H H  in England 
should examine the m onitoring and quality 
roles o f their U S colleagues and determ ine 
w hether contracting  and service delivery o f 
H T H H  in the U K  health care system could 
also benefit from increased pharmacist in ­
put. O ne lim itation o f this study is that some 
trusts provide the entire package o f care to 
patients at hom e whereas others contract for 
some aspects with a commercial provider,
Bcrkner S, McCallum D, 
Schwartau ;N, ct al. Organisation and 
operation of a home parenteral nutrition 
program with emphasis on the pharma­
cist’s role. Mayo Clinic Proceedings 
1980;55:94-8.
2 McAllister JCD. The role of the phar­
macist in home health care. Drug Inteil 
Clin Pharm 1985; 19(4):282-4.
5 Juergens JP. Nurses’ use of pharmacists 
‘ cognitive services in home care agencies 
in Mississippi. Am J Hosp Pharm 1993; 
59(11):2370-1.
4 lliffc S. Hospital at home: from red to 
amber? BMj 1998;316:1761-2.
5. Department of Health. The new NHS: 
modem and dependable. Government 
W hite Paper, 1997. Cm 3807. London, 
ILM Stationery Office, 1997.
6. * Loader J, Sewell GJ. The current posi­
tion in England concerning home-based ‘ 
ambulatory infusion provided under 
EL<95)5. Pharm J 1998;261 :R42.
necessitating varying levels o f  pharm acist 
input. Future developm ent o f  the role of 
pharmacists in H T H H  should include as­
surance and m onitoring o f the quality of 
care delivered by both comm ercial and 
N H S providers.
R e f e r e n c e s .
■ ■‘ V
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Continuing professional development for pharmacists: 
a strategic approach
By Claire Grout, Jenny Dorey and Jane Hough
Introduction R ecruitm ent and retention are 
crucial issues in hospital pharmacy at p re­
sent and are likely to worsen with the “fal­
low year” approaching. A recent survey has 
show n th a t 13.7 per cent of all pharm acist 
posts w ere vacant in N H S hospitals in E ng­
land, W ales and Scodand in July,. 1998.1 R e­
cru itm en t and retention  difficulties have led 
to  reductions in service, or refusal o f 
requests for new  services, in half o f all hospi­
tals. T h e  Berkshire and Oxfordshire contin­
u ing professional development (C PD ) 
project was established to support individual 
developm ent o f  pharmacists, in line w ith de­
partm ental needs, as an aid to  recruitm ent 
and re tention . A pharmacist was appointed 
to  lead the  project, with funding from  the 
Berkshire and Oxfordshire Education C o n ­
sortium .
Method Following discussion with the pro­
ject steering com m ittee (representatives 
from  each trust involved in the project), a 
pilo t study was perform ed. Ten pharmacists 
w ere recruited, ranging from B to F  grade, 
and representing  a variety of different roles 
w ithin hospital pharmacy. Each pharmacist 
developed a portfolio of evidence o f 
achievem ent and highlighted developm ent
Oxford Raddiffe Hospitals NHS trust
... - ' _.   '■  ~ -
needs, related to  a series o f criteria. T hese 
criteria, developed after discussion with a 
num ber o f practitioners, were designed to 
be applicable to  all pharmacists. In  discus­
sion with the project pharmacist, a personal 
developm ent plan was produced, which was 
approved by the line manager. T h e  process 
was evaluated by a structured interview with 
each pharmacist.
Results A num ber o f different activities were 
included on the personal developm ent 
plans, such as courses, reading and working 
through case studies o r questions, shadow­
ing, or undertaking new tasks. T h e  project 
pharmacist identified suitable material 
wherever possible. All pharmacists involved 
in the pilot study found the process very 
helpful and motivating. T hey  all felt that a 
m entor was needed to  facilitate the process 
and provide ideas for development. Al­
though there had been some initial concern 
regarding the time needed for the process, 
this was no t found to  be a problem, particu­
larly as they became more reflective in  their 
approach.
Discussion T h e  Governm ent has reinforced 
the im portance o f C PD  in achieving good 
clinical practice.2 T h e  project described is 
working towards achieving this aim for 
pharmacists. W ith  modification to  the port­
folio structure and the criteria following 
feedback from the pilot study, the project 
will be rolled ou t to all hospital pharmacists 
in the area. Each personal developm ent plan 
will be linked to individual appraisal and ob­
jectives. T h e  project pharmacist will act as 
m entor to  all pharmacists, liaising w ith each 
individual’s line manager. It is suggested that 
for new  posts individuals are appointed on 
flexible grading, so that a pharmacist has the 
opportunity  to develop to  a higher grade 
w ithin the post, linked to objective criteria.
Enthusiasm  in the project is encourag­
ing and it is hoped that the m otivation p ro ­
vided by individual continuing developm ent 
will prom ote retention o f staff.
ACKNOWLEDGMENT: Thanks to the Project 
Steering Committee, the pilot study partici­
pants, and the Berkshire and Oxfordshire Ed­
ucation Consortium for their support.
R e f e r e n c e s
1. National hospital pharmacy recruitment 
and vacancy survey 1997-8. NHS Phar­
macy Education and Development 
Committee, December, 1998.
2 . A  first class service: quality in the N e w  
NHS. London: Department of Health, 
1998.
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Survey of home infusion care in England
Jill  Lo a d e r , G r a h a m  Sew e l l , a n d  Sh iv a u n  Ga m m ie
Am J Health-Syst Pharm. 2000; 57:763-6
The Pharmacy Abroad section of AJHP features brief, informal, and topical communications 
related to pharmacy in other countries. Contributions are welcomed from pharmacists abroad 
or from pharmacists who have traveled abroad.
AJHP also encourages pharmacists from outside of the United States to submit traditional 
manuscripts (e.g., scientific studies, descriptions of practice innovations), which are evaluated 
for publication in the primary sections of the journal
The N a tio n al -Health Service (NHS) was founded in 1948 by the government o f the United 
Kingdom on the principle that the 
care it provided would be available to 
all, irrespective of means, on the basis 
o f need and that most services would 
be provided free o f charge at the 
point o f  use. The NHS is funded 
through national income taxes. Gov­
ernment health policy is implement­
ed through the Department o f Health 
(run by elected officials led by the 
Minister for Health, who reports di­
rectly to the Prime Minister) and is 
managed by the NHS Executive (run 
by appointed civil servants). The 
NHS Executive has eight regional of­
fices that manage the 100 Health Au­
thorities (HAs) in England.
During the late 1980s, HAs were 
given the resources to  purchase 
health care for their local popula­
tions. The resources were to cover 
health promotion, public health, and 
all health care provided in the com­
m unity and through hospitals. Pro­
viders o f health care competed for 
contracts to deliver their services. 
(The NHS is currently undergoing a 
reform that will move responsibility
for purchasing health care from the 
HAs to prim ary care.)
Physicians (general practitioners, 
or GPs) and health care profession­
als working in the community are 
the public’s primary access to health 
care (primary care). GPs may refer 
their patients to specialist physicians 
in hospitals (secondary care), who in 
tu rn  may seek advice from specialty 
hospitals (tertiary referral centers).
Acceptance of home infusions has 
been slow in England because o f the 
way health care is funded through 
the NHS, the lack of incentives to 
change current practice, and the ex­
istence o f other priorities.1 There is 
no direct cost to the patient or an 
insurer when a patient is admitted to 
the hospital, and therefore there is 
no direct financial pressure from  
them to reduce the length o f stay.
J i l l  L o a d e r ,  M R P h arm S , is Ph.D. student, De­
partment of Pharmacy and Pharmacology, Uni­
versity of Bath, and Pharmaceutical Advisor, 
Wiltshire Health Authority, Wiltshire, United 
Kingdom. G ra h a m  S e w e ll ,  P h .D ., M R P h arm S , 
is Professor of Clinical Pharmacy and Pharmacy 
Practice, University of Bath, and Consultant 
Pharmacist, Plymouth Hospitals NHS Trust, Ply­
mouth, United Kingdom. SHIVAUN GAMMIE, 
P h .D ., M R P h arm S , is Pharmaceutical Advisor,
Before 1995, some GPs prescribed 
infusions for their patients and some 
home infusions were organized and 
paid for via secondary or tertiary care 
(the hospitals, or NHS trusts). In 
1995, the government issued a direc­
tive that instructed HAs to buy pack­
ages of care for patients at hom e 
whose treatments included “the de­
livery of drugs together with other 
products and equipm ent needed to 
adm inister them ” (e.g., total par­
enteral nutrition [TPN], intravenous 
antimicrobials, and antineoplastic 
agents).2 The HAs contracted only 
for those patients for whom  GPs 
were previously prescribing drugs; 
hospitals continued to pay, out o f 
their own budgets, for patients they 
were already treating with home in­
fusions.
, The objective o f this study was to 
collect information on the purchas­
ing and provision o f home infusions 
in England. Specifically, we sought to 
identify
• The indications for home infusions,
• The number of patients receiving 
home infusions,
• The contract mechanisms,
• The providers of various elements of 
home infusion care,
• The geographic distribution of pa­
tients receiving home infusions, and
• The mechanisms for monitoring 
quality and outcomes.
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United Kingdom.
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M ethods. Surveys were conducted 
of all the purchasers and providers of 
hom e infusion care in England for 
the period from April 1997 to De­
cember 1998. We visited regional 
m eetings o f pharm aceutical and 
medical advisers of the 100 HAs to 
explain the objectives of the project 
and to distribute written question­
naires on the purchasing o f home in­
fusions. We conducted a telephone 
survey o f all the hospitals in England 
(excluding those specializing in men­
tal health and learning disabilities) to 
establish which were involved in car­
ing for patients receiving hom e infu­
sions. This was followed up with a 
written questionnaire to elicit further 
information from those who did pur­
chase or provide home infusions for 
their patients. Finally, we sent a writ­
ten survey to the six commercial pro­
viders o f home infusions in England. 
This questionnaire was designed in 
conjunction with members o f the in­
dustry, who advised us on what in­
formation the companies might be 
willing to share in this commercially 
sensitive area.
The anonymity o f all survey par­
ticipants was ensured to encourage 
frank reporting.
Results. Indications for home infu­
sions. The main indications for home 
infusions in England were administra­
tion of TPN for Crohn’s disease and 
short-bowel syndrome, antimicrobial 
agents for cystic fibrosis, antineoplastic 
agents (continuous infusions), defer­
oxamine for thalassemia, and antivi- 
rals for HIV infection.
Table 1 shows the percentage of 
responding HAs and hospitals p ro­
viding home infusions for patients 
under their jurisdiction. The hospi­
tals were more likely to provide antine­
oplastic agents and antivirals for HIV 
infection than the HAs, but the HAs 
m ore commonly had contracts for 
providing home TPN than the hospi­
tals. The reason is probably that fewer 
GPs were prescribing antineoplastic 
agents and antivirals for their patients 
before the 1995 government directive.2
Number of patients. In many cases, 
neither the hospitals nor the HAs 
were able to specify the num ber of 
patients receiving hom e infusions. 
While an HA may take on responsi­
bility for contracting for the provi­
sion of, for example, home parenteral 
nutrition for the patients in its area, it 
may leave the provision o f other 
types of home infusions, such as in­
fusions of antineoplastics or deferox­
amine, entirely to the local hospital 
(Table 1). The HA may not even be 
aware that patients are being treated 
at home with such other infusions.
It was not easy to interpret the re­
sults for patient numbers. When the 
question was left blank, this could 
have meant either (1) that no patients 
were being treated at home with that 
drug or for that condition or (2) that 
the participant did not know if there 
were any o f these patients.
The largest num bers of patients
had their care either supplied or p u r­
chased by hospitals (Table 2). The 
largest numbers o f patients were re­
ceiving antineoplastic agents or anti­
microbial agents for cystic fibrosis; 
far fewer were receiving hom e TPN 
infusions, although the largest ex­
penditure was on adult and pediatric 
home TPN.
Contract mechanisms. HAs gener­
ally have bulk contracts with local hos­
pitals for providing specified services 
in order to avoid the large administra­
tive costs of individually billing for ev­
ery service provided. Less than half 
(46%) of the HAs purchased home in­
fusions under a separate contract One 
quarter (26%) added the money, taken 
from GPs’ budgets, to their bulk con­
tracts with the hospitals and left it to 
the hospitals to purchase or provide 
home infusions. Fifteen percent used 
a separate contract for som e drug 
products and a bulk contract for oth-
Table 1.
Percentage of Health Authorities and Hospitals Providing Home 
Infusions
No. (%) Respondents 
Providing Home infusions*
Indication Health Authorities Hospitals
Administration of antim icrobials for cystic
fibrosis 40 (46.0) 43 (45.7)
Antineoplastic th erap y 5 (5.7) 39(41.5)
Administration o f antivirals for HIV infection 9(10.3) 14(14.9)
Total parenteral nutrition adm inistration 47 (54.0) 41 (43.6)
Deferoxam ine adm inistration 22 (25.3) 30 (31.9)
Adm inistration of enzym es for Gaucher's 
disease 5 (5.7) 5 (5.3)
Adm inistration o f im m unoglobulins 2(2.3) 5 (5.3)
Adm inistration o f terbu taline 2(2.3) 2 (2.1)
Pain relief 0(0) 5 (5.3)
Adm inistration o f ep o p rosteno l 2(2.3) 1 (1.1)
Adm inistration of antim icrobials for o th er 
indications 0(0) 8(85)
•Responses citing any number of infusions greater than zero were counted.
Table 2.
Number of Patients Receiving Home Infusions
No. Patients*
Indication Health Authorities Hospitals
Adm inistration o f antim icrobials for cystic fibrosis 446 879
A ntineoplastic therapy 33 990
Administration of antivirals for HIV infection 25 83
Total parenteral nutrition adm inistration 234 449
Deferoxam ine adm inistration 114 264
•Numbers are normalized (divided by percent response rate and multiplied by 100).
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T ab le  3.
Providers of Specific Elements of Home Infusion Care____________
No. (%) R espondents 
Elem ent o f Care and Provider____________ Health Authorities________Hospitals
Drugs 
Hospital pharm acy 
Commercial com pany  





Com munity hospital or district nurses
Other
Equipm ent and supplies 
Hospital
Commercial com pany
Primary care or com m unity  hospital
O ther
H e a lth  A u th o r i ty  S u r v e y
ers. Very few HAs have used bidding 
for the purchase of home infusions.
Comments submitted by hospital 
pharmacists indicated that there is a 
lack of coordination in the hospitals 
with respect to the purchasing and 
provision of home infusions. One 
pharmacist wrote, “The situation is 
very complex—diffuse and vague ac­
countability—very fragmented. In 
short, a mess!” Another stated, “I 
have been trying to find out about 
cystic fibrosis patients, as I am sure 
we have some. Unfortunately, I have




22 (22.9) 143 (62.4)
39 (40.6) 30(13.1)
25 (26.0) 48 (21.0)
10(10.4) 8(3.5)
H o s p ita l  S u rv e y
not found anyone who can answer 
these questions.”
The commercial providers of 
home infusions stated that care for all 
home infusions was more often pur­
chased by a hospital or HA on an 
individual-patient basis than under a 
contract.
Providers ofvarious elements of home 
infusion care. Table 3 gives the distri­
bution of providers of medications, 
nursing care, and equipment and sup­
plies for patients receiving home infu­
sions. The hospitals were the major
suppliers of all three when care was 
purchased or provided by hospitals. 
Even when the HAs purchased care, 
the hospitals were still the major pro­
viders of drugs and nursing care 
(closely followed by commercial home 
care companies); commercial provid­
ers most frequently provided equip­
ment and supplies.
The HAs were more likely than the 
hospitals to purchase a package of care 
for home infusions from a commercial 
provider. There was significant input 
from district nurses (primary care) in 
providing nursing care for patients re­
ceiving home infusions.
Geographic distribution. Figure 1 
shows the geographic distribution of 
patients receiving five specified types 
of home infusions in the eight re­
gions of the NHS. There was geo­
graphic variation in the number of 
patients being treated with home in­
fusions, and the HAs generally pur­
chased care for fewer patients than 
the hospitals.
Quality- and outcomes-monitoring 
initiatives. Twelve HAs expressed con­
cern over the lack of auditing of the 
quality of patient care, and 11 said they 
had no way of knowing whether they 
were getting value for their money. 
Only 18 (19.1%) of 94 hospitals said 
they had an audit system for measur­
ing the quality of care, and only 12 
(12.8%) had an audit system for mea­
suring patient outcomes.
Five of the six commercial home 
care providers in England were not 
aware of any HAs or hospitals with 
whom they had contracts having any 
audit systems for measuring patient 
outcomes or benchmarking their 
services against those of other pro­
viders. Four were aware of contract 
HAs or hospitals having audit sys­
tems for measuring their services 
against agreed-upon service specifi­
cations or for monitoring the servic­
es they provided.
One commercial provider stated, 
“Virtually all our business is noncon­
tractual. Often patients are tendered 
for individually but in a nonformal
35 (32.7) 134(61.5)
47 (47.0) 72 (33.0)
13(12.1) 5(2.3)
12(11.2) 7(3.2)
Figure 1. G eographic distribution o f patients receiving specified typ es o f hom e infusions in En­
gland.
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fashion (i.e., hospitals ring for quotes 
and usually go for the cheapest!).”
Discussion. Home infusions are 
gaining acceptance in England, but 
not uniformly. This may reflect dif­
ferences in the geographic distribu­
tion of the conditions being treated.
There are many mechanisms for 
purchasing and providing home infu­
sions in England. It is not uncommon 
for home infusions to be provided on 
an ad hoc basis. This makes it difficult 
to obtain a clear and accurate picture 
of the home infusion market. It was 
impossible in this study to obtain in­
formation from all of the many health 
professionals who may be involved in 
the provision of home infusions.
The percentage of HAs providing 
home infusions was smaller than that
found in a telephone survey by other 
researchers,3 possibly because we re­
quested more detailed information in 
our written survey and because our 
survey was directed at different pro­
fessionals within the HAs.
The lack of monitoring of the 
quality of care received by patients at 
home and of their clinical outcomes 
is of concern. Most purchasers are 
not monitoring their contracts for 
quality, and providers are not re­
quired to demonstrate continuous 
quality improvement or even a mini­
mum level of service.
The current restructuring of En­
gland’s NHS creates an opportunity to 
review the mechanisms used to pur­
chase and provide home infusions. A 
system whereby all home infusions are
purchased via the same mechanism 
would seem a sensible first step. Quali 
ty and outcomes monitoring should be 
urgently addressed.
Conclusion. A survey of home in­
fusion care in England found deficien­
cies in coordination of services, quality 
control, and outcomes monitoring.
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